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Abstract  
Introduction:  Criticisms of the mandated patient information leaflets (PILs) supplied 
with all medicines include being difficult to read and overly negative. Two adaptations 
suggested to address this are: 
1) Inclusion of headline section 
2) Inclusion of additional information about potential benefits of the medicine. 
Aims: To explore the impact of a headline section and benefit information in PILs on 
patients’ satisfaction, understanding and medicine-taking behaviour. 
Methods: Two scoping literature reviews informed the nature of exemplar PILs with a 
headline section and benefit information to be presented to medicine users. These PILs 
were used first in focus groups to explore opinions of the adaptions, and then the 
headline section was user-tested. A survey assessed the nature and availability of 
benefit information in current PILs. Finally an interview study explored the thoughts of 
actual medicine users about the inclusion of benefit information.  
Findings: The reviews found a small body of literature about a headline section. In 
contrast, there was a large body of heterogeneous research on benefit information -
used to develop exemplar PILs. Focus group participants viewed headline sections 
positively and, when user-tested, was used about a third of the time to locate key 
information. Benefit information was more controversial; many struggled to understand 
it, with an emotional response in some, who appear to over-estimate medicine benefits.  
The emotional response was less pronounced in the actual-user group, although some 
surprise and disappointment remained at the perceived low level of benefits.  
Conclusions: A headline section was viewed positively, and in user testing it was used 
to find key information. However, perceived low level of benefit proved a significant 
barrier to benefit information, with some unwilling to engage with it. More research is 
needed to allow informing patients about both the potential benefits and harms of 
medicines – allowing them to make informed decisions.  
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  Introduction Chapter 1
The inclusion of a headline section and information about the benefits of 
medicines in patient information leaflets. 
 Introduction 1.1
Medicines are the most common intervention in the NHS. Most people will take a 
medicine at some point in their life. In the UK and across Europe all licensed medicines 
are legally required to be provided with written medicines information; this takes the 
form of a patient information leaflet or PIL. This thesis focuses upon potential ways to 
improve the content and format of patient information leaflets in order to better support 
patients to access and understand information about their medicines. The principal aim 
is to explore the inclusion of two distinct adaptations that have been considered for use 
in a PIL. These adaptations relate to the following: 
[1] The format of the information: an exploration of the inclusion of a headline or 
summary section in patient information leaflets 
[2] The content of the information: an exploration of the inclusion of information about 
the benefits of medicines in patient information leaflets. 
Including both a headline section and ‘benefit’ information in a PIL have been identified 
as developments that may have potential in assisting patients to better access 
information about their medicines. They might also help patients to understand more 
about their medicines and encourage them to make informed decisions about their use. 
This thesis aims to explore patient perspectives on the inclusion of a headline section 
and ‘benefit’ information in a PIL. 
Initially this doctoral research focused solely upon the impact of providing a headline 
section in a patient information leaflet. The focus of the work was broadened in order to 
incorporate additional research into the inclusion of benefit information, which was a 
focus of interest of the researcher prior to commencement of the PhD studies. An 
international research project, examining the inclusion of one type of benefit information 
had previously been undertaken and provided some of the foundation for part of this 
PhD research (Hamrosi et al., 2012). 
This introductory chapter begins with an overview of the history and role of patient 
information leaflets for medicines. There is also a discussion about the nature and 
context of a headline section and benefit information. The chapter ends with a summary 
of the rationale for the PhD research and its aims and objectives.  
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 The history and legislation of patient information 1.2
leaflets 
The term patient information leaflet (PIL) specifically refers to the mandated leaflet that 
is legally required to be provided with all packs of licensed medicine, whether the 
medicine has been prescribed or bought without prescription. The UK has regulated the 
patient information provided with medicines since 1977, although until 1999, few 
medicines came with leaflets similar to those available today.  
In 1992 a directive from the European Commission on the labelling of medicinal 
products for human use and on package leaflets paved the way for the introduction of 
leaflets for the patient with all medicines (Council of the European Communities, 1992). 
It should be noted that the legislative term is a Package Leaflet or PL. However 
researchers and practitioners in the UK generally use the term Patient Information 
Leaflet or PIL, and that will be the term used in this thesis. 
The aim of the directive was to provide a standardised format of leaflet intended for the 
patient, which would provide a high degree of consumer protection and ensure access 
to full and comprehensible information about medicines (Council of the European 
Communities, 1992). The directive came into force in 1999, from which time member 
states had 18 months to implement the directive into national legislation to ensure 
medicines were accompanied by a PIL within a 5 year transition period. 
The leaflets were required to reflect the content of the Summary of Product 
Characteristics (SmPC), which is a document required by the European Commission 
before a medicinal product can be marketed. The Summary provides a description of 
the product in terms of its chemical, pharmacological and pharmaceutical properties. 
Detailed guidance on the order and content of the PIL is provided by the Quality Review 
of Documents product information templates (QRD template) provided by the European 
Medicines Agency (Co-ordination Group for Mutual Recognition and Decentralized 
Procedures - Human, 2011). The order of the information should be: 
 Identification of the medicine 
 Therapeutic indications 
 Information necessary before taking the medicine 
 Dosage 
 Description of side effects 
 Additional information 
The information provided must be in a format that is accessible and comprehensible to 
patients. Design of the leaflet is not something covered in either the Directive or 
national legislation, but it has been stipulated that it must be written in clear and 
20 
 
understandable terms for the patient and be clearly legible (Council of the European 
Communities, 1992). The nature of what type of information must be provided has since 
been more clearly defined following the leaflets becoming mandatory. 
The introduction of PILs improved access to written information about medicines, and 
these leaflets are frequently the only written information that a patient will  receive about 
their medicines (Medicines and Healthcare Products Regulatory Agency, 2012a). 
Provision of these leaflets also responded to patients’ desire for information about their 
medicines which include information about the following: 
 Side effects 
 What it does and what it’s for 
 Dos and don’ts 
 How to take it. (Dickinson and Raynor, 2003) 
The inclusion of these leaflets in medicine packs has been shown to have some 
positive impact on knowledge and satisfaction, however, a criticism patients frequently 
made about leaflets is that they are too difficult to read and contain too much  jargon 
(Raynor et al., 2007, Ley, 1988)  
In 2005 the EU published a further directive which required that pharmaceutical 
companies undertake ‘consultations with target patient groups’  in order to ensure that 
the leaflets provided with medicines meet a specific standard which facilitates ease of 
use for the general population (European Commission, 2004) . As a result, all leaflets 
now undergo a performance-based testing process, usually the technique known as 
‘user-testing’. This is a type of diagnostic testing, concerned with finding out what is 
wrong with a document. In a user-test people who are representative of likely users of 
the medicine are recruited to read the leaflet and answer questions which measure its 
performance (Ley, 1988, Raynor et al., 2011). This Directive was designed to lead to 
the development of PILs which better meet patients’ needs for clearly written and 
presented patient information.   
Also in 2005, the MHRA commissioned a report from the Committee on Safety of 
Medicines Working Group on Patient Information called “Always Read the Leaflet” 
(Medicines and Healthcare Products Regulatory Agency, 2005a). The aims of this 
report were: 
 To advise on a strategy to improve the quality of information provided with 
medicines within the regulatory environment, in order to meet patient needs 
 To propose criteria against which the quality of patient information can be 
assessed to assure the safe and appropriate use of the medicine and the process by 
which these will all be monitored 
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 To advise on key cases which could impact significantly on public health and to 
set standards for other products. 
The report suggested a number of ways of improving the information provided with 
medicines highlighting changes to the leaflet to incorporate:  
 The use of a headline or key information section on a PIL.   
 The inclusion of more information about the benefits of the medicine. 
Consideration regarding the use of these interventions has been given a higher profile 
recently in EU pharmacovigilance proposals (European Commission, 2009).  Other 
international organisations, such as the US Food and Drug Administration (FDA), have 
also recognised the importance of providing critical drug information in a highlighted 
section of a written document and have made recommendations on moving towards 
better risk communication by striking a balance and conveying information on benefits 
as well as harms (Fischhoff et al., 2011, Food and Drug Administration, 2009). 
Currently, little is known about patient preference for, and the effectiveness, of these 
two interventions. There is need for research; to explore the potential impact of both a 
headline section and benefit information on patient satisfaction, knowledge and 
potential medicine-taking behaviour. This research aims to explore how such changes 
might be implemented in current patient information leaflets by evaluating the impact of 
including a headline section and benefit information in PILs for patients in the UK. 
 Medicines information and the empowered patient 1.3
For people to optimise the safe and effective use of their medicines  it is important that 
they receive good quality and easy to use information that informs them about their 
treatments (Raynor et al., 2007). The use of medicines is often sub-optimal (National 
Institute for Health and Care Excellence, 2009) and the role of good quality information 
is important in ensuring that patients: 
 Get the right medicine 
 Take medicines correctly (which can improve health outcomes) 
 Take medicines safely 
 Reduce wastage (Picton and Wright, 2013). 
Providing patient information can fulfil several distinct roles. In an analysis of published 
discourses on patient information leaflets Dixon-Woods (2001) described patient 
information leaflets as being developed with systematic differences depending upon the 
discourse from which they originated. The two different discourses described are: 
 Patient education 
 Patient empowerment. 
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The dominant discourse on the role of patient information leaflets has been described 
by Dixon-Woods (2001) as grounded in patient education. The patient education 
approach is biomedical in origin and it tends to use patient information as a means of 
educating the patient from a health professional perspective, rather than from a patient 
perspective (Dixon-Woods, 2001).  
The patient education approach presumes that the purpose of the leaflet is to reinforce 
the values and views of the healthcare professional. PILs are frequently being viewed 
as something that can compensate for patients’ inadequacies in knowledge, 
understanding and medicine-taking behaviour. The goal of information provided for the 
purpose of patient education is to improve adherence to medicines. According to this 
discourse patients are frequently viewed as incompetent, non-compliant entities that 
need educating about medicines in order to achieve the desired effect of adherence to 
medicines (Dixon-Woods, 2001). 
However, in recent years there has been a shift away from what might be termed 
paternalistic concepts of compliance and adherence to medicines. Healthcare providers 
are now encouraged to facilitate shared-decision making with patients and use 
information to support patients making informed-choices, as opposed to educate about 
compliance with treatments (Charles et al., 1997). Consequently, the concept of 
adherence, and the ways in which healthcare providers address it, has changed and 
this in turn has impacted upon the role of medicines information. 
Non-adherence to medicines is no longer viewed as something which arises from 
patient incompetence or non-compliance, but instead is viewed as a normal state of 
being which is influenced by multiple factors such as patient knowledge, beliefs and 
concerns about medicines and perceptions of treatment and health (National Institute 
for Health and Care Excellence, 2009, Horne et al., 1999).  
Using this approach the role of medicines information should be to focus less on 
education and more on patient empowerment with an aim to provide information that 
facilitates informed choices. This helps patients develop their knowledge and 
understanding about medicines whilst addressing any concerns associated with the 
medicine in an accurate and balanced way.   
Dixon-Woods describes ‘patient empowerment’ as an approach that views patients as 
“experts in their own needs or preferences” (Dixon-Woods, 2001). This approach 
acknowledges that patients may have difficulties in understanding complex medical 
information, but views them as competent with engaging with information according to 
their own beliefs and experiences. The aim of patient empowerment is to “build up the 
capacity of patients to help them become active partners in their own care, to enable 
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them to share in clinical decision-making, and to contribute to a wider perspective in the 
health care system” (van den Berg and Donyai, 2010). 
As perspectives on engaging patients in medicine-taking have changed over the years, 
so has the role of the patient information leaflet. Initially the PIL was instructional 
information about medicines designed to educate patients. However, initial PILs were 
often full of jargon and as something to protect the manufacturers, rather than to 
support the patient with their medicine-taking. As a result leaflets were subject to a 
great deal of criticism regarding the quality of the information they included (Raynor et 
al., 2007).  
An increased interest in creating PILs which meet the needs of patients over the last 
decade has meant that the potential users of medicines are now actively recruited in 
order to test the design and readability of the leaflets to ensure that they meet patients’ 
needs. There has also been a body of research developing the best methods of 
communicating written information about medicines (Nicolson et al., 2009, Grime et al., 
2007, Raynor et al., 2007). From this research it is apparent that patients want 
medicines information that provides sufficient detail to enhance their understanding 
about medicines; also that written information should not be a substitute for spoken 
information from healthcare professionals (Grime et al., 2007). It is apparent that 
patients’ desire information that can help them make decisions about their treatments, 
both when initially prescribed a medicine and also throughout the course of their 
treatment.   
Research undertaken recently has highlighted the desire for information about the 
benefits of medicines which needs to be provided to balance the information about the 
potential harms of the medicines (Hamrosi et al., 2012). Also there is evidence of a 
growing desire for medicines information to be tailored to an individual’s personal needs 
in order to facilitate decision-making using targeted information (Dickinson et al., 2013). 
The information landscape continues to change and patients are increasingly becoming 
interested in having information that meets their specific needs and which helps provide 
them with knowledge about a medicine, rather than information which is purely 
prescriptive. The EU has responded to patient need for high quality information by 
mandating the user-testing of leaflets to ensure they are written in a manner 
comprehensible to the layperson. User-testing is a type of diagnostic testing that 
focuses on the layout and wording of PILs, however does not necessarily address 
issues with content and the scope of the information provided.  Improvements have 
been made to the leaflets as a result, although common criticisms of leaflets remain and 
user-testing can only respond to patient need and preference to a limited amount. PILs 
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are still viewed as too lengthy and full of jargon. Patients desire information that is clear 
and reliable, which they can use to help make decisions about treatments. In order to 
make decisions about treatments patients need good quality information which they can 
easily read and understand and they also need information about the likelihood of 
benefit and risk of harm presented concomitantly in the leaflet.  
The idea of a headline section is something which is designed to respond to the 
challenges that patients have to face when reading a PIL which they may view as 
complex and lengthy. The inclusion of information about the benefits of treatment will 
ideally provide balance and enhance positive judgements about medicines (Bersellini 
and Berry, 2007b). 
 Headline section background 1.4
A headline section is an adaptation, suggested by the MHRA report as something that 
might be used to address some of the concerns that patients express about the length 
and complexity of PILs. These concerns can be a disincentive for patients to read the 
PIL (Medicines and Healthcare Products Regulatory Agency, 2005a). It is known that 
not all patients read the PIL and that some only read part of the leaflet and therefore 
might miss out on reading important information about their medicine. Research 
measuring the proportion of patients who read a PIL has shown varied findings. Lower 
proportions of readership, at 40%, were reported by Raynor and Knapp (2000) 
compared to higher proportions of 89% reported by Vander Stichele et al (1991).  
The inclusion in a PIL of a headline section has been considered as something which 
might address this. A headline consists of a summary of the key messages on the safe 
and appropriate use of the medicine.  It should be presented at the beginning of the PIL 
in order to maximise visibility and the likelihood of it being read (Medicines and 
Healthcare Products Regulatory Agency, 2005a) 
A headline section could be presented in a number of different ways with the key 
information being highlighted using techniques such as bold, italics, large or small type 
or the use of boxes and outlines.  The following type of information has been suggested 
as having potential for inclusion in a headline section. 
 Why the patient should take the product 
 The maximum dose of duration of treatment 
 Potential side effects/ withdrawal reactions (symptoms to look out for, especially 
for common or serious side effects) 
 Contraindications 
 Important drug interactions 
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 Circumstances in which the drug should be stopped 
 What to do if the medicine doesn’t work 
 Where to find further information. 
 
 
Figure 1: MHRA example of a headline section using an outlined box. 
 
The use of a headline or summary section in written instructions is not a widely 
researched area.  There is a small amount of literature which suggests that a summary 
in text can be useful to aid patient recall of information (Hartley and Truman, 1982, 
Hartley, 2004) However there are some concerns that the use of certain techniques, 
such as boxes and outlines can separate the information from the main body of text and 
this can impact negatively upon a reader’s comprehension. Hartley suggests that there 
is little evidence for these concerns, but the use of boxes and outlines remains 
controversial (Hartley, 2004).  
The MHRA gives no specific guidance on techniques to summarise key information, 
suggesting only that it should be at the beginning of the leaflet and that it should contain 
bullet-pointed information about key safety messages (Medicines and Healthcare 
Products Regulatory Agency, 2005a). Little is known about patient preferences for 
format of a headline section and whether the addition of this adaptation will encourage 
those who usually do not read PILs to access more information about their medicines. 
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This research aims to address this gap in the evidence-base and evaluate whether 
patients can find and understand key safety messages presented in this way. 
 Harm information background 1.5
While there is little research into the most effective method of presenting a headline 
section, in comparison the field of risk communication is well studied. There is a large 
and diverse research-base exploring the presentation of information about harms and 
benefits to patients, although the research-base examining the impact of presenting 
the benefits of treatments is smaller. 
Patient information leaflets currently contain both textual and numerical descriptions of 
the possible harms associated with taking the medicine.  The provision of this 
information is important for a number of reasons. Firstly it informs patients about the 
potential adverse effects of their treatments for which they can identify and seek help if 
needed. It is also important to assist them in making informed decisions about whether 
to take the treatment (Knapp et al., 2001, Knapp et al., 2009a). 
The risk of harm described in a patient information leaflet relates to the likelihood of 
experiencing a side effect from taking the treatment. In order to communicate the 
potential for harm the European Union initially recommended use of qualitative 
descriptions (also called ‘verbal terms’) for five bands of risk, ranging from very rare 
(affecting < 0·01% of the population), to very common (>10%) (European Commission, 
1998). 
Patients value information about the side-effects of their treatments, and side-effect 
information is frequently cited as the most important information that patients wish to be 
told. However, research has shown that these frequency descriptors can lead to over-
estimations of risk estimates (Berry et al., 2003b). This may in turn lead to patients 
making decision about their medicines which are not based on accurate assessments 
of the information.  
In their document ‘Always Read the Leaflet’, the MHRA acknowledge that patients 
express concerns after reading about the potential side effects of the medicine. They 
suggest the possibility of the inclusion of additional ‘positive’ information in a PIL as 
means of providing more balance in a leaflet which in turn could minimise these 
concerns. This has been subsequently referred to as ‘benefit’ information. 
Patients are limited in their ability to make informed decisions due to the lack of 
information available on both the risk of harm and the likelihood of benefit (Peters et al., 
2014). Both are needed to support patient decision-making and initially this thesis 
aimed to assess inclusion of improved information about both risk and benefit 
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information.  However a decision was made to narrow the focus to information about 
benefits alone for the following reasons: 
1) There is a large field of research on the presentation of harm information, 
including good quality systematic reviews (Akl et al., 2011a, Waldron et al., 
2011). There has been no similar ‘systematic’ collation of the research on 
benefit information. 
2) PILs already contain information about risks but little about benefits. As patients 
want balance, it can be argued that there is a greater need to research best 
methods of presentation of benefit information in a PIL. 
 Benefit section background 1.6
Patients want both information about the risk of harm and the likelihood of benefit 
presented in medicines information, although as the previous section highlights, 
previously patient information leaflets were only mandated to include information about 
the potential harms of a treatment (Raynor et al., 2007). There are fewer studies that 
focus upon the provision of benefit information to patients, when compared to those 
with a focus on the presentation of risk of harm, and these suggest a mix of 
consequences associated with presenting benefit information to patients.   
Some studies have shown that presenting benefit information has a positive effect upon 
patient judgement and intention to take a medicine (Bersellini and Berry, 2007b, Amery, 
1999). Others have found that patients are more influenced by information on the 
adverse effects of medicines, rather than the benefits (Fried et al., 2011). It has been 
shown that there can be significant concerns associated with the provision of benefit 
information to patients. Previous work to which the author contributed found that the 
provision of benefit information provoked strong feelings of shock and anxiety when the 
benefits of an anti-platelet medicine were presented to a representative sample of 
medicine-users from both the UK and Australia (Hamrosi et al., 2012). 
There is no agreed definition of what benefit information encompasses. Benefit 
information tends to refer to information about how the medicine works and how 
effective it is.  In ‘Always Read the Leaflet’ the MHRA describe benefit information as 
additional information that describes the positive effects of taking a medicines and 
refers to several key points it might include: 
 Why it is important to treat the disease and what the likely clinical outcome 
would be if the disease remained untreated; 
 Whether the treatment is for short term or chronic use; 
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 Whether the medicine is being used to treat the underlying disease (i.e. 
curative) or for control of symptoms. If the latter, which symptoms will be 
controlled and how long the effects will last; 
 Whether the effects will last after the medication is stopped; 
 Where the medicine is used to treat two or more discrete indications, all should 
be succinctly described as above; 
 Where to obtain more information on the condition. 
Figure 2 shows an example provided by the MHRA which presents such additional 
textual information about the benefits of a medicine. The MHRA state that any 
additional information must be compatible with the Summary of Product Characteristics, 
be useful to the patient and not be promotional (Medicines and Healthcare Products 
Regulatory Agency, 2005a). 
Without benefit information 
PRODUCT contains beclometasone propionate which is one of a group of medicines 
called corticosteroids. These have an anti-inflammatory action and are used to treat 
asthma. 
 
With benefit information 
PRODUCT contains beclometasone propionate which is one of a group of medicines 
called corticosteroids, or “steroids”. Corticosteroids prevent attacks of asthma by 
reducing swelling of the air passages and are sometimes called “preventers”. You 
should take this medicine regularly every day even if your asthma is not troubling you. 
Using PRODUCT can help prevent severe asthma attacks which sometimes need 
hospital treatment and if left untreated could even be life-threatening. 
This medicine should not be used to treat a sudden asthma attack; it will not help. You 
will need to use a different inhaler (“reliever”) to deal with these attacks 
 
Figure 1: An example of benefit information as provided in 'Always read the 
Leaflet'. 
There is no agreed best format for the presentation of this type of positive information. 
In addition it does not encompass numerical benefit information – how likely a person 
taking the medicine is to benefit personally. This contrasts with the fact that currently 
PILs are required to contain numerical information about the potential harm a medicine 
might cause, which is displayed as information on side effects.  Alongside this are 
criticisms of current PILs that they do not achieve a balance in providing patients with 
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facts about their medicine and are too negative with insufficient information on the 
benefits of the medicine (Raynor et al., 2007).The MHRA has recommended 
consideration be given to the inclusion of ‘positive’, benefit information in PILs in order 
to address this (Medicines and Healthcare Products Regulatory Agency, 2005a). 
A major challenge of risk communication is that it is complex. Patients are vulnerable to 
‘innumeracy’ and can misinterpret both textual and numerical information depending 
upon its format; different methods have been associated with over-estimations of risk 
and have been found to be ‘biasing’ (Gigerenzer, 2002, Knapp et al., 2009c, Berry et 
al., 2004, Carling et al., 2008, Goodyear-Smith et al., 2011, Berry, 2006). It is unclear 
which method of numerical presentation is most effective at communicating benefits to 
patients when presented in a written format.  
Further research is essential to identify the most useful formats for communicating 
benefit information and to assess the impact of making changes in this manner to 
regulated PILs on patient knowledge and understanding and health-related behaviours. 
  The rationale of the research and expected outcomes 1.7
The primary purpose of this study is to improve the quality of written information about 
medicines, by developing evidence-based changes to written medicines information 
that incorporate the suggestions made above. The key objective is to explore how the 
users of medicines view the addition of a headline section and benefit information in 
their PILs and produce recommendations about   how to present key safety messages 
in a headline section and information about benefits in a balanced format that patients 
find usable. 
The motivation behind the research is to support patients to make informed, 
autonomous decisions, and help them get the most out of their medicines. It fits within 
the remit of the NHS White Paper which aimed to put patients first and states ‘no 
decision about me without me’ (Department of Health, 2010).  As a result the patient will 
be placed at the focus of the research as participants, but also as assessors of the 
readability and usability of the PILs which will be developed. This will be done through 
the process of user-testing, which assesses the performance of a written document 
(Raynor et al., 2011, Raynor, 2008).  
The project aims to build up an existing base of knowledge in the two fields of:  
1) information design, specifically with regards to the headline section and;  
2) harm/ benefit communication.  
The research aims to investigate how the inclusion of benefit information might impact 
upon a patient’s knowledge, understanding and future health behaviours.   
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The expected outcomes of the research are the development of evidence-based PILs 
containing changes to format and content, a deeper insight into patient preferences 
about the use of a headline section and benefit information and the ways that these 
impact upon health-seeking and information-seeking behaviour. The research will also 
test the potential of providing this information to patients for the first time and assess 
understanding and behavioural intentions and whether this can impact upon the safe 
and effective use of medicines.   
  Research aims and objectives 1.8
  Research question 1.8.1
What is the impact of the inclusion of a headline section and information about 
the benefits of medicines in patient information leaflets on patients’ satisfaction 
and potential understanding and medicine-taking behaviour? 
  Research aims 1.8.2
 To investigate methods for the presentation of a headline section in a regulated 
PIL. 
 To investigate methods for the inclusion of information about benefits in a 
regulated PIL. 
 To explore patient preference for a headline section and information about the 
benefits of medicines. 
 To explore how the inclusion of both headline and benefit information in a 
regulated PIL can impact upon patient knowledge and understanding of 
medicines. 
 To explore the impact of the inclusion of both a headline section and benefit 
information on potential medicine-taking. 
An initial aim of the research was to investigate the effect of combining the headline 
section with the benefit information into one adaptation. As the research progressed it 
was apparent that participants responded to the two adaptations differently and that 
these differences made it difficult to research the effect of combining benefit information 
in a headline section within the timescale of the work. As a result an investigation of this 
has not been included as part of the over-arching aims of the work.  
The thesis presents 5 empirical studies. They are as follows: 
Chapter two describes 2 literature reviews which were conducted concurrently and 
which review the breadth and depth of the literature on the optimum methods of 
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presenting information in a headline section and the presentation of information about 
benefits in written medicines information. 
Chapter three presents the findings from a focus group study which explores the 
opinions and attitudes of users of medicines on the inclusion of both a headline section 
and information about the benefits of medicines. This chapter focuses upon preference 
for format and explores the potential impact on self-reported knowledge and medicine-
taking behavior with the aim to identify the range of response that the interventions 
provoke. 
Chapter four reports the use of ‘user-testing’ to explore how readers use a headline 
section in a PIL in a scenario-based test of the finding and understanding of key 
information. 
Chapter five reports a survey of 100 PILs currently in circulation in the UK. The aim of 
this chapter is to determine the extent to which information about the benefits of 
medicines is currently included in a regulated PIL. 
Chapter six describes the final study, an exploration of the impact of the provision of 
benefit information on the attitudes and beliefs that real-life users of medicines hold 
about their treatments. This study recruited patients receiving a prescription for 
simvastatin and used semi-structured interviews to explore preferences for format, 
understanding and the potential impact on behaviour. This study aimed to highlight 
whether there were any differences between the opinions and attitudes of those 
receiving hypothetical information and those receiving benefit information about the 
medicines which they were already using.  
  Funding and support for the PhD studentship 1.8.3
The research was supported by the Academic Unit of Pharmacy, Radiography and 
Healthcare Science, University of Leeds and by the UK medicines regulatory body, the 
Medicines and Healthcare Products Regulatory Agency (MHRA).  The MHRA has a role 
in regulating the quality of the information provided with patient information leaflets. The 
Academic Unit of Pharmacy, Radiography and Healthcare Science, University of Leeds, 
has a track record in undertaking research into medicines information.  
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Figure 2: The structure of the thesis. 
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Chapter 2: 
Scoping Literature Review 
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  Scoping literature reviews. (Study 1) Chapter 2
What does published research tell us about the inclusion of a headline 
section and the inclusion of information about benefits in written medicines 
information? 
 
  Introduction  2.1
Chapter two reports two scoping literature reviews undertaken to explore the published 
research on both the inclusion of a headline section and the inclusion of information 
about the benefits of medicines in written information.  
This chapter describes the methods used to undertake the literature reviews and 
presents a narrative description of the findings of the literature collated. The ultimate 
aim of the review is to identify potential formats that can be used in the later stages of 
the PhD to develop leaflets which contain a headline section and information about the 
benefits of medicines. The chapter is presented in 4 sections: 
 [1] The methods of the review. 
 [2] Findings: The use of a headline section in written information. 
 [3] Findings: Information about the presentation of the information about 
benefits in written information. 
[4] Application of findings to later studies in the thesis.  
The aim of this review is not specifically to critically appraise the body of research but 
instead to collect and collate a range of options that have the potential for use in the 
later stages of the research. However, a critical evaluation will be part of the review and 
each study will be evaluated using a generic critical appraisal tool. The aim of such 
critical appraisal is to provoke discussion on the quality of the research in the field, 
rather than be used to define the inclusion of research into the review (Long et al., 
2002).  
The final part of this chapter will present the conclusions of the review and make 
recommendations about the options that have the most potential for presenting both a 
headline section and information about the benefits of medicines in PILs that can be 
used in the next stages of the research.   
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 Aims and objectives 2.2
[1] Headline section 
Aims 
 To undertake a scoping review to identify published research on the 
presentation of a ‘headline’ section. 
Objectives 
 To identify the extent, range and nature of the research on the use of a headline 
section to summarise key points of information within a piece of information. 
 To summarise the different methods for presenting a ‘headline section’ and the 
potential impact on the reader’s ability to find and understand key information.  
[2] Benefit 
Aims: 
 To undertake a scoping literature review to identify the best techniques for 
presentation of information on potential benefits in written health 
communications that can be replicated in a patient information leaflet. 
Objectives: 
 To identify the extent, range and nature of the research on the presentation of 
information about benefits in health communications that can be replicated in a 
patient information leaflet. 
 To explore the different methods and formats of benefit presentation 
 To collate and summarise key findings on the best ways to present benefit 
information in health communications that be replicated in a PIL. 
 To explore the impact different methods of benefit presentation might have on 
satisfaction, knowledge and potential medicine-taking behaviour. 
Overview of Method 
A scoping literature review was undertaken using the framework developed by (Levac 
et al., 2010) and building upon the methods described by Arksey and O’Malley 
(2005).The method is suited to the appraisal of a body of studies which focus on a 
similar topic but use different methods. 
The method differs from a traditional (systematic) review, as it is based on an iterative 
and interpretative approach to the collection and collation of the literature as opposed to 
a more rigid process which apply pre-determined criteria of methodological quality to 
the literature. The aim of this review is not to evaluate efficacy or effectiveness, but 
instead to “map the range and scope of the literature and explore its utility and 
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importance based upon the relevance, credibility and contribution of evidence” (Davis et 
al., 2009, P.1389). 
Although a scoping literature review differs from a systematic review in several ways, it 
also shares several similarities, for example the requirement for the review to be 
conducted in a rigorous and transparent way.  A well-executed scoping review requires 
a framework that is well-defined and robust.  In order to ensure that the methods of the 
review were rigorous and transparent a framework defined by the Centre for Reviews 
and Dissemination was applied (Centre for Reviews and Dissemination, 2009). This 
framework uses core principles which can be applied to the review to facilitate rigour 
and transparency in its various stages. The framework describes the structure of a 
review which includes the following stages: developing a search strategy; defining 
inclusion criteria; identifying the research evidence; selecting the studies; extracting the 
data; assessing the quality of the studies and synthesising data to present a coherent 
narrative of the scope and range of literature. These stages are applied here to the 
fields of the headline section and benefit information presentation. 
 Search strategy 2.3
A search strategy was developed with the assistance of health librarians and an 
information design expert (BP). Search terms were developed and combined MeSH 
headings and Boolean operators to expand and refine the review topics (see appendix 
1 for the combination of search terms used). Two searches were developed, one for 
headline and one for benefit and which were run concurrently.    
A range of different resources were searched including medical databases and peer-
reviewed journals in the fields of pharmacy and information design (see table 2). Only 
English language papers were retained. The literature searches were run over a period 
between 24.04.11 and 13.06.11.   
Electronic databases: 
 CINAHL 
 MEDLINE 
 The Cochrane Library 
 EMBASE 
 Web of Science 
 PsychINFO 
Theses databases: 
 ProQuest (Dissertation and Theses database) 
37 
 
 Index to theses 
Reference Lists: 
 Key papers were searched to help refine the search strategy.  The reference 
lists of all included papers were assessed for their relevance. 
Relevant Journals 
The contents table of the following journals were searched for potentially relevant  
literature. 
 International Journal of Pharmacy Practice 
 Information Design Journal. 
  Study selection 2.3.1
For both the headline section and the benefit section there were several phases of data 
selection. Criteria for each phase were developed iteratively and refined in light of the 
results of the search, based on familiarity with the research.   
The different phases for each part of the literature review are described below. The 
initial screening was undertaken by one reviewer (RD).  However, two reviewers (RD & 
DKR) screened all the full text papers for relevance and eligibility to the study according 
to the refined inclusion criteria.  Differences of opinion were discussed until consensus 
was reached. 
  Phases of study selection for headline section 2.3.2
Phase one  
Initially references were screened for relevance by viewing the title and, where the 
scope of the paper was unclear, abstract. Papers were required to meet at least one of 
the criteria for inclusion to be included in phase two. Criteria for inclusion: 
The use of a Headline section to present key information: 
 Does the paper refer to a method of presentation of key/ summary/ important 
information in written information? 
 Does the paper refer to instructional design of written information?  
 Does the paper refer to the use of boxes and outlines, (occasionally referred to 
as boxed-asides (Hartley, 2004)) or similar technique to convey information?  
 Does the paper refer to the use of a warning sign or the presentation of hazard 
information within a body of text?  
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Phase two 
A mechanism to eliminate studies that did not relate to the original search question was 
designed. The inclusion and exclusion criteria were devised and refined iteratively, 
depending upon the studies that were retrieved during the first stage of the literature 
search, based on an increasing familiarity with the data.  There followed a process of 
sifting of the data where the inclusion and exclusion criteria were applied to each 
abstract title in order to evaluate relevance. 
Table 1: Inclusion/ exclusion criteria for phase two of the scoping review. 
Headline Include Exclude 
Type of study All primary empirical  
Research 
Opinion, discussion 
articles 
Population of  
Interest 
Information for patients or consumers Information for  
Experts 
Intervention Use of summary section / boxed aside/ 
headline to communicate key 
information in written information 
 
 
Phase three 
The next phase of study selection involved a more detailed process for examining 
the relevance of the papers.  Full copies of each text were obtained. (When copies 
were unavailable the first author was contacted for further information).  
The full text article was read and a decision made about inclusion into the scoping 
review.  The criteria used can be viewed in table 2. 
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Table 2: Inclusion/ exclusion criteria for phase three of the scoping review. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Phases of study selection for benefit section. 2.3.3
The initial search was run in Medline  The original search terms (see appendix 2) were 
very broad and there was a lack of precision in the definition of terms which led to the 
retrieval of large numbers of irrelevant references (England, 2000, Anonymous, 2003).  
For practical reasons the search strategy was revised and additional limits imposed.  
The search was limited to references after 1984, a date set after the publication of a key 
paper in this field (George, 1983).  
Large numbers of references were initially identified and, even after limiting the search, 
approximately 60,000 references were searched. Advice was sought on managing the 
Types of studies 
 Empirical qualitative or quantitative primary research, or systematic 
reviews. 
 (Exclude non-empirical research) 
Population of interest 
 Patients, general public  
 (Exclude information intended for practitioners such as doctors etc.) 
Types of interventions: Include 
 Presentation of a summary of the most important points of information in a 
document 
 Use of a method of highlighting such as a box or shading to present key 
information. 
 Attention to the order of key information within an instructional document. 
Types of interventions: Exclude 
 Use of ‘data boxes’ for example in computer programming 
 Interventions that cannot be replicated in a patient information leaflet 
 Labels, signs and warnings 
Types of outcome measure (papers to meet one or all of the criteria) 
 Understanding of information  
 Readability 
 Knowledge of treatment effects – recall of information  
 Satisfaction with medicine (treatment)  
 Decision-making (promotion of informed decision-making)  
 Adherence to medicines (treatment) – changes to medicine-taking 
behaviour 
 Cost 
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volume of references.  Tools such as the de-duplication facility don’t work on large 
numbers of references, therefore it was not possible to export reference lists in their 
entirety into reference managing tools in order to perform de-duplication processes.  In 
consultation with a health librarian (Mark Clowes) a number of smaller searches with 
less breadth were developed.  Methods of searching such as (bracketing terms) and 
using the adj3/ SAME function to provide precision were utilised.  These searches were 
run adjacent to keyword searches already identified. The refined search strategy was 
used to search the remaining databases (see appendix 3).  
The adoption of such limits in a search has the potential to exclude relevant papers.  
However, for practical reasons, it is sometimes essential to take this risk.  The limits 
reduced the number of references retrieved, however significant numbers of articles 
were still identified and the number of papers assessed as relevant.  Within a scoping 
review it is acceptable that decisions are made about the length of time span and 
language and imposed iteratively. A scoping review is not a linear process, but instead 
requires the researcher to reflect on each stage and adapt the search as required 
(Arksey and O'Malley, 2005). 
Initially the study aimed to assess inclusion of improved information about both risk and 
benefit information.  However the volume of the research on risk information was too 
large to search within the time constraints of the study a decision was made to narrow 
the focus to information about benefits alone. 
As a result there were four phases of data selection. Criteria for each phase were 
developed iteratively and refined in light of the results of the search based on familiarity 
with the research.   
Phase one  
Initially references were screened for relevance by viewing the title and, where the 
scope of the paper was unclear, the abstract. Criteria for inclusion were: 
 Does the paper refer to presenting, communicating, informing or educating 
patient about harms, risks, or examine patient perceptions of harms and risk? 
 Does the paper refer to presenting, communicating, informing or educating 
patient about risks, or examine patient perceptions of benefit? 
 Does the title make reference to a specific method of communication about 
risks, for example use of graphical display, icon array, presentation of 
probability? 
 Does the title make reference to a specific method of communication about 
benefits, for example the Number Needed to Treat (NNT) statistic? 
 Does the title make reference to framing of risk? 
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Phase two 
A mechanism to eliminate studies that did not relate to the original search question was 
designed.  Inclusion and exclusion criteria were devised (although to some extent these 
were refined post hoc based on increasing familiarity with the data).  The next phase of 
data sifting employed the application of the inclusion and exclusion criteria to the 
abstracts of these papers that had been identified as potentially relevant by title alone. 
Table 3: Phase two criteria for benefit information 
 
 
 
 
 
 
 
 
 
 
 
 
 
Risk-benefit Include Exclude 
Type of study All primary empirical research 
 
Opinion, discussion articles 
Population of interest Patients, general public Healthcare professionals 
 
Intervention Presentation of risk information 
(side effects/ harms/ adverse 
events) 
Presentation of harm information 
in any format  
Presentation of benefit 
information (effectiveness 
information such as NNTs, 
efficacy data) 
Framing of risk information 
in written information 
Verbal communication of risk 
alone 
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Table 4: Inclusion/ exclusion criteria for phase three of the scoping literature 
review - Benefit. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Types of studies 
All empirical qualitative and quantitative primary research.  Systematic reviews. 
(Exclude non-empirical research) 
Population of interest 
Patients, general public  
(Exclude information for specialists such as Doctors etc.) 
Types of interventions: Include 
 Presentation of patient outcome measures such as mortality 
 Presentation of numerical risk/ benefit data such as absolute risks, relative 
risks, numbers needed to treat, natural frequencies 
 Diagrams, graphics and charts 
 Use of patient narratives and vignettes  
 Framing (loss or gain) 
Types of interventions: Exclude 
 Spoken presentation of risk (for example during consultation) 
 Educational programmes of risk education 
 Techniques to calculate and present individualised risk 
 Interventions that cannot be replicated in a patient information leaflet 
 Computer formatted risk presentations such as interactive web based graphics. 
 Decision aids and risk calculation tools 
 Interventions where the explicit intention in the paper is to persuade, promote 
or increase adherence to or participation in health-related behaviours.  
 Diagrams, graphics and charts 
 Alternative graphic displays for example visual analogue scales and icon arrays 
(20 papers with a focus on graphical presentations of benefit were initially 
retrieved however, these were excluded later on in the review) 
Types of outcome measure 
 Understanding of information  
 Readability 
 Knowledge of treatment effects – recall of information  
 Satisfaction with medicine (treatment) decision-making (promotion of informed 
decision-making)  
 Adherence to medicines (treatment) – changes to medicine-taking behaviour 
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Phase Four 
The following criteria were used to eliminate papers with a focus on risk or harm: 
Table 5: Refining the review from risks and benefits to risks 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In order to ensure the transparent reporting of the process involved in the review, the 
PRISMA flow chart was adopted to record the flow of information, and the number of 
references searched for each phase of the review (Moher et al., 2009). See Figure 4 for 
the PRISMA flow chart. 
 
 
Include: Benefit Information 
Papers that assess the impact of:  
 presenting survival figures, such as survival curves and graphs 
 Treatment effects for example the outcome of choosing a surgical 
procedure or medicine.  This also includes treatment risk reduction 
 Screening effects 
 Information about interventions that lead to a postponement of, or a 
reduced likelihood of an adverse event. 
Include papers about the presentation of generic risk/ benefit information.  
These are papers that assess a specific technique as opposed to a specific 
type of numerical data. For example the comparison of an icon array to a bar 
chart. The comparison of an (in full) ARR to an RRR or a probability with no 
context as to what the figures entail – these papers test numeracy to some 
extent. 
Exclude: Risk Information  
Papers that assess the impact of only: 
 The presentation of information about side effects 
 The presentation of mortality figures 
 The presentation of information about the risk of disease 
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Figure 3: PRISMA diagram to show the flow of the scoping literature review.
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  Collating and summarising results 2.3.4
Headline: From a search of 8,702 initial references, 3 papers were included in the 
narrative synthesis. 
Benefit: From a search of 64,838 initial references, 87 were included in the narrative 
synthesis.  
Meta-analysis was not possible due to the heterogeneity of the retrieved research in 
these fields. Instead a descriptive synthesis using the narrative synthesis methodology 
was undertaken.  
 “A narrative synthesis refers to an approach to the systematic review and synthesis of 
findings from multiple studies that relies primarily on the use of words and text to 
summarise and explain the findings of the synthesis”  (Popay et al., 2006, P.5).  
The strengths of a narrative synthesis in this context include:  
 It is appropriate when the data are heterogeneous and when meta-analysis is 
not possible, or not the focus of the review.  
 It provides a systematic and structured framework to the process which is 
transparent and replicable. 
In order to collate the retrieved data, a data collection form was developed.  The form 
was designed to replicate that used in Cochrane systematic reviews (Higgins and 
Green, 2001). This is a widely used format, which is commonly understood and 
presents the essential key findings of a research study (see appendix 4).   
The retrieved literature was organised according to different categories and sub-
categories and these were evaluated for common linkages, themes and findings. 
Attempts were made to form groupings and clusters, for example on groups of 
participants such as age, or on research designs or interventions. The results are 
presented as a narrative description.  
 Study quality assessment 2.4
Although the scoping literature review method does not specifically set out the 
requirement for an in-depth assessment of study quality, the studies retrieved were 
evaluated for quality using a generic research appraisal tool (Long et al., 2002). This 
critical assessment was used to illuminate the findings as opposed to being used to 
determine inclusion or exclusion of the research article into the review.  
The findings are presented in two sections; headline and benefit. The benefit 
information section contains several sub-categories which present the range of formats 
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of benefit information and how the research identified impacted upon issues such as 
knowledge, behaviour.  
 Study findings: Headline section 2.5
 General findings 2.5.1
The initial screening (phase 1) identified 86 potentially relevant papers. These were 
screened by abstract (phase 2) with 19 papers included for screening by full-text (phase 
3).  Three papers met the inclusion criteria and were included.   
Two of these papers used a similar headline method, called a Drugs Facts Box, which 
used a tabular format to summarise numerical information. (Schwartz et al., 2007, 
Schwartz et al., 2009) 
Dolk et al. (2011) used a headline section as described by the MHRA (Medicines and 
Healthcare Products Regulatory Agency, 2005a).  This was a highlighted section 
containing key safety information in a textual format and was presented within a body of 
text (Dolk et al., 2011). 
The studies used different methods to evaluate the impact of the headline section.  
Schwartz et al (2007) recruited a convenience sample (n=274) into a cross-sectional 
survey which aimed to evaluate whether participants could use and understand a Drugs 
Facts Box.  Schwartz et al. (2009) undertook 2 randomised controlled trials to test 
whether the Drugs Facts Box improved knowledge and judgements about medicines in 
comparison to a direct-to-consumer (DTC) drug advert. One trial recruited 231 people 
into a ‘symptom’ drug box arm and the second, 219 people into a ‘prevention’ drug box 
arm. Dolk et al. (2011) recruited 80 participants to evaluate the value of a headline 
section on the perception and effectiveness of a PIL using user-testing. 
 Impact on ability to find information 2.5.2
There is no evidence to show that a headline section impacts positively or negatively 
upon people’s ability to find information. Research into the Drugs Facts Box did not 
assess this.  Dolk et al. (2011) looked at whether patients could find the information and 
reported that the headline section did not have an impact on the participants’ ability to 
locate information. 
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 Impact on understanding of Information 2.5.3
Dolk et al (2011) compared a regulated PIL with or without a headline section and found 
that the information presented was comprehended as well with or without the headline 
section present. However, the sample size was small and real differences may have 
been undetected.   
Schwartz et al. (2007) found that the Drugs Facts Box aided the retrieval and 
understanding of risk and benefit information.  Most participants were able to use the 
box and retrieve information to answer the questions set.  The authors reported a 
positive correlation between participants’ understanding of the information and their 
educational attainment.  
Schwartz et al. (2009) reported that most participants found the Drug Facts Box ‘very 
easy’ or ‘somewhat easy’ to read.  The use of the Drugs Facts Box was associated with 
a decreased perception of the magnitude of side-effects.  With regards to the benefits of 
the medicines, the Drugs Facts Box promoted an accurate perception of the 
effectiveness of each medicine relatively. It was reported that the Drugs Facts Box 
resulted in more accurate knowledge about the magnitude of side-effects because of 
the inclusion of data about the baseline risk.  
It was also reported that the use of the Drugs Facts Box improved the accuracy of 
patients’ judgements about their medicines, with participants more likely to choose 
appropriate drugs and less likely to over-estimate the benefits of the treatments.   
Overall, the use of headline section did not negatively impact upon the understanding 
the participants had about their medicines.  Schwartz et al. (2009) were able to show a 
positive impact upon patient understanding about their medicines.   
 Preferences for a headline section 2.5.4
There appeared to be no negative concerns about the inclusion of a headline section in 
general.  Participants stated that they felt it ‘important’ to have an included data 
summary similar to what was provided in the Drugs Facts Box (Schwartz et al., 2009). 
Participants expressed strong positive opinions about the headline section within a PIL; 
however there was little evidence that participants used the headline to locate 
information during the user-test (Dolk et al., 2011).  
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 Behavioural impact of a headline section 2.5.5
The research findings on the Drugs Facts Box suggested it might impact upon 
medicine-taking behaviour.  The research showed it could influence a patient’s choice 
so they were less likely to take a medicine after they had read and understood the 
information about the drug’s effectiveness.    It could be argued that this is attributable 
to the content of the risk-benefit information as opposed to the format.  There was no 
evidence of behaviour change resulting from the headline section in the regulated PIL, 
although this was not a primary outcome measure of that study.  
 Headline section discussion 2.6
In summary, there is little evidence to suggest that a headline section has either a 
positive or a negative effect on a participant’s ability to find and use key information, 
although only one of the papers (Dolk et al. 2011) tested this explicitly.   
Dolk et al. (2011) was well-designed and used a method appropriate to deliver the 
objectives outlined. However, there were limitations with the study design which 
potentially impact upon the strength of the findings. There was limited reporting of 
participant characteristics, specifically educational attainment.  As a result it is difficult to 
ascertain whether participants were more or less-educated than the average medicine-
user.  This raises concerns about the applicability of the findings to the general 
population. While the study found that participants did not necessarily use a headline 
section, the sample size was small (although this is common in user-testing).  As a 
result there is the possibility that the study failed to measure the positive impact of a 
headline section and that the finding that patients did not use the headline section may 
be false. More research is required in this area to ensure a false-negative result has not 
been reported.  
Neither of the Schwartz studies assessed a participant’s ability to find information in the 
headline section in the first instance.  The Drugs Facts Box had a different context to 
the headline section suggested by the MHRA, replacing text within a direct-to-consumer 
(DTC) drugs advert, which are common in the USA  (Dolk et al., 2011, Bell et al., 1999, 
Wolfe, 2002).  DTC adverts tend to be promotional rather than informational and have 
been criticised for containing incomplete data (Woloshin et al., 2001, Wolfe, 2002). In 
both studies the Drugs Facts Box was presented in isolation and not embedded within a 
body of text. This can impact on the applicability of these findings in a European setting, 
where a headline section in a mandated PIL, would be presented alongside other text.  
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There are also limitations concerning the lack of representativeness of the sample for 
both these research studies. Schwartz et al. (2007) recruited participants with above 
average quantitative skills. Consequently, this makes it difficult to extrapolate from the 
findings and apply them to a general population of medicine-users. Even with additional 
quantitative abilities many participants still could not understand the information 
provided.  This was more significant where participants were required to use the Drug 
Facts Box to work out the absolute difference in the proportion of women with breast 
cancer in the tamoxifen versus the placebo groups.  71% achieved this, which means 
29% could not.  Participants of a lower education attainment did less well using the 
Drugs Facts Box, getting more answers incorrect, although the authors concluded that 
most participants, even those with lower formal educational attainment, were able to 
understand and use the tabular data.  This has important implications when considering 
the relevance of these findings to how the intervention might be applied to the general 
population of medicine-users. 
Participants recruited to the 2 randomised trials (Schwartz et al., 2009) also had slightly 
higher educational attainment than the general population.  This might affect the 
applicability of the findings by leading to an over-estimation of a patient’s ability to use 
and understand the Drugs Facts Box.  
It must be noted that the number of people answering questions correctly was variable, 
ranging from 55%-93% correct answers.  While the Drugs Facts Box did increase 
understanding and knowledge, this was not for all participants. When evaluating the 
impact of the Drugs Facts Box in the prevention group on the understanding of side-
effects, 51% of participants correctly answered questions about side-effects in 
comparison to 16% of the control group.  While this suggests improvements in 
knowledge in comparison to the control, it is important to note that at least half the 
participants did not understand the side-effect information, even with the improved 
intervention. 
The survey assessing the outcome measures was completed in the participants’ homes 
and researchers did not observe how the participants used the information, and 
whether this was intuitive or time-consuming.  Between 52% and 71% participants 
reported that the box’s data table was “very easy” or “easy” to understand; this still 
suggests that many participants did not associate ease of use with the data-table 
presented. 
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On the whole the studies included in this review were well-designed and generally 
methodologically robust.  Flaws in their sampling strategies bring into question the 
applicability of the findings to the wider population of medicine-users.  Schwartz et al 
(2009) fail to address they key issue of whether patients could find and use a summary 
section in the first instance, and while Dolk et al. (2011) suggests that there is no 
evidence that a headline section was utilised by participants undertaking user-testing, 
the small sample does not provide strong evidence for the utility, or lack of utility, of a 
headline section. 
There is a wide range of research, including a systematic review,  which supports  the 
view that the provision of good quality information can impact positively on a patient’s 
knowledge and health outcomes (Bishop, 1996, Barlow and Wright, 1998, Macfarlane 
et al., 1997, Raynor et al., 2007).  Evidence suggests that patients value PILs, but there 
is a gap between the information that is currently provided and the information that 
patients desire (Raynor et al., 2007). Several key principles, shown to promote patient 
understanding, can be utilised to facilitate the role that good quality information design 
can have in improving the content and layout of leaflets so they better meet patient 
needs. Although these key principles do not specifically suggest the use of a headline 
section, techniques integral to such a section, including the use of bullet points to 
organise lists and short headings that stand out, are recommended in order to optimise 
engagement of the reader with the information.  
There is an argument that a section in a piece of written text such as a box or outline 
may be detrimental to the reader’s comprehension (Hartley, 2004). Thomas (1984) 
suggests that the use of a boxed-aside may ‘disrupt the flow of the running text’, which 
may lead the reader to skip over the important information.  However, there is lack of 
empirical research in this area which evaluates the utility of this technique and whether 
a headline section might impact negatively on a person’s ability to find the information 
contained within the headline text.  
Although it did not meet the criteria for inclusion in this review, there is a large body of 
research on warning design which recommends a number of basic principles to 
consider when creating warning signs. Wogalter and Vigilante (2003) notes the 
importance of getting noticed as the first requirement of an effective warning. He also 
highlights the need to pay attention to layout and placement (Wogalter and Vigilante, 
2003). The body of work evaluating the impact of warning sign design raises several 
issues. A significant proportion of the research was not directly comparable to a 
‘headline’ section, with the interventions differing in purpose and design (for example 
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much of the research focused on pictorial design, which did not meet the criteria for 
inclusion in this review). 
Dickinson et al (2010) stated that many readers need help with reading documents 
such as PILs and that highlighting key information with bold text and type size is often 
appreciated by the less skilled readers of documents. However the paper 
acknowledges the need for more research in this area (Dickinson et al., 2010). The 
current review has not included any evidence to suggest that a headline section would 
be detrimental to the users of medicines information. However, it has also not shown 
any optimal methods for the presentation of such a section nor whether this intervention 
is useful for the readers of medicines information. 
 Study findings: Benefit  2.7
 General findings 2.7.1
There was a large body of literature identified that explores the impact of different 
formats of benefit information. The findings have been organised into several different 
categories in order to provide a narrative account of the breadth and scope of the 
literature.  
For pragmatic purposes, a decision was made to report, in detail, findings which are 
most relevant to the use of benefit information in a PIL. As a result, papers which focus 
upon the presentation of formats such as graphs have not been included for a detailed 
narrative synthesis in these findings. Graphical formats of benefit presentation are not 
viewed as a technique that would be feasible for use in a PIL where space is limited – 
and as good-quality communication using graphs requires significant space. This 
review therefore focuses on the textual and numerical formats of the presentation of 
information about the potential benefits of medicines, although the research into some 
graphical formats will be discussed when the studies are compared with other formats 
relevant to the review. This is congruent with the methods of the scoping literature 
which permits selective reporting of the most relevant literature over the least relevant 
(Arksey and O'Malley, 2005). 
In total 87 studies were included for analysis: 7 of the included papers were systematic 
literature reviews, 5 had  a focus on providing probability or generic harm-benefit 
information, and 2 had a focus on the ‘framing’ of healthcare interventions. 
The primary research papers which focused upon presenting benefit information 
reported on several different methods of presentation (table 5). 
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Table 6: Type and topic of research papers included in the scoping literature 
review.  
 
The majority of the research was published since 2000.  Although the earliest 
publication date was 1989, relatively few studies were published before 2000.  The 
numbers of publications retrieved grew throughout the 2000s, with the largest number 
of papers being published in 2010 (n=18). This indicates a growing interest in the field 
of harm and benefit communication. 
 Studies of different methods of benefit  2.7.2
 Studies of textual information 
Five papers described research evaluating the provision of benefit information in a 
textual format. Three were highly relevant and focused upon the provision of a short 
written statement about medicine benefits in a patient information leaflet (Bersellini 
and Berry, 2007a, Bersellini and Berry, 2007b, Vander Stichele et al., 2002). 
These statements highlighted detailed information about the drug action, as well as 
further information about the relationship between the nature of disease and drug 
action. The studies were well-described and used different methods: a factorial 
randomised trial  (Bersellini and Berry, 2007a, Bersellini and Berry, 2007b) and a 
 
Risk-benefit Include Exclude 
Type of Study All primary empirical 
research 
 
Opinion, discussion 
articles 
Population of interest Patients, general public Healthcare professionals 
 
Intervention Presentation of risk 
information (side effects/ 
harms/ adverse events) 
 
Presentation of harm 
information in any format  
 
Presentation of benefit 
information (effectiveness 
information such as NNTs, 
efficacy data) 
 
Framing of risk information 
in written information 
Verbal communication of 
risk alone 
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parallel-groups randomised controlled trial (Vander Stichele et al., 2002). Bersellini 
(2007a & 2007b) used interventions based on recommended EU guidelines on 
medicines information.  The limitations of these studies were that they were undertaken 
with healthy volunteers and not necessarily a medicine-taking sample. 
 Studies of numerical information 
20 papers evaluated the presentation of numerical information about benefits. These 
were all quantitative studies, although one combined this with a qualitative element 
(Studts et al., 2005). The majority used a controlled-design and many were randomised. 
Predominantly surveys and questionnaires were used to collect data.  
Six studies did not have a control group. These tended to measure patient preference 
for format and presented a mix of different benefit formats, presented as summary 
statistics. (Malenka et al., 1993, Sarfati et al., 1998, Hux and Naylor, 1995, Bhandari 
and Tornetta, 2004, Studts et al., 2005, Misselbrook and Armstrong, 2001). 
The research aims were broadly similar; to evaluate the impact of format on 
understanding and intention to take a treatment. The exceptions to this were studies by 
Fagerlin et al. (2007) and Fried at al. (2011) which aimed to test whether the provision 
of comparative risk information changed risk perceptions.  
The studies that focussed upon determining the best format can be broadly grouped 
into 3 categories (a) studies examining summary statistics, (b) studies examining 
probability formats (c) studies comparing textual formats with numerical formats. 
a) Studies examining summary statistics 
Several studies examined the impact of presenting multiple summary statistics that 
represented the likelihood of an event occurring. Commonly these included the 
following: 
 absolute risk reduction (ARR) 
 relative risk reduction (RRR) 
 numbers need to treat (NNT) 
 numbers need to screen (NNS)  
 odds ratio (OR) 
 relative risk (RR) 
 events rates (ER) 
 tablets needed to take (TNT) 
 whole numbers (WN) 
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 absolute survival benefit (ASB) 
 postponement of adverse event.  
The papers were varied and used a range of methods. Three studies tested multiple 
formats against each other in randomised trials.(Carling et al., 2008, Sheridan et al., 
2003, Natter and Berry, 2005). Natter et al (2005) also compared forms of absolute risk 
and relative risk with and without baseline information, using a questionnaire-based 
study with a two-factor between-subject design to examine patient estimates of risk.  
Six papers presented multiple formats of summary statistics to participants and 
evaluated format based on preference for format and/or willingness to take the 
treatment (Bhandari and Tornetta, 2004, Halvorsen et al., 2007, Hux and Naylor, 1995, 
Malenka et al., 1993, Sarfati et al., 1998, Studts et al., 2005)  
Finally two papers presented different formats of one type of single summary statistic. 
Kristiansen et al (2002) provided different values of NNT to patients, ranging from an 
NNT of 10 to an NNT of 400 and measured intention to choose a treatment (Kristiansen 
et al., 2002). Gyrd-Hansen et al (2003) evaluated the impact of different values of ARR 
and RRR provided with baseline risks (Gyrd-Hansen et al., 2003). 
b) Studies examining probability formats 
4 studies evaluated probability statistics such as frequencies, natural frequencies or 
percentages. Commonly these included the following: 
 probabilities 
 natural frequencies 
 percentages 
 variable frequencies 
 combined formats e.g. percent and natural frequency. 
These studies used different study designs and measured different outcomes such as 
preference for format, impact of format on decision-making and ability of patient to 
make ‘trade-offs’ using the data. One experimental study compared how conditional 
probabilities and natural frequencies could improve understanding in older adults and 
people with low literacy (Galesic et al., 2009b).  
Three studies randomised participants into groups which received different types of 
probability format. Cuite et al (2008) randomly assigned participants to a variety of 
studies where participants received either ‘1 in n’, frequency or percentage formats. 
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They measured a number of different outcomes, including participants’ ability to 
undertake a variety of mathematical operations using the different formats and 
understanding of different risk level (Cuite et al., 2008). Woloshin & Schwartz (2011) 
undertook a parallel-group trial, randomising participants to receive information on the 
risks and benefits of a drug presented in 1 of 5 formats; [1] a natural frequency, [2] a 
variable frequency [3] percent [4] percent plus natural frequency [5] percent plus 
variable frequency (Woloshin and Schwartz, 2011). Finally Tait et al (2010a) measured 
the different risk and benefit trade-offs that patients might make when evaluating benefit 
information. The study design used an internet survey and randomised participants to 
four scenarios comparing two hypothetical drugs. Each scenario presented a balance of 
risk and benefits of the drugs presented in different formats. The balance between 
perceived risks and benefits and ability to comprehend risk-benefit information was 
measured according to 2 types of knowledge: gist knowledge, which is a measure of 
ability to understand the essential meaning of the information presented and verbatim 
knowledge which is the ability to correctly identify the numerical risk and benefit 
statistics.  
c) Studies examining a combination of summary statistic and probability 
format. 
Two studies compared a combination of summary statistics and probability formats. 
Bergus et al (2002) randomly presented different treatments for symptomatic carotid 
artery disease and also randomised patients to receive information about risk, either 
before or after benefits with an aim of evaluating whether or not the order of risk-benefit 
information impacted upon decision-making (Bergus et al., 2002).  
Misselbrook and Armstrong (2001) used a postal questionnaire to assess patients’ 
willingness to take a medicine after reading the benefits presented as one of ARR, 
RRR, NNT and personal probability of benefits. The participants viewed all formats of 
risk presentation. 
 Descriptive summary of studies testing combined formats 
14 papers presented research evaluating a combination of different formats. These 
papers tended to compare either textual formats, numerical formats or graphical 
formats. The papers were varied, recruited a variety of samples and presented multiple 
formats of benefit information. They were categorised according to two groups: 
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(a) Studies comparing textual formats with numerical formats 
Two studies compared verbal descriptors, where levels of risk were described using 
words such as ‘common’, ‘uncommon’ or ‘rare’ (France et al., 2008) and ‘somewhat 
likely’ or ‘moderately  greater’ (Vahabi, 2010) with percentage and probability formats. 
The results of these studies were conflicting, France et al (2008) used a short 
questionnaire survey design to measure whether numerical information, in the form of 
percentages were better understood, and found that patients found it difficult to 
accurately predict the frequency of the terms ‘uncommon’, ‘common’ and ‘rare’. Vahabi 
et al (2010) randomised participants to receive a breast health information brochure and 
measured comprehension and preference. The study showed that while nearly two 
thirds of participants preferred the numeric format, comprehension was highest among 
participants who received probabilistic information in a verbal format. 
(b) Studies comparing numerical and graphical formats 
12 studies compared a variety of different formats of numerical and graphical formats. 
Comparisons included: 
 Visual (bar graph) and verbal (textual statement) (Parrott et al., 2005) 
 Percentages, frequencies, population figures (Timmermans et al., 2008) 
 Text, tables and pictographs (Tait et al., 2010b, Tait et al., 2010a) 
 Percentage probability and pictograph (Fuller et al., 2001) 
 Bar chart, pictograph, survival curve and textual description (Davis et al., 2010) 
 Population frequencies (with varying denominators) and icon arrays (Garcia-
Retamero et al., 2009) 
 Absolute risk, relative risk and NNT, anchoring to familiar risk, bar charts, 
thermometer scales, crowd figure formats and a combination (Edwards et al., 
2006) 
 AR expressed as frequency ‘v’ RR expressed as percentage and text only ‘v’ 
graphical image (Sprague et al., 2011) 
 Line plot, bar chart, pie chart, icon array and numerical information in either AR 
or RR (Garcia-Retamero et al., 2010) 
 RR, AR, NNT, OR, natural frequency and graph (bar chart and 10x10 people 
charts) (Goodyear-Smith et al., 2011)  
The methods and settings of the studies were varied. Several studies presented 
participants with multiple formats and measured preference for format and other 
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reported outcomes such as understanding or intention to take  (Goodyear-Smith et al., 
2008, Goodyear-Smith et al., 2011, Fuller et al., 2001, Davis et al., 2010).  
Two studies by Garcia-Retamero et al (2009 and 2013) used large samples of German 
and American participants who were representative of the population. One study 
measured differences in these samples’ abilities to undertake mathematical operations 
using various graphs compared to numerical information presented as an AR or RR.  
The second study explored the concept of denominator neglect, which is the focus on 
the number of times a target event has happened (numerators), without consideration 
of the overall number of opportunities for it to happen (denominators) (Garcia-
Retamero et al., 2013). The findings of this study suggested effective ways to address 
these phenomena which are of relevance to those presenting risk-benefit information in 
health communications. 
One study by Fried et al (2011) presented various magnitudes of benefits (presented as 
pictograms). The study has been included for discussion here as the study outcomes 
are relevant due to their evaluation of patient preference for treatment depending upon 
the magnitude of benefit compared to the magnitude of adverse effects. The study 
presented varying degrees of benefit and evaluated a participant’s willingness to take a 
medicine (Fried et al., 2011).  
A group of studies randomised participants to different arms receiving various formats 
in order to measure differences in preference and performance of numerous graphical, 
numerical and textual formats. The studies had varying aims and used a variety of 
different settings and populations. Timmermans et al (2008) did not describe whether 
their study participants were randomised to receive health scenarios. They recruited 
students who were presented with 4 scenarios which described the benefits of 
treatments using one specific format; a percentage, frequency or icon array. They 
measured understanding, risk perception and emotional response.  
Two studies undertaken by Tait et al examined different presentations of risk; both 
compared text, tables and pictograms (icon arrays) (Tait et al., 2010b, Tait et al., 
2010a). Both studies recruited large numbers of parents into experiments examining the 
impact of benefit information about hypothetical analgesics used in a children’s clinical 
trial.  They used a randomised controlled trial design, where the control scenario 
described the benefits and risks using words. The experimental arms presented a table 
and a pictogram. The study evaluated the impact on both gist and verbatim knowledge 
as well as perception of risk. 
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Edwards et al (2006) recruited participants from the Diabetes UK website to a 
randomised controlled trial which examined different formats of web-based patient 
information.  Intervention groups received either the basic control group information 
plus additional numerical information (AR, RR and NNT formats), anchoring 
information, graphical information (bar charts, thermometer charts and icon arrays) or a 
combination of these. Anchoring information refers to a method which relates the harm 
and benefit information to more everyday events which the user would be expected to 
be familiar with, such as the risk of a road accident or of winning the lottery. This study 
measured both the satisfaction with each format and also the decisional-conflict 
experienced by the parents. 
Sprague et al (2010) assessed how the presentation of risk information influenced the 
ability of participants to interpret healthcare information using a survey with a 2X2 
factorial design. They recruited a sample of Native Americans and presented an icon 
array and a combination of benefits presented in the form of risk reductions and 
absolute risks, using a scenario about a hypothetical cancer in which to frame the 
information. 
Finally Parrot et al (2005) randomised participants to receive either a textual or 
graphical intervention describing LDL cholesterol and LDL receptor genes. Both 
interventions were lengthy and complex and due to their inappropriateness for inclusion 
in a PIL the findings from this study shall not be described in significant detail in this 
review. 
Summary 
There is a wide range and scope of research which explores the inclusion of information 
about the benefits of treatments in written information. The breadth of the literature 
includes several systematic reviews and significant numbers of individual primary data 
studies which use multiple methods and present a variety of formats of benefit 
information. These have been broadly categorised as: 
 Studies presenting words 
 Studies presenting numerical formats 
 Studies using graphical formats (not discussed here) 
 Studies presenting a combination of formats. 
A number of different scenarios have been used to present benefit information and they 
range from cancer treatments, medicines for cardiovascular disease to pain relief 
medication presented within the context of clinical trial for children.  
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Multiple outcome measures have been used to measure the impact of providing benefit 
information, including: 
 Preference for format 
 Understanding of format 
 Impact upon intent to take treatment. 
The findings according to these outcomes will be presented in the following sections. 
 Preference for and satisfaction with benefit information 2.7.3
 Studies presenting ‘words’ 
There is limited evidence that the provision of a short textual statement can enhance 
patient satisfaction with information when compared to no information or information 
that does not contain textual information about the benefits of treatments.  
Bersellini et al (2006) showed that the inclusion of an effectiveness (benefit) statement 
and information regarding the rationale for treatment in a PIL positively influenced 
people’s satisfaction with the leaflet. This study is highly relevant due to its specific 
focus on benefit information in medicines information. The study employed a robust 
method to measure participant satisfaction and provides empirical justification for the 
use of a textual benefit statement in a PIL in order to increase satisfaction with 
information.  
 Studies presenting numbers 
A consistent finding from studies measuring satisfaction with numerical formats was the 
preference for RRRs over other formats. This format tended to be viewed as easy to 
understand and as providing a bigger impact on participants (Bhandari and Tornetta, 
2004, Natter and Berry, 2005, Malenka et al., 1993, Gyrd-Hansen et al., 2003, Sarfati et 
al., 1998, Carling et al., 2008).  
However, these studies were frequently limited because they lacked a detailed 
evaluation of the performance of RRRs in enhancing risk perception or understanding. 
It was apparent from the research that while many participants preferred this format, the 
RRR statistic had the potential to mislead and encourage participants to be more likely 
to choose a treatment even if the treatment was associated with significantly increased 
risk of harm (Natter and Berry, 2005, Bhandari and Tornetta, 2004) 
A limited amount of research suggests that the absolute survival benefit (ASB) (a 
method which described the absolute reduction of risk of death attributable to taking 
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chemotherapy) is a useful format. This technique was noted to be preferable to RRR, 
ARR and NNT when presenting the benefits of cancer treatments (Studts et al., 2005). 
Few other studies have assessed the impact of ASB, so the research on this technique 
is limited. This technique is also one limited to treatments for diseases which have the 
potential to be terminal, such as cancer, and might not be effective to communicate the 
benefits of medicines for chronic non-life threatening conditions. The study did not 
assess the performance of the technique compared to the other formats, focussing 
upon self-reported preference and influence on decision-making. The use of the ASB 
statistic appears a feasible option for presenting the survival benefits of cancer 
treatments but may not be applicable to presenting the benefits of other treatments.  
Two studies undertaken by Carling et al (2008 and 2009) identified different 
preferences for the presentation of benefit information: RRR (2008) and natural 
frequencies (2008). These were large sample studies with well-defined methods. The 
first study showed that participants preferred RRRs (52%) compared to ARR, NNT, ER, 
TNT and whole numbers (presented as natural frequencies) (25%). However, 
participants in the second study which used a similar research design reported a similar 
preference for natural frequencies (31%) compared to RRRs (30%). 
To conclude, there is evidence that RRRs are preferred by participants but preference 
is not indicative of performance, or relevance, and other outcome measures should be 
considered when considering which format of numerical presentation is suitable for use 
in a PIL.   
 Studies presenting a combination of formats 
The retrieved studies evaluating the impact of combined formats of benefit presentation 
on preference and satisfaction were complex and heterogeneous, examining different 
formats presented in multiple combinations and styles. It is difficult to draw firm 
conclusions about the most preferred format, but RRRs, natural frequencies, icon 
arrays and bar charts were consistently preferred when presented.   
(a) Words and numbers 
Two studies measured the preference for words (with verbal descriptors) versus 
numbers (Vahabi, 2010, France et al., 2008). Using a survey, they presented 
participants with either a numeric or textual format, which used terms such as 
‘somewhat likely’ or ‘moderately greater’. They found a greater preference for numerical 
formats compared to textual formats. 
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(b) Numbers and graphs  
12 papers researched a combination of graphical and numerical presentations of 
benefit. Four of these studies specifically measured preference for format.  Parrot et al 
(2005) suggest that a textual/numerical format is better comprehended than a 
graphical format. The research design used and the formats of benefit information 
presented were very complex. The authors concluded that participants preferred a 
textual/numerical format of benefit presentation (which incorporated percentages) as 
opposed to a graphical format.  However both formats presented were complicated and 
contained a mix of different types of data. It was also challenging to interpret the 
message the graph was trying to convey and this may impact upon the usefulness of 
the findings. 
The study did propose that where participants associated quality with the format, they 
were also more influenced by the persuasiveness of the message. The authors 
concluded that the textual format was preferred and interpreted correctly more 
frequently as it was more familiar, although one critique of the study is that the 
textual/numerical format may have been preferred because the graphical format was 
too complicated, and that the use of a simple graph might yield different findings. 
Goodyear-Smith et al (2008 and 2011) undertook two studies measuring preference for 
format with patients from medical practices in New Zealand.  Of the numerical formats, 
relative risk or natural frequencies were preferred. NNTs were the least liked format. 
Graphical format was preferred to numerical format in both studies by about half the 
sample.  
Edwards et al (2006) undertook a qualitative analysis of several different risk 
presentation formats, including detailed numerical information (AR, RRR, NNTs), 
anchoring, graphical (bar charts, thermometer scales, crowd figure formats) and a 
combination of formats. Preference was self-reported. Participants reported that 
graphical representations, in particular bar charts, were helpful. Numerical information 
was also perceived as helpful. The participants recruited were well informed about their 
health and this might affect the applicability of the findings to a wider population.  
 
 Summary 
Preference for format varied depending upon the type of formats presented. It was 
apparent that participants appear to prefer some benefit information compared to none, 
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with additional information about the rationale of treatment impacting positively upon 
satisfaction with information.  
Graphical formats are mostly popular, with icon arrays and bar charts being preferred 
by many participants. With regards to numerical formats there is a tendency for people 
to prefer RRRs, however it has also been shown that RRRs can be misleading. Natural 
frequencies also appeared to show measures of increased satisfaction among some 
people. 
Preference for a particular format is not indicative of performance, although it has been 
shown to influence how a patient might respond to a particular format of benefit 
information. This may be because, if participants are satisfied with the format of 
information, this may facilitate engagement with it. 
 Effects on participant knowledge and understanding 2.7.4
(including risk perception) 
The impact on knowledge and understanding was evaluated in a number of studies. 
There are different types of understanding that can be addressed facilitated; some 
studies assessed the impact benefit information had upon verbatim knowledge such 
as the ability to correctly identify numerical harm and benefit statistics.  Studies 
assessing verbatim understanding often presented participants with a format of benefit 
information and requested them to undertake a mathematical operation, which was then 
evaluated as correct or incorrect.  
Other studies examined the impact on understanding in more detail, examining the 
abilities of participants to use and apply the benefit information to a participant’s own 
situation. There were a small number of studies evaluating gist knowledge alongside 
verbatim information. These studies often used assessments of patient values and/or 
beliefs about their treatment, to assess whether the decisions made were consistent 
with patient values and whether the format of benefit information influenced this. Others 
explored risk perception measuring how the information provided placed the benefits 
in context. 
Several key findings were apparent: 
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 Studies presenting ‘words’ 
Three studies evaluated how the inclusion of a textual statement about the benefits of 
medicines could influence a participant’s understanding of their treatment (Bersellini 
and Berry, 2007a, Bersellini and Berry, 2007b, Vander Stichele et al., 2002).  
 
These studies all compared the inclusion of additional textual information about the 
benefits of a medicine; including more detailed information on the rationale and 
effectiveness of treatments. A variety of outcomes were measured, using various rating 
scales, which included judgements about side effects, (risk perception) (Bersellini and 
Berry, 2007b, Bersellini and Berry, 2007a) and knowledge about medicines (Vander 
Stichele et al., 2002). All studies reported that the inclusion of a textual statement about 
the benefits of medicines increased knowledge about the medicine and the perception 
that the benefits of the drug were greater than the harms, in comparison to those who 
received no benefit information. Those who did not receive benefit information reported 
higher perceptions of risk as opposed to benefit. (Vander Stichele et al., 2002). The 
provision of benefit information using words was found to improve judgement but not 
necessarily knowledge (Bersellini and Berry, 2007a, Bersellini and Berry, 2007b), 
although Vander Stichele et al (2002) reported an increase in knowledge about the 
medicine.  The provision of written benefit information was not shown to improve 
behaviour or understanding, but led to a more balanced benefit-harm perception. 
 Studies presenting numbers  
The previous section reported that there was evidence that RRRs are a commonly 
preferred format. However, when measuring how RRRs influence a person’s risk 
perception and understanding of medicines, there is evidence that this format can lead 
to over-estimations of benefit. Much of the literature comparing RRRs to other summary 
statistics and probability formats suggests that RRRs are very persuasive and can 
encourage people to make decisions that are not necessarily in line with their values. 
(Hux and Naylor, 1995, Sarfati et al., 1998, Carling et al., 2008, Malenka et al., 1993).  
This finding is reinforced with the findings of a systematic review and meta-analysis 
which evaluated the use of alternative statistical formats for presenting risks and risk 
reductions (Akl et al., 2011a).This study used a clearly reported and robust method for 
undertaking a systematic review and a well-described and comprehensive search 
strategy was performed. The review included studies that were undertaken both in 
patient and healthcare professional populations.  The interventions of interest included 
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presentations of risk (e.g. frequencies and probabilities) or of a risk reduction (e.g. 
RRR, ARR, NNT) of the same evidence about health.  There was a rigorous 
assessment of study quality, which included RCTs, non-controlled trials and cross-over 
studies.  The meta-analysis was well-executed and included an appropriate I2 test for 
heterogeneity, plus several pre-planned subgroup and sensitivity analyses.  
35 studies were included for meta-analysis, this included: 8 comparisons of natural 
frequencies versus probabilities; 31 comparisons of RRR versus ARR; 23 comparisons 
of RRR versus NNT; and 21 comparisons of ARR versus NNT. Some of the studies 
were included in this analysis, however many were excluded from the scoping literature 
review reported here, due to their focus on health professionals. As a result the findings 
from the systematic review by Akl et al (2011) have only some bearing on the findings 
of the scoping review as a whole (although it can be argued that the effective 
understanding of benefit information by healthcare professionals is applicable to a 
patient population as statistical summaries that perform poorly with healthcare 
professionals are also likely to be difficult for patients to understand). 
The review showed that numerical presentations of harm and benefits are better 
understood when presented as natural frequencies compared to probabilities (a 
moderate effect size was noted). RRRs were noted as being more persuasive and were 
perceived as more effective when compared to ARRs or NNTs.  RRRs conveyed a 
more accurate understanding than NNTs (a large effect size was noted) but not as 
accurate as that conveyed by ARRs.  
This review is the most systematic and up-to-date review of the evidence on summary 
statistics. However one significant omission in the published studies is that there has 
been no assessment of the impact of statistics on behaviour. Overall the quality of the 
evidence was moderate, mostly because of the lack of use of objective measures to 
assess outcomes; the findings must therefore be interpreted in light of this. This reflects 
a need for some larger studies, preferably using controlled designs, to evaluate the 
effectiveness of these types of summary statistics, in particular any upon behaviour.  
Research by Carling et al (2008) also highlights the persuasiveness of using RRRs to 
communicate benefit information. This study explored participants’ values and the 
importance they placed on treatment consequences  (Carling et al., 2008). When 
participants were presented with benefits in the form of RRRs they were more likely to 
take a statin, than if the benefits were presented in another format.  This influence on 
decision-making existed regardless of the participants’ values on taking medicines.  
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Other studies also examined the interpretation of RRRs and the context in which they 
were presented.  Sheridan et al (2003) used a randomized experiment in which  
participants were presented with 4 different formats of benefit information: RRR, ARR, 
NNT or a combination of the three. The findings showed that participants were better 
able to interpret the benefits of a treatment when an RRR was presented as well as  the 
baseline risk of disease (Sheridan et al., 2003).  
Two other studies also explored the importance of providing a baseline or comparative 
risk on risk perception. The provision of baseline risk information can facilitate more 
accurate understanding of risk estimates (Fagerlin et al., 2007, Natter and Berry, 2005).  
Several studies examined the impact of providing NNTs and NNS’s to participants. The 
NNT was frequently shown to underperform compared to other formats as it was more 
frequently misinterpreted (Sheridan et al., 2003, Sarfati et al., 1998). Kristiansen et al 
(2002) showed that participants were often insensitive to the size of NNTs. A limitation 
of this study was that it did not present risks alongside benefits and it is possible that 
participants might be more accepting of NNTs with small value in the absence of having 
to make trade-offs between risks and benefits. All in all, NNTs were shown to be 
problematic, but the research was limited as it did not present the NNTs in realistic 
contexts; it is difficult to draw firm conclusions about the issues associated with their 
use. More research evaluating the use of NNTs to present information about benefits 
will be valuable.  
Natural frequencies were frequently associated with increased preference and 
understanding (Carling et al., 2008, Carling et al., 2009).  Natural frequencies and 
percentages were shown to perform better than other formats when participants had to 
undertake three mathematical operations on risk probabilities presented either as a 
percentage,  ‘1 in n’, or a natural frequency.  The study showed that natural frequency 
and percentage formats resulted in a similar degree of accuracy. (Cuite et al., 2008). 
Natural frequencies were feasible for use in a sample of older participants, although this 
study only recruited a small sample and contained methodological flaws. Recruitment of 
older people is a strong feature of this research making the findings representative to 
the general medicine-taking population. This study concluded that natural frequencies 
helped both elderly and younger patients understand the predictive values of medical 
screening tests (Galesic et al., 2009b).  
Dahl et al (2007) tested participants’ understanding of postponement of adverse 
disease events and concluded that lay people can discriminate between levels of 
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treatment effectiveness when they are presented in terms of a postponement of an 
adverse event. Despite the feasibility of these methods in some health contexts, there is 
little unequivocal evidence to suggest that absolute survival benefit or postponement of 
an adverse event are preferable to other methods and the use of this technique is 
limited in a patient information leaflet as it might not be applicable for medicines used 
for some symptomatic conditions.  
 Studies comparing a combination of formats 
15 studies examined the impact of various combinations of formats of numerical, 
textual and graphical information on participant understanding. The findings were 
varied. 
a) Words compared to numbers 
Two studies compared how presenting benefits as either verbal descriptors or a 
numerical format, such as a natural frequency (Vahabi, 2010) or a percentage (France 
et al., 2008), could impact on comprehension of benefits. France et al (2008) reported a 
small study designed to examine whether the use of percentages was a feasible 
technique to describe risks to patients with chest pain in an emergency room. This 
study was not designed to examine which method was most effective, but was instead 
a feasibility of use study. They identified that patients could better understand side-
effect frequencies when expressed as a percentage.  
Conversely Vahabi et al (2011) identified that verbal descriptors improved the 
comprehension of probabilistic information regarding breast cancer screening. This 
study also identified other factors which impact upon comprehension of benefit 
information such as the participant’s format preference, education and perceived benefit 
of early detection of breast cancer. 
The review of the literature in this field does not provide any unequivocal answer 
regarding the utility of textual benefit information compared to numerical.  
b) Numbers compared with graphs 
Seven studies showed that graphical formats were better understood than numerical 
formats and improvements of accuracy of interpretation of risk were associated with 
graphical formats. So frequently, graphical formats were found to perform better than 
numerical statements alone (Garcia-Retamero et al., 2010).   
Different graphs were identified to perform better in various studies. The following 
formats were all identified as having the highest impact on measures of comprehension 
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and understanding: Kaplan-Meier survival curve (Davis et al., 2010), population chart 
(Fuller et al., 2001) table (Tait et al., 2010b) and bar chart (Garcia-Retamero et al., 
2010). The format most likely to be identified as optimal in improving risk perception 
and understanding was the icon array (Sprague et al., 2011, Garcia-Retamero et al., 
2010, Tait et al., 2010a). On the other hand, Timmermans et al (2008) associated the 
icon array with increased emotional response and described how this had a negative 
impact upon participants’ risk perception. This study had many methodological flaws; 
the sample was highly educated compared to the general population, no methods of 
randomisation were reported and the subjective outcome measures might impact upon 
the veracity of the findings by introducing the potential for biased reporting of outcomes 
which cannot be objectively measured.  (Timmermans et al., 2008).  
Many of the studies above assessed understanding of the information, as well as the 
ability to correctly interpret the information presented. This is known as ’verbatim’ 
knowledge and they did not evaluate how different formats might impact upon ‘gist’ 
knowledge. Four studies examined the impact of the provision of a variety of formats of 
benefit information on both verbatim and gist understanding.  
Galesic et al (2009) evaluated both accuracy and perception of risks associated with 
receiving a number of icon arrays in comparison to numerical information presented as 
ARR or RRR. These studies found that icon arrays were helpful for both low and high 
numeracy participants and, contrary to Timmermans’ findings, suggested that icon 
arrays reduced perceptions of risk experienced by participants. (Galesic et al., 2009a) 
Two highly relevant and well-designed studies by Tait et al (2010b, 2010c) concluded 
that the pictograph was optimal in communicating both verbatim and gist knowledge 
about the benefits of treatment when compared to a numerical statement or a table.  
Both studies used similar methods of recruitment and similar interventions: numerical 
statement, tables and pictographs. Participants randomised into a pictograph arm were 
observed to have higher levels of both gist and verbatim understanding than those 
receiving either text or a table format. Tables were better comprehended than text. 
These findings were corroborated by 3 systematic literature reviews in this field. The 
most recent of these reviews (Bunge et al, 2009) aimed to survey the quality criteria for 
evidence-based patient information. The criteria this study used were only partially of 
relevance to the scoping review, and several categories of ‘evidence-based patient 
information’ were not considered relevant .  However, it included for review several 
interventions of interest such as information on the benefit and harm of the intervention, 
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patient-orientated outcome measures (e.g. mortality and quality of life), the presentation 
of numerical data, verbal presentation of risks, diagrams, graphics and charts and loss 
and gain framing;  all of which can be techniques used to convey benefit information to 
patients. 
The review was clearly described and, in terms of quality, it used an a priori study 
design and met several of the criteria on the AMSTAR checklist. The methodological 
quality of the included studies was appraised using both the SIGN and the EPOC 
checklist. The studies retrieved by the review were heterogeneous and a descriptive 
approach was undertaken. 
There was good evidence for the presentation of numerical data or graphical 
presentations in comparison to others types of intervention. Natural frequencies were 
identified as better understood than probabilities.  Caution was recommended when 
using RRR, which resulted in over-estimations of probabilities. It was suggested that 
ARR leads to better understanding than RRR. When evaluating the impact of textual 
presentation of risks, a more accurate understanding was reported if numbers were 
used instead of words. There was a tendency to over-estimate the effect when verbal 
descriptors were used. Finally it suggested that with regards to diagrams and graphics, 
there was little consensus as to what were the best methods. 
These findings were similar to those made by Visschers et al (2008) who used a 
literature search method to identify a number of research studies which presented 
probability information in risk communication.  The review used a well-described 
method to identify and collate the findings of general studies on probability presentation 
in risk communication. The studies included were heterogeneous and no meta-analysis 
had been undertaken.  However, the researchers used a method of evidence weighting 
to rank the quality of the findings.   
The findings of the descriptive analysis included the following basic recommendations: 
[1] use the same denominator in probability information throughout the risk 
communication to avoid denominator neglect; [2] a step by step description of a 
probability calculation is recommended to present risky situations that include false 
positives; [3] be careful about presenting risks as RRRs as they can lead to over 
estimations of risk; [4] information using NNTs should be provided with caution; [5] take 
the context of the risk communication into account when selecting appropriate verbal 
probability expressions for a risk message; [6] present both verbal and numerical 
information in a risk message; [7] graphs are a useful means to present probability of 
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harm (Visschers et al., 2009). The findings are unsurprising, have been corroborated by 
other research and ultimately offer no definitive answer to the best method of benefit 
presentation.  
Trevena et al (2006) undertook a systematic review to identify the research literature in 
a number of areas. One area in particular was relevant to this scoping review and 
focussed on effective formats for representing probabilistic information. The methods 
used to undertake the review were of moderate quality. The review included RCTs only 
and data were extracted by 2 independent data extractors. The search strategy was 
reasonably comprehensive, although grey literature was excluded. An appraisal of 
quality assessment undertaken using a quality checklist for the systematic reviews and 
the Cochrane Handbook grading system for the RCTs.   
A descriptive analysis suggested a number of recommendations including that numbers 
lead to a more accurate perception of the benefits than words when probabilistic 
information is presented. One RCT suggested that natural frequencies were better 
understood than probabilities. The utility of presenting baseline risk when presenting 
risk reductions was highlighted. Graphics were suggested to be useful and there was 
some evidence that bar charts and survival curves can help participants understand the 
benefits of interventions. Framing risks as either a loss or a gain can influence patient 
preferences. Again, these findings echo those from the systematic reviews described 
already and the findings of the primary research reported elsewhere in this scoping 
review.  
 Summary 
There is not a definitive answer as to which format is better at promoting understanding 
and accurate measures of risk perception when different formats are compared. It is 
apparent that the provision of benefit information in a textual form is useful, but that 
numerical and graphical formats have been frequently shown to help patients make 
more accurate estimations about the benefits of their treatment.  
RRR formats have been shown to lead to over-estimations of risk and should be 
avoided.  If they are used, then comparative information, such as baseline risk 
information, should also be provided.  
Natural frequencies have been shown to be understandable, particularly if an individual 
has to undertake a mathematical operation. The interpretation of NNTs has been shown 
to be problematic, but the research assessing their utility was flawed and did not 
evaluate their use in context.  
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Several different graphical formats were found to be useful in improving knowledge and 
promoting understanding, including survival curves and tabular formats. Some good 
quality studies found that icon arrays were more understandable in comparison to 
different formats, although this was not unanimous. Bar charts were also shown to help 
improve accuracy. 
More research in this area would be valuable particularly to evaluate the role of NNTs in 
benefit communication. 
 Effects on participant behaviour 2.7.5
This review collated a body of evidence that looked at the potential for stimulating 
behaviour change through the use of different formats of benefit behaviour. However, 
the literature identified did not assess the long-term impact of providing such 
information and there is very little research that examined the impact of benefit 
information in a natural setting or in real-life situations.  
Several key themes were identified from the published research literature.  
 The persuasive nature of RRRs was tested, with several studies suggesting that 
RRRs might encourage behaviour change that is not based on an accurate 
understanding of the treatment effects and which might not be in line with 
patients’ values. Goodyear-Smith et al (2011) used a real-life scenario to assess 
the impact of benefit information and found that the RRR tended to be 
persuasive in encouraging a participant to take a particular medicine. The study 
concluded that RRRs, while simple to understand, can be difficult to 
comprehend in the absence of any baseline risk information and can lead 
participants to make decisions that are not in line with their values. So some 
formats are more persuasive than others, but not necessarily informative.  In 
particular the use of the RRR has been shown to influence choice without 
helping patients understand or make decisions in line with their values.   
 There is also evidence that benefit information can adjust patients’ 
expectations of treatment and impacts upon their self-reported medicine-
taking behaviour. It has been shown that the provision of information about 
potential benefits, as opposed to no benefit information, helps patients get a 
deeper understanding of their treatments and also consider their options in more 
detail. The benefit information presented in Bersellini et al (2006 & 2007) 
impacted upon a participant’s intent to take the treatment. This is important as it 
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suggests that patients might alter their behaviour in light of receiving more 
information about a treatment.  
 In a RCT which provided improved benefit information in the form of a Drugs 
Facts Box compared to a direct-to-consumer advert, Schwartz et al (2009) found 
that the provision of benefit information meant that participants were better 
informed, but less enthusiastic about the medicines and this reduced their 
intentions to take the treatments. Fagerlin et al (2007) also reported similar 
behaviours, noting that providing people with comparative risk information 
changes their perceptions of risk. In their research they found that people who 
perceived that they had a higher than average risk may feel compelled to take a 
treatment and might not consider the trade-offs in risks and benefits.   
 
 Other influences on patient behaviour. 
Patients do not make decisions about their treatments in isolation and there are a 
number of other influences on decision-making that were identified in the published 
research. 
a) Context 
The context of the information is important. Providing patients with comparative risk 
information changes their perceptions (Fagerlin et al., 2007). Also ensuring benefit 
information is realistic and relevant means participants are more likely to make 
decisions that reflect their behaviour in real-life situations. Some of the interventions 
were also presented in a context that was not transferable to the UK, for example the 
findings from the studies evaluating the impact of the Drugs Facts Box as a means of 
improving a DTC advert, might not be relevant in a UK setting due to restrictions on 
direct-to-consumer advertising. (Schwartz et al., 2007, Schwartz et al., 2009) 
b) Numeracy 
Participants with higher numeracy appeared to find it easier to undertake any 
mathematical operations that were required in several of the studies. Numeracy was 
assessed in most studies using the Subjective Numeracy Score, which is an 
appropriate validated tool (Zikmund-Fisher et al., 2007). A few studies, for example 
Garcia-Retemaro et al (2010), found that providing visual aids as well as numerical data 
to people with lower-numeracy, helps them make more accurate assessments of risk 
reduction (Garcia-Retamero et al., 2010).  
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Hess et al (2010) explored the role of subjective numeracy and observed how cognitive 
differences in the ability of people with low-numeracy in perceiving graphs, compared to 
people with higher numeracy can lead to problems with the accurate extraction and 
processing of information (Hess et al., 2011).  Other studies concluded that the less 
numerate population might benefit from graphs but might also also have less ability to 
interpret the graphs accurately.(Brown et al., 2011, Hawley et al., 2008). 
c) Age 
It was observed that some older people struggled to interpret benefit information more 
often than younger adults (Fuller et al., 2001), although formats such as natural 
frequencies were observed to be helpful to rectify this (Galesic et al., 2009b). It is 
important to note that many of the research studies recruited samples from the general 
population, and this means the average age of participants may be younger than the 
average age of medicine-users, therefore the findings might not be applicable.  Older 
users of medicines are under-represented in the research. 
d) Hope and uncertainty 
The concept of hope was also observed to be an influencing factor on perceptions of 
treatment benefit. In a qualitative study it was also viewed that inherent uncertainty in 
life can undermine confidence with probabilistic information and that patients value 
honesty but that this should not preclude hope (Thorne et al., 2006). 
 Summary 
It is apparent that there is the potential for behaviour change, depending upon the 
format of benefit information.  It has been shown that some formats can mislead 
patients into making decisions that are not in line with their values. There is evidence 
that RRRs in particular are persuasive.  
Icon arrays and bar charts have also been shown to have the potential to help patients 
make better informed decisions. The can improve a participant’s verbatim and gist 
understanding of their treatment.  
Familiar and simple formats appear to yield more understanding and help patients 
make better decisions as they reduce the cognitive effort required to make sense of 
often complex information. 
Understanding the right format for the right patients is an ideal, and healthcare 
practitioners need to be aware that different formats can evoke different responses and 
behaviours in different people. There are techniques that patients need in order to get 
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the most out of visual aids. Ideally visual aids should be well-designed to support the 
participants to do this and to modify any incorrect expectations about treatment risk 
reduction.  
Poorly designed or unclear information is of no use, or worse still misleading and 
confusing. Therefore the choice of format might be dependent on the goal of the 
communication. 
There is a need to undertake research into the different formats of benefit presentation 
in a more naturalistic setting to understand the impact on actual, rather than intended 
behaviours and on long-term behaviours. A need has been highlighted for more 
research, especially high quality RCTs, assessing the impact of providing different 
formats of numerical information on patient behaviour. 
 Studies examining the impact of the framing of information 2.7.6
about treatment benefits. 
Framing refers to the way in which a scenario or decision might be differently 
presented, perhaps as having either a negative or positive outcome. It has been noted 
that the framing effect is a cognitive bias which influences choice between two identical 
choices when framed as a gain or a loss.  Two systematic reviews also met the criteria 
for inclusion (Tversky and Kahneman, 1981, Edwards et al., 2001, Akl et al., 2011b) .  
18 studies were identified which evaluated the impact of ‘framing’ information about the 
benefits of treatments on the attitudes, satisfaction, knowledge and behaviours of 
participants. The studies have been broadly grouped to into 3 categories: Studies which 
evaluate the impact of framing on treatment choices; Studies which evaluate the impact 
of framing and other characteristics; Systematic reviews on framing. 
a) Studies which evaluate the impact of framing on treatment choices 
Attribute (or statistical) framing 
Overall, there was a small amount of evidence suggesting that attribute framing, the 
use of a negative or positive frame in which to present information has the potential to 
influence attitudes and decision-making regarding different treatments. Four studies 
were identified which explored a range of different treatments and used different 
research designs, although only 3 studies are discussed in detail as Zimmerman et al 
(2000) tested a modified decision board technique that would not be suitable for use in 
PILs (Zimmermann et al., 2000).  
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The remainder of the studies tested whether a negative or positive attribute frame 
impacted upon attitudes or decisions towards treatments. The studies tested different 
treatments, in different populations and different types of attribute framing. Bigman et al 
(2008) examined the impact on participant attitude of statements about HPV 
vaccination framed in a variety of ways. Two key findings were that positive framing 
was influential and correlated with an increased perception of the effectiveness of the 
vaccine and that when presented as a mixed frame, the order of the framed information 
was also influential (Bigman et al., 2010). 
O’Connor et al (1989) compared the effects of framing and level of probability on 
patients’ preferences for cancer chemotherapy. Participants were either healthy 
volunteers or cancer patients and were randomised into one of three groups receiving 
three different types of framed information: (1) a positive frame in which the probability 
of survival was given; (2) a negative frame in which the probability of dying was given; 
and (3) a mixed frame in which the probability of surviving and dying were given. The 
study was well-designed, and the recruitment of a real-life sample added strength to the 
findings. An evaluation of preferences for treatment was undertaken and it was found 
that a positive framing was influential, encouraging a participant to be more likely to 
choose a treatment than if the same treatment was presented in a negative frame, 
although this was only statistically significant if there was a 50% probability of survival. 
The study also noted that participants would make trade-offs about their treatments and 
that cancer patients were more likely to choose toxic treatments than healthy 
volunteers. This early study suggests a link between experiences of illness and 
willingness to accept different values of risks and benefits. 
A large-scale randomised trial compared 3 valence framing presentations of the 
benefits of antihypertensive medication in preventing CVD (Carling et al., 2010). 
Valence-framing refers to when individual choices are influenced by outcomes that are 
either positive or negative, whereas ‘true’ framing refers to the manipulation of 
objectively equivalent information into either a positive or negative frame (Carling et al., 
2010). The study’s limitations included that it did not recruit real-life patients making 
actual decisions about their treatment, although it did recruit a nationally representative 
sample (from the USA and Germany). Participants were randomised to receive one of 
three scenarios which contained numerical information about the benefits of an anti-
hypertensive, based on realistic clinical trial data. These scenarios were framed either 
positively or negatively, or negative by year, and one group received no framed 
numerical information. The participants’ values and ’intent to take’ were assessed. 
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Participants were then shown all the different types of information (with the aim that 
they have the information to make a ‘fully-informed’ decision) before a final measure of 
the outcomes was taken.  
This study was relevant to the review as it found that providing both the negative and 
positive framed information resulted in participants being less likely to take a medicine. 
However, the provision of information about the benefits of a medicine in a positive 
frame led to participants making decisions that were most consistent with those made 
by everyone when they were given more complete information and asked to make a 
more fully-informed decision.   
b) Goal (or behavioural) framing 
5 studies examined the impact of using ‘goal’ framing, where the consequences of 
performing, or not performing an activity are depicted as either a loss or a gain. Often 
this is emphasised as a specific type of behaviour, for example negative-framed 
messages emphasise losses, and positive framed messages emphasise gains to 
health. 
Some of the studies were of limited relevance to the outcomes of the review. Two 
papers undertook multiple experiments using hypothetical scenarios with limited 
reference to how people make real-life decisions about healthcare treatments (Peters 
and Levin, 2008, Fischer et al., 2008). Some experiments used scenarios based on 
theories of risky decision making, such as risky stock trading, and the discussion of 
these papers has been limited to the studies undertaken which focus specifically on 
conveying the benefits of treatments. 
The remaining studies (Hoffner et al., 2009, Hevey et al., 2010, Brug et al., 2003, Lalor 
and Hailey, 1989, Leader et al., 2009) examined the impact of providing various health 
messages which were goal- or loss-framed.  These studies used a number of different 
hypothetical scenarios to convey the health message ranging from breast cancer self-
examination (Lalor and Hailey, 1989) to sun screen use (Hoffner et al., 2009, Hevey et 
al., 2010) to a selection of nutrition education messages (Brug et al., 2003). 
Questionnaires were used in all these studies to measure the impact of the framed 
messages. The studies commonly assessed the impact of goal ‘v’ loss framed 
messages on the participant’s intent to carry out specified health behaviours. 
The findings suggested that goal-framed messages were associated with increased 
uptake of beneficial health behaviours, although many reported subtle nuances that 
impacted on this general trend. Hoffner et al (2009) reported subtle differences between 
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the perceptions of men and women and also how having ‘involvement’ in a particular 
issue might impact on decision-making. They noted that where participants reported 
little involvement in the scenario, a loss-frame was effective in changing behaviour 
(Hoffner et al., 2009).  
Hevey et al (2010) noted that the participant’s report of body consciousness moderated 
the effectiveness of the frame, with gain-framed health or appearance messages having 
the strongest effect on sunscreen use for those high in body consciousness compared 
to those low in body consciousness (Hevey et al., 2010). Another paper did not report 
any significant evidence of framing effects, but noted that their use of a non-involved 
population of students meant that the information they provided was of a very low 
personal importance to the sample and that this potentially impacted upon the findings 
(Brug et al., 2003). 
Framing different aspects of a goal with regards to influencing a health choice was 
assessed by Leader et al (2009). They noted that when the benefits of HPV vaccination 
were framed as a cervical cancer prevention tool, rather than a sexually transmitted 
infection prevention tool, this increased the reported intention to vaccinate (Leader et 
al., 2009). 
Only one paper assessed the long-term impact of framed messages on health 
outcomes. The study was a small questionnaire study. It was non-randomised and used 
a student population (n=55).  Although not of high quality, it evaluated the impact of the 
intervention provided (a pamphlet that described the need to do breast self-examination 
presented in either a positive or negative frame), after 4 months. The study found that 
neither the negative- nor the positive-framed interventions were effective in promoting 
breast self-examination practice unless the individual already felt susceptible to breast 
cancer (Lalor and Hailey, 1989). 
c) Studies that combine both attribute and goal frames 
Two hundred undergraduates were recruited to receive 4 variations of pamphlets about 
a flu vaccination in an experimental survey design which manipulated frame valences 
(positive or negative) and methods (attribute or goal) in order to explore the effects on 
perceived risk (Ferguson and Gallagher, 2007). 
The results suggested that ‘personal outcome effectiveness’, that is the perception of 
how effective the vaccine is, indirectly linked framing to intentions. The study suggested 
that goal framing increased personal outcome effectiveness (and encouraged more 
people to think the vaccine was effective) than attribute framing. The study was 
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theoretical in its approach, using the results to build upon and integrate models of 
health and non-health behaviour and it made no suggestions on how their findings 
might be used to improve the communication of benefits of treatments. 
 Studies which evaluate the impact of framing and other characteristics 
A series of studies examined a range of different factors that might also influence how 
people perceive and interpret framed benefit information. These additional factors 
included age, cognitive impairment, numeracy, ‘involvement’ and ‘vagueness’ 
(Shamaskin et al., 2010, Zamarian et al., 2010, Kuhn, 1997, Garcia-Retamero and 
Galesic, 2010).  A range of different methods, populations and interventions were 
described.  
Shamaskin et al examined impressions of positively and negatively framed health 
messages that were presented in in pamphlets to 25 older (age range 64 to 86) and 24 
younger adults (age range 18-23). This uncontrolled study found that older adults, 
relative to younger adults preferred and remembered positive messages, rather than 
negative ones. Older adults also appeared more likely to misremember negative 
messages to be positive. To confirm these findings, more research is required. 
Zamarian et al (2010) recruited 3 comparative groups of adults (a healthy control, a 
group with mild cognitive impairment and a group with Alzheimer’s disease) who were 
shown statements about the outcomes of 20 unknown medicines which were described 
either positively or negatively. All three groups judged the positively-framed medicines 
more favourably. This was more pronounced in the comparison groups. This small-
scale study suggests that framing might be more influential in groups with cognitive 
impairment, but further research is required to support these findings. 
In a series of 3 experiments, Kuhn et al (1997) examined the impact of ‘vagueness’, 
presented as vague probabilities, and framing. An example of vague probabilities 
included the following;  
1) a vague point estimate: a verbal qualifier of the base point estimate (“estimated 
to be around”) 
2) a low-high range: a range of two probability values centred on the base 
probability value (“estimated to be between”) with the low value presented first; 
or 
3) A high-low range: the same range of two probability values with the high value 
presented first.(Kuhn, 1997) 
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These studies were small and used hypothetical scenarios. They reported that 
participants were averse to vagueness and that framing impacted upon decisions, 
however they made no suggestions as to the best methods for framing treatment 
options when the probabilities are vague. 
 
The ‘involvement’ of adult women in making a decision about child immunisation was 
evaluated in a 2x2 factorial study undertaken by Donovan and Jalleh (2000). The study 
found that positively framed messages were more influential, encouraging women to be 
more likely to seek information or adapt the recommended behaviour, as opposed to 
the negatively framed behaviour. This was especially so for low-involvement 
participants. There was no framing effect reported for high-involvement participants. 
This study was poorly reported and the sample size was not accurately reported 
(Donovan and Jalleh, 2000). 
 
Two final studies examined interventions to reduce framing-effects.   The first study 
explored the impact of a de-biasing technique used to reduce the framing effect 
(Almashat et al., 2008). The de-biasing technique consisted of a questionnaire which 
listed advantages and disadvantages of each treatment and is an intervention unlikely 
to be used in a patient information leaflet. 
 
The second, large-scale study used a randomised questionnaire to measure the impact 
of providing negatively and positively framed information to high- and low-numeracy 
participants. In addition, some participants received the framed information presented 
as a visual aid (an icon array, horizontal bar chart, vertical bar chart, or pie chart). The 
study reported that low-numeracy participants were more susceptible to framing than 
those with high- numeracy and that the provision of visual aids was an effective means 
to reduce the impact of framing (Garcia-Retamero and Galesic, 2010).  
 Systematic reviews on framing 
Two reviews were identified that collated research undertaken into framing effects. 
Edwards et al (2001) undertook a systematic literature search to identify papers which 
examined the presentation of risk information. This included a review of the effects of 
framing and other information manipulations on patient outcomes. The review was 
partially relevant, but obtained papers excluded by this review (the inclusion/exclusion 
criteria differed slightly). The literature review searched a variety of sources and there 
was a review of the quality of the methods of the papers included; however it was not 
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clear how this was undertaken. The review presented a narrative synthesis of the 
studies included, although where possible statistical meta-analysis had been 
undertaken. Analysis of the literature (4 studies) on attribute framing suggested there 
was no clear pattern of findings regarding the effects of negative and positive framing.   
With regards to goal framing, it was noted that there was a clear pattern which supports 
the greater effects of loss framing in promoting behaviour actions to protect against risk.  
The final review was a Cochrane systematic review (Akl et al., 2011b) which evaluated 
the effects of attribute and goal framing of the same information on understanding, 
perception of effectiveness, persuasiveness and behaviour of health professionals, 
policy makers and consumers. In terms of quality this study had clear methods, quality 
assessment and analysis. A meta-synthesis was undertaken of the relevant papers.  
The review included trials that were not included here, due to their focus on the 
presentation of risks, as opposed to the benefits of treatment. The review included 35 
papers involving 16,342 participants (all health consumers) and reported 51 
comparisons. Much of the evidence was reported as low to moderate in quality and a 
great deal of heterogeneity was reported. The review concluded that both attribute and 
goal framing had little, if any, consistent effect on health consumers’ behaviour. This is 
contrary to common beliefs about framing and is an interesting finding. The review 
considers that framing effects are more likely under specific but, as of yet, 
undetermined conditions and that more research is required to investigate these 
conditions.   
 Summary 
18 studies and 2 reviews were identified and incorporated in this part of the review. 
There is a range of research that has been undertaken into how the framing of 
information about the benefits of treatment impacts upon patient attitudes, knowledge 
and behaviours in relation to treatments. It was apparent that the research is varied and 
difficult to compare directly, although similarities exist. Much of the research is 
quantitative and on the whole used controlled experiments to assess the impact of 
framed information on treatment choice, although several uncontrolled studies were 
also identified. 
The studies examined the impact of both attribute and goal framing, with the impact of 
additional factors such as numeracy, involvement, age and cognitive impairment also 
being incorporated in a number of multi-factorial studies. These studies show the range 
of potential influences on how people perceive benefit information and the way it is 
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framed.  However due to their small size, and often low quality design and reporting, 
they may not provide a definitive answer as to the impact of external factors, such as 
age and cognitive impairment, on understanding the benefits of treatments when 
framed in different ways. 
The most striking finding was that contrary to the wider belief that framing impacts on 
behaviour, and to the findings of many of the individual research papers, it was shown 
that framing does not necessarily impact on behaviour. This also supports the theory 
that the framing of benefit information can impact upon patient understanding and 
behaviour. A systematic review did not find evidence that framing had any significant 
impact upon health consumers’ behaviour. This review was of good quality and used 
robust methods to pool the findings of 35 randomised and quasi-randomised controlled 
trials. The review focused upon both risk of harm and risk of benefit communication, 
whereas the scoping review reported here focuses solely upon the communication of 
benefits. However it is relevant, as it shows how a meta-analysis of studies can improve 
the power of findings: it may change the view about the effects of framing which has 
possibly arisen from the findings of multiple, lower quality studies. When biased  or poor 
quality studies are eliminated then the findings are contrary to the general belief that 
framing impacts upon patient choice. It is important to note that this review identified a 
great deal of heterogeneity among the research undertaken in this field.   
To conclude, there is wide range of research into the effects of framing. The body of 
literature is varied and shows that different frames of health information can potentially 
impact upon understanding and behaviour. However, when the data from good quality 
randomised controlled trials are pooled the framing effect is not shown to have any 
impact upon health behaviour.   
 
 Evaluation of the quality of the research in the review 2.7.7
 Scope and range of the methods 
The research undertaken into examining the effects of the presentation of benefit 
information in written health communications is large and heterogeneous. The body of 
research presented multiple methods, aims and outcomes and the types of format of 
benefit presentation were multiple and complex.  
There were a range of different research designs.  Several studies were small scale 
studies, examining the feasibility of presenting benefit information, e.g. Fuller et al 
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(2001 & 2002) who recruited n=50 and n=42 respectively.  The weight of the findings of 
these studies needs to be taken into account, while they offer an insight into use of 
benefit information, it is possible that their findings are subject to Type-II statistical 
errors and that they might not be appropriately powered in order to derive statistically 
significant findings. 
Several studies recruited large samples in a series of robust, well-described 
randomised trials. Gyrd-Hansen et al (2003) recruited n=3201 participants into an 
innovative study using a near full factorial design to explore different representations of 
ARR and RRR, and baseline risks. The series of studies undertaken by Tait et al 
(2010a, 2010b, 2010c), Zikmund-Fisher et al (2007) and Carling et al (2008, 2009, 
2010) also show the strength of the research being undertaken in this area. These are 
large-scale randomised trials examining a variety of different types of benefit 
information, collecting good-quality data and drawing conclusions which are significant. 
The body of literature also includes several systematic reviews. In particular the 
Cochrane reviews undertaken by Akl (2011a & 2011b), which combine the findings of 
RCTs on both the presentation of summary statistics and the effects of framing, offer 
substantial contributions to the field. 
 Representativeness of scenarios used 
The majority of the research used hypothetical scenarios in which the benefit 
information was presented in the context of illness and treatment. The level of realism 
within these scenarios impacts upon the findings of the study upon the potential 
applicability of the findings in a wider setting. 
The research included in this review used a number of different types of scenario.  
Ideally a study would recruit a real-life sample from the same group for whom the 
intervention is intended, and observe the impact on the actual decisions and behaviours 
made by the participants. Ideally the intervention would also be realistic and grounded 
in the evidence-base. Few studies achieved this. Some studies used simple scenarios 
based on fictitious illnesses and treatments. Several studies, whilst using robust 
methods were limited by their use of hypothetical scenarios. Often this research 
presented the benefits of a hypothetical drug, treatment for a hypothetical disease or 
the effects of a hypothetical screening programme. 
For example, Zikmund-Fisher (2005) used an experiment where participants were 
randomised to view one of 4 survival graphs presenting different magnitudes of benefit 
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associated with a treatment for a hypothetical illness called Crawford’s Disease 
(Zikmund-Fisher et al., 2005).  Others presented scenarios about ‘life threatening 
disease’ (Malenka et al., 1993) a ‘medical treatment’ to prevent ‘serious illness’ (Gyrd-
Hansen et al., 2003) or generic risks about cancer  (Cuite et al., 2008). The benefits of 
using these ‘generic’ scenarios about risk is that they allow the researchers to present a 
number of different risk values that might not be measurable in real-life situations and 
test the impact of these on participants’ attitudes and behaviours.   
Kristiansen et al (2002) recruited a large sample of the Danish population to evaluate 
their preference to consent to a hypothetical drug that reduces the risk of heart attack.  
They presented a series of different magnitudes of benefit and evaluated a participant’s 
intent to take the hypothetical medicine.  The findings were striking as the number of 
participants consenting to take the medication remained the same for all of the different 
magnitudes of benefit. The study concluded that NNTs were not understood as they 
had little impact upon the proportions that consented to treatment.  However, it is 
important to note the context in which the scenario was delivered.  The hypothetical 
drug was used to treat a heart attack, an illness likely perceived as severe by patients. 
Also the benefits of the medicine were presented in isolation and no harm information 
was present. In a real life situation most participants would make a trade-off between 
the potential harms and benefits of their treatment and may not accept such a small 
magnitude of benefit as was found in this research. It is also possible that participants 
might not accept such small benefits as represented by the larger NNTs for illnesses 
perceived as less severe.  This illustrates the limitations of using hypothetical scenarios 
and applying the findings of these studies to real-life situations. Such studies provide an 
insight into how benefit information might impact upon understanding on behaviours, 
but this insight is limited. 
Bersellini et al (2006) and Garcia-Retamaro et al (2010) presented participants with 
fictitious scenarios which were realistic but used fictitious medicines and also lacked 
presenting associated harm information.  Very few studies presented benefit 
information in the context of both benefits and harms. The exception is a series of 
studies undertaken by Tait et al (2010a) that explored how participants make risk and 
benefit trade-offs before making decisions about treatments (Tait et al., 2010a). There 
is a need for more research using real-life health scenarios in order to explore the 
authentic impact that benefit information might have. 
The use of hypothetical drugs in scenarios was common although some studies 
presented real clinical trial data. Galesic et al (2009a) used a hypothetical statin 
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medicine as part of a comparison with other drugs but the benefits of the hypothetical 
statin were based on data generated from actual clinical trials (Galesic et al., 2009a). 
Hux and Naylor, (1995), presented participants with benefit data from the Helsinki Heart 
study in order to evaluate how three different formats of the same data impacted upon a 
participant’s willingness to take the drug (Hux and Naylor, 1995, Frick et al., 1987).  
Some studies used real-life situations to facilitate hypothetical decision-making about 
treatments. Others presented comparative benefit information for different interventions 
for example different treatments for symptomatic carotid stenosis (Bergus et al, 2002).  
A study which explored whether NNT expressions performed better than ARR and/or 
RRR expressions used generic scenarios and presented treatment benefits out of 
context.  The findings showed that as a result of the hypothetical scenario, patients’ 
personal involvement in the tasks was reduced. This might impact upon how the people 
process information.  The study concluded that highly involved participants process 
information in a detailed and integrative way compared to those who are less involved, 
who process information more superficially (Sheridan et al., 2003).  This emphasises 
the importance of undertaking research which uses a scenario relevant to the subject, 
and also leads us to consider the representativeness of the sample. 
 Representativeness of sample 
The representativeness of the sample recruited to a research study also could impact 
upon the generalisability of the findings. Several studies recruited patients and used 
scenarios, which were of high-relevance to the real-life situation of the participant. 
Bhandari et al (2003) recruited patients presenting at a fracture clinic into a study which 
assessed preference for treatment for hip fracture and presented 5 different types of 
benefit information.  However, the sample was small and the study only assessed 
patient’s preference for format, nevertheless, the use of real-life sample and scenario is 
a strength of this research. Sheridan et al (2003) also recruited patients from a hospital 
waiting room, however provided participants with a hypothetical scenario.   
Malenka et al (1993), Hux et al (1995), Bergus et al (2002) and Galesic et al (2009) 
recruited participants who were either patients or those likely to make a similar 
treatment choice in the future.  The findings of these studies have importance resulting 
from the participants’ ‘involvement’ in the hypothetical decisions. 
Several studies recruited samples that were representative of the general population. 
However some had flaws in their sampling strategy that led to the recruitment of an 
unrepresentative sample. Fagerlin et al (2007) recruited women from a hospital 
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cafeteria to test how providing comparative risk information impacts upon risk 
perceptions. They recruited a convenience sample which included a high proportion of 
health care professionals who may not be representative of the general population. 
Galesic et al (2009), Cutie et al (2008), Schwartz et al (2009, 2007) and Gyrd-Hansen 
(2003) all employed recruitment strategies resulting in an above average highly-
educated sample.  The findings of their studies must be interpreted in light of this. 
Studts et al (2005) recruited pre-clinical medical students to undertake an experiment 
where participants received one of four vignettes examining preferences on 
communicating the benefits of adjuvant chemotherapy.  Although the findings are 
relevant, notably that the use of absolute survival benefit was preferred over negatively 
framed methods,  it is important to note that these findings might be biased by the 
samples’ higher numeracy and potential familiarity with different formats of risk and 
benefit presentation.   
Non-representative samples were commonly used in experiments, such as those 
recruiting undergraduate students to research health conditions that were not common 
in the younger population.  Price et al (2007), Timmerman et al (2008) and Studts et al 
(2005) all recruited undergraduates who often have higher numeracy skills than the 
general population (Price et al., 2007).  Another challenge with using participants who 
are not representative of the population of interest is that they might not have the same 
‘involvement’ that a patient with experience of the disease has. This has been shown to 
affect participants’ interaction with decision-making and the processing of information 
(Rothman et al., 1993).  It is important that in the context of research into medical 
treatments the most representative sample is the population likely to use the medical 
treatment and this population might not be demographically similar to the general 
population. Studies examining a disease that occurs predominantly in the older 
population should recruit representatively from the older population, for example the 
sample recruited by Natter et al (2005) had a mean age of 28.2. They asked 
participants to consider a scenario about ‘flu vaccination and it is possible that the 
sample might not have involvement in the scenario and that this might impact upon the 
applicability of the findings. 
Few studies adequately evaluated the impact of providing benefit information to actual 
patients in real-life scenarios. Bergus et al. (2002), and Bhandari et al. (2003) Galesic 
et al. (2009) all recruited patients and presented them with a scenario that was specific 
to the participants’ condition.  Whereas Hux and Naylor (1995), Goodyear-Smith et al. 
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(2008) and Malenka et al. (1993) recruited patients and presented them with scenarios 
which were hypothetical and unrelated to their condition.  
Several studies recruited large and representative samples and presented scenarios 
which were realistic and had significant relevance to the sample. Tait et al (2010a, 
2010b 2010c) undertook a series of large-scale studies evaluating the impact of 
providing parents with information about a clinical trial in order to examine decisions 
about enrolling a child in the trial.   
To conclude, the methods used in much of the research in this field mean that the 
findings are potentially biased, mostly due to a tendency not to recruit representative 
samples, but also because of the problems inherent in using hypothetical scenarios as 
the setting for studies. Well-designed studies in this field used both a realistic scenario 
and also recruited a population which was representative of the target population. The 
findings of such studies are likely to be more generalisable. Caution should be used 
when applying the findings to different populations, especially when a sample has a 
high level of educational attainment. 
  Overall benefit scoping review findings 2.7.8
This review has shown the diversity and scope of research being undertaken into the 
effects of presenting benefit information to the general population. There is a great deal 
of breadth and range to the type of research being undertaken. There are a number of 
different methods that can be used and some of these formats have been more 
thoroughly researched than others.  
It is apparent that there is a significant amount of research focussing on the feasibility of 
presenting different formats to patients, and there is some good quality evidence that 
patients can use different formats of benefit information, and find its inclusion in written 
health communication provides them with more detail about likely benefits. It is 
apparent that its inclusion is preferable to absence.  
The research has shown that benefit information is complex, it can be challenging to 
present and difficult to interpret. Poorly designed benefit information is not valuable at 
conveying accurate treatment benefits. 
There is a large amount of research of a good quality that shows how different formats 
can have different influences on patient perceptions of risk.  For example it is well 
known that benefit information presented as an RRR can increase over-estimations of 
benefits and increase a participants intent-to-take a treatment, without improving their 
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understanding about what the information really means. It is apparent that techniques 
such as natural frequencies and ARRs tend to help patients make decisions about 
treatments that are in line with their values. For people to get the most out of the benefit 
information, it is therefore important for it to be presented in context. There is good 
evidence suggesting that the presentation of baseline risks can help improve accuracy 
of risk perception. 
There is also a good deal of research that suggests the benefits of using graphical 
formats such as bar charts and icon arrays on improving the accuracy of risk estimation 
on patients perceptions (not presented in this review). These methods have been 
proved to be effective in some circumstances. 
However it is also important to note that other areas are less well-researched.  For 
example, there is some evidence recommending that NNTs be avoided as they are not 
easily interpreted by participants.  However the research proposing these findings is 
flawed and did not present the NNTs in a context that was applicable in real life. There 
is a need for more good quality research, especially high quality RCTs, assessing the 
impact of providing different formats of numerical information on patient behaviour, for 
example. 
It is also important to note that in some situations, where there is an absence of 
evidence, that this does not mean there is evidence of absence of effect. Formats 
where there is a lack of research, or where research has not shown positive effects may 
still be effective, it may be that design flaws or the size of research studies have not 
resulted in real positive effects being noted (Altman and Bland, 1995). 
There is no definitive answer as to which type of format is better. Although it is apparent 
that different formats can have different impacts, so understanding the aim of the 
benefit information when choosing which format to use is important. Some formats, 
such as the RRR, can promote behaviour change.   
There is also a need to understand more about how an individual’s perspectives, values 
and circumstances can influence risk understanding. How the context in which people 
live with risks and benefits and how people can influence the risk in question impacts 
upon their perceptions of benefit information, and on their beliefs and behaviours 
(Edwards et al., 2003). More qualitative studies examining these concepts in detail 
would add valuable context to the body of literature. 
The body of work is also lacking in research that has been undertaken in a naturalistic 
setting, with real-life patients being given actual benefit information and which assesses 
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the long-term and actual impact on behaviour. There is clearly a gap in the literature 
which assesses the feasibility of providing actual benefit information, which is relevant 
to a specific health condition to patients with that health condition and assessing the 
impact that it has.  
There is also a need to undertake more research about the presentation of benefit 
information in context i.e. with the presentation of benefit information alongside the 
presentation of existing risks about treatments. Tait et al have undertaken some good-
quality large-scale studies evaluating the impact of this on patient decision-making. 
More research on how patients make trade-offs between real life risks and benefits 
would add significantly to the literature (Tait et al., 2010a, Tait et al., 2010c, Tait et al., 
2010b).  
 Application of the findings  2.8
 Headline section 2.8.1
The idea of the use of a headline section in medicines information internationally has 
been receiving a higher profile in recent years (Medicines and Healthcare Products 
Regulatory Agency, 2005a, Food and Drug Administration, 2009).  However, there has 
been very little research undertaken into how a headline section might impact upon a 
patient’s knowledge, understanding and use of medicines information.  Much of the 
research in this area has focussed upon ‘warning’ labels, incorporating research into 
signs, symbols and labels. The context of this research differs slightly from the aims of 
this review; as a result, the findings of reviews should be interpreted accordingly.   
The evidence-base focussing specifically upon a summary of key information in a 
written document is almost non-existent and, before a decision is made to incorporate 
this adaptation into medicines information, there is a need for further research. In his 10 
top tips on writing medicines information, Dickinson and co-authors suggest “Now ask 
the experts: patients” (Dickinson et al., 2001). Clearly there is a need to undertake 
relevant research with patients in a naturalistic setting to assess how they use and 
understand information provided in a headline section in written medicines information.  
This is essential to assess the utility of such a technique and to ensure it aids patients 
with finding and understanding key information about their medicines, rather than 
hindering them (Hartley, 2004). 
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Key findings and application:  
 No evidence was identified that confirms that a headline section might be 
detrimental to the reader, encouraging them to skip over a boxed section in a 
body of text. It is unclear whether a headline section in a PIL has the potential to 
be detrimental to a reader. 
 There is no evidence to suggest that a particular format of headline section is 
optimal.  
 As a result the type of headline section identified by the MHRA will be 
considered for use in this research.(Medicines and Healthcare Products 
Regulatory Agency, 2005a) 
 Benefit information 2.8.2
There is a large and heterogeneous body of research exploring the potential impact of 
including information about the benefits of treatments in written health information. The 
findings are equivocal and the evidence suggests no clear format which is best suited to 
use in a PIL. The review of the literature revealed a number of key findings which will be 
useful to guide the development of benefit statements to be used in exemplar leaflets in 
the following stages of research in this thesis. 
The addition of a textual statement about the effectiveness of a medicine can enhance 
a reader’s preference for information and understanding about the benefits of a 
treatment in context and would be a feasible addition to a PIL (Bersellini and Berry, 
2007b, Bersellini and Berry, 2007a, Vander Stichele et al., 2002).   
The presentation of numerical information about the benefits of treatments provokes 
varied responses. RRRs in particular can be misleading and persuasive, leading people 
to make decisions that might not be line with their values (Carling et al., 2009). The 
review has also shown the necessity of providing baseline information when presenting 
numerical information (Sheridan et al., 2003, Fagerlin et al., 2007, Natter and Berry, 
2005) 
It has also shown the potential for natural frequencies to communicate the benefits of 
medicine (Akl et al., 2011a). Graphical formats of benefit communication, such as icon 
arrays and bar charts, also have great potential and have been shown to improve risk 
perception and understanding of medicines. However, their use in a regulated patient 
information leaflet is limited due to the space required to adequately communicate 
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graphics. (Space is at a premium in a PIL). There is no clear evidence that framing 
impacts upon patient understanding or behaviour. (Akl et al., 2011b). 
Key findings and application: 
 The use of an RRR format is not recommended. 
 The use of a textual statement has been shown to improve risk perception. 
 The use of a natural frequency has been shown to be useful 
 There is limited research into the impact of NNTs, although some findings 
suggest this format might be difficult for some people to understand.  More 
research would be valuable. 
 There is no clear evidence that framing impacts on patient understanding or 
behaviour and as a result a combined frame will be presented. 
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 Focus groups (Study 2) Chapter 3
Patient perspectives on the inclusion of headline section and information about 
benefits in a patient information leaflet 
 
 Introduction 3.1
The two scoping literature reviews (chapter 2) identified several potential approaches to 
the inclusion of a headline section and information about benefits in a regulated PIL. 
This chapter describes how these approaches were used to develop PILs. which were 
then used as stimulus materials in focus groups to explore the perspectives of real-life 
users of medicines about the inclusion of a headline section and information about 
benefits.  
The chapter is presented in several sections:  
Firstly the methods of the study will be described and the justification for the use of 
these methods explained. [3.2 Methods, 3.3 Recruitment, 3.4 Stimulus materials,3.5 
Data analysis]  
Two sections that follow describe, respectively, the findings for the headline section 
and the benefit information strands of the study. This includes the presentation of data 
collected during the focus groups, which will be used to inform the findings of the study 
and provide context about the perspectives of the participants on the two interventions 
included in the leaflet. [3.6 Study findings, 3.7 Headline discussion, 3.8 Benefit 
information]   
Finally there will be a discussion about the results of the study which will be placed in 
the context of existing literature. Consideration will also be given to how the findings 
can be applied to the next stage of the research in order to further explore the impact of 
a headline section and information about the benefits of medicines in a PIL. [ 3.9 
Discussion, 3.10 Conclusion] 
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  Research aims and objectives 3.1.1
Headline section aims 
The study aimed to: 
1) Identify preferences and suggestions for presenting a headline section in 
regulated PILs. 
2) Explore how the inclusion of a headline section in a PIL impacts upon 
knowledge and satisfaction with medicines, and potential medicine-taking 
behaviour. 
Six objectives specific to the headline section were identified to guide the design and 
conduct of the study: 
 Identify the range of opinions on the inclusion of a headline section in a PIL. 
 Identify the range of preferences for different formats of a headline section in a 
PIL. 
 Map the range of factors that affect preference for headline section in a PIL. 
 Identify the impact that the inclusion of a headline section has on people’s 
understanding of, and satisfaction with, their medicines and medicines 
information. 
 Describe the potential impact on medicine-taking behaviour. 
Benefit information aims: 
The study aimed to: 
3) Identify preferences and suggestions for presenting benefit information in 
regulated PILs. 
4) Explore how the provision of benefit information in a PIL impacts upon 
knowledge and satisfaction with medicines, and potential medicine-taking 
behaviour. 
Six objectives specific to benefit information were identified to guide the design and 
conduct of the study: 
 Identify the range of opinions on the inclusion of benefit information in a PIL. 
 Identify the range of preferences for different formats of benefit information in a 
PIL. 
 Map the range of factors that affect preference for benefit information in a PIL. 
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 Identify the impact that benefit information has on people’s understanding of, 
and satisfaction with, their medicines and medicines information. 
 Describe the potential impact on medicine-taking behaviour. 
 Methods: headline and benefit. 3.2
 Methodology 3.2.1
This is a qualitative research study which uses focus groups as a data collection 
method. It applies a generic qualitative research approach, employing both descriptive 
and interpretive techniques to explore the opinions of users of medicines about 
suggested changes to the leaflets provided with medicines. A generic approach is 
described as one which “seeks to discover and understand a phenomenon, a 
process, or the perspectives and worldviews of the people involved” (Caelli et al., 
2003).  
A qualitative approach is essential in order to explore and understand differing patient 
perspectives on a headline section and information about benefits in PILs, which can 
then be used to inform further leaflet development in the later stages of the research. 
There are a range of qualitative approaches which could be used to inform the methods 
for this study - approaches which are more or less suited to different epistemological 
perspectives and different aims.  
Alternative approaches considered include grounded theory (Glaser and Strauss, 
1967), which is an inductive qualitative method designed to generate theory about a 
specific topic where little is known about it. A key feature of this approach is its iterative 
process, theoretical sampling and system of analysis (Lingard et al., 2008). Other 
interpretive approaches include phenomenology, an approach designed to describe 
the common meaning for lived experiences of a concept or phenomenon, and 
ethnography, which focuses on understanding culture. An ethnographic approach 
tends to examine a large group of individuals sharing a common culture (Creswell, 
2013).  
These methodologies have well-established strengths but are not appropriate for this 
study. Cultural roles no doubt impact upon medicine-taking and access to medicines 
information but this research does not intend to explore that aspect in detail - therefore 
an ethnographic approach is not suitable. Likewise, the methods of grounded theory are 
not appropriate to the aims of this study which are, initially, simply to understand in 
more detail medicine-users’ preferences and opinions on the interventions of interest. 
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The aims of the initial focus groups are to test preferences for content and format of the 
leaflet; therefore a generic qualitative approach is best suited to this goal.   
Generic qualitative research, also referred to as qualitative description, is a pragmatic 
method which is compatible with the use of questions such as “why”, “how” and “what”, 
which qualitative research examines.  Sandelowski summarises qualitative description 
as research which offers a comprehensive summary of an event in the everyday terms 
of those events (Sandelowski, 2000). This approach tends to be the least theoretical on 
the spectrum of qualitative methodologies and has been criticised for its lack of 
theoretical position. It has also been criticised for being less interpretive than methods 
which describe an event in terms of a conceptual, philosophical or other highly abstract 
framework (Thorne, 2008). However, Sandelowski (2000, 2010) refutes this view, 
claiming that qualitative description produces findings which are ‘closer’ to the data than 
those produced by grounded theory or phenomenological research, as the method is 
less transformative. The aim of qualitative description is to present the facts of the case, 
a comprehensive summary of an event, in everyday language (Sandelowski, 2000).  
Qualitative description is an appropriate method as it is both pragmatic and meets the 
aims of the study (which are ultimately practical as opposed to theoretical). While it has 
been criticised as being the least theoretical approach, it is not atheoretical and the use 
of theory can be woven into the methods to provide breadth and depth to the findings 
(Sandelowski, 2010). This approach assumes an ‘a priori’ understanding of the subject 
and uses the expert knowledge of the researcher, and the research team, to set 
priorities and develop the research questions and topic guide in a way that other more 
theoretical approaches might not. Again this is something that reflects the practical aims 
of developing recommendations for a regulated PIL, which is the intention of this body 
of research. 
  Data collection methods 3.2.2
Focus groups are an appropriate method for data collection in the context of this study, 
as they can collect large amounts of data and facilitate an environment which allows for 
the sharing of different perspectives. They also encourage group discussion and debate 
about stimulus materials, such as the exemplar leaflets, which may be less dynamic in 
an individual interview (Kitzinger, 1995, Geis et al., 1986, Holstein and Gubrium, 1995).  
A topic guide was used to stimulate discussion during the focus groups. The questions 
were developed around the central topics of the research study and used a modified 
‘knowledge, attitudes and beliefs’ framework to explore the different perspectives on the 
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changes to the PILs. With regards to attitudes towards the interventions, there was a 
specific focus on patient satisfaction (Ajzen, 1991) (Appendix 5). 
 Research Ethics consideration 3.2.3
Research ethics approval was obtained from School of Healthcare Research Ethics 
Committee, University of Leeds on 26 April 2012 (SHREC/RP/271). 
 Recruitment 3.3
Participants were recruited from fliers placed in community pharmacies and distributed 
amongst community elderly action groups that were within travelling distance of the 
University of Leeds.  Approximately 1000 flyers were distributed across Leeds (See 
appendix 4).  A further e-mail flier was sent to the members of the University of Leeds, 
School of Healthcare service user group. The fliers stated that interested participants 
should contact the researcher and an email address and telephone number was 
enclosed. 
Participants were evaluated against the inclusion criteria, using brief questions about 
medicines use, educational attainment and whether they were a practising healthcare 
professional with expertise in medicines information; then allocated to appropriate 
groups accordingly. The initial contact also provided an opportunity to discuss or 
provide further information over the phone or via e-mail. 
The sample was a convenience sample, with the inclusion criteria set to recruit a group 
of participants who were typical of the population of medicine-users. A research pack 
was sent to interested participants comprising a confirmation letter (which also provided 
instructions on how to read the different leaflets), a patient information leaflet about the 
research and 3 exemplar PILs. Participants were advised to read the leaflets before 
attending the focus groups, although it was stated that they need not read the whole 
leaflet, just familiarise themselves with it. (Appendices 6&7) 
Inclusion criteria 
 Aged over 50 years 
 Current prescription for at least one medicine 
 Able to read a patient information leaflet written in English. 
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Exclusion criteria 
 Current prescription for sumatriptan and simvastatin (the medicines used to 
develop the leaflets), as they may have prior knowledge about the medicines, 
which could impact on their perceptions of the benefit information.  If a 
participant was prescribed one of these two medicines, they were allocated into 
a focus group for the alternative medicine (i.e. a participant with a prescription 
for sumatriptan was eligible for inclusion in the group receiving leaflets based on 
simvastatin, and vice versa).  
 Employed in a job that involved providing medicines information to patients.  
 Visual impairment that prevents them from reading a standard leaflet. 
 Setting 3.3.1
Focus groups were held in a meeting room at the University of Leeds. Six focus groups 
were undertaken during June and July 2012, with between 6-9 participants recruited to 
each group. In total 42 participants were recruited, a sample size which facilitated a 
variety of perspectives and experiences, without the groups being too large to manage 
and without the themes that arose from the groups becoming too repetitive. 
The focus groups were divided so that 3 groups received exemplar leaflets for 
Janatriptan (n=23) and 3 focus groups received them for Rebastatin (n=20). RD and an 
additional moderator ran all the groups. The groups were held at the University of 
Leeds and lasted between 1 hour 30 minutes and 2 hours. The groups were held at 
various times to accommodate participants’ schedules. 
A brief PowerPoint presentation was used to emphasise the focus of the discussion i.e. 
either on the headline or the benefits information. The slides included: 
 the percentage and natural frequency benefit information from the exemplar 
leaflets. 
 the positive and negatively framed statements - in order to generate discussion 
about preference for different framings of information. The statements were 
labelled ‘positive’ and ‘negative’ and referred to as such during the focus groups 
in order to highlight the difference between the statements in a way which was 
easy for the participants to refer to.   
 Groups were run by RD and a moderator. RD presented the questions from the topic 
guide, facilitated the discussion and kept the groups to time. Each focus group was run 
in a similar order. The topic guide questions and the benefit statements were presented 
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in the same order throughout. The moderator made notes of topics and concepts being 
discussed and observed the level of participation from the group.  
Participants were provided with written information about the study prior to their 
involvement in the focus group and were advised that they were free to leave the group 
at any point. Consent was obtained prior to commencement of the group discussion. 
 Participants 3.3.2
58 potential study participants contacted the researcher. 16 were excluded due to being 
unable to attend the groups, because they were a practising healthcare professional or 
because, after receiving further information about the study, they declined to be 
involved. The final sample comprised 42 participants, of whom 29 were females, and 
they had an age range of 50-89. 
Table 7: Participant characteristics. 
Category Sub-
category 
FG1 FG2 FG3 FG4 FG5 FG6 Total 
N  7 8 6 6 9 6 42 
Women  3 5 5 5 7 4 29 
Age range  56-78 51-70 54-63 57-64 50-81 58-89 50-89 
Education No 
qualifications 
- - - 1 - - 1 
 Foundation - - 1 - - 3 4 
 Intermediate 2 - - 1 3 1 7 
 Advanced 5 2 4 3 3 - 17 
 Higher - 6 1 1 3 2 13 
Ethnic 
group 
White British 6 8 6 6 9 2 36 
 British Asian 1 - - - - 1 2 
 British 
Caribbean 
- - - - - 1 1 
 British Other - - - - - 2 3 
Items of 
medicine 
1-5 6 7 6 5 6 3 33 
 6-10 - 1 - - 2 2 5 
 11-15 1 - - - 1 1 3 
 No data - - - 1 -  1 
Exemplar 
medicine 
 JANA REBA JANA REBA JANA REBA - 
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 Stimulus materials 3.4
In total 6 leaflets were designed, based on 2 different medicines;  
 Simvastatin -  given the  hypothetical name Rebastatin 
 Sumatriptan -  given the hypothetical name Janatriptan  
The headline and benefit information are shown in Figures 7-10, the full leaflets are 
shown in appendix 9.  
The leaflets were as follows: 
[1] Rebastatin: Typical 
[2] Rebastatin: Headline 
[3] Rebastain: Benefits 
[4] Janatriptan: Typical 
[5] Janatriptan: Headline 
[6] Janatriptan: Benefits 
Each focus group considered either Rebastatin or Janatriptan, hence each participant 
viewed only 3 leaflets. 
The typical leaflets were designed to resemble typical patient information currently 
provided with medicines in the UK. The headline section leaflets contained a summary 
of key information about the medicine. The benefit sections comprised 4 different 
benefit statements which were presented as a series of flaps, with a different colour 
used to highlight each benefit section.  
The section below describes the justification for the choice of design of the interventions 
and the justifications for choosing the medicines for which the leaflets were designed. 
 Choosing the medicine 3.4.1
Leaflets were designed based on two different medicines used for different conditions: 
1) Sumatriptan – used for the symptomatic conditions of migraine or cluster 
headache. 
2) Simvastatin – used for the asymptomatic conditions of hypercholesterolaemia, 
hyperlipidemaemia and the prevention of cardiovascular events.  
Medicines used for different treatment goals were chosen specifically to facilitate a 
deeper level of enquiry about how perspectives on the interventions may vary 
depending upon the purpose of the medicine. It has been shown that people have 
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different perceptions about the severity of different illnesses and this may impact upon 
the balance of risk and benefit that patients will accept with their medicines (Simes and 
Coates, 2001, Leventhal et al., 1998).   
Previous research exploring the inclusion of benefit information in a PIL for a commonly 
prescribed heart medicine found the numerical benefit information to be unwelcome and 
something which evoked strong responses from participants recruited to a similar focus 
group study (Hamrosi et al., 2012). The numerical benefit information provided to the 
participants in that study was an NNT presented as: 
If 100 people took this medicine for 2 years 
 3 of them will be saved from having a heart attack 
 1 of them will be saved  from having a stroke 
One of the findings from that study was participants were surprised that the level of 
benefit was as ‘low’ as 1 - 3 in 100. This aims of this study are to explore whether 
similar responses to numerical information are evoked with medicines that have higher 
magnitudes of benefit.    
It was also decided to choose medicines for long-term conditions, the rationale being 
that these are the most commonly prescribed, they consume most of the national drug 
budget and are more likely to be associated with problems such as non-adherence.  
Advice was sought from experts in prescribing and medicine management, including a 
GP (n=1), pharmacists (n=5) and a nurse prescriber (n=1), on which medicines would 
be most appropriate for the research.  Advice was also sought from an experienced 
patient advocate (GD) on the potential issues that might arise from choosing different 
types of medicine.  
It was agreed that any medicines chosen had to meet the following criteria: 
 Have commonly acknowledged safety issues (data provided from the MHRA on 
adverse drug reporting was used a criteria to measure this).  
 Have data available for risks and benefits. 
 Be commonly prescribed in a population that can be pragmatically recruited to a 
research study. 
Medicines excluded from consideration included: 
 Medicines with multiple indications. Development of the benefit statements is 
complex and the addition of several benefit statements for different indications 
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was challenging for this exploratory work. Therefore the use of a medicine with 
few indications, ideally one, was appropriate. 
 Medicines with complex instructions for use; it was considered that such 
instructions have the potential to lead the participants away from the focus of 
discussion about the benefits. 
The medicines were given hypothetical names, Janatriptin and Rebastatin, to ensure 
that they could not be confused with currently available medicines. The leaflets also 
contained a highlighted section which stated that these leaflets were for research 
purposes only. 
 Designing the headline section 3.4.2
The scoping literature review (See chapter 2) was designed to provide the rationale for 
developing the headline sections used here. However, the review found no clear 
evidence for the best way of presenting such summary information. As a result, the 
headline sections were developed based on that used by the MHRA in their publication 
‘Always Read the Leaflet’ (Medicines and Healthcare Products Regulatory Agency, 
2005a).  
The MHRA criteria are given in full in figure 5. The key points relevant to the current 
study are: 
- Concise, key information. 
- Information on safe and appropriate use. 
- Presented at the beginning of the leaflet. 
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Both headline sections used in the study complied with these proposals. Both leaflets 
presented the headline section at the beginning of the leaflet. The headline was 
highlighted using a grey shaded box. Six short, bullet-pointed pieces of key information 
about the safe and effective use of the medicine were presented. The headline section 
contained a brief textual statement about the benefits associated with the medicine. 
 Concise key information on the safe and appropriate use of a product  
 A focus on information that the patient must be aware of for safe and effective 
medicine use. 
 Headline information at the beginning, presented to maximise visibility and 
likelihood of being read. This might include highlighting the text or using a 
larger font size. 
 Information presented as a short series of bullet points – in most cases 2  - 6 
points should suffice; however, there is no “standard” length with discretion 
needed in deciding the number and type of headlines. There may be some 
simple products for which no headlines would be necessary 
 Only the key messages on safe and appropriate use of the product. As a 
general principle, the section should be kept short in order that patients do not 
rely on it as a substitute for reading the main body of the PIL. 
 The most essential messages, bearing in mind the product and its therapeutic 
context. Typically these may relate to: 
o why the patient should take the product; 
o the maximum dose or duration of treatment; 
o potential side effects/withdrawal reactions (symptoms to look out for, 
especially for common or serious side effects); 
o contraindications; 
o important drug interactions; 
o circumstances in which the drug should be stopped; 
o what to do if the medicine doesn’t work; or 
o where to find further information. 
 “Positive” information on the anticipated benefit of taking the medication 
should be included (usually as the first bullet point) - to provide balance and 
context for the “negative” information referring to possible adverse events. 
Positive information should be limited to short factual statements stating the 
licensed indication (eg “Your doctor has prescribed [PRODUCT] because it is 
a treatment for X). Specific efficacy data or other product claims should not be 
included. 
 A standard form of wording indicating the patient should read the rest of the 
leaflet. The date of the latest revision of the leaflet should be stated, so that 
long-term users will be aware when there is a need to re-read the PIL. 
 Consistency across all products containing a particular drug substance and/or 
drug class is encouraged.(Medicines and Healthcare Products Regulatory 
Agency, 2005a) 
Figure 4: MHRA proposals for headline sections in PILs 
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Underneath the headline was a statement advising that the user read the remainder of 
the leaflet. 
In Always Read the Leaflet, the MHRA presented an exemplar headline section for 
Carbamazepine in a box with an outline. Expert opinion on the presentation of summary 
information in a box within a body of text suggests caution when using this technique as 
it might lead to the reader skipping over the boxed information and ignoring it, although 
the literature review in Chapter 2 did not identify any research which confirmed this 
theory (Hartley, 2004). A decision was therefore made to present the headline section 
in a grey shaded box, rather than a boxed outline, placed prominently at the top of the 
PIL. The use of textual signposts in the headline followed the same format as those 
used in Always Read the Leaflet.  
The key messages included in the headline were agreed by the pharmacist members of 
the research team (TR and JM).  
 Designing the benefit information 3.4.3
The findings of the scoping literature review (chapter 2) did not show any particular 
method of benefit presentation to be superior and a decision was made to present 
participants with a number of different formats. Absolute risk formats were used rather 
than relative risk reduction statistics, in line with the findings of the scoping review.  
The formats chosen were highlighted in the scoping literature review as those that had 
positively impacted upon patient preference and understanding in comparison to other 
formats. Natural frequencies and absolute risk reductions have been shown to facilitate 
understanding of numerical data and increased satisfaction with information (Carling et 
al., 2009, Carling et al., 2010, Tait et al., 2010a). Textual statements were identified as 
adding value to the information about medicines provided in a PIL and improved 
understanding about medicines and satisfaction with the information (Bersellini and 
Berry, 2007a, Bersellini and Berry, 2007b).  
A number needed to treat (NNT) statistic was also chosen. Research into the NNT has 
shown that it is frequently misinterpreted; however the research in this area is limited 
and further research of its potential in a naturalistic setting would be welcome (Sheridan 
et al., 2003, Sarfati et al., 1998, Kristiansen et al., 2002).   
As a result the following statements were created: 
1) A textual statement of the rationale and effectiveness. 
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2) One using percentages to describe the ARR (presented using a combined 
frame). 
3) One using a natural frequency to describe the ARR (presented using a 
combined frame). 
4) One using a Number Needed to Treat expression.  
The use of graphical formats was discounted for practical reasons, despite evidence 
that they can aid understanding. In the context of a PIL it is difficult to incorporate their 
use, as to be able to accurately display such information requires space. This is at a 
premium on a PIL. Also well-designed graphics tend to rely on the use of colour, which 
might not be possible in all PILs. 
 Source of benefit information 3.4.4
Several data sources were considered for generating the numerical data in the benefit 
statements. The ‘gold standard’ for studies into the effectiveness of medicines is a 
systematic review of trials with meta-analysis. Consequently if a Cochrane systematic 
review exists on the chosen medicines, then data would be used from this source. 
Sumatriptan 
Data were derived from a Cochrane systematic review on the effectiveness of 
Sumatriptan (oral route of administration) for acute migraine attacks in adults (Derry et 
al., 2012).  
The Cochrane review presented multiple outcomes for the effectiveness of sumatriptan. 
Headache relief at 2 hours was chosen as the relevant outcome, after discussion with 
the same experts as above. Using this outcome generated an NNT with a denominator 
of 4 (4 people need treating for 1 to benefit). This was deemed sufficiently different from 
the denominator for simvastatin of 20. 
Simvastatin 
A Cochrane systematic review was available, but it combined data from different types 
of statin and included trials on primary and secondary prevention (Ward et al., 2007).  
As PILs are medicine-specific it is essential that data are medicine-specific, and not an 
aggregate of information from a group of medicines. NICE guidelines on lipid 
modification were also considered, however they also presented combined data on the 
benefits of different statins.  
As a result, a single large randomised placebo-controlled trial of cholesterol-lowering 
with Simvastatin in secondary prevention was chosen: the Heart Protection Study 
105 
 
(2002)  (Heart Protection Study Collaborative Group, 2002).This was an independently 
funded study which recruited over 20,000 participants to explore the effectiveness of 
simvastatin compared to placebo. 
One of the key outcomes measured by the Heart Protection Study was the reduction in 
major vascular events, specifically major coronary event, any stroke or 
revascularisation. After discussion with experts in prescribing and medicine 
management, including a GP (n=1), pharmacists (n=5) and a nurse prescriber (n=1), it 
was decided that these events would be those that patients would want to know about 
when making decisions about their treatment.  
 Creating the benefit statements 3.4.5
The benefit expressions were derived using a risk generator, which calculates formats 
of risk/benefit by comparing the outcomes of different treatment effects in clinical trials 
(Spiegelhalter, 2012). The results were checked with pharmacists with expertise in 
research and medicines management (RK and DA) for accuracy. With regards to the 
format of the NNT statistic, there was no evidence in the published research to suggest 
whether to present the numerator or denominator first in the benefit statement. 
However, the majority of the research on NNTs presents the denominator first (Carling 
et al., 2009, Carling et al., 2008, Sheridan et al., 2003, Bhandari and Tornetta, 2004, 
Studts et al., 2005, Sarfati et al., 1998, Hux and Naylor, 1995, Edwards and Elwyn, 
1999). This format is also reflective of the wording used in the natural frequency 
statements. Therefore the denominator was presented first in the benefit statements in 
order to provide consistency. 
Several statements were generated and there followed several rounds of amendments 
where they were revised until they were readable, consistent and understandable. A 
consensus agreement was made on the statements amongst RD, DKR, PK and JM. 
  Production of leaflets 3.4.6
The leaflets were produced to imitate standard leaflets. Three leaflets were developed 
for each medicine: 
1) Usual leaflet, which contained the information that would usually be included in 
a PIL. 
2) Headline leaflet. This leaflet contained a grey shaded box containing key 
information about the medicine. The box was entitled ‘Important things you 
should know about XXX’ (Figure 6&7). 
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3) Benefit leaflet. This leaflet contained the four benefit statements shaded in 
different colours. This was to facilitate ease of discussion with participants who 
would be unfamiliar with the technical terms used for each type of statement in 
the literature. They could therefore refer to the ‘orange’ or ‘blue’ statement, for 
example. The statements were presented in a series of flaps that overlaid each 
other and opened up in a booklet style, so only one statement could be read at a 
time (Figure 9&10). 
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Important things that you need to know about Janatriptan 
 Janatriptan is used to treat migraine – only use if your doctor has confirmed you 
have migraine attacks. 
 Janatriptan only works when a migraine attack has started. It will not stop you 
from getting an attack. 
 Do not take Janatriptan if you have ever had heart, circulation, or blood pressure 
problems, or have had a stroke (Read Section 2: Before you take Janatriptan) 
 Do not take Janatriptan at the same time as other migraine medicines. Also, 
some other medicines affect Janatriptan. This includes medicines for depression 
and some antibiotics (Read ‘Taking other medicines’ in Section 2) 
 Janatriptan may harm the unborn baby. Talk to your doctor before taking if you 
are pregnant. 
 After taking Janatriptan you may feel chest pain or pressure for a short time. If 
this feeling is very bad, or does not go away, talk to a doctor straight away.  
 
Figure 5: Example of the headline section used: Janatriptan. 
Important things that you need to know about Rebastatin 
 Rebastatin is used to lower levels of cholesterol and other fats in your blood 
called tri-glycerides. This can help reduce your chance of getting heart problems. 
(Read Section 1: ‘What Rebastatin is and what it is used for’) 
 You need to keep to your cholesterol-lowering diet as well as taking this 
medicine. 
 Some medicines affect how Rebastatin works. This includes medicines for fungal 
infections, HIV/AIDS, antibiotics and depression. (Read ‘Taking other medicines’ 
in Section 2) 
 Rebastatin can cause serious muscle problems in a very small number of 
patients.   If you get unexplained pain in your muscles, or they feel tender or 
weak - stop taking the medicine and talk to your doctor at once. 
 Do not drink grapefruit juice while taking this medicine. This is because it could 
increase your risk of muscle damage. 
 If you are pregnant or trying to get pregnant or breast feeding you must not take 
Rebastatin (Read Pregnancy and Breast-feeding in Section 2). 
 
Figure 6: Example of the headline section used: Rebastatin. 
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Figure 7: Example of the headline section in situ in leaflet. 
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PURPLE: 
 
Janatriptan reduces the swelling of blood vessels in the brain and can improve your 
chance of having a less severe migraine headache after 2 hours.    
 
 
BLUE:  
The chance of having a less severe migraine headache after 2 hours is 32%. This 
becomes 57% for people who take Janatriptan. 
This means that the chance of not having a less severe migraine after 2 hours is 68%. 
This becomes 43% for people who take Janatriptan. 
  
ORANGE:  
In 100 people like you, 32 will have a less severe migraine headache after 2 hours. This 
becomes 57 in 100 of those people who take Janatriptan.  
This means that in 100 people like you, 68 will not have a less severe migraine 
headache after 2 hours. This becomes 43 in 100 of those people who take Janatriptan. 
 
GREEN:  
If 4 people like you take Janatriptan, 1 of them will have a less severe migraine 
headache after 2 hours. 
 
 
Figure 8: The four benefit statements - Janatriptan. 
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PURPLE: 
 
Rebastatin can lower levels of cholesterol and tri-glycerides in your blood and can 
reduce the chance of you having a heart attack or stroke. 
 
 
BLUE:  
The chance of not having a heart attack or stroke over the next 5 years is 75%.  This 
becomes 80% for people who take Rebastatin.  
This means that the chance of having a heart attack or stroke over the next five years is 
25%. This becomes 20% for people who take Rebastatin.  
  
ORANGE:  
In 100 people like you, 75 will not have a heart attack or stroke over the next 5 years.  
This becomes 80 in 100 of those people who take Rebastatin. 
This means that in 100 people like you, 25 will have a heart attack or stroke over the 
next 5 years. This becomes 20 in a 100 of those people who take Rebastatin. 
 
GREEN:  
If 20 people like you take Rebastatin over the next 5 years, 1 of them will be stopped 
from having a heart attack or stroke. 
 
Figure 9: The four benefit statements - Rebastatin. 
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Figure 10: Example of benefit statements in situ in leaflet. 
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 Data analysis 3.5
The focus groups were audio-taped and 3 were transcribed by the researcher (RD) and 
3 by an external company. RD and the moderator of each focus group met after each 
group to discuss the outcomes from the groups and consider dominant themes and 
striking perspectives. As a result, field notes were prepared to support the data 
analysis.  
The general methodological approach to the study was described in chapter 3.2.1; what 
follows is a brief description of the approach used for data analysis. The framework 
analysis approach was used to analyse the data in this study. Data analysis in 
qualitative descriptive studies tends to use a form of content analysis and framework 
analysis is a well-described framework which can be applied to the content of depth 
descriptions collected through methods such as focus groups or interviews (Creswell, 
2013).  
Other methods, such as grounded theory, were considered. Grounded theory is 
characterised by a process where data collection and analysis occur simultaneously, 
with the aim being to use what is uncovered in the interviews to build upon during 
further interviews. This is particularly useful when very little is known about a subject 
(Glaser and Strauss, 1967).  Framework analysis does not have an underlying 
epistemological grounding in the same way as grounded theory, but is instead a 
practical response to the challenge of undertaking qualitative research with specific 
outcomes in a short time scale. (Lacey and Luff, 2007) It is pertinent to the underlying 
intentions of this study, which are based in applied health research. The aim of this 
enquiry is not necessarily to uncover a ‘new’ theory but instead to generate new 
information and incorporate that with knowledge already acquired, to respond to 
objectives driven by policy on medicines information.  
Framework analysis is well-suited to the pragmatic aims of this study. Its roots are in 
applied policy research and the approach is particularly appropriate for projects with 
explicit aims, such as this one. This method is being increasingly used in applied health 
research due to its systematic approach, which allows the researcher to undertake a 
meticulous approach to qualitative analysis leaving an effective and transparent audit 
trail (Smith and Firth, 2011). One criticism of the ‘generic’ qualitative descriptive 
approach is that it is not thorough and that its methods are not always adequately 
described (Caelli et al., 2003). The use of the framework approach addresses this issue 
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as one of the strengths of framework analysis is that it is systematic and leaves a clear 
data trail, which facilitates rigour (Spencer et al., 2003). 
This method is effective for analysing cross-sectional descriptive data, enabling 
different aspects of the phenomena of interest to be captured (Smith and Firth, 2011). It 
is a thematic approach, which is considered less in-depth than grounded theory. 
However it usually provides richer findings than content analysis. Using the framework 
approach enables the researcher to develop a framework and analyse various aspects 
of the captured phenomena across the entire framework. This facilitates the production 
of an emergent account of the data which develops from a basic thematic description of 
the phenomena to a deeper description which allows for the creation of themes and 
typologies and can explore relationships across the range of interviews or groups.  
The following phases were undertaken:  
a) Familiarisation with the data 
The audio-recordings were listened to and the transcripts and field notes were read 
several times, although were not double-checked for accuracy by other members of the 
research team. Emerging themes were considered and discussed with the research 
team.  
b) Identifying a thematic framework 
A thematic framework was developed, which is a list of concepts or themes that can be 
applied in order to organise or code the data into initial themes. The initial coding 
framework was developed from familiarisation with one focus group. Each line of the 
focus group was considered and initial thoughts on its meaning, were noted (appendix 
10). 
These initial themes were then refined and grouped into a thematic framework, which 
contained 9 substantive themes with a number of sub-themes. RD developed the initial 
framework and applied it to 1 focus group initially. Another researcher (JM) 
independently used the framework to code the same focus group as a reliability check.  
RD and JM compared the similarity in coding and any discrepancies or disagreements 
were resolved through discussion and consensus. Two further researchers (TR and PK) 
checked the applied framework to sections of the same focus group to assess its 
usability and relevance.  
There was consensus among the researchers concerning the thematic framework 
developed for the headline section. There was less unanimity in applying the codes 
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associated with the benefit information; as a result some amendments were made to 
clarify definitions of codes.  Comments from all members were taken into account, to 
ensure the framework was agreed.  
c) Indexing 
The thematic framework was applied to all the focus groups and used to code the data. 
An initial check of a segment of coding of an interview by JM confirmed unanimity in its 
application. 
d) Charting 
The data were then sorted according to each theme. This allowed the researcher to 
focus on the distinctions and details within each theme. The data were then 
summarised into a thematic chart where a matrix for each substantive theme was 
developed with sub-categories heading each column. The individual participants and 
their comments were charted across the rows. The aim of this process is to summarise 
the data, while retaining the original meaning in a format which allows for easy 
referencing between different cases (appendix 12). 
e) Mapping and interpretation. 
There followed a process of mapping and interpretation where the different cases were 
compared across the matrix, to develop a descriptive account of participants’ opinions. 
There also followed a deeper, multidimensional analysis of the data where themes were 
described and grouped according to similarities and differences.  
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Figure 11: An example of the analysis exercise undertaken to develop the 
categories and sub-categories. 
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Typologies were developed across the cases, resulting from a cross-case analysis of 
the charts, with attention being paid to any deviant cases. The initial codes were 
grouped and refined until a clear and organised group of categories and sub-categories 
emerged. See appendix 16 for the refinement and emergence of the main categories 
and typologies. 
An example of a chart was checked by another member of the research team (JM) who 
had also moderated the focus groups. JM was provided with an example of the data 
trail from interview to coding to charting through to the process of mapping and 
interpretation. The different stages of mapping and interpretation were discussed and 
the emerging categories agreed by consensus. 
 Study findings: Headline section 3.6
Overall there was a great deal of consensus within and amongst the different groups on 
the subject of the inclusion of a headline section in a patient information leaflet. The 
majority of the participants in all groups felt that a headline section would make for a 
positive addition to a PIL and, although a small number voiced concerns about the 
headline, all but one expressed a preference for the leaflet containing the headline 
section.  
The findings were grouped into categories and sub-categories that related to the initial 
research questions that focused on opinions on the headline section in a PIL and how 
this might impact upon patients’ satisfaction and understanding of their medicines.  The 
key findings are given below under the following headings: 
 Noticing the headline 
 Engaging with the headline 
 Influence of the headline 
 Desirable features 
 Format 
 Noticing the headline 3.6.1
 The headline was noticeable 
The preliminary information given to the participants drew their attention to the headline 
section. This means it was difficult to evaluate how noticeable participants found the 
headline section. However, most participants reported that they felt the headline section 
was something that drew their attention. 
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“I thought it was excellent. It leapt out and the white font on the grey background 
leapt out and was in your face and the fact that the paragraph had a grey 
background to it as well...I think your eyes are drawn to it.” (F, 61, FG2, REBA) 
Several features aided participants in noticing the section. The position of the headline 
at the beginning of the leaflet was identified as contributing to it being noticeable. 
“I like it because it’s right at the front, it’s not at the back, you notice it straight 
away, it’s like, you know, this is it, read this first because if you read it and then 
you get down there and you think, urgh, because it’s repeating itself so if you’ve 
got it there it’s... you’ll read that first.”  (F, 62, FG4, REBA) 
 
“Exactly, and it’s near the beginning, so you don’t have to wade through.” (F, 58, 
FG6, REBA) 
It was felt that the beginning of the leaflet was an important place because it enabled 
the reader to access important information immediately. 
“I think it makes good use of the beginning of the leaflet. I think it is a good place 
for it. Because that’s not immediately apparent in the first leaflet [usual leaflet], 
that that’s the very beginning, or near the very beginning. Because the very 
beginning of the information leaflet is an important place and it should be giving 
you the stuff that you really want to know immediately there. I think it was well-
positioned and it does function.” (M, 60, FG3, JANA) 
 It appeared ‘important’ 
The choice of wording, in particular the heading ‘Important things...’ was also viewed as 
something that drew some participants’ attention. 
“When I see ‘important things’, I would read it, just that word alone would draw 
me towards, to read this part. Not at the moment but when I see ‘important 
things’, you know, automatically I will want to read It”. (F, 69, FG6, REBA)   
 The shading is ‘eye-catching’   
Several participants reported that the grey shaded box drew their attention and helped 
them notice the information: 
 “I think the tint makes you feel it’s important to read, it’s catching your eye. 
Otherwise it’s all just the same thing.”(M, 64, FG1, JANA) 
 
However, there was some discussion in the groups about the choice of colour for the 
tint, with some participants concerned that the choice of black font on a grey tint might 
reduce the readability of the text. 
“In another leaflet you might use a different coloured tint altogether that made it a 
little bit more legible.” (F, 68, FG1, JANA) 
 
118 
 
There were frequent discussions in several groups about a similar feature on the leaflet, 
which was an artefact of the research process. This was the yellow highlighted section 
that stated ‘This leaflet is for research purposes’. It was common for participants to 
prefer the yellow tinted box to the grey colour chosen for the headline section. Despite 
this attraction to the yellow highlighting, participants were aware of the potential 
limitations of using colour in leaflet and some expressed concerns about cost as well as 
readability for visually-impaired populations, such as those with colour blindness and 
older people. One participant spoke of having a problem with her vision and how she 
had found the shaded section easy to read as it helped it stand out. 
“I find the grey box very useful because I don’t actually see white, I see a shade 
so that being shaded makes it stand out a bit more, yeah.  That definitely drew 
my attention straightaway.” (F, 67, FG5, JANA) 
Only one participant expressed concerns about how noticeable the headline section 
was, as she thought it was a typing or printing error: 
“I looked at it purely because I thought that had been some typing error or 
photocopying error. The grey didn’t stand out for any other reason, so that was 
the reason I looked at it. I wouldn’t say I was particularly impressed with it. The 
font was slightly larger than the font on the leaflet in that area, but it didn’t attract 
me. It certainly didn’t make me look at that bit more than the first one, except that 
at first I thought it was a printing error.” (F, 56, FG3, JANA) 
 
However, other participants in the same focus group felt that even if the reader initially 
thought the shading was an error it had still drawn their attention and that it would help 
them engage better with the information. 
 Engaging with the headline 3.6.2
 Current leaflets are challenging to engage with 
One key finding that emerged was the difficulty that participants had in engaging with 
and understanding current PILs, which they felt were unappealing, too technical and 
generally quite a challenge to read. 
 “I always read, but I do find it far, far too difficult and too much information” (F, 
70, FG2, REBA) 
“This (leaflet) is a very long piece of paper and it would put most of us senior 
citizens off” (F, 69, FG, REBA) 
Patients found them time consuming to read and the information difficult to navigate. It 
was apparent that several participants undertook different behaviours to help them 
manage the volume of information in a leaflet. This included circling and highlighting the 
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text, ‘skimming’ through the leaflet and picking out information that was perceived to be 
relevant. These behaviours were aimed at making it easier to obtain relevant and 
important information. 
“I read them. They can get complicated. I tend to make notes if it’s of reference to 
me, you know, circle things that I’m also taking.” (M, 61, FG4, REBA) 
 
 Reduces the challenge of reading the leaflet 
As a result, for several participants the headline section was a welcome addition to the 
leaflet, as they felt the summary aided them in trying to make sense of the information 
provided. 
“I think it’s recognition that the whole of the leaflet is quite an arduous read that 
you have to plough through it. So I feel they are offering some new major points, 
important points, right up there. It almost shows a bit of respect for the patient 
having to read this, because you might need a summary. It doesn’t mean that you 
don’t read the rest of the leaflet, because you do! It highlights the important 
points. That’s what it says it is doing, and as far as I can see, that’s what it does.” 
(M, 60, FG4, JANA) 
 
The inclusion of the headline section appeared to ease the challenge of accessing 
relevant information in a document that patients felt was difficult and technical. It 
lessened the cognitive burden apparent for many patients that can result from an 
overload of information and so stopped the leaflet feeling quite so daunting: 
 
“I think that’s a brilliant idea, so I mean if you don’t want to go through the 
daunting task of reading the whole leaflet, it draws your attention to that which 
means that that is the most, what she says, important things.” (F,62, FG4, REBA) 
 
“I think that it’s quite clear and less intimidating than some of the more detailed 
stuff you get later.” (M, 64, FG5, JANA)  
 “It’s more user-friendly” (F, 70, FG2, REBA) 
Several participants also felt that the headline section was a technique that responded 
to how arduous some people find the task of reading the leaflets and finding relevant 
information about their medicines. The headline provided a useful summary that 
patients reported as easing the burden of reading what is perceived as a challenging 
and boring piece of technical writing. It was viewed as more user-friendly: 
“ I preferred it to the first one because it’s a bit of a summary and you need a bit 
of a summary at the top if you are just having a bit of a quick read” (F, 54, FG3, 
JANA) 
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 The influence of the headline section 3.6.3
Participants reported that the headline section had the potential to impact positively 
upon both their satisfaction and understanding with the information they received, but 
also potentially upon their medicine-taking behaviour.  
 The influence upon patient satisfaction with medicines information 
Participants reported they were satisfied with the contribution the headline section 
made to the leaflet: 
 “I think it’s very good because it’s bringing the main, the most important 
things…so even if you don’t see the rest of it you are reading the most important 
things” (F, 57, FG4, REBA) 
“The box is brilliant” (F, 63, FG4 REBA) 
There was a good deal of enthusiasm about the inclusion of the headline section and all 
participants except one said they preferred the leaflet with the headline section. The 
headline was viewed as concise, informative and a positive addition to the leaflets.  
“Yes, it’s very short and sweet. You can read it and understand it”. (P5, F, 68, 
FG6, REBA)  
 
 The influence on knowledge and understanding about medicines. 
The headline section was viewed as a technique that had the potential to improve a 
reader’s ability to understand more about his or her medicines. 
“I think it would encourage more people to read the highlighted section and if you 
made that section good enough and accurate enough and short enough and 
clear enough, they would pick up the gist of it very quickly through that 
highlighted section.”(M, 63, FG1, JANA) 
Current leaflets were viewed as lengthy and impenetrable whereas a positive attribute 
of the headline was that the information was presented in smaller, bite-size chunks, 
which several participants felt, might help them to retain information.  
“I think that having it précis so it’s something that relates to you very quickly and 
which tempts you to go on and read a bit more about it, providing then you don’t 
have to go through the whole leaflet to get to it. I think you would be very tempted 
to read that section.” (M, 56, FG3, JANA) 
“It was a little list of do’s and don’ts that you can cross reference with the leaflet. 
Even if you can’t be bothered to read what is written in the rest of the leaflet, you 
can follow that grey box and you’ll be OK.” ( M, 65, FG2 REBA) 
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 The influence on health behaviours 
There was no evidence that the headline section would impact upon the medicine-
taking behaviours of any of the participants, nor was there any evidence that it would 
significantly impact upon informed decision-making, i.e. encouraging participants to 
make decisions that were in line with their values. However, it was apparent that the 
headline section had the potential to influence attitudes and behaviours towards the 
use of medicines information. Throughout the focus groups, both positive and negative 
repercussions were discussed in response to the provision of information containing a 
headline. 
a) Encouraging the non-reader 
The headline was viewed as something that might encourage people who were usually 
reluctant to read their leaflets, or who found the information difficult to process, to read 
more about their medicines in the first instance. Some participants who stated they did 
not always read their leaflets reported that they would be keener to read the headline 
section. 
“I think what I would do; I would scan it (the headline section). I wouldn’t read all 
of it, but I would scan it… would think ‘right, that’s not relevant for me, not 
relevant for me’. But yes, I would actually read it.” (F, 70, FG5, JANA) 
Some participants still reported that they would read it especially if the prescription was 
new.  
 “I think I’d be more likely to read it earlier on.” (M, 59, FG 2, REBA) 
 
b) Discouraging the reluctant reader 
A small number voiced concerns that the headline section might actively discourage 
them from reading the rest of the leaflet: 
 “Personally for me, I think I’d read less of the leaflet, because those things down 
there aren’t relevant to me, so I wouldn’t read them, unless it was the first time 
and if it was the first time then I would probably read them because I do tend to 
read everything the first time” (F,56, FG 3, JANA). 
“The only thing is, that some, who would not ordinarily, or who might not read the 
leaflet if they think that’s the most important thing, will they think the rest doesn’t 
matter? It’s quite possible.” (M, 89, FG1, JANA) 
 
One participant considered that this decision was the prerogative of the reader, who 
needs to take responsibility of her own medicine-information needs. 
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“I think it’s very good because it’s bringing the main, the most important things so 
even if you don’t see the rest of it you’re reading the most important things. But 
then, as I say you cannot spoon-feed everyone. People are adults, they have to 
take responsibility” (F, 57, FG 4 REBA) 
 
c) Overall impact 
Concerns were expressed that the headline section would not engage all users of 
medicines and that it had the potential to discourage further reading of the leaflet. 
However, participants acknowledged the challenge in communicating about medicines 
effectively and noted that although many users of medicines were unwilling or unable to 
engage, the headline section might benefit more people than it would impact on 
negatively. The communication of medicines information was frequently viewed as a 
two-way process between the sender and the receiver; participants felt that there was 
responsibility on the receivers’ part to engage in this process. 
On balance, it was considered that the inclusion of the headline section was still 
beneficial as it may encourage those who wouldn’t usually read a leaflet to read the 
important points. 
“If you did see the summary that might be all that you would read. I’m the sort of 
person who would read it anyway. But I feel that some people, who might not 
read a leaflet, might not read that and go any further, but as you say, it does 
seem that it’s the important points and these are the bits that we need to tell them 
and I think it’s a good thing.” (M,51, FG 2, REBA) 
 
Other concerns included that the headline section was not very influential and that it 
might not contribute to significant changes in behaviours that promote and support the 
safe and effective taking of medicines. However, again it was accepted that the 
headline section was an improvement to what was available already and, while it might 
not have a substantial impact on the safe and effective taking of medicines (although 
this was not assessed during this study), it may help people to better engage with their 
medicines information and inform them about important aspects: 
“I think, particularly in elderly people who may have sight problems or who may 
not feel comfortable reading, and I think they may feel comfortable in the 
knowledge that they may not have to wade through the leaflet. But it might not 
change what they do…but they might have more knowledge than they would 
otherwise.” (F, 61, FG 2, REBA) 
 
Despite some minor concerns about the headline section discouraging the reading of 
the rest of the leaflet, most participants felt that the headline was a concise and 
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informative précis. They expressed the view that it treated them with respect, helped 
them to engage with their medicines information, encouraged a better understanding of 
medicines and had the potential to encourage some readers to at least engage with a 
small, but important part of the leaflet. 
“What I could picture somebody doing is cutting that out and sticking it on their 
notice board or sticking it on their pillbox, something like that. Because that’s a 
real memory aid…that’s it all in a bullet point! And then they have got a full copy, 
because they have probably got more than one of these, sitting in the back of a 
drawer somewhere. And every other one, they just bin.” (M, 65, FG 2 REBA) 
 
 Desirable features of a headline section 3.6.4
 The content of the headline section 
Many of the participants appeared satisfied with the content of the headline as 
presented. They felt it was concise, informative and reflected what they wanted to know 
about their medicines: 
“I prefer this one as well (Headline leaflet) because it is everything about the 
medicine in a nutshell, there and then.” (F, 69, FG6, REBA) 
“Also, what it contained. I felt it was very, very helpful and it referred to other 
things within the further content of the leaflet and you could follow that up if you 
wanted to. I thought that was really good.” (F, 61, FG2, REBA) 
When asked about their preference for the type of information that should be included in 
a headline, it was apparent that safety concerns were a high priority. Participants 
wanted to know about important, pertinent issues with their medicines, especially issues 
that they felt might be potentially harmful: 
“I preferred it (the headline leaflet) to the first one because I think it’s a bit of 
summary and you need a bit of a summary at the top so if you are just having a 
bit of quick read...it should have the main things, the most dangerous things...If 
you take it with this, then you will die!” Those sort of things. Then if you need to 
find out a bit more you can read the rest of the blurb underneath it. But I think a 
summary with the vital facts is really useful.”  (F, 54, FG3, JANA) 
Some of the issues commonly reported as desirable in a headline section included drug 
interactions, contraindications,  side-effects, allergies, how much and when to take, 
where to find further information, what to do if you have a problem.  
It was commonly reported that it was useful for the headline section to contain some 
information about what the medicine is for. This information appeared to help provide 
context to both the medicine and the information provided in the headline and enable 
the individual to apply the information to their own situation. 
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“And I love the fact that it tells you what it’s for. You know, the first point is that it 
is for migraines. Because I was given lots of things for chemotherapy and I didn’t 
know what they were for and I was trying to look at them and see because I didn’t 
know. I wanted to see which were steroids and which were...because I didn’t 
want to get them all mixed up. And it’s easier if it’s very obvious on them.” (F, 54, 
FG3, JANA) 
While there was a clear tendency for participants to want their attention drawn to key 
safety messages, there was some conflict on how this should be achieved. For some 
participants the headline section was the ideal opportunity to provide ‘in your face’ 
warnings about the potential danger of the medicine. 
“To me the issue is, rather than having this (refers to headline). It’s nice, but it’s 
verbose. It still takes some reading. But to have that ‘take care’ or ‘danger if’, in 
black and white, so it’s really in your face...It needs to frighten you...’danger if’ 
and at the bottom ‘get back in touch with your doctor’” (M, 56, FG1, JANA) 
Some older participants found this approach to be concerning and something that could 
potentially discourage them from taking their medicines. 
“I’d find that frightening...the old people that I am living with, if they saw ‘danger’ 
they would get frightened and, like my friend, just throw their tablets away. (F, 78, 
FG1, JANA) 
The need to strike a balance between informing about potential harms without being too 
alarmist was noted. 
 Concerns about repetition 
Another area where a need for balance was identified concerned the amount of 
repetition in the leaflets. A small, but vocal minority in FG1 disliked the amount of 
repetition.  
“I agree with you in so far as the information is included word for word and line for 
line in the shaded section to the section which is headed in this leaflet ... I think 
we are in danger of making the leaflet bigger again by putting that section in, 
when the information is already there. I would have thought they could condense 
the information and have a new heading for it and that new heading would be 
‘important things that you need to know about JANA and what it is used for’ to 
combine the two rather than, you’ve got it there and you’ve got it here, you can 
just rule them 2 out and put a combined new paragraph in, that’s my thought on 
it.” (M, 63, FG1 ,JANA) 
The concern about repetition stimulated some debate about the role of the headline in 
FG1, which was not apparent in the other focus groups. There was conflict about the 
amount of repetition, in particular what constituted too much and what was in fact a 
necessary emphasis on key information.  
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One participant noted the need to strike a balance to ensure the headline section 
functions in providing and reinforcing clear and concise essential information, but keeps 
superfluous repetition to a minimum: 
“If you cut out all the repetition then it could become confusing. But you need to watch 
that you don’t repeat things that don’t need repeating and there are a lot of superfluous 
bits that you could cut down on and still make it clear.” (F, 68, FF 1, JANA) 
 The format of the leaflet 3.6.5
 “If they look good it might encourage you to read them.” (M, 60, FG4, 
JANA) 
The headline format chosen was popular; participants felt it was well-set out and 
noticeable. The headline appeared to achieve its objectives but was viewed as 
functional, basic and visually unattractive. 
“If they look good it might encourage you to read them. And this (the headline 
section) is almost industrial grey and it has a very fine print and a whole list of 
things that are very uninviting” (M, 60, FG3, JANA) 
It was apparent that the users of medicines desired information that was more attractive 
and aesthetic, but which remained functional: 
“The other thing that bothers me, they are all the same the leaflets. Not one 
contains any icons, any pictures, any logos, any exclamation marks, just to make 
it [a] more attractive and [b] more pleasant to read. You don’t need a lot, just little 
logos, icons which will help. All you have got is thousands of words, all mingling 
into the other” (M, 76, FG1, JANA). 
Many suggestions were made as to the type of techniques that might help and such 
suggestions varied. Using a coloured headline was a popular suggestion, as well as the 
use of bold font, a large font size, logos and icons, underlining, italics, upper-case 
lettering and the use of a border (rather than a shaded box). There were many such 
suggestions but, at the same time, it was clear that participants were cautious about 
using too many techniques, preferring to ‘keep things simple’. They also expressed a 
desire for ‘uniformity’ of the leaflets and for the leaflets to be aesthetically pleasing. 
 Sign-posting 
One final recommendation about the headline section referred to the issue of sign-
posting, to allow the reader to cross-reference within the leaflet. This issue was only 
raised in one group where some participants reported difficulties in using the headline 
to find the more detailed (maybe better) information that was further down in the leaflet.  
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 “I think it’s quite useful to have that there and I do think that something like that 
might be a bit better in being a bit bigger and then having your cross-referencing. 
So you have your important information you’ve got it and if you read this bit alone 
you’ve got more information, but if you want more you know where to find it...” (F, 
68, FG1, JANA) 
 
  Headline discussion 3.7
The aim of this qualitative study was to examine the potential impact of providing a 
headline (or summary) section in a regulated PIL on the satisfaction, knowledge and 
potential medicine-taking behaviour of medicine-users. The findings are supportive of 
the inclusion of a headline section in a regulated PIL and include suggestions for 
improvements made by participants.  
The headline section, presented in this research, as a summary of key points of 
information about a medicine in a grey shaded box, was seen as a valuable addition by 
almost all participants. There was very little dissent or conflict expressed about the 
inclusion of the headline section. 
The headline section was viewed as noticeable, something that drew the eye and 
appealing. A key finding was how daunting reading an existing leaflet was perceived to 
be. This is something that has been noted in previous research, including a systematic 
review which identified how patients felt there was a significant gap between patient 
information leaflets and information that patients would value (Raynor et al., 2007). 
Despite improvements to leaflets produced since the review, possibly resulting from 
guidelines which aim to improve the readability of PILs (European Commission, 2009), 
it appears that patients still perceive shortcomings. Patients still view the information 
leaflet as technical documents that are difficult to read and use.  
 Key Finding: The headline section reduced the burden 3.7.1
patients felt in finding important and relevant information 
The headline section was viewed as a potential solution to the daunting prospect of 
reading existing leaflets. Participants felt it responded to the arduous and challenging 
task they had themselves of summarising the key, important facts about their 
medicines. They felt the inclusion of the headline section treated them with respect and 
lightened the load of retrieving important information, in comparison with existing 
leaflets. 
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Cognitive load theory could be used to explain participants’ acceptance and high levels 
of satisfaction with the headline section. This theory describes how cognitive resources 
are focused and used during learning and attempts to provide a framework to illustrate 
how cognitive processes and instructional design are linked (Chandler and Sweller, 
1991, Sweller and Chandler, 1991). According to the theory, complex instructions are 
better understood when design is focused on reducing the cognitive load placed upon 
the reader when engaging with them.  
The theory assumes that an individual’s cognitive load may vary due to both intrinsic 
and extraneous factors. The intrinsic load refers to the inherent difficulty of the 
information content. Medicines leaflets are inherently complex, they can include difficult 
concepts, and this cannot always be altered because of the legal framework. However, 
according to cognitive load theory, the use of good instructional design, which pays 
attention to the different factors which impact upon understanding, can change the 
extraneous cognitive load placed by the materials onto the reader. It is feasible that the 
headline section works to reduce the extraneous load, which aids understanding and 
increases the satisfaction the participants experienced after receiving a leaflet with a 
headline section (Paas et al., 2003, Sweller and Chandler, 1991). 
The theory describes several different instructional effects which can be used to reduce 
extraneous cognitive load. Some of these effects are relevant to the headline section 
and it is probable that its use contributes to understanding and satisfaction in the 
following ways:  
(a) It is plausible that the inclusion of the headline section in a large body of text 
contributes to the redundancy effect, which occurs when unnecessary information is 
presented. A common complaint about the leaflets in general was the amount of 
information they contained that participants felt was not relevant to them. The headline 
section potentially reduces the superfluous information patients wrestle with when they 
first encounter a leaflet and helps prioritise key issues and facilitates understanding. 
(b) Participants reported using several coping techniques to manage the amount of 
information provided in a PIL. For example skimming the leaflet, or picking out the 
important parts. It was apparent that, for the participants, the key information about the 
medicine was scattered amongst the leaflet, and their attention was split by searching 
amongst the different sections to find the information relevant to them. This could 
potentially increase the chance of a split-attention effect occurring, which according to 
cognitive load theory can cause illegibility. Reducing the split-attention effect by 
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consolidating the essential information might potentially increase legibility of the leaflet. 
(Cooper, 1998, Paas et al., 2003)  
(c) Cognitive Load Theory also supports the theory that ‘chunking information’ 
together minimises extraneous load and increases the legibility of an instructional 
document (Cooper, 1998). The aim of the headline section is to consolidate key 
information on the safe and effective use of medicines and the findings support the 
theory that chunking of information is beneficial to readers.  
 
 Key Finding: Patients noticed and engaged with the 3.7.2
headline section 
Most participants noticed the inclusion of the headline information, even if (in one case) 
it was because they felt a mistake had been made during the printing. Most participants 
felt the headline section drew their eye and provided them with important information 
they needed to know.  Participants spoke highly of the headline section, often stating 
that they could see the difference between the headline leaflet and the usual leaflet 
immediately and that their initial reaction was that the difference was an improvement.  
While this was commonly reported, and something that participants were enthusiastic 
about, it is important to note that the ability of the participants to notice the headline was 
not tested. The headline leaflet was provided with instructions on how to find and use 
the headline section, which would impact on perceptions of noticeability. In a natural 
setting it is possible that the findings might be different. 
 Key finding: Good design is essential  3.7.3
Participants valued well-designed leaflets which looked attractive and were well set out. 
Current leaflets were perceived to have significant failings attributed to poor design. 
They were viewed as boring and complicated and did not encourage patient 
engagement. The groups had several ideas about improvements, which included the 
increased use of colours and symbols to help make the leaflets more aesthetically 
pleasing. A common concern was the size of the font, and this has been noted in 
previous research (Raynor et al., 2007).  
The headline section was viewed as an improvement to the leaflet, although it was 
apparent that a segment of the groups found it to be similar to the current leaflets in its 
lack of appeal. A general recommendation is to improve the aesthetic of the leaflets and 
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pay attention to good design.  If a headline section is to be included, attention should be 
paid to ensure it is aesthetically pleasing, yet remains functional and usable. 
There is little research in this field that focuses specifically upon the use of summary 
sections, such as a headline section, in medicines information. The use of techniques 
such as boxes and outlines have been suggested to be problematic in instructional 
design generally, because they can separate the information from the main body of text 
and this can impact negatively upon a reader’s comprehension (See chapter 2). Hartley 
suggests that there is little evidence for these concerns, but their use remains 
controversial (Hartley, 2004).  
 Key findings: What information is important? 3.7.4
The headline sections for both Janatripatan and Rebastatin were seen as having a 
good balance of information. Section 4.5.2 describes the list of key information 
identified by the MHRA as important to consider for inclusion in a headline section. The 
same types of information were identified as important in the focus groups. There were 
few deviations from this list, and the list of key issues did not differ significantly in any of 
the groups. 
The issue of the sign-posting of the information contained in the headline was raised 
during one focus group. Several participants stated that they desired each piece of key 
information in the headline section to be more effectively cross-referenced, so they 
could find it more easily in the main text.  This group received the leaflet for Janatriptan, 
which contained 2 textual sign-posts in the headline section which directed the reader 
to the section of the leaflet where additional information could be found; however it did 
not appear to be commonly noticed in the focus groups. The issue of sign-posting is 
important. The reader should be able to find important information about his or her 
medicines with ease and attention should be paid to ensure that the headline section 
facilitates this. 
 Study findings: Benefit information 3.8
It was apparent that for most participants the benefit information presented in the focus 
groups provoked a range of strong responses. The individual responses were often 
varied and fluid, changing throughout the course of the focus groups as participants 
engaged with the information and shared and explored new perspectives. This meant 
that for some participants, their initial responses transformed as they developed a new 
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understanding. However, frequently participant’s initial responses were often very 
pervasive and did not appear to change when the participants were asked again about 
their preferences at the end of the focus groups.  
Four main categories were identified which map the range of responses about the 
benefit information, they are as follows: 
1. Initial reactions to general benefit information 
2. Preference for the inclusion of benefit information and preference for format. 
3. Barriers to engaging with benefit information 
4. The impact of the benefit information 
The first category of findings aims to present the participants’ perspectives based on 
their initial ‘gut’ feelings and reactions. There follows a category that describes the 
preference for the different formats of benefit information and maps the range of 
response about each statement. Category 3 presents the multiple barriers to engaging 
with the benefit information and explores how this might impact upon decision-making 
about medicines. The final category explores the impact of the benefit information on 
understanding and knowledge and explores how patients reported this might impact 
upon their future medicine-taking behaviour. 
 Initial reactions to general benefit information 3.8.1
There was a range in terms of participants’ ability to understand the information within 
the groups. It was apparent that the benefit information provoked varied initial, gut 
reactions, ranging from acceptance to hostility. The strongest negative reactions were 
reserved for the numerical data in particular, and where possible the reactions 
described are differentiated between the textual and the numerical format.   Four 
different types of participant initial response to the benefit information were identified. 
 Non-engagement 
One type of response noted from several participants was that of non-engagement, 
where the participant did not like, nor wish, to engage with the benefit information. (This 
was particularly evident when numerical benefit statements were discussed). Textual 
benefit information was tolerated, but viewed as unnecessary or superfluous. This 
response was characterised by a lack of interest through to a strong dislike for the 
benefit information.  
These participants frequently stated that they would do what the doctor advised and 
that they did not wish to engage with the benefit information.  They did not appear to be 
active participants in decision-making, preferring to take without question medicines 
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that the doctor prescribed. However when questioned on their understanding of the 
information, they did seem potentially able to understand the benefit information and 
could express opinions on the different formats when asked to do so. However, the 
benefit information was not welcomed in a PIL. These views tended to be immovable 
and fixed. 
 Non-understanding 
The information presented was challenging for most participants and many struggled to 
understand it. However, there was a small group who did not appear to understand the 
information at all. It was very difficult to gauge the opinions of this group on the different 
formats and often when questioned about a preference for format, or on how the 
information might impact on them, they would answer with a vague question about 
medicines information in general.   
“I liked the purple [textual] because it was a nice soothing colour, it reminded me 
of lavender” (F, 54, FG3, JANA) 
Their opinion again tended to be immovable and fixed, with a lack of interest in the 
inclusion of benefit information (particularly in numerical form) in a PIL. 
 Positive appreciators 
A small number of participants expressed a positive response about the inclusion of 
benefit information. This group appeared to understand the information and welcomed 
its inclusion in a PIL whole-heartedly. For this group, the information led them to feel 
they were being treated with respect and enabled them to make choices about their 
medicines. The positive appreciators’ opinions were subject to change when discussing 
preference for format, but they remained positive about the inclusion of the benefit 
information itself.   
 The concerned majority 
The majority of participants found the benefit information very challenging to interpret, 
irrespective of format. For this group the benefit information induced a number of 
emotional responses. These responses were often fluid and changed through the 
course of the focus groups as the participants had the opportunity to talk about the 
benefit information and explore different perspectives and contexts. This group was not 
homogenous but incorporated a number of different initial reactions to the benefit 
information, which were often emotional. Several different types of initial response were 
noted: 
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a) Surprise at the poor benefits 
It was common for participants to express shock and surprise at what they perceived to 
be poor benefits of the medicines. The benefit information was viewed as negative and 
participants were genuinely surprised at how few would benefit from taking the 
medicines. The likelihood that people would benefit from taking the medicines was not 
as good as they expected. 
A few participants expressed their opinions on what a good benefit would be, 
suggesting that many may over-estimate how likely their current treatments are to 
benefit them. 
“It was a surprise, but I wasn’t surprised at how many people benefited. It was 
how many didn’t. And I just presumed, maybe because I’ve never had a migraine, 
but that these medicines, say maybe 90% did benefit the patient.” (F,56 FG3, 
JANA) 
“19 out of 20 is good pill.” (M, 89, FG6, REBA) 
There were no differences in perspective for either of the medicine groups. Both 
medicines were perceived to have poor benefits and were not as good as expected. 
b) Fear and nihilism  
The benefit information had a very unsettling effect on many of the concerned majority. 
Several people were upset about the inclusion of the ‘numerical’ benefit information: 
they reported being frightened by the numbers and found this information depressing. 
The inclusion of the numerical benefit information appeared to shake these participants’ 
faith in their medicines. 
“If your doctor is prescribing you medicine then you trust your doctor. That they 
are prescribing the right medicine and you have a kind of belief system that if he 
is prescribing that then it’s going to be better and if, for some reason, something 
happens then you go and speak to your doctor. But I think it [the numerical 
formats] takes away that belief that you’re going to get better if you start seeing 
these numbers. So, the medicine might not work as well because you’ve already 
in your mind said as well.” (F, 58, FG6, REBA) 
A large concern some participants held was that this information would remove faith in 
medicines so much that the medicine would no longer work. They believed that 
negative thoughts about the medicine would impact negatively on effectiveness.  
There was turmoil for some participants as they tried to come to terms with the 
revelation that the medicines were not as effective as expected. People either 
expressed a loss of faith in their medicines or lost value in the information they were 
given, declaring it meaningless and questioning the point in taking their medicines. This 
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was an emotive and upsetting process and characterised by high states of anxiety, 
concern and nihilism, as the meaning and hope that the medicine once represented, 
dissipated, leaving fear and confusion. 
“I just thought this is preposterous! A friend of mine is actually in this situation and 
I was telling her about this and she said ‘That’s what’s on mine and I absolutely 
give up’. It made her so depressed and she just thought ‘What’s the point in 
taking this if I’ve only got this chance?’ And I know my brother would think ‘why 
bother?’ And it’s almost like playing God to say, because there is no guarantee 
that anybody’s not going to have a miracle cure. So, no. I thought they [the 
benefit statements] were quite crazy.” (F, 70, FG2 REBA) 
 
c) Denial of the ‘facts’ 
After the initial response of fear and nihilism there occasionally came a second 
response which saw the veracity of the benefit information being disputed. Participants 
appeared to try and deny the ‘facts’. Some wished to ignore the information entirely and 
did not want to see it included in a PIL. 
“To me there is no help in at all in the information it’s giving me. It’s very negative 
and I don’t want to know about it.” (M, 89, FG6, REBA) 
Others disputed the accuracy of the information. It was common for participants to 
express a mistrust of statistics and to question the trustworthiness of how the numbers 
had been generated. 
“People who know the statistics though, they say ‘the old “lies, damned lies and 
statistics.”’ Can you trust them though? Do you know the parameters? It can be 
meaningless.” (F, 69, FG2, REBA) 
The use of statistics and numbers in wider society, particularly in advertising, appeared 
to bolster the suspicion of the use of statistics, as people were aware of the ways in 
which ‘bad science’ has been used to advertise beauty products, supermarket deals 
and broadband speeds. The applicability of the statistics to the individual’s situation was 
often deeply debated.  
“Well, they can only give averages can’t they? They test on a thousand 
people…and then they get averages from that and there will always be 
exceptions.” (F, 54, FG3, JANA) 
“It’s such a generalisation all of this, because nobody can tell you what’s going to 
happen to everybody.” (F, 70, FG2, REBA) 
A suggestion to overcome this mistrust was to include the source of the information in 
the leaflet with the benefit information. 
134 
 
“You could even say ‘clinical trials have shown that’, because people then know 
that’s what this is and it’s not something that has just come out of the GP’s head” 
(F, 61, FG2, REBA). 
These feelings of statistical mistrust were not universal, with other participants trusting 
the source of information and accepting the information given: 
“I would make the assumption from any information given that these numbers, 
which are included in this leaflet that they haven’t been plucked out of the air. 
That there are clinical reasons behind it. So it doesn’t worry me. And I wouldn’t 
nit-pick bits off it” (F, 59, FG2, REBA) 
Some participants voiced concerns that the other participants were downplaying the 
relevance and meaning of the information because the information provoked feelings of 
discomfort. Two participants in particular were dissident voices, speaking against their 
fellow participants and questioning their haste to dismiss the reliability and meaning of 
the numerical information. 
 “But it’s obviously not meaningless. It may not mean what you want it to mean, 
but it means something” (M, 69, FG2, REBA) 
There was a definite conflict about which type of benefit information is valued and 
despite this denial of the ‘facts’, it was apparent that the participants still wanted benefit 
information in their patient information leaflets. They just didn’t want the (poor) benefit 
information provided in the study. 
“There does seem to be a bit of a difference between everybody’s view of 
choosing the purple [textual], but what comes out in the discussion is that we 
want to know the facts. Is that a fair comment?” (M, 60, FG3, JANA) 
 
 Preference for and the influence of the format of benefit 3.8.2
information 
 Textual benefit information 
There was a good deal of enthusiasm for the textual benefit information; its inclusion in 
a PIL was popular in the focus groups. It was almost always preferred to the original 
leaflet, without such information. Participants found the textual benefit information to be 
very informative: 
“If [you] do get migraines you need to understand what was happening. I need to 
know what’s happening and what will improve it. That would help me having that 
information.” (F, 54, FG3, JANA) 
One participant felt the textual information reinforced the GP’s decision to prescribe the 
medicine: 
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“I think the doctor is prescribing this tablet...The doctor’s going to guess. He has 
an array of tablets so he has to decide. If he decides on this one, I think at the 
same time as prescribing he’ll say, “this may help you, it may not, but try it” and I 
think with that information, and backed up by the purple [textual], we won’t lose 
anything.” (M, 76, FG1, JANA) 
The textual information was always viewed as the most positive and hopeful of the 
different benefit statements: 
“If I was glimpsing at the leaflet, I’d want to see the purple one that gives you 
confidence in taking it.” (F, 52, FG2, REBA) 
“I’ve got here, the mauve one [textual]. It’s the best. Keep it clear and simple and 
optimistic.” (F, 69, FG2, REBA) 
It was also preferable because it was viewed as simple, but this was in comparison to 
the numerical formats, which were viewed as complex and tricky to understand.  
“The simplest way of giving information is the purple one [textual]; there is no 
need for a calculator.” (M,64, FG1, JANA) 
However, a small group of participants noted that the purple information was often quite 
vague, and while it included further information about how the medicine would benefit 
the patient, it was vague about the likelihood and more information was required for a 
patient to understand this in context. 
“I didn’t like the purple [textual] because it was a bit too vague.” (F, 79, FG4, 
REBA)  
So for some participants, after initially preferring the textual information, when they later 
assessed how their understanding had been affected by the various statements, it 
became apparent that the textual statement did not inform very much. These 
participants began to feel that they needed information added to the textual statement 
to understand more about how likely the medicine would be to help them. There was a 
constant conflict between simple information and information that put the benefits into 
perspective. For some participants a compromise was to incorporate numerical 
information into the textual statement. 
“If you’re going to try and simplify it, why don’t you just use the purple one 
[textual]...then on the back you put all the positive statements like you’ve got on 
the orange [natural frequency].” (M, 64, FG5, JANA) 
For one participant it became apparent that the textual information, which was her 
preferred format initially, had misled her. During a discussion about using the benefit 
information to inform a decision on purchasing an OTC medicine, she acknowledged 
that she would be more likely to purchase a medicine that included a textual benefit 
statement and would not choose one that contained a NNT statement, even though she 
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could now see that the medicines had the same benefits. For some it appeared that the 
textual statement offered an illusion of benefit, which was removed when the numerical 
information was considered alongside it. 
Other concerns about the textual information included that it was repetitive and that the 
information provided was already mostly included in the leaflet and that in total it was 
just too much information.  
There were a few suggestions on improvements that could be made to the textual 
statement. For example changing the wording of the benefit statement so it contained 
the word ‘may’ instead of ‘can’ to convey the uncertainty that participants experienced 
when reading the numerical information, but without resorting to the ‘frightening’ 
numbers.  
 Percentages 
On the whole the percentage format was viewed as complicated. People found it 
‘mathematically confusing’ and muddling. Many participants were inexperienced with 
using numbers and did not find the percentage format intuitive. For those who were 
familiar with using numerical data, such as in their working life, the percentage format 
was more popular. 
“It might be an age thing that, I don’t know. I’m a teacher but we’re probably all 
quite au fait with percentages, so we don’t mind them” (F, 50, FG5, JANA) 
Where people were able to engage with and understand the percentage information it 
was apparent that it helped to put the benefit information into perspective and provided 
some comparative information about those who didn’t take the medicines. As a result 
people could make an informed decision about how likely the medicine was to benefit 
them: 
“When I first read the sentence and it said in ‘100 people like you’, I thought it 
meant taking the tablets, ‘people like you’, that’s the first thing I thought. So I got 
really confused when I got to the second sentence I thought ‘it doesn’t mean 
that!’ I had to read that again. It means people with migraines; it’ll get better in 
32% of people anyway, on its own’” (F, 68, FG1, JANA) 
However, it was apparent that for some participants this comparative information was 
confusing and difficult to interpret. Occasionally participants struggled to understand the 
relevance of providing this baseline information, as this extended excerpt from the first 
focus group shows: 
“Participant 5: Why do we want to know that people who don’t take the tablet? 
Why do I want to know the results of people who don’t take the tablet? It’s not 
important to me, if somebody is not taking the tablet. It’s not important to me...the 
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only thing that is important to me is 57% of people of people who take this tablet 
are better off… 
Participant 6: They’re not, that’s exactly what they are not!  Only 25 are better, 
not 57, because 32 will get better anyway… 
Participant 2: The numbers are semantic, let’s say 57% are better if they take the 
tablet, then you don’t need to know how many people are better off if they don’t 
take the tablet 
Participant 6: But you do need to know 
Participant 2: But let’s say that 57% are better off and you don’t need to know 
how many people are better off if they don’t take the tablet...Say 57% are better 
off if they do take and actually 93% are better off if you don't. Now do you want to 
know about it? 
Participant 5: No, all I want to know is... 
Participant 2: But I've just told you that 93% of the people will be better off if they 
don't take the tablet 
Participant 5: Awwwww! 
Participant 2: So you do want to know about it? 
Participant 5: No, no, no, no! 
Participant 6: But you do if 32 are going to get better anyway why would you take 
the tablet? 
Participant 5: To improve your chances 
Participant 6: But by only 25% 
Participant 5: But it doesn't matter! 
Participant 2: You need to know 
Participant 5:  No you don’t need to know the %, but you don't!  What you need to 
know is that you are better off taking the tablet than not taking the tablet. That's 
all you need to know. The percentage doesn't matter!” (M, 56, F, 68 & M, 76 in 
FG1, JANA) 
The percentage also proved a challenge for one participant who, although they 
understood the information, had concerns that the reader would intuitively try and make 
the percentage figures add up to 100%, which would cause confusion: 
Participant 7: But you know what I mean, I’m looking for things… if you are going 
to have percentages you are going to look for things that add up to 100%  
Participant 6: but the 32 ain’t in the 57%… 
Participant 7: yes, I know… but you’ve got to go digging to get to that. I’d be 
thinking 32, 89, where’s the other 11!” (M, 63 & F, 68, FG1) 
It was therefore apparent that for some participants the percentage information had the 
potential to mislead by encouraging misinterpretations of the benefit data due to 
mistakes in making calculations using the data provided.  
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 Natural frequencies 
The natural frequency format did not seem to provoke such extreme reactions in 
comparison with the other numerical formats. For many, the removal of the percentage 
made the statement instantly easier to read and it was generally viewed as 
understandable and user-friendly. Participants tended to have fewer objections to the 
inclusion of the natural frequency. 
”And it's better, just taking away the percentage sort of thing, it does make it a bit 
easier to read.” (F, 63, FG3, JANA)  
However, there were still concerns about this format. Some found it challenging to 
interpret and it was viewed as quite wordy.  The first sentence in particular was viewed 
as tricky to understand.  The phrase ‘in 100 people like you’ appeared to provoke a 
negative response as people questioned ‘who are people like me?’  It was common for 
participants to question whether the ‘people like me’ were similar in age, ethnicity and 
gender to them. There were occasionally concerns about the relevance of the numbers 
to the participants’ personal situations.  
 NNTs 
NNTs were viewed as comparatively easy to read, especially in light of some of the 
other formats. Many of the participants felt they were quite simple to understand. 
However the message they gave was viewed very negatively and it was apparent that 
the benefits were surprising. These views were held regardless of the type of medicine. 
“The [NNT], it’s not terribly positive is it! But it’s easy to understand.” (F, 54, FG3, 
JANA) 
The NNT was viewed as straight to the point and, by some people, quite honest. 
“The green one is almost like a television advert. “If 20 people like you...this will 
not...” It’s really direct and it’s just like something you would get on the television 
basically, that has got the limited time and space to say it, so basically it just 
throws the punch straightaway and gets the point home.” (F, 57, FG4, REBA) 
For some participants it appeared to convey a sense of accuracy and the small 
numbers it presented were easy to relate to. 
“I suppose it’s narrowing down to a small group of people and you think, “there’s 
something here” One of us would have less of a migraine if I take this tablet and I 
think I’d like to be that one please.” (F, 50, FG5, JANA) 
It did appear to make people more aware about the benefits of their medicines, but this 
awareness was not always welcomed: 
“I found the [NNT] a bit depressing ‘Oh it will only improve 1 in 20 in 5 years’, well 
I wouldn’t bother.” (F, 70, FG2, REBA) 
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Frequently the NNT caused confusion about what happened to the other 3, or other 19, 
patients. This was disconcerting and unsettling for those participants and fed into the 
feelings of fear and nihilism that were identified. For some participants it appeared to 
stimulate them to reject the medicine. 
One lone participant felt that the NNT was presented in a way that was too positive. He 
felt that the information could put a greater emphasis on the uncertainty associated with 
the treatment: 
“I’d say it even stronger, I’d put in front of it ‘most people do not benefit from 
taking this medicine, in fact most do not, but a large minority of people do benefit 
from taking this medicine’ and then put the 4 people like you taking the drug, 1 
will benefit. So you have 1 vote for the NNT.” (M, 60, FG3, JANA) 
 Framing 
The majority of the participants preferred the information when presented in a positive 
frame. The negative frame contained a double negative, which the participants found 
challenging to read. 
“The one with the double negative, I was going backwards and forwards trying 
to figure out that!” (M, 56, FG1, JANA) 
The combined frame was also viewed as challenging to read: 
“Yes, you cannot present both because it gets confusing. Like in my situation 
[making a choice about chemotherapy] with that doctor where he was getting 
confused between people living and people dying or getting better and we were 
going around in circles” F, 54, FG3, JANA) 
Overall, participants felt that it was important to put the benefit information in a positive 
frame, because the benefit information was supposed to be positive. 
“You are trying to focus on the positive benefits of the medicine, so I think the 
statement needs to be positive” (F, 57, FG4, REBA) 
 Alternative formats 
A few participants suggested alternative formats that they thought they might prefer to 
see in a PIL. The most popular suggestion was the inclusion of a graphical format or 
chart, although several members of the groups voiced concerns that they would not 
understand the graphs. These members tended to be older group members. 
It was apparent that a few members of the focus groups mentally converted the benefit 
data into a relative risk format. It appeared they felt this gave them the biggest benefits 
and was preferable to the small benefits they perceived in the other formats: 
“I think the purple if it can be altered to say JANA can improve your chances by 
25% of having less of migraine after 2 hours is the simplest way of doing it. I think 
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this 1 in 4, 1 of them, it sounds as though you have got very little chance! Well it’s 
a bit negative; if it can improve your chances by 25% it’s more positive.” (M, 76, 
FG1, JANA) 
One final suggestion was to present the benefit information in a similar way to how the 
side-effect information is presented (which is a form of natural frequency), so the 
methods of data presentation are uniform. 
“When they do the side effects they say may affect up to 1 in 10 people, may 
affect up to 1 in 100 people. So they are using these rough figures and there’s 
nothing to stop them using these rough figures there.” (M, 56, FG1 JANA) 
 Barriers to engaging with benefit information 3.8.3
There were several barriers which prevented or limited a participant’s willingness to 
engage with the benefit information. A lack of willingness then influenced people’s 
ability to make informed decisions about their medicines. The following influencing 
factors were identified from the data: 
 It’s complex 
A common complaint about the benefit information was that it was complex and very 
hard to understand. People found it ‘muddling’ and ‘mathematically confusing’. It was 
viewed as hard to interpret and too complicated. A problem, methodological in origin, 
was the presentation of the all benefit statements in one leaflet. This led to some 
participants trying, and struggling, to understand the different methods used to calculate 
each statement and finding the maths overwhelming. Many understood the general idea 
that the figures presented were different statistical representations of the same data, 
but couldn’t work out the maths to get from the percentage to the NNT, for example. 
This led to some distraction and frustration with the numerical statements. All in all the 
biggest complaint about the numerical benefit statements was that they were simply too 
difficult to understand. Some participants could not comprehend their meaning at all.  
Conversely, some participants understood the benefit information well, and there were 
occasions when these participants would explain the different calculations of benefits to 
their fellow participants with confidence and ease. Surprisingly, these participants were 
not always receptive to the inclusion of benefit information in PILs and the complexity of 
the information was not the only factor that influenced whether people would engage 
with it. 
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 The unsettling nature of chance and uncertainty  
While some participants could comprehend the chance that the medicine would benefit 
them with relative ease, for others this was a challenging concept. Participants wanted 
more certainty than the benefit information, particularly the numerical information, could 
offer.  
“I would rather have a sentence that said it will always work.” (F, 68, FG1, JANA) 
 
The uncertainty about the effects of the medicine was very unsettling. People were 
worried that they would not be the one who was saved and found it difficult to 
understand how the medicine would benefit them individually. Occasionally this 
stimulated a desire for more information, in order to put this uncertainty into context. 
However, this in turn provoked concerns about being overburdening with information 
and it was challenging to find a balance that suited the needs of all the participants. 
 “It puts people off!” 
As a result of this uncertainty and unease there were also concerns that the information 
would only serve to put people off reading the information or would encourage them to 
make bad (uninformed) decisions that might impact upon their medicine-taking. 
“Participant 7: you don’t [need the benefit information], because it just puts 
people off... 
Participant 6: And 25% wouldn’t take it.” (M, 63 and F, 68 FG1, JANA) 
On the whole, concerns about people being ‘put off’ from reading their leaflets, or taking 
medicines were about how this information might impact on others, such as friends and 
families. Participants in the focus groups felt they would see their GP before making 
decisions about taking a medicine.  
 Passive decision-making and the advice of the GP.  
 “I’d just do what the doctor says.” (F, 81, FG5, JANA) 
 
A big influencing factor on whether people wished to engage with the benefit 
information was how strongly people valued their GP’s advice. There was a range of 
preferences for their relationship with GPs, with some participants seeing themselves 
as bearing the main responsibility for medicine-taking decisions and others preferring a 
more paternalistic relationship with their GP, where they follow the GP’s advice with 
little questioning. It was apparent that the GP’s recommendations about taking a 
prescribed medicine impacted significantly on a decision to take a medicine and that for 
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many these appeared to overrule any thoughts on effectiveness that arose from the 
interpretation of the benefit information.  
“The numerical information allows you to make an informed decision. It gives you 
the facts and the figures. But you wouldn’t stop taking a drug without seeing a 
doctor would you?” (M, 51, FG2 REBA) 
Some participants were incredulous at the suggestion that they might use the benefit 
information to help them make decisions about their medicine. Many participants, 
particularly older participants who received prescriptions for larger numbers of 
medicines, did not appear open to shared decision-making or engagement with the 
benefit information at all. Instead they took a passive role and relied on the GP to make 
decisions on their behalf. 
  “It’s your doctor’s job to tell you what is right.” (F, 74, FG5, JANA) 
 
A negative impact of providing the benefit information was that on occasions it 
undermined the faith people had in their medicine, and also the trust in their GP. 
“The blue one, I would question why the doctor even give it to me in the first 
place because it only becomes 80%. There’s only 5% difference between the 
ones who don’t and do. So, what’s the point in taking this medicine in the first 
place? I looked at all these different colours it was too confusing. It didn’t really 
add anything in the information that I would really want to know, because the one 
where it says about the purple one ‘it can lower and it can do this’...well, the 
doctor wouldn’t give it if it wasn’t supposed to do what he wanted it to do.” (F, 58, 
FG6, REBA) 
This was a very troubling and alarming situation for the participants to find themselves 
in and often reinforced the feelings of fear and nihilism that they had reported initially.  
“The green one, it set my heart pumping fast because it says one of them you 
stop having a heart attack. I thought, well...are we 1 in 19 that can have a heart 
attack? I don’t think, probably the wording, but I wouldn’t give anybody this 
information, that 1 out of 20 it stops heart attacks. What of the other 19 that it 
states what happens? Does that mean it won’t work for us? It’s a concern for me. 
I feel that way and it will set me with negative thoughts.” (F, 69, FG6, JANA) 
A very troubling concern was that the numerical benefit information, which was 
frequently perceived as negative, would impact on the values people placed on their 
medicines, and therefore upon the effectiveness of the medicine. A deeper concern was 
that this would encourage patients to give up on the hope that their medicines would 
help. 
“You want to think that you’re not going to be the other three that it doesn’t have 
an effect on. But now you have got this seed planted it might not work. Whereas, 
if you didn’t have the information...Then it’s like the placebo, but the other way 
round.” (F, 56, FG3 JANA) 
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The final barrier to engagement with the benefit information in order to facilitate 
decision-making appeared to be a sense of inertia that was generated alongside the 
prescription for a medicine. A few participants stated that if they had received a 
prescription for a medicine (or in the case of an OTC medicine, purchased a box) they 
would take the medicine anyway, regardless of their interpretation of benefit 
information. 
“Well if I’d been prescribed it anyway then surely the fact that I’ve been 
prescribed it and I’ve gone and got it means that I’m gonna take it, I’m not being 
facetious but I mean surely you’re making that decision, you’ve made that 
decision anyway before you even get to reading the leaflet.” (F, 57, FG4, REBA) 
This raised some questions about whether the leaflet was the right place for this 
information as some participants stated they wanted to have this information before 
they received a medicine, so they could make a decision. Others felt that benefit 
information was something that their GP should impart. 
Only one felt that the leaflet was the perfect place for this information. 
“I think that seems like a good reason to come clean. To put it in the patient 
information leaflet, because you know, that's what it is: An information leaflet, it is 
not advertising. I think that the patient deserves to be treated with enough respect 
to have this information, and to be able to understand this information. I didn't 
know either how few people would benefit from this medicine.” (M, 60, FG4, 
JANA) 
 Personal experiences  
Previous experiences with medicines appeared important in decision-making and could 
be a barrier to a person’s willingness to engage with the benefit information. 
Participants appeared more comfortable in making decisions which were familiar to 
them in some way. For example, decision-making might be influenced partially by their 
previous experience in taking a medicine or by their friends and family’s experiences. 
“I’ve never had any adverse effects...I think if you have had adverse effects your 
opinion, your thoughts on it would be very different. I don’t have any adverse 
effects so I find it difficult to say ‘well, I wouldn’t do this and I wouldn’t do that.” (F, 
74, FG4, JANA) 
“I would also watch out for friends and colleagues who've taken statins in the 
past, I don't know how many years, and presumably they haven't all survived or 
haven’t all been killed by heart attack so I would watch out for that.” (M, 69, FG2, 
REBA) 
 
It was apparent that there was an emotional context to decision making that participants 
prioritised. 
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 How high are the stakes? 
The seriousness of the illness was something that was identified as an influencing 
factor on whether participants wanted this information in the first place, and also on 
whether the participants felt the benefit information could help them in making decisions 
about their medicines. Some participants were more receptive to receiving benefit 
information if their illness was perceived as life threatening. 
“This is looking at a migraine treatment rather than a cancer treatment. It’s very 
different. I would respond differently to statistics about a migraine treatment and 
statistics about a life or death situation, potentially.” (F, 56, FG3, JANA) 
One participant (FG3) in particular talked poignantly about receiving benefit information 
when she was offered chemotherapy for breast cancer.  However, another in the same 
group who also had experience of cancer stated she did not necessarily want to receive 
the benefit information. 
The severity of the illness might also be something that would impact upon decision-
making more than the benefit information. Despite the poor perceived benefits of the 
Janatriptan medicine, some participants often stated that they would still take the 
medicine if they were desperate. 
“I’m fortunate I don’t suffer with migraine, but the people that do, you know, who I 
know suffer from it, you feel they’d do anything because of the pain and if you 
went to the doctor and they said, “look, it only works in a quarter of the cases,” I 
think I would still have a go at it because I’d be searching for anything that would 
relieve the pain.” (M, 67, FG5, JANA) 
It is also interesting to note that discussion about the severity of illness did not appear 
to differ between the two groups for the medicine types. There was no immediate 
difference in opinions from the groups for the statin medicine and the group for the 
migraine medicine. These differences were drawn out when a disease such as cancer 
was talked about.  
 The context of the decision  
The context of the decision could also be a barrier to engaging with the benefit 
information. Participants often found it easier to comprehend the utility of the benefit 
information when presented with a scenario where they had to make decisions between 
two medicines which might be purchased over the counter, as opposed to a medicine 
that had been prescribed by a GP. 
“I think if it was an over-the-counter medicine, and you can buy medicines in 
supermarkets now. I think people need to know that you could take this and get 
benefit but people need to know that you could get no benefit and I think you 
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need to know that. I think if you get it is a prescription then your GP should give 
you some guidance and he should know you and as to whether it could help you, 
but I think if you're buying it and it is a drug that is going on general release in the 
supermarket, and I think in that case then the information has to be given and 
they should be given in more bullet points and it has to be more dot, dot, dot or 
people don’t read it.” (F, 63, FG3, JANA) 
 
 Loss of hope 
Hope was frequently identified as a motivating factor that impacted upon medicine-
taking. Medicines provided hope that the patient would recover from an illness or 
symptoms. It appeared that the provision of numerical benefit information took away 
that hope.  
“I like my hope. I must have this idea that most medicines are going to help me 
and they are not going to hurt me. They’ve got to be positive and doing some 
good. I think that is not going to be 100%, it might be 1%. It’s got to be doing 
some good or I wouldn’t be taking it.” (F, 56, FG3, JANA) 
As a result this often discouraged the participants from either wanting the benefit 
information, or from taking the medicines. 
“So when you are giving me very little hope and telling me this is what is going to 
happen to me I don’t want to know.” (M, 56, FG1, JANA) 
“They [benefit statements] weren’t of any interest to me because I’m a very 
positive person and if my doctor has prescribed the medicine for me I hope it will 
work. I don’t want to know who it didn’t work for or who it did or what percentage 
of people. It would make me more poorly, yes, that is my feelings about it.” (F, 69, 
FG6, REBA) 
The numerical information was generally found to be lacking in hope. What participants 
tended to want was benefit information that was more optimistic, more encouraging and 
more positive. Often this was the textual format of benefit information. 
“Keep it clear and simple and optimistic.” (F, 69, FG2, REBA) 
 “Participant:  I like number three with the purple statement. 
Interviewer: Do you think that’s encouraging? 
Participant: Yes I do think people need encouraging.” (F, 52, FG2, REBA) 
 
The information has to be able to instil confidence in the patient:  
“I think that is a keyword, confidence. You have got to have confidence in your 
GP. I need to have confidence in the medicines and the leaflets. To me they 
should confirm that confidence that your GP has given to you to take them and 
they should give you warnings if you are feeling unwell when taking this. And to 
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me this is too much! It should be short, sharp, to the point, the positives!” (F, 52, 
FG2, REBA) 
In order to make the benefit information more encouraging participants would 
occasionally reword and recalculate the information to make it sound more positive and 
encouraging to them. Sometimes they would recalculate the percentage to make the 
benefits sound larger or  occasionally insert words such as ‘greatly’ or ‘increases’ 
instead of ‘this becomes’, in order to put a positive spin on the benefits. The lack of 
‘positive spin’ appeared disheartening: 
 “It is a positive benefit even though it's not a big figure.  But it wouldn't stop me 
taking them. It doesn't exactly put a positive spin on them.” (M, 51, FG2, REBA) 
There were a few participants who were exceptions to the general feeling that the 
benefit information was negative, often these were a lone voice in the groups. For these 
participants the benefit information truly was benefit information, which gave them hope 
and encouraged them to take their medicines optimally: 
“I was really happy to see something positive about the medicine. I’ve never been 
a medicine taker; I’ve never liked taking medicines. When I was given tablets for 
my blood pressure I was absolutely mortified. I was really fighting not to take 
them. So for me, to see something positive about why I am taking the medicine 
helped me...a little...not a lot. Because when I read the leaflet I think ‘urgh!’ but 
there is a reason as to why I will benefit from it. Comforting I guess.” (F, 59, FG2, 
REBA) 
 The impact of the benefit information 3.8.4
 Developing understanding and knowledge 
It was apparent that some groups did not engage with, nor understand, the information 
sufficiently for them to develop any further knowledge or understanding of their 
medicines. Sometimes the benefit information was disorientating and unsettling. In 
some people it stimulated reactions of shock and disbelief and their initial reaction was 
to reject the information.  However, there was a group of participants who, once they 
had expressed their shock, disbelief and concerns about the medicines, appeared then 
to develop a better understanding of the numerical information and this translated into a 
deeper awareness about their medicines: 
“I like the orange one first [natural frequency] and the green [NNT] second. You 
like to know what you are taking and what’s going to happen.” (F, 68, FG6, 
REBA)  
Even though the information was at times alarming, some participants still valued its 
inclusion.  
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“It would frighten me, but it would make me more aware.” (F, 53, FG4, REBA) 
It was apparent that the benefit information did help some participants understand more 
about the benefits of their medicines (although this was not always welcomed). This 
was especially apparent when participants compared the different statements with each 
other, particularly comparing the textual statement with a numerical one: 
“I’m kind of a sock-it-to-me person and if I got the purple I know that I would have 
to do work. I would zoom in onto ‘can’ improve your chance and I’d need to get 
some harder information…If the information was there in the first place I would 
feel the information leaflet was treating me with respect  and was saving me a lot 
of hassle in the first place.” (M,60, FG3, JANA) 
Several of the participants did develop a deeper understanding of the benefits and how 
they would impact upon them. In particular they learned that the benefits were smaller 
than expected and this offered them a new perspective on their medicines and 
potentially impacted upon the choices they might make. Often in the groups there were 
interesting exchanges as the meaning of the information became clearer during 
discussion: 
“Interviewer: If you had to make a decision between 2 medicines, so suppose you 
had another migraine medicine, do you think having this numerical information 
might help? 
Participant 1: Oh yes! It would do, especially if they were a different price as well. 
Particpant2: And if one had a better success rate…but obviously no one would 
buy the other medicine would they? 
Participant 1: Well, they would have to improve it wouldn’t they! 
Participant 2: They would, wouldn’t they? You think you are getting the best don’t 
you, but that’s not always the case is it? 
Participant 6: Would that mean that you would not buy the green, you wouldn’t 
buy the green but you would buy the purple? 
Participant 1: Yes, that would make a difference to me. 
Interviewer: Because the purple might not be as good as the green and they’ve 
not told you? 
Participant 1: And it sounds so positive. 
Participant 2: It’s not actually until you start talking about it that you begin to 
realise...it’s not as easy as just producing a leaflet.” (F, 54, F, 56 & M, 60, FG3, 
JANA) 
Despite initial reservations about the benefit information it was apparent that the 
information made an impact on some participants’ understanding of the benefits of their 
medicines. This knowledge provoked concern, although it was frequently felt that the 
information should be provided as a general principle: 
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“This is about the general principle of people being given the information so they 
can make the decision, because even if things are prescribed, we as individuals 
make the decision to take that medicine or not, and I think that the more 
information you have helps you make an informed decision.” (F, 68, FG1, JANA) 
 Making choices and decisions about medicines 
Despite the multiple barriers to engaging with the information, having ‘some’ benefit 
information available was viewed as important. It was reported that the benefit 
information had the potential to influence choices about medicines, even though the 
information caused considerable conflict. For some participants it was an enabling, 
empowering force that encouraged them to weigh up the pros and cons of their 
medicines, although this was not universal amongst participants.  
o Encouraging active decision-making 
The benefit information was identified as helpful in supporting people to make 
judgements about their medicines. This was particularly distinct where participants were 
already active decision-makers. 
“Basically it gives you something to work on, it brings in real statistics and things 
you can actually relate to and you can make judgements. It helps you make the 
judgement yourself. It’s presenting you the facts as opposed to just statements 
and claims. I mean, they are very important to know facts. Because so many 
companies, medical companies make claims about things and then years down 
the line those claims are all undone and it’s disproving and whatever. But if 
you’ve got facts, proven facts and figures, then I think it makes it more credible to 
you and you can make a more reasoned judgement about it, basically make your 
own decision without accepting that they say this is the best and whatever, you 
can actually decide yourself how good you think it is” (F, 57, FG4, REBA) 
The provision of benefit information encouraged several participants to state that they 
would consider seeking additional advice from their GP or pharmacist about the 
medicines in order to  understand more about the benefits of taking the medicine.   
“If people are on a lot of medication and they don’t know whether they should 
take another tablet, and if they know they’ll get better without taking the tablets, it 
may make them change their mind and say ‘I’m not going to take it because the 
chances aren’t increased that much’. So I think, for some people, that information 
is very relevant” (F, 68, FG1, REBA) 
So while the information was frequently viewed as surprising and shocking, it did 
appear to stimulate the need for additional information about medicines from some 
participants. This was apparent even for those who did not like, nor believe the 
information was relevant.  
In focus group 6, one participant was particularly vociferous about his dislike of the 
benefit information in all formats. However, the information provoked a response from 
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him. It made him aware that the medicine (Rebastatin) was not as effective as he had 
expected and this caused him to reflect on his medicine-taking behaviour. He decided 
he might choose not to take a medicine with such poor benefits and would seek advice 
from his GP. It was not an uncommon response for participants to report that they 
would alter their information-seeking behaviour after reading the benefit information. 
This participant’s response was deeply emotional, but other responses were more 
positive. In particular the benefit information often stimulated the weighing up of the 
risks and benefits of a treatment and the consideration of making trade-offs. 
o Weighing up the risks and benefits 
The benefit information did appear to stimulate a risk-benefit analysis where the 
potential side effects were considered alongside the benefits of the medicine. 
“Well, initially I went for the purple [textual] but I have had second thought about 
that and am trying to understand why. I think I’d like to know how much better the 
chance I’ve got, and I’m a figures person anyway, so I think I will go for the first 
sentence of the blue [percentage] because that seems to be quite simple and you 
can see that 32% get better without taking this tablet, so I’d be looking at the side 
effects and thinking ‘is that migraine really that bad, do I really want these side-
effects when 32% get better anyway? Maybe I’ll live with it.’ The other one 
doesn’t really tell me how much better, it doesn’t give me anything to compare it 
with. So now that I’ve read it…When I first read it I thought [the textual] that’s 
quite simple, that’s better. For the most people, well…it probably is better. But 
now I want to know how much better.” (F, 68, FG1,JANA )  
This was not always a comfortable process, and provoked concern in some 
participants, especially in light of the unexpectedly low level of benefits. 
“I think, to me, there’s more of a concern of all the different, possible side effects 
you can have. To me, I feel worse when I read all the things you can have 
because I look and say “well, if these are the things I could possibly have, does 
that outweigh what this pill is actually going to do for me?” So that makes me 
nervous.” (F, 58, FG6, REBA) 
It was also noted that the benefit information might not initially provoke the weighing up 
of the risks and benefits prior to the initial decision to take a medicine, but it was 
important information that might help to influence long-term decisions: 
“If I was suffering a side-effect, all of a sudden it would become really important 
to me” (M, 64, FG5, JANA) 
Often this was a process that was very personal and dependent upon multiple factors 
that included an understanding of the facts that were presented, but also reflected on 
the individual’s personal values and experiences. 
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 Discussion 3.9
The aims of this qualitative research study were to provide further insight into the 
provision of benefit information in a PIL and to explore how the benefit information 
might impact upon knowledge, satisfaction and behaviour. A further objective was to 
identify preferences and suggestions for presenting ‘benefit information’ in a regulated 
PIL. Our findings show a significant range of opinions on the inclusion of benefit 
information.   
It was apparent that many participants welcomed the inclusion of positive information 
about the benefits of their medicines in a PIL when presented in a textual format. 
Participants wanted more information about how their medicines worked and how likely 
they were to benefit from taking them. However, the inclusion of numerical benefit 
information was more divisive. Some participants welcomed the provision of ‘facts’ 
about their medicines. For others the numerical information was difficult to understand 
and there was a great deal of shock at the perceived low benefits which appeared to 
cause turmoil and distress in some participants. Several key findings were drawn from 
the focus groups. 
  Key finding: Numerical benefit information is difficult to 3.9.1
understand 
Effectively communicating risk and benefit information is a challenge. People might not 
possess adequate numeracy skills to interpret data accurately and some statistical 
formats have been shown to be misleading, persuading people to make decisions about 
treatments that are not well-informed (Gigerenzer and Edwards, 2003, Akl et al., 
2011a).  The benefit statements used in the exemplar leaflets did not use summary 
statistics shown to be persuasive, such as relative risk formats. Both the natural 
frequency and percentage formats used absolute numbers in order to promote 
understanding and reduce the risk of patients being misled or unfavourably influenced 
(Bhandari and Tornetta, 2004, Malenka et al., 1993, Gigerenzer, 2002). However, a 
curious finding was that occasionally the participants converted the numerical 
statements into a relative risk. This appeared to be done to enhance the benefits of the 
treatment and make the benefits appear bigger, and more positive. This mirrors the 
findings of other studies which suggest that relative risk formats can be easily 
understandable, but can mislead patients who perceive bigger benefits of treatments 
with the absence of absolute risk information (Carling et al., 2008, Carling et al., 2009, 
Carling et al., 2010). 
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Misinterpretation of the data and confusion about its meaning was common and many 
participants struggled to understand the numerical benefit statements in any format. 
Providing comparative information has been shown to enhance understanding of risk-
benefit probabilities. Gigerenzer and Edwards (2003) recommend the use of a 
reference class when giving probability and frequency information (Fagerlin et al., 2007, 
Gigerenzer and Edwards, 2003). This information was provided in the percentage and 
natural frequency formats, with the reference class being the number of people who 
would suffer a side-effect without the treatment. However, several participants found the 
provision of this comparative information confusing and could not understand its 
relevance.  
However, for some participants the provision of the reference class appeared to help 
clarify the information and promoted an understanding of benefit of the treatment in 
context. The findings from this study suggest that while the provision of a reference 
class can help reduce misunderstanding of probability information, this is not the case 
for everyone and some people struggled to comprehend the meaning of such numerical 
formats.   
No numerical format was preferred above all others, nor identified as the easiest to 
understand; one limitation of the research is that the participants’ understanding of the 
formats was not formally tested. A range of opinions were expressed about the different 
formats, and individual experiences, of medicine-taking were influential.  Familiarity with 
the format appeared to influence preferences; however it is important to note that 
preference has not been found to be indicative of the performance of different numerical 
formats in conveying understanding. 
Natural frequencies were often identified as understandable. This echoes the findings in 
the wider research literature that natural frequencies can aid understanding and foster 
insight into numeracy (Galesic et al., 2009b, Gigerenzer et al., 2007). Their use is 
promising in the context of medicines information and they appeared here to generate 
less nihilism and concern than percentage formats or NNTs. However, it was apparent 
that they were not understood by all, they often caused confusion and the wording of 
the natural frequency was not always popular. Occasionally it provoked a negative 
response. Numerical information about the harms of medicines (side-effect information) 
in legislated PILs is currently provided in the form of a natural frequency.  
The NNT statements were generally viewed by the participants as the simplest 
numerical format to understand. The research literature on NNTs has mixed findings, 
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with some evidence showing that they can be easily understood, although this research 
often focuses on understanding among healthcare professionals (Rajkumar et al., 1996, 
Riegelman and Schroth, 1993). Other research has shown that lay people find it difficult 
to interpret NNTs; that they can lead to misinterpretation; and that NNTs lack contextual 
information which can moderate reactions to small but important benefits (Kristiansen et 
al., 2002, Hamrosi et al., 2012). The biggest challenge with the NNTs shown in the 
current study is that the information they conveyed was perceived to be very negative. 
There is a need for more research into this area, in order to measure which formats 
promote accurate understanding of treatment benefits and to examine whether different 
formats of numerical information influence decision-making and medicine-taking in 
participants who receive numerical benefit information in their medicines information.   
  Key finding:  Patients frequently over-estimate the benefits 3.9.2
It was apparent that over-estimations of benefit were common. Participants were 
shocked by the perceived low benefits of the treatments and reported that they 
expected benefits to be much higher.  Hamrosi et al (2012) found similar views and 
reported that when participants were shown an NNT stating “if 100 people took the 
medicine then 1 would be prevented from having a heart attack and 3 from having a 
stroke”, participants expected benefits of at least 50 in 100 experiencing beneficial 
treatment effects. We found that participants also expected higher level of benefit and 
they reported expectations of treatment benefits such as 90% of those taking the 
medicine experiencing a benefit or 19 in 20 benefiting. These differences in expectation 
of benefit between these studies could be attributed to the adjustment heuristic, which 
anchors people to a specific figure (in this case the NNTs used in each study). As the 
NNTs varied, with lower benefits in the Hamrosi et al (2012) study, the participants 
adjust their expectations from the initial anchor which results in differences in their final 
expectations (Tversky and Kahneman, 1974). In this study, where the benefits were 
higher, it seems that the participants expected treatment benefits that were higher still. 
The expectation of better benefits was apparent regardless of whether the participants 
received a leaflet with a higher or a lower NNT.  So the groups receiving leaflets for 
Janatriptan, where the benefits were reported as “4 people need to take the medicine 
for 1 person to benefit” also perceived the benefits as very poor and were surprised at 
the low numbers who benefited (this was regardless of format). This was a surprising 
finding, as it was expected that there might be more satisfaction with the benefit 
information when larger benefits were presented. It is possible that the severity of the 
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condition the medicine is used to treat impacted upon perceptions of, and expectations, 
of benefit. 
Janatriptan was portrayed as a medicine used to treat migraine, a debilitating but not 
life-threatening condition, whereas the portrayed purpose Rebastatin is the prevention 
of heart attack or stroke, which are both life-threatening conditions. It is possible that as 
a result of the difference in health outcomes,  patients will cope and react differently 
with the threats they pose (Leventhal et al., 1998, Cameron and Leventhal, 2003). For 
an illness perceived as less of a threat, such as migraine, the participants may make 
different trade-offs, expecting bigger benefits and fewer side effects. Whereas, when 
the threat is more severe, for example a heart attack, the participants may accept 
smaller benefits and, possibly more side-effects, in the hope that they will be the one to 
be saved. This phenomenon has been observed in studies of people making decisions 
about whether to accept chemotherapy treatment for cancer. It has been noted that 
cancer patients are frequently more willing to risk the adverse effects of chemotherapy 
for a smaller benefit due to the social and emotional context of a life-threatening 
disease and because of the high values they place on the potential beneficial outcomes 
of the medicines, which can ultimately save their life (Matsuyama et al., 2006, 
O'Connor, 1989). 
This is another area that would warrant more research in order to develop a deeper 
understanding of the reasons why patients tend to over-estimate the benefits of their 
medicines and to development of strategies to help people understand medicines in 
context.  These needs to be considered in light of the feelings of nihilism and fear that 
were evoked when participants read the numerical benefit statements in the exemplar 
leaflets. In addition, an understanding of how benefit information is perceived alongside 
side-effect information, for a range of conditions, will provide insight into the best 
methods of supporting patients with making decisions about their medicines.  
  Key finding: Textual information is preferred, but numerical 3.9.3
information can help with judgements 
There is evidence that good quality textual benefit information can support patients to 
make better judgments about their medicines (Bersellini and Berry, 2007b, Bersellini 
and Berry, 2007a). However, in the absence of numerical information about how likely a 
medicine is to benefit the taker, it was apparent in these studies that participants found 
it difficult to weight up the advantages and disadvantages. 
154 
 
Participants in the current study frequently stated that they preferred the textual 
statement to numerical statements and it was apparent that some would make different 
decisions about taking the same medicine depending upon whether the benefits were 
presented textually or numerically. They were more likely to choose a medicine after 
reading the textual benefits, which were viewed as encouraging, and stated they would 
not take a medicine when the same benefits were represented in a numerical format. 
The numerical format aided some participants to gain a deeper insight into how likely 
the medicines were to work for them. This suggests a greater susceptibility for over-
estimation of benefit with an exclusively textual statement.  
Criticisms of the textual statement were that it was vague and lacking in context. 
However, the textual format was very popular, and participants felt the inclusion of 
additional information about how their medicines worked and how likely they were to 
benefit them was a step forward. There is need for more research into how a textual 
statement can be enhanced in order that it can provide good quality information and 
convey the uncertainty inherent in many medical treatments. 
  Key finding: Numerical benefit data can have an influence 3.9.4
over understanding and potentially behaviour, regardless of whether 
it is desired 
Regardless of its popularity, the numerical information frequently had an impact on 
many participants’ satisfaction with medicines and medicines information, their level of 
understanding and their potential behaviour. Often this impact was unwelcome and 
many reported high levels of dissatisfaction and concern about the treatments 
presented. Clearly this is not ideal. One aim of providing factual information about 
medicines to patients is to help with informed decision-making where “a reasoned 
choice is made by a reasonable individual using relevant information about the 
advantages and disadvantages of all the possible courses of action, in accord with the 
individual’s beliefs” (Bekker et al., 1999).  
It was apparent that the provision of numerical benefit information caused significant 
anxiety and dissatisfaction among many participants. Moderate levels of anxiety have 
been shown to be helpful in promoting good decision-making, as it encourages people 
to explore all their options. However, high levels of affect are associated with the 
increased use of a heuristic, or rule of thumb, to make a decision, as opposed to 
reasoned judgement (Bekker et al., 1999, Loewenstein and Lerner, 2003, Tversky and 
Kahneman, 1974). This is particularly influential when people are weighing up the risks 
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and benefits of different hazards. It is possible that the provision of numerical 
information about the low perceived benefits, combined with a high perceived threat of 
side effects (which is a common concern with medicines) (Raynor et al., 2007) 
increased the anxiety people experienced and impacted upon their abilities to make 
reasoned judgements.  
More research is required to understand how the provision of benefit information in 
patient information leaflets impacts upon decision-making and whether it leads to 
people either making reasoned judgements or increasing the likelihood that they will 
rely upon an affect heuristic to make a decision.  
  Key finding: A positive frame is valued 3.9.5
It is well known that the way that information is framed can influence decisions, 
especially when these decisions involve risks and benefits. This is known as the 
framing effect and is an example of how cognitive biases towards choices can influence 
decisions (Tversky and Kahneman, 1981). The benefit information in this scenario was 
presented as a combined frame in an attempt to avoid unduly influencing decision-
making about medicines. However, the combined frame was viewed as challenging to 
read, and was quite cumbersome when compared to either a frame that was exclusively 
positive or negative. The presentation of the numerical information in a positive frame 
was clearly preferred by the majority of participants. It also appears that this was more 
easily understood. This preference for a positive frame reflects the participants’ desire 
to have information that is optimistic and encourages medicine-taking. 
This is an interesting finding, as the aim of the benefit information was not to promote 
‘adherence’ to medicines by encouraging people to take them, but instead to provide 
more detailed information about medicines with the aim of enabling patients to make 
informed-decisions. It appears that some people value a more paternalistic approach to 
medicine-taking and see the medicines information leaflet as instructional documents, 
that tell you how to take medicines, rather than information sources that help with 
decision-making. Hamrosi et al (2012) also noted that participants did not want always 
benefit information to help empower them to make better decisions; instead it was 
desired because of a sense of ‘knowing’. 
So while the positive frame was preferred, caution must be applied when considering 
the framing of benefit information, as positive frames have been shown to be more 
persuasive than negative frames. However, in the context of a PIL it is important to note 
that the increased amount of information, as provided by the combined frame (which 
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was said to be cluttered and difficult to read), appeared to increase affect; as did the 
negative framed statement. As a result a positive frame appeared to be more effective 
in conveying the benefits of the treatments. 
More research is required to evaluate the impact of different frames in patient 
information on a wider scale and to explore the development of a less cumbersome 
combined/neutral frame.  
  Key finding: Participants valued their GPs advice 3.9.6
It was apparent that the most trusted source of advice about medicines, and the biggest 
influence over decisions to take a medicine, was the GP. A concerning effect of the 
benefit information was that, for some participants, it appeared to shake their faith in 
their medicines and in turn their confidence and trust in their GPs. 
Written information is frequently viewed as having a supportive role, with GPs providing 
a crucial role in providing education and information about medicines. It is important to 
ensure that any benefit information provided in a PIL does not undermine the 
confidence that a patient has in their GP, but is instead informative and an aid to 
decision-making. Many people stated an interest in having discussions about the 
benefits of their medicines, in particular the statistical benefits, with their GPs. 
Healthcare professionals should rise to the challenge of providing patients with this 
complex information in a format which suits the educational abilities of the individual 
and the desires of the individual while being mindful that not all patients want this 
information. 
 Conclusions 3.10
 Headline section 3.10.1
The inclusion of a headline section in a PIL was welcomed by participants in a series of 
focus groups. The section was viewed as an adaptation that helped participants better 
engage with their leaflets and which responded to their perceptions of current patient 
information leaflets being arduous to read and complicated. Participants reported high 
levels of satisfaction with the inclusion of a headline section and felt that it had the 
potential to help them understand more about their medicines and influence the safe 
use of medicines. The users of medicines information value good design and desire 
leaflets, and the headline section, to be visually appealing and practical to use. 
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The impact on understanding and behaviour was not assessed directly by this research, 
but patients reported the potential for the headline to allow them to access more 
information with ease and to encourage them to read some of leaflet as opposed to 
none of the leaflet. Further research is required to assess the impact of the headline on 
understanding and behaviour. 
There were some concerns about the headline section discouraging a reader from 
accessing information elsewhere in the leaflet, but many felt the headline had the 
potential to encourage someone who might not otherwise read the leaflet to read the 
highlighted key information. More research is required to assess whether the inclusion 
of a headline section in a PIL influences patients in finding information and/or 
understanding more about their medicines. 
 Benefit information 3.10.2
The provision of benefit information in PILs raises important questions about how the 
benefits of medicines are currently conveyed to patients. It is apparent from the 
participants in this study that over-estimations of the benefits of medicines are common 
and that patient expectations are not always in line with the realities of the health 
outcomes that medicines can provide. It is concerning that patients do not appear to 
have realistic expectations of the benefits of their treatments and that the provision of 
this factual information can cause anxiety and fear.   
The findings of this study highlight several areas of conflict about the provision of 
benefit information, which are not easily resolved. The textual benefit information was 
preferred by the majority of participants but did not provide all of them with sufficient 
information to make informed decisions. The numerical benefit information often helped 
patients understand the limitations of their treatment and encouraged more reasoned 
decisions about whether to take a treatment. However it was viewed as unpopular and 
increased anxiety.  
Presently there is a great deal of interest in improving risk-benefit communication based 
on the view that it is important that patients receive fair and unbiased information about 
medicines, so that they are aware of how likely their treatments are to benefit them. 
Currently this information is not necessarily received by patients in any standardised 
format, if at all.  It is possible that the PIL, an instructional and factual document, and 
which is a legal requirement in the UK and European Union, is a good place for 
presenting standardised benefit information. For patients to make informed decisions 
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about their treatments it is vital that they receive facts so they can make decisions 
which are in line with their values and experiences (Department of Health, 2010, Bekker 
et al., 1999, Charles et al., 1997, Carling et al., 2009). Benefit information also allows 
patients to weigh-up the harms and benefits of treatments and provides 
communications that are balanced.  
However, numerical benefit information is not useful for all participants. Several 
participants struggled to understand this information and could not apply the data to 
their situation in order to help make decisions. Some found its inclusion very off-putting 
and there is the potential that it might impact negatively on decision-making, leading 
patients to reject their medicines because of emotion rather than reasoned decision. 
One of the biggest concerns about providing the benefit information was its potential 
impact upon hope for recovery and faith in healthcare. The uncertainty that the benefit 
information conveyed was unsettling for some participants and generated feelings that 
medicines had little value or meaning. The benefit information also appeared to have 
the potential to undermine the confidence that participants had in their medicines and in 
their GP. This could suggest that a PIL is not the right place for benefit information of 
this kind.  
The findings show no consistent approach to the appropriate presentation of benefit 
information, and this needs to be resolved before it is included in a PIL. There is the 
potential that improvement to textual benefit information could help inform patients 
about medicines without creating the unease that numerical data tends to provoke. 
However, there remains an ethical quandary about whether benefit information, 
especially in a numerical format, should be made available to patients; although with 
the increase in usage of web-based resources and the increase in open access journals 
containing trial data, it can be argued that this data is already freely available to the 
public. It is therefore essential that this information be well communicated in order to 
promote informed-decision making and help people take their medicines safely and 
effectively.  
More research is required into understanding how this can be done without causing the 
anxiety that participants felt when faced with this surprising numerical data and without 
leading them to employ affect heuristics to interpret its meaning. Patients need to be 
able to have good quality factual information, whilst retaining their faith and trust in their 
GPs and in their medicines. Before steps are taken to incorporate benefit information in 
PILs more research is needed to resolve these issues. 
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 Strengths and limitations of the methods  3.11
 Headline section 3.11.1
The use of summary information, like headline sections, is currently being 
championed by medicines regulators such as the MHRA and the FDA, however 
there is very little research in this field which assesses the impact of the headline 
section. This research study contributes to the field, with an in-depth exploration of 
the impact of including a headline section in a PIL on patient satisfaction, 
knowledge and potential behaviour. 
The research recruited a representative sample of active medicine-takers to 
examine their opinions on the inclusion of a headline section in regulated PIL. 
Although the study used a convenience sample, it covered a range of attributes 
including gender, age, medicine use and levels of education.  The sample included 
a higher than average number of women, which is not unusual in health research. 
The participants were more highly-educated than the general population and 
therefore the sample potentially contained a high number of people with higher than 
average literacy skills. This could impact upon the applicability of the findings to 
populations with lower levels of education and more research in this population is 
required as a result. 
Finally, while the research explores the potential impact of the headline on patient 
satisfaction, knowledge about medicines and medicine-taking behaviour, it was not 
designed to test any actual changes in understanding and behaviour. The actual 
impact on a patient’s knowledge and understanding and on their medicine-taking 
behaviour is not known. More research designed to test this will be valuable.  
 Benefit information 3.11.2
This study is an exploration into the opinions of the users of medicines on the 
inclusion of benefit information in their medicines information. There has been little 
previous research in this field, with most research into the communication of 
treatment benefits focusing upon preference and understanding. Very little is known 
about the deeper impact of providing this information and the range of opinions and 
impact on the inclusion of benefit information in this context. This research 
contributes significantly to the field by providing a qualitative investigation into the 
presentation of benefit information in medicines information.  
160 
 
The strengths of this research are its inclusion of real-life users of medicines 
combined with the use of real clinical trial data to generate the benefit statements. 
Most research in this area has focused on exploring the preferences and 
understanding of non-representative samples, and has recruited samples who 
might not take medicines. A non-representative sample might not have the same 
deep involvement in making decisions about medicines, and as such the findings 
from these studies might not be applicable to real-life users. A significant amount of 
research in this area has used hypothetical treatments, which are not always based 
on real-life data, in order to explore understanding of numerical formats of treatment 
benefits. In this study, although the medicines were given hypothetical names, the 
benefit statements were based on actual clinical trial data.  The findings of this 
study are generated from focus groups with actual users of medicines presented 
with benefit information of actual treatments and asked to consider how this 
information might influence them. The next step in undertaking research in this field 
might be to explore how this information impacts upon decisions; that is the 
decisions that are made by users of medicines making choices about actual 
treatments.  
This study adds weight to the findings of Hamrosi et al (2012) by examining the 
impact of providing benefit information with higher levels of benefits in PILs for 
different conditions. As a result there is greater understanding about how people 
respond to different values of benefit information.  
This study did not report any measures of understanding, such as literacy and 
numeracy, and it is possible that participants stated that they understood the 
information when they actually did not. This suggests the need for further research 
into how the different formats impact upon understanding and medicines beliefs. 
One objective of the research was to identify which type of format was preferred in 
a PIL. It was apparent that participants valued a textual format, but the textual 
format we provided was perceived as vague. It was apparent that many participants 
would make different decisions about their treatments when the information was 
presented numerically, as opposed to textually. It is possible that there is a need for 
a quantitative analysis into which formats best promote understanding when used in 
the context of a PIL. 
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The provision of the multiple formats of benefit information occasionally contributed 
to an additional challenge in interpreting the information. Many participants 
struggled to understand the formats and there was a sense of ‘information overload’ 
caused by reading, and trying to calculate how the different formats related to each 
other. Potentially this could lead to a sense of ‘cognitive burden’, where the inherent 
difficulty of the information places a burden on the patient which hinders their ability 
to engage with the information (Chandler and Sweller, 1991). This is something that 
would be reduced in a naturalistic setting, as only one format would be used in a 
PIL, and this additional burden was not observed in every participant. Several 
participants understood all the formats, and some did not understand any, and the 
presence of the multiple formats did not appear to make a difference to this. It is 
possible that the leaflet designed for the research caused increased difficulties in 
comprehension of the benefits that would not exist in a real-life PIL. The findings 
must be interpreted with this in mind. 
The labelling of the framed statements as ‘positive’ or ‘negative’ may have 
influenced the participants in their preference of statement. Also, the use of the 
colours to highlight the different benefit statements may have had an influencing 
effect and be a possible confound (Elliot and Maier, 2014). 
Finally, it is important to note that the participants in the sample were generally well-
educated. A small number held professional qualifications and were familiar with 
statistical concepts. Their understanding of the numerical information is likely to be 
greater than the general population, and although the study recruited a mixed 
sample of education levels, it was apparent that many of the participants had very 
good numeracy skills. This will impact upon the generalisability of the findings. 
 Application of the findings 3.12
 Headline section 3.12.1
The headline section was viewed as a positive inclusion within a patient information 
leaflet. The participants in the focus groups raised very few concerns about the 
inclusion of this adaptation in a PIL. The design of the headline section presented in the 
focus groups was largely viewed as favourable, although participants raised the need 
for better signposting.  
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The findings of these focus groups will be used to improve the design of the headline 
section and the next stage of the work reported in this thesis will involve the user-testing 
of this intervention in order to assess whether a headline section can help people find 
and understand key information about their medicines. 
 Benefit section 3.12.2
The inclusion of benefit information in a PIL is a complex topic and appears to provoke 
strong feelings in people, who frequently find it to be surprising and upsetting. The 
focus groups did not reveal a clear best format.  
At this stage it would be difficult to measure whether participants can find and 
understand benefit information in a PIL, as there is still a great deal of uncertainty about 
which format is most effective at conveying the benefits of treatment whilst minimising 
any decisional conflict. As a result of this uncertainty and the evocation of negative 
emotional responses, it is also unclear whether a leaflet is an appropriate place for this 
information. Little is understood about how the actual users of medicines might respond 
if this information was provided about the medicines they are prescribed. More research 
into how benefit information impacts upon the knowledge, understanding and behaviour 
of the real-life users of medicines is needed.  
Consequently, in terms of benefit information, the findings of the focus groups will be 
used in a number of ways: 
 To develop the benefit statements further in light of the reported preference and 
understanding for format. 
 To develop further research questions that explore the patient’s understanding 
of the benefits of their medicines, in particular which explore participants’ 
tendency to over-estimate the benefits of medicines. 
 To understand in more detail the impact of providing benefit information to 
actual users of medicines, as opposed to a sample comprising those who are 
not required to make a real-life decision about medicine-taking. 
As currently little is known about the provision of benefit information in regulated PILs, 
and participants appear unfamiliar with this concept, a more detailed investigation into 
the type of benefit information that is already available in PILs would be useful. This 
would improve our understanding of current benefit information, and allow the 
categorisation of the different types of benefit information currently provided to the 
users of medicines. 
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  User-testing a headline section (Study 3) Chapter 4
Do patients use a ‘Headline’ section in a PIL to find key information about their 
medicines? The findings from a user-test study. 
 
 Introduction  4.1
The preceding chapter described the findings from Study 2, a focus group study which 
explored patient preferences for the inclusion and format of a headline section, and 
benefit information, in a regulated PIL. Participants reported very positive opinions on 
the inclusion of a headline section, believing it to be a valuable addition to a PIL. It was 
viewed as an adaptation which might help relieve the cognitive burden that current 
leaflets appear to place on patients and something that responds to their desire for well-
designed, succinct information which captures the key facts about their medicines. (The 
findings from  the benefit section were equivocal and as a result this study does not 
address the user-testing of benefit information, but focuses solely on the headline 
section). 
Good quality written information is important for the safe and effective use of medicines 
and it is known that patients value good quality written medicines information to support 
their medicine-taking and want well designed patient information leaflets that meet their 
needs (Dickinson and Raynor, 2003, Grime et al., 2007). The headline section appears 
to respond to this need and the findings of study 2 are in line with the limited literature 
on this topic, supporting the view that a headline section has the potential to encourage 
readership of at least some parts of a leaflet, especially for those who might not 
otherwise read the entire leaflet.  
A limitation of study 2 is that it did not evaluate whether a person could effectively use a 
headline section in practice. Currently little is known about the effectiveness of a 
headline section in a PIL and how people might use it. This chapter describes a user-
testing study which aims to explore how people use a headline section. A previous 
user-testing study which compared patients’ use of a leaflet with a headline section and 
one without did not show any difference in their ability to find and understand key 
information. This study did note that the headline section was valued as a positive 
inclusion to the leaflet by the research participants. It concluded with the need for 
further research in a more naturalistic setting to determine if the addition of a headline 
would encourage patients to read at least that section (Dolk et al., 2011). The current 
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study used a different medicine to that tested in the study by Dolk et al (2011), although 
the  headline sections in both studies were based on the MHRA examples published in 
‘Always Read the Leaflet’ (Medicines and Healthcare Products Regulatory Agency, 
2005a). A key difference in the user testing process in the current study was that 
participants were not allowed to read the PIL immediately before the test took place 
(normal practice when undertaking testing of conventional PILs). This was because one 
of the limitations of that study identified by the authors was that allowing participants to 
read the PIL in advance allowed them to ‘make a mental representation of its structure 
before answering the test questions which may have led to a reduction in the effect of 
the headline section’ (Dolk et al., 2011). The key differences in the methods and 
findings of Dolk et al and the current study will be discussed in more detail in the 
discussion section (chapter 7). 
This chapter will describe the methods used and present findings from both the 
quantitative and qualitative elements of the user-test study. Finally the chapter will 
conclude with a discussion of the findings and consideration will be given to the wider 
application of a headline section in regulated PILs. 
 Aims and objectives 4.1.1
Aims 
To explore how readers use a headline section in a PIL to find and understand key 
information about their medicines. 
Objectives 
 To use performance based user testing to evaluate how frequently participants 
use a headline section to locate key information about their medicines.  
 To evaluate the frequency of use of textual and visual signposts in the headline 
section. 
 To determine general views on the headline section and how it might be 
improved. 
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 Methods 4.2
 Methodology 4.2.1
User-testing employs both qualitative and quantitative methods to test whether key 
pieces of information in a written document can be easily found and understood. The 
choice of this method supports the pragmatic approach used to underpin this thesis; 
which is practical in its objectives and aims to develop recommendations on the best 
ways to design PILs containing a headline section which meet the needs both of the 
public and the standards set out by the appropriate regulatory bodies.  
A pragmatic research approach suits this aim as it focuses on the outcomes of the 
research - meaning the actions and consequences of the inquiry take priority over the 
underlying epistemological foundations. This study reflects this perspective as it is less 
focused on one system or philosophy, but instead concentrates on using the using 
appropriate methods of data collection which best answer the research question and 
which can facilitate practical applications of the research for the future (Creswell, 2013).  
The pragmatic approach may incorporate the use of multiple methods of appropriate 
data collection to best answer a research question and can therefore include both 
qualitative and quantitative techniques. User-testing is a method which employs both 
methods to test the readability of written information. It is currently the gold-standard 
method in performance-based testing for patient information leaflets to ensure they are 
legible, clear and easy to use (European Commision, 2009). In Europe PILs are under a 
legal obligation to be tested with the target patient group. Therefore it is expected that 
this method is appropriate to measure outcomes which are applicable to the real-world 
and thereby facilitate the production of a headline section that meets the requirements 
of European regulators of medicines.  
The strengths of user-testing include that it recruits potential real-life users of medicines 
to test the information, and responds to the unpredictable ways that a reader might use 
a piece of information (Sless and Shrensky, 2007). This is rather than relying on other 
methods, such as readability formulae, which may test aspects of the ‘readability’ of 
written information, but do not test whether patients can actually find and use the 
information they need (Meade and Smith, 1991) (Raynor, 2008). 
There is a growing body of literature using user-testing as a research method to 
improve the readability of other types of written healthcare information. User-testing has 
been shown to improve the readability of many health documents, ranging from patient 
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information leaflets, clinical trial patient information sheets  (Knapp et al., 2009b) 
healthcare instruction booklets, (Brooke et al., 2012) (Knapp et al., 2010) and 
healthcare appointment patient information (Lasser et al., 2006).  
 Design 4.2.2
The process of user-testing consists of a number of steps:  
 Firstly 12-15 key points of information from the leaflet are identified that are 
relevant to the medicine’s safe and effective use.   
 A questionnaire is developed that:  
(a) Determines whether people can find and understand each piece of information 
(quantitative) and 
(b) Gathers additional comments from the participants on the documentation being 
tested through a qualitative semi-structured second part of the interview.  
 Rounds of 10 participants are recruited from the target population and 
interviewed using the questionnaire.  The aim is for all participants to be able to 
find each piece of information, and be able to express it in their own words 
(Raynor et al., 2011, Dickinson et al., 2001). 
 The results of both the quantitative and qualitative parts of the questionnaire are 
then examined to determine if there are faults within the document. If so, good 
practice in information writing and design are employed to rectify those faults 
and the revised document tested on another cohort of 10. 
 Training 4.2.3
Prior to commencement of the user-testing, the researcher undertook training at Luto 
Research, a University of Leeds spin-out company that provides user-testing services. 
She shadowed a trained user-tester and observed several user-testing interviews 
undertaken at the organisation. This enabled her to observe the way in which the 
questionnaire was administered and consider the role of the researcher when providing 
prompts to the participants. Insight was also gained from a Luto staff member with 
experience in questionnaire design for user testing. 
 Participants 4.2.4
20 participants were recruited to 2 rounds of user-testing (10 participants in each 
round). Participants were members of the public who had an expressed an interest in 
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participating in research and who had provided their details to Luto Research.  A 
database search identified potential recruits who met the inclusion criteria.   
Inclusion criteria: 
 aged over 50 
 had not previously taken part in a user-test   
Exclusion criteria 
 had received a prescription for the type of medicine on which the exemplar 
leaflet was based (a statin medicine) 
 unable to read a PIL in English  
 a healthcare professional or in a role where they provide information about 
medicines. 
Potential participants were then contacted by the researcher by telephone, to confirm 
their eligibility. Spoken information about the research was provided and if they 
expressed interest in taking part, a date for interview was agreed and an information 
sheet about the study was posted to them. 
The following demographic details were recorded: 
 age 
 highest level of educational attainment 
 use of written documents as part of their work 
Each round of participants was recruited to a similar profile of age, education and use of 
documents.   
 Materials 4.2.5
a) Patient Information Leaflet.  
Choice of medicine for the leaflet 
In Study 2, two exemplar PILs were studied, one for a ‘statin’ medicine to lower 
cholesterol, and one for a ‘triptan’ medicine for migraine. It was decided to undertaken 
user testing on the former, i.e. for the hypothetical medicine Rebastatin (based on the 
real-life medicine simvastatin). This was because simvastatin, which Rebastatin is 
based on, is commonly-prescribed. Also, the safe and effective use of simvastatin 
requires patients to be aware of  several key issues such as adverse effects and dietary 
restrictions. This information is well-suited to the concept of a headline section. 
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Design of the headline section 
The leaflet contained a headline section, presented as a grey shaded box. The section 
was inserted at the beginning of the leaflet, and contained 7 key points of information 
about the medicine. The headline section was titled, using a darker shade of grey, 
‘Important things you need to know about Rebastatin’ and the 7 pieces of key 
information were presented as bullet points.   
The headline section was developed in accordance from guidance from the MHRA 
(Medicines and Healthcare Products Regulatory Agency, 2005b, Medicines and 
Healthcare Products Regulatory Agency, 2005a).  Previous research into the use of a 
headline section (Dolk et al, 2011) was also utilised to develop the headline section in 
accordance with the evidence-base and with the findings of study 2 which suggested 
the following: 
a) The grey-shaded box format was an acceptable presentation of a headline 
section and was viewed as noticeable. 
b) A need for improved navigation through the leaflet, hence the development of 
graphical markers.  
c) The nature of the points of the headline used during the study was acceptable 
and responded to participant desire for key information.   
The exemplar leaflet was presented in a two column format and printed on 2 sides.  The 
two column format is recommended by the MHRA as the short line length helps poorer 
readers (Medicines and Healthcare Products Regulatory Agency, 2012a).   
A small icon in the bottom right hand corner instructed the reader to ‘turn over’ (figure 
13).  The layout and content of the leaflet followed guidance provided by the European 
Commission (European Commission, 2009) and the Co-ordination Group for Mutual 
Recognition and Decentralized Procedures – Human on the presentation of patient 
information leaflets (Co-ordination Group for Mutual Recognition and Decentralized 
Procedures - Human, 2011). The content was based on a standard leaflet for a 
simvastatin medicine and the key information included in the headline section was 
proposed by the pharmacist supervisors (DKR and JM). A graphic designer (BP) was 
consulted and he redesigned aspects of the headline section, in particular the 
signposting, according to the findings of the focus group work which underpinned this 
research. (Chapter 3) 
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Figure 12: Headline section used in the leaflet. 
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Figure 13: Photograph of the headline section to show positioning in the 
leaflet. 
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Textual signposting 
Where the headline section contained additional information which was expanded upon 
in the main body of the leaflet, there was a textual signpost directing the reader to the 
appropriate section of the leaflet where the additional information could be found, e.g. 
‘See Section 1: What Rebastatin is used for?’  If the information provided in the 
headline was discrete and not elaborated upon elsewhere in the leaflet or if additional 
information was available in multiple places then a textual signpost was not included.  
Graphical signposting 
‘Graphical markers’, such as  were included after the textual signpost for 3 of the key 
points.  This was an additional signpost designed to direct the reader using a visual 
cue.  These signposts were repeated in the body of the leaflet, where the appropriate 
information was to be found.   
b) Questionnaire. 
The purpose of the questionnaire was to:  
- Test a participant’s ability to find and understand 15 key pieces of information.  
- Determine participants’ general views on the document, and its positive and 
negative points. 
User testing can be undertaken to assess the readability of all of a document, or just 
one part. The latter is referred to as a ‘focus test’. However, it was decided not to ‘focus 
test’ the headline section because: 
- We need to know if the addition of a headline section impinges on the 
effectiveness of the rest of the leaflet.  
- Some of the points in the headline section are sign-posted to text in the main 
body of the leaflet. 
Hence the questionnaire was developed to cover all aspects of the leaflet. 
The questions are listed in Figure 14; and there were 6 questions related to information 
in the headline section.  For 4 questions the answer could be found in its entirety in the 
headline section (questions 1, 3, 7 & 9).  Two questions (questions 6 & 10) were 
devised to test whether the headline section would be used as a point of reference to 
find additional information elsewhere in the leaflet and whether the reader would use 
either the textual or visual signpost.  
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The user-test questions were presented in a different order to how the information 
appeared in the leaflet. This was to ensure that the participant had not learnt that the 
points of information in the questionnaire were sequential in terms of placement in the 
PIL. 
For the second, qualitative, part of the interview a brief topic guide was prepared 
covering 6 points – see Figure 15. 
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  Question Main 
leaflet 
section 
Headline 
Section? 
Textual 
signpost 
Graphical 
signpost 
1 What is Rebastatin used for? 1 Yes n/a n/a 
2 What does the leaflet tell you to do 
before you start taking this medicine 
if you drink large amounts of 
alcohol? 
2 No No No 
3 Suppose you are pregnant, what 
information does the leaflet give 
about whether or not you can take 
this medicine? 
1 Yes Yes No 
4 What is the usual dose of 
Rebastatin for people with Coronary 
Heart Disease? 
3 No No No 
5 What group of medicines does this 
medicine belong to? 
1 No No No 
6 Imagine you are already taking 
Rebastatin and would like to take an 
antibiotic, what does the leaflet tell 
you to do? 
2 Yes Yes Yes 
7 How does Rebastatin affect your 
chance of having a heart attack? 
1 Yes n/a n/a 
8 How many people are likely to feel 
sick after taking this medicine?  
4 No No No 
9 Suppose you start to take 
Rebastatin, what information does 
the leaflet give about your diet? 
1 Yes No No 
10 Unexplained pain in your muscles 
can be a sign of muscle problems. 
What can happen if you get these 
muscle problems? 
2/4 Yes Yes Yes 
11 Suppose you forget to take 
Rebastatin and it is nearly time for 
your next dose, what does the 
leaflet tell you to do? 
3 No No No 
12 Imagine you are taking this medicine 
then you develop a rash, with weak 
legs, what does the leaflet tell you to 
do? 
4 No No No 
13 Why should you not drink grapefruit 
juice while taking this medicine?  
2 Yes No No 
14 Suppose you are already taking 
Rebastatin and you need to have an 
operation, what does the leaflet tell 
you to do? 
2 No No No 
15 Imagine you already have a kidney 
problem, what information does the 
leaflet give you about the dosage of 
the medicine? 
3 No No No 
Light grey shading refers to questions assessing use of headline 
Dark grey shading refers to questions assessing use of headline and signposting 
Figure 14: User-testing questionnaire. 
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The questionnaire was initially piloted with 2 participants to evaluate the usability of the 
questionnaire in a test scenario. The characteristics of the participants are reported in 
table 7. Both the questionnaire and leaflet performed well and no significant issues 
were identified (appendix 17). However the order of the questions was changed to 
ensure a more even spread of the questions that focused on the headline section 
throughout the questionnaire.  
 Procedure 4.2.6
Interviews were conducted in an interview room with the researcher (RD). The 
participant was welcomed into the room and the aims and procedures of the research 
discussed and written consent obtained. The participant was then provided with the 
exemplar PIL and the user-test began immediately. The researcher administered the 
questionnaire, asking each question in the order specified in figure 14. The participant 
was able to refer to the leaflet as required throughout the user-test. The user-test was 
timed and audio-recorded (with permission).  
The researcher recorded the following outcomes: 
 Whether the participant could find and understand the answers to the question. 
(Using a dichotomous score of yes/no). 
 The time taken to locate the answers. 
 The number of prompts required to help clarify the question. (Prompts include 
rephrasing or restating the question). The same prompts were used for each 
user test. For example, if a participant responded with a partial answer, the 
question “Does the leaflet provide any additional information?” would be used to 
prompt a more complete response.  
 The location in the PIL from where the answer was found. In particular, it was 
noted whether the answer to the question was found from the headline section. 
If the location where the information was found was not obvious to the 
interviewer, she asked the participant to point it out on the PIL.  
 Whether the participant used the textual or graphical signpost. (This was 
evaluated through observation and questioning if necessary). 
Following the user-test questions general qualitative questions were asked in order to 
explore perceptions of the headline section. 
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 What is your impression of the leaflet in general? 
 What did you think about the ‘important things’ section at the beginning of the 
leaflet? 
 Most leaflets don’t, at the moment, have this ‘important things’ section – would 
you like them to have such a section, or do you prefer leaflets as they are? Can you tell 
me why you would prefer/ not prefer an ‘important things section’? 
 Can you recommend any improvements to this section? 
 Do you think you would do anything differently if your leaflets came with this 
section? Prompt: might you just read this section? 
 What did you think about the way you were sometimes directed in the ‘Important 
things’ section to further information in the main leaflet/ 
Figure 15: Qualitative questions. 
 Data analysis 4.2.7
Data analysis comprised of two distinct phases, that relating to quantitative data and 
that relating to qualitative data. 
Quantitative 
The performance of the leaflet was measured in the following ways: 
1) The total number of answers that were found or not found, was recorded. 
2) If answers to questions were found and understood by 80% or less of 
participants, this was taken as an indication that there was an issue which might 
need to be resolved. This is in accordance with the threshold recommended in 
EU legislation on the testing of medicine leaflets. 
3) Whether the information was located in the headline section was recorded for 
each question (where relevant). This enabled the researcher to compare and 
contrast the use of the headline section use across the questions. 
4) The number of opportunities to use the headline section and number of times 
the answer was located in the headline was recorded. 
5) Whether a signpost was used was noted for each question where this was 
relevant. 
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Qualitative 
The qualitative data were analysed using content analysis. The interviews were listened 
to and transcribed verbatim by RD. A process of familiarisation followed where the 
interviews were listened to again, the transcripts re-read and notes made. The data was 
then charted according to participants’ responses by question (appendix 18). This 
enabled the researcher to explore any common responses and explore the data 
according to participant response and characteristics.  
A process of mapping and interpretation was undertaken. Each response was 
summarised and the summaries grouped into corresponding themes. The themes were 
grouped into coherent categories and sub-categories. Appendix 19 shows part of this 
process.  
 Research ethics  4.2.8
The research was approved by the University of Leeds, School of Healthcare Research 
Ethics Committee (SHREC RP/271). 
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 Quantitative results 4.3
20 participants were recruited and formed 2 rounds of 10. Their characteristics are 
reported in table 8. 
Table 8: Participant characteristics 
 
*1=attended school, 2 = attended college or further education, 3= graduate level education 
** Lit = regularly uses written documents as part of work. No lit = does not regularly use of written documents as part of 
work, or are currently not working or are retired. 
 General performance of the PIL 4.3.1
Overall the leaflet performed well. The data collected in round 1 identified 2 problematic 
questions. These questions were: 
[1] What does the leaflet tell you to do before you start taking this medicine if you 
drink large amounts of alcohol? Found 7/10 and understood 7/10 
[2] Imagine you are already taking Rebastatin and would like to take an antibiotic, 
what does the leaflet tell you to do? Found 8/10 and understood 7/10 
As the issues identified with the questions were not related to the use of the headline 
section, a decision was made not to make changes in between the rounds as changes 
would not impact upon the use of the headline section. 
Category Sub-
category 
Pilot 
(n=2) 
Round 1 
(n=10) 
Round 2 
(n=10) 
Women  2 7 6 
Age 50-59 1 5 4 
 60-69 1 3 4 
 70+ 0 2 2 
Education* 1 1 5 2 
 2 0 3 6 
 3 1 2 2 
Literature 
use** 
Lit 2 5 5 
 No Lit 0 5 5 
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In round two at least 80% of the participants found and understood all the information. 
(Which is in accordance with the threshold recommended in EU legislation on the 
testing of medicine leaflets) (European Commission, 2009).  No significant problems 
with the leaflet were identified. 
As a result of this the presentation and analysis of the results will focus on those 
questions relating to information found in the headline section. 
 Using the headline section 4.3.2
The following questions related to the headline section: 
(a) Self-contained pieces of text which are replicated in the main body, with no 
additional information there 
1] What is Rebastatin used for? 
2] Suppose you are pregnant, what information does the leaflet give you about 
whether or not you can take this medicine? 
7] How does Rebastatin affect your chance of having a heart attack? 
8] Suppose you start to take Rebastatin, what information does the leaflet give 
about your diet? 
13] Why should you not drink grapefruit juice while taking this medicine? 
(b) Piece of text which is expanded upon in the main body of the leaflet 
6] Imagine you are already taking Rebastatin and would like to take an 
antibiotic, what does the leaflet tell you to do? 
10] Unexplained pain in your muscles can be a sign of muscle problems. What 
can happen if you get these muscle problems? 
It was apparent that the headline section was used by the participants, although it was 
not used all time. When the data were collated a range of frequencies of headline use 
was identified, depending upon question type.  
 
Table 9 shows the scoring for the questions which assessed the frequency of use for 
the headline section, whilst table 10 shows the scoring for the use of the signposts. The 
findings were as follows: 
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Table 9: Frequency of use of the headline section 
 
Round Headline  Q1 Q3 Q6 Q7 Q9 Q10 Q13 
1 Headline 
used? 
Yes 8 2 0 2 7 0 8 
No 2 8 10 8 3 10 2 
2 Headline 
used 
Yes 10 4 0 3 4 0 7 
No 0 6 10 7 6 10 3 
 
Light grey shading refers to questions assessing use of headline 
Dark grey shading refers to questions assessing use of headline and signposting 
 
Question 1:   
 What is Rebastatin used for? 
The headline was most frequently used for question 1. This was the first question and 
the majority of the participants looked immediately at the beginning of the leaflet in the 
headline section. (18/20, 90%) 
Question 6 and 10: 
 Imagine you are already taking Rebastatin and would like to take an 
antibiotic, what does the leaflet tell you to do? 
 Unexplained pain in your muscles can be a sign of muscle problems. What 
can happen if you get these muscle problems? 
 
These questions tested the frequency of use of the headline as a tool for directing the 
reader to related information included elsewhere in the leaflet.   
While the participants could not locate the complete answer to these questions in the 
headline, it could be used as a tool to direct the reader to the relevant information that 
was in the main body of text.  It was observed that the headline section was not used as 
a prompt in locating the answers for either of these questions. Instead participants used 
the main body of the leaflet where this information was repeated, often several times for 
each question, to retrieve the correct answers. For both questions, the answers were 
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predominantly found in Section 2: Before you take Rebastatin. Although for question 10 
the answer was occasionally (n=4) found in Section 4: Possible side effects.  
The headline section was used infrequently for the remaining questions (Q3, 7, 9, 13). If 
the information was self-contained in the headline section, then there appeared to be a 
greater chance that the headline would be used to locate it. For example, both Q9 and 
Q13 had answers that were found either in the headline or in only one other place in the 
leaflet. Neither of these pieces of information could be easily found under a logical 
heading elsewhere in the leaflet.  For example information about Pregnancy could be 
found under a sub-heading:  Pregnancy and Breastfeeding, which was highlighted in 
bold. The answers to these 2 questions were contained within larger bodies of text and 
were often isolated (i.e. not surrounded by relevant information as they were stand-
alone statements). For question 9 the headline was used 11/20 times (55%) and for 
question 13 the headline was used to locate the answer 15/20 times (75%). 
Question 3, which referred to whether the medicine could be taken during pregnancy, 
was found 6/20 (30%) in the headline. Information about pregnancy was available in 2 
places in Section 2.  
And finally, question 7, which was located in two places in the leaflet, but presented in 
the headline alongside other information about the uses of the medicine. This headline 
was used to locate this information 5/20 (25%). 
To conclude, there were 140 opportunities for the reader the use the headline section 
find or assist with the location of important information. The headline was used, in total, 
for 55/140 opportunities (39%).   
 Use of the signpost 4.3.3
Two questions, Q6 and Q10, were designed to test whether participants used the 
signposts by being designed so that the participant could find a partial reference to the 
answer in the headline, but to find the full answer they needed to use the signpost to 
find the answer elsewhere in the leaflet. The headline was not used to retrieve the 
answers to these questions. However, it was observed that some of the participants 
noticed and used the textual signpost for some of the other questions when the 
headline section was used.  1 participant reported they had used the textual signpost on 
question 1 and 4 participants reported usage of the signpost on question 4. One 
participant stated they had noticed the signpost during their qualitative interview but 
there was no evidence it was used. 
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Table 10: Frequency of use of the signposting (both textual and graphical) 
Round Textual (T)or 
graphical (G) 
Score Q1 Q3 Q6 Q7 Q9 Q10 Q13 
1 Signpost 
noticed 
Yes 1 (T) - NO - - NO - 
No - - NA - - NA - 
2 Signpost 
noticed 
Yes - 4 (T) NO 1 (G) - NO - 
No - - NA - - NA - 
 
 
Light grey shading refers to questions assessing use of headline 
Dark grey shading refers to questions assessing use of headline and signposting * 
T = Textual signpost, G=Graphical signpost. 
 Qualitative results 4.4
Overall the majority of the participants described the headline section as a valuable 
inclusion in a PIL. Only one participant did not voice positive views.  
 Helping people engage with information  4.4.1
The headline section was viewed as a useful tool to assist the reader to engage with 
information; however a small number of participants stated they either did not see the 
headline section initially or at all: 
“I didn’t realise why that was there and I haven’t really read that much. That’s like 
the bullet points of what is going to be in the information leaflet.” (P17, F, 60) 
Those that noticed the headline tended to view it as a useful aid in assisting the reader 
find key facts about the medicine. The highlighting of the section was viewed as helpful 
in emphasising the key information and bringing it to the reader’s attention: 
“I’d probably be more likely to read that bit because it is highlighted in bold and it 
appears to carry the most important type of information. “ (P8, M, 56) 
It was also viewed as noticeable and helpful because of its prominent position, at the 
beginning of the leaflet: 
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“I think you are right to put it first because that’s the most important things.” (P10, 
F, 63) 
Usual leaflets were viewed as long and difficult to retrieve information from: 
“I think it’s a good idea because quite often you look at a leaflet and you think 
there is an awful lot of information and you think, I’ll read it when I need to, and 
that’s the last you see of it.” (P3, F, 63) 
The headline was viewed as a tool which aided the reader to locate important 
information from a mass of information, that might not all have the same relevance (or 
be as important): 
“Well, it brings you to important facts straight away, rather than trying to find 
individual facts throughout the leaflet. You can go straight to that and the most 
important parts of the document.” (P9, M, 50) 
It was viewed by some as essential in helping patients find information quickly. Speed 
of retrieval of important information was viewed as important for many participants and 
some held the view that they could obtain key information by glancing at their leaflets, 
rather than having to search though for specific points: 
“I think from a glance at the front you can identify if you are going to fall into any 
categories where this might be a risk.” (P12, F, 58) 
“I think this is more informative this way. Straight away you get the answers to 
some questions.” (P20, F, 82) 
“I liked it because it is clear and because it stands out from the rest of it. You 
have the key points in bold and I think people are more geared up now for looking 
for the bullet points and you can go, ‘yeah, yeah, need to know about that, don’t 
need to know about that’. And it’s just easier to pick out the information rather 
than getting a mass out of it.” (P3, F, 63) 
Finding information quickly was particularly important when people were concerned 
about the risks associated with taking a medicine: 
 “I think you can read and you think ‘I can’t really take this’ straight away.” (P12, 
F, 58) 
 Suggested improvements to the headline section 4.4.2
Not all participants suggested improvements to the headline section; they felt that the 
headline met their needs regarding the information it contained in its current format. 
When suggestions were recommended, they fell into 3 categories: content, format and 
the leaflet as a whole.   
a) Improvements to the content of the headline section 
Key recommendations were for the headline section to contain more information about 
side-effects, drug interactions and dosage: 
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“I think saying a little bit more about the dosage and ‘stop taking it if’...” (P3, F, 
63) 
“You haven’t got anything there about side-effects. I think you should…you 
should have it in your box thing…I think you should say like anything this 
medicine can cause side effects, please see section whatever.” (P4, F, 62) 
One participant suggested that the information presented be simpler and less technical: 
I would have as much information under a simple heading, such as ‘do not’ and 
advising you. I would have it like this, because some can get a bit 
technical…medical.” (P10, F, 63) 
b) Improvements to the format of the headline section 
Suggestions to improve the format of the headline included to enhance the noticeability 
of the headline by using either a text box or a coloured box: 
“I would put a more clear boundary around it so it is separated from the rest, 
because there is nothing to make it stand out. Even making this little box, the 
headline, a brighter colour and the one that screams ‘important’ is red. Otherwise 
you turn it over and there is nothing there that particularly separates it. If there 
was a border around it and it was a separate colour then I would be inclined to 
read that before I go anywhere else. Obviously, if there are things in there which 
apply then I will go elsewhere in the leaflet. I shouldn’t need to read the whole 
thing.” (P16, M,57) 
The use of larger, or bolder, text was also raised as a suggestion, and this also related 
to the use of text to emphasise key points. For example, it was suggested that more 
emphasis be placed on the statement ‘Now read this entire leaflet’ using bigger letters. 
c) Improvements to the leaflet as a whole. 
One suggestion was to adapt the design of the leaflet in some way so it emphasised the 
headline section.  A small number suggested the leaflet take a booklet format, with 
different pages (with a difference emphasis on each page). Another suggestion was 
that the leaflet should be folded so that the headline is the first thing the patient sees 
when they remove the leaflet from the box: 
“I think it is a good idea, if these are folded in such a way that it is on the front 
when you pull it out. You may well get people to at least read that little bit.” (P6, 
M, 65) 
“The benefit of that (the headline) is that you would see the whole thing in 
one….actually, you could just fold up the leaflet so that the first thing that comes 
up is the important things you need to know because, then, if it is clear with a 
visible border around it, it’s probably more likely that people will take that in and 
read it.” (P16, M, 57) 
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 Signposting and navigation 4.4.3
On the whole, the headline itself was positively viewed as a tool that could help 
participants locate and retrieve information about the medicine:  
“It gives the headline and which section to go to.” (P16, M, 57) 
a) Graphical signposts 
When prompted to express their views most participants were generally quite positive 
about the graphical markers, considering them to be a potentially useful tool in aiding 
with finding information. However, several participants stated that they had not noticed 
the graphical markers at all and despite the participants’ enthusiasm for this tool, the 
graphical marker was commonly skipped over or ignored or misunderstood: 
 “Oh like A, B and C, Oh yeah I didn’t notice them. I didn’t see them and I 
should’ve and I didn’t. I didn’t see them. I didn’t take any notice. I think a lot of 
people are like me though. Aha, like A goes with A. Yeah. No, I didn’t see them. I 
didn’t take any notice of them or I would have found them answers quicker.” (P1, 
F, 52) 
“Oh right, yeah, I’ve only just noticed these I’m afraid…so yeah, I think I’ve 
answered that [question about using the graphical markers]. They seem like a 
good idea, but I obviously missed them.” (P8, M, 56) 
Suggestions to address this included the use of colour and a bolder design for the 
markers: 
 “I think if that B was in bold, done in a similar manner, but bold rather than 
shaded. I think it would stand out more.” (P5, M, 65) 
While the graphical markers did not appear to hinder the reader in any way, a number 
of participants misunderstood their purpose, were confused about their purpose or 
didn’t notice them at all:  
“No, it’s not very clear. You know, your A, Bs… I didn’t know what they were. 
I can’t see how it adds up. It’s A,B & C. I would put a number on it.” (P10, F, 
63) 
 
b) Textual signposts 
Not everyone noticed the textual signposts and some participants reported they skipped 
over them when looking for information elsewhere in the leaflet. One participant missed 
the existing textual signposts but recommended that the headline would be improved 
with a textual signpost: 
“It could say ‘look at section 4 or section 5.’” (P10, F, 63) 
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However, it was apparent that others did notice and appeared to value the inclusion of 
the textual signposts.  Some participants described how they helped them navigate the 
leaflet. This was particularly in reference to specific information such as pregnancy or 
muscle damage: 
“You can see it and I found what I was looking for quite easily because you have 
got captions and I could follow it quite simply.” (P12, F, 58) 
“Yeah, once or twice I [used the textual signposts]. I did because those 3 
questions looked at, in particular, the muscles, the grapefruit, the pregnant, yeah, 
for those.” (P20, F, 82) 
One participant noted how the headline and the textual signposts responded to how 
people use information in the age of the internet. People are more geared up for bullet 
points and this participant felt the headline like using a webpage: 
“I think that’s very good, particularly for those who are impatient. Some people 
will read things from top to bottom. Quite a lot of us won’t. I know I don’t. I will 
pick out the key point and think ‘yes, I need more of that.’ So if there is something 
which says to me ‘if you want to know more about this go here, then it’s the 
equivalent of if you are on a website. You get the little thing that say’s click here 
and it throws you into that section. I think that because people get a lot more 
information on the internet now we get a bit lazy and expect to click through, but 
in the days when written information came on pieces of paper and no other way, 
you were expected to read through to the end.” (P3, F, 63) 
 Reported influence on behaviours 4.4.4
The participants reported 3 ways in which the inclusion of a headline section might 
impact upon the way in which they, or others, read their leaflets. 
a) People might read more of their leaflets 
Not all the participants read all of their leaflets. A small group stated that the headline 
section might encourage them to read at least the ‘important things’ section. It was 
considered that the summary of important information might also encourage them to 
access and find other relevant information further on in the text: 
“I think if [the headline] highlighted something I was concerned about then I would 
read more of the information.” (P11, F, 56) 
[I would read] possibly more if there is something in there which rings a bell with 
you.” (P6, M, 65) 
“I think this is good because it gives you a brief insight into what problems there 
might be and then you would be inclined to look at the rest of it.” (P18, M, 64) 
Overall, the headline was frequently viewed as an innovation which might encourage 
more people to read their leaflets:  
187 
 
“If you’re the type of person who doesn’t read leaflets at all, then maybe there is a 
greater chance that they would read that rather than nothing at all. If you could 
get the absolute most important information in their memory, then that would be a 
good innovation.” (P8, M, 56) 
b) People might read less of their leaflets 
Some participants noted that they might only read the headline section and may not be 
encouraged to read elsewhere in the leaflets: 
“I think I would be more liable to read that bit and not any of the other, just read 
the important things bit and not read any of the other.”  (P2, F, 56) 
Some had concerns that others might not read the whole leaflet if the headline section 
was present in a leaflet: 
“I try to think that I read all my leaflets, but I think that some people might just 
read that bit and think ‘I’ve read it!’ and really they should read the whole lot.” 
(P15, M, 67) 
However, it is important to note that some participants reported that only reading the 
headline section was more of the leaflet than they would read normally and that the 
headline section itself enabled them to see the important information, rather than wade 
through the text to try and find relevant information, which frequently led them to give up 
on reading the leaflet. This could potentially lead to a more streamlined accessing of 
information: 
“I think when people are on medicines they read the most important things and 
the side effects, not everything. That’s what I read into. I don’t look for everything. 
But, what it is with me is it takes me a while to register things and I think I would 
go for the most important things. “(P1, F, 52) 
“I’d go straight to that section, rather than turn it over and look it over. I’d go 
straight to that part straight away.” (P8, M, 56) 
To summarise, some participants reported that the inclusion of a headline section might 
mean they read less of their leaflet, they felt that this was still beneficial as the more 
targeted information meant they would still find and retrieve more important information 
from their leaflet than if they had a leaflet without a headline, which they found difficult 
to read.  
c) People would not change their behaviour. 
A few participants stated that they would not change their behaviour if their leaflet 
contained a headline section and that they would continue to read the leaflet as they 
usually did: 
“I would read it as it comes.” (P20, F, 82) 
“I would read it all anyway.” (P17, F, 60) 
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Finally, one participant made a comment about getting used to the headline section. 
Although he found himself skipping over the headline section during the user-test, he 
noted its utility in the long-term: 
“Once I had worked out what it was for, I found it more useful.” (P8, M, 56) 
It is possible that the headline section might become more useful a tool if people 
became familiar with it if it was routinely included in a regulated PIL. 
 Discussion 4.5
The aim of this research was to determine how people use a headline section by user-
testing a PIL incorporating a headline section. The results showed that a headline 
section was used just over a third of the time (in total, for 55/140 opportunities (39%).  
Other notable findings included that 18/20 (90%) of participants used the headline 
section to find information when they initially began the user-test which suggests it was 
the first place a participant looked in the leaflet when initially trying to find important 
information. The results also suggest that there was a tendency for patients to use a 
headline section to locate self-contained pieces of information which might not be 
naturally positioned elsewhere within the leaflet.  
The headline did not appear to be commonly used as a signpost for the reader to look 
elsewhere in the leaflet. In particular, the graphical markers used to signpost the reader 
elsewhere were not used at all. This could be a failing in the design of the graphical 
markers specifically used in this leaflet and participants reported that the use of bigger 
and bolder graphical markers might draw their attention.  It is possible that further 
research into the use of graphical markers might suggest a method of best practice. 
Participants were observed to use the textual signposts to assist with navigation of the 
leaflet, although this was infrequent and the textual signposts were only helpful for a 
small minority of people. However, neither of the signpost methods used appeared to 
hinder the reader in any way and for those that did use them they appeared to help the 
participant navigate the leaflet. It is possible that if either type of signposting was 
routinely used in PILs, people would come to learn their function. 
The qualitative findings suggested that the participants valued the presence of the 
headline section. On the whole the headline was viewed as a useful tool which helped 
the reader engage with the information; it was noticed by participants and appealed to 
those with concerns about the length and complexity of current PILs. (Dixon-Woods, 
2001, Grime et al., 2007, Raynor et al., 2007) It was suggested that the headline 
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responded to people’s needs for information that can match the type and format of 
information provided on a website; short, succinct information that can be accessed 
easily.  
These findings echo those of another study (Dolk et al., 2011) and also the findings 
from the study reported in chapter 3, which also found that patients valued the headline 
section and were enthusiastic about its inclusion in PILs. This is a strong and consistent 
qualitative finding. 
User-testing, as a method, combines qualitative and quantitative aspects of enquiry to 
identify flaws in a piece of information.  There is a growing body of research supporting 
its use in evaluating and improving the performance of written documents (Knapp et al., 
2010, Brooke et al., 2012, Raynor, 2013). It has been shown to improve the readability 
of PILs and ensure that they are fit-for-purpose.  It is commonly used and is the gold 
standard for testing the performance of PILs in Europe. However, the method has 
limitations. The user-testing method uses small numbers and so, with regards to the 
quantitative findings, cannot give statistical certainty (Knapp et al., 2009b). However, 
these small numbers are well-suited in identifying any key issues with the leaflet and it 
is often apparent if there is an issue with the leaflet after only a few user-test 
participants (Raynor, 2013).   
The method has also been criticised for using a summative approach with its focus on 
reaching performance targets set by regulators, rather that the formative approach for 
which it is designed, i.e. the ‘test, amend text and layout, test’ cycle (Raynor et al., 
2011). However, this study was not bound by pre-defined performance targets. This 
study planned an iterative approach to evaluate performance. As the leaflet consistently 
performed well for the headline section questions, no amendments were required to the 
leaflet between the rounds of testing.  
With regards to the wider literature, it has been suggested that a headline section has 
the potential to be beneficial and engage patients in reading about their medicines 
(Medicines and Healthcare Products Regulatory Agency, 2005a). However, relatively 
little is known about the use in practice of a headline section in medicines information. 
Hartley (2004) suggested that the inclusion of a ‘boxed aside’ which is used to 
emphasise text within a larger body of text in educational materials might encourage the 
reader to skip around the highlighted section and ignore the important text. The 
headline section used during this research was presented at the top of the leaflet and 
not within a body of text. The user-testing showed that the headline section was used 
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on about a third of occasions to locate relevant information.  There was no evidence 
that the participants skipped over the headline section; instead the user-testing findings 
suggest that the headline section was the first part of the leaflet that the reader viewed.  
Similar research exploring the use of the headline section used a 2x2 factorial design to 
compare the impact of a leaflet with a headline section with a leaflet without a headline 
section on a reader’s performance and perception (Dolk et al., 2011). The headline 
section used by Dolk et al (2011) was similar to the headline used in this study and was 
one chosen by the MHRA to illustrate headline sections (Medicines and Healthcare 
Products Regulatory Agency, 2005a). Dolk et al (2011) did not find any difference 
between PIL designs in participants’ ability to find and comprehend the information 
provided. Both the headline section and non-headline section groups performed equally 
well.  It was noted that there was no evidence that the headline section had a negative 
impact on the reader, but nor did it have a positive impact. Dolk et al (2011) used a 
traditional user-testing format, in which participants were given time to read and 
familiarise themselves with the entire leaflet before the user-test commenced. It might 
be considered that as the participants had read the entire document prior to the test 
they assumed that the headline was a summary and when asked to respond to the 
questions neglected to use it in favour of the leaflet as a whole.  
The research reported in this chapter was a follow on study from Dolk et al (2011) 
which explored the use of the headline section in a more naturalistic setting, using a 
modified user-testing approach. The setting was still experimental but the user-test was 
adapted in order to replicate what might happen when a patient initially receives a PIL.  
It was hypothesised that the headline might be useful to help a reader find key 
information when they are unfamiliar with the leaflet and are first looking at it. Therefore, 
the aim of this study was to evaluate whether the headline section was used in a 
modified user-test scenario where the participant did not have the opportunity to read 
the leaflet prior to commencement of the test.  
The user-test in this research did not use the same methods as Dolk et al (2011) as 
there was no leaflet without a headline section control group. The findings show that in 
a ‘modified’ user-test scenario, where a participant did not have the opportunity to 
familiarise themselves with the leaflet, the headline was used about a third of the time 
to source important information. It was noted that the headline was used to locate 
information to answer the first question (18/20 opportunities (90%)), which suggests 
that the headline is seen and used immediately by a participant who is unfamiliar with a 
leaflet.  
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 Strengths and limitations of the methods 4.5.1
This use of this method complements the pragmatic approach used in this study.  An 
important objective of this body of work was to ensure that the findings from the 
research can be applicable to the real world and provide guidance (recommendations) 
on the incorporation of a headline section in patient information leaflets. User-testing is 
a diagnostic process that can facilitate that and is currently the process used to regulate 
PILs before they are licenced.  Since 2005 it has been mandatory for PILs in the EU to 
be user-tested to ensure that leaflets are legible and easy-to-use (European 
Commission, 2004).  
The evidence-base for the use of this method to test patient information has developed 
significantly over the past few years and applying this process to a leaflet has been 
shown to develop information which responds to a patient’s needs and which can 
improve the reader’s ability to find and understand key pieces of information (Raynor et 
al., 2011, Knapp et al., 2010).  
User-testing is a more suitable method to test the performance of a piece of writing 
compared to content-based testing methods (See section 4.2.1).  
However there are some limitations with the use of this method and with the application 
within this thesis. User-testing is a method that was intended to be diagnostic and 
developmental, rather than one used for evaluation, so it can be difficult to use the 
approach to make firm conclusions about the effectiveness of the headline section.  
User-testing has also been criticised for the use of a small sample size. The choice of 
rounds of 10 for each user-test is a convention that is not necessarily evidence-based. 
However, it is accepted that this diagnostic approach can be useful in identifying 
problems with information using only small numbers. Sless (2004) uses an analogy of a 
creaking step in order to demonstrate how a small sample can be helpful in identifying 
and addressing issues with a piece of information: 
 “Suppose you have a staircase that had a few creaking steps: every time 
someone went up the staircase you could hear it creak annoyingly a number of 
times. How many people would you need in a sample to climb up and down the 
staircase to find the location of the creaks, and should you have a representative 
sample of staircase users to find out which steps creak? Would the sample size 
be important? Clearly, there are types of consideration – so much a part of social 
science research – are not relevant in this context. By analogy, the same is true 
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of document testing. Moreover, as with the staircase, to find out if the problem in 
a document has been fixed does not need a large representative sample of 
users”(Sless. D, 2004, P.31). 
User-testing does not rely on undertaking statistical sample size calculations to 
generate a powered sample and this may enhance the possibility of making a type-II 
error, which is the failure to reject a false null hypothesis.  Also, the user-testing study 
did not have a control group. It is possible that a controlled trial with a larger sample 
might come to different conclusions about the inclusion of a headline section in a PIL. 
Dolk et el (2011) used a controlled design in a user-testing study of leaflets with and 
without a headline section and found no difference in a participant’s ability to find and 
understand information (Dolk et al., 2011). It is possible that the inclusion of headline 
section has no discernible impact on the reader’s ability to find and understand 
information in a leaflet. However, there is no evidence that it hinders the reader either, 
and the findings from the qualitative study suggest it is a popular and welcome inclusion 
in a PIL. 
 
Participants were recruited with a mix of genders, ages, educational ability and use of 
literature in everyday life. This adds to the representativeness of the research; however 
it is important to note that the type of people who engage in research of this type may 
differ with regards to their health literacy from the population as a whole. 
 
It is also important to note that the user-test is an artificial situation and this might 
impact upon how participants use and find the information. Certainly it is possible that 
the use of the questionnaire impacted upon how participants used the headline by 
diverting the reader elsewhere in the leaflet to answer the next question. This may 
impact upon the findings, leading to an under-reporting of the use of the headline 
section as the user-test diverted the participant’s attention away from the headline in a 
way that might not happen in a naturalistic setting. 
To conclude, there are some limitations to the findings from the user-testing study, 
however it is important to note that the use of user-testing complements the pragmatic 
approach used and reflects the methods used currently to test PILs prior to licencing in 
the EU.  
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Impact of the research and recommendations for further research. 
Participants tended to use the headline to locate discrete pieces of information; 
therefore a suggestion is that the headline section should include and prioritise such 
pieces of information. For example, in the leaflet used for this experiment, information 
about diet did not necessarily have a natural and noticeable place in a typical PIL 
structure and tended to be found more frequently in the headline than information that 
had a larger section dedicated to it, such as complex information about adverse events. 
Lengthy and complex information, which could be found elsewhere in the leaflet, did not 
appear to be found during the experiment in the headline, but instead in the appropriate 
section in the leaflet.  
The headline did not appear to be commonly used as a method for the reader to be 
signposted to elsewhere in the leaflet. The textual signposts were used more frequently 
than the graphical signposts, although both were used infrequently. The findings of this 
study suggest that caution should be given when considering the use of graphical 
markers. Leaflet designers should ensure they are noticeable but some participants 
reported they were confusing, so consideration should be given to whether they aid the 
reader to find and understand information before they are routinely included.  
One suggestion was to have the headline section folded so it is the first thing seen 
when a patient removes the leaflet from the box. This is a novel idea and the use of 
this, and whether it encourages participants to read the headline section, would be 
something that could be explored in more detail using a modified user-testing process 
in future research.   
 Conclusion 4.6
Inclusion of a headline section aims to assist a reader to locate important information 
about key issues associated with their medicines in a PIL. Previous research into a 
headline section did not show that it performed any better than a leaflet with a headline 
section in helping readers find and understand key information about their medicines. 
This study has shown that a headline section in a PIL is used to locate key information 
about a third of a time. The research suggests that there does not appear to be any 
negative impact from including a headline section in a PIL and that it is a technique that 
is highly valued by the consumers of medicines information. The use of a headline 
section in a PIL should be considered as a way of communicating key safety issues 
about medicines in patient information. 
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  Content survey of benefit information (Study 4) Chapter 5
The inclusion of information about the benefits of treatments in patient 
information leaflets: A content survey of 100 leaflets 
 
 Introduction 5.1
Chapter three presented the findings of a focus group study in which medicine users 
were presented with different formats of benefit information in PILs to explore 
satisfaction and preference for these formats, as well as the potential impact on 
knowledge about medicines and medicine-taking behaviour.  With regards to the 
provision of information about benefits in medicines information, the findings were 
equivocal.  It was apparent that benefit information, particularly numerical benefit 
information, had the potential to provoke an emotional response in some people. 
Participants valued textual benefit information and there was a strong desire for 
information about the benefits of treatment to be included to balance the concerns that 
many people have about the side-effects of their treatments. 
This chapter describes a survey and content analysis designed to examine the type and 
frequency of benefit information that is currently provided in regulated PILs. The aim of 
this study is to explore the prevalence and range of benefit information presented in 
PILs currently available for a sample of 100 medicines commonly used, or newly 
available in the UK.  
There is no standard definition of what ’benefit’ information might be. Carrigan et al 
(2008) refer to it as: 
‘Any information that described the potential benefit to health from taking the 
drug, over and above a simple description of how the drug worked.’ (Carrigan et 
al., 2008, P.307) 
Benefit information could refer to a number of different elements including quantitative 
and qualitative information about a medicine's efficacy and overall capacity to treat 
disease. Recently there has been an increased interest in describing what benefit 
information might entail, with both the MHRA and the EMA undertaking consultations 
with patients and other stakeholders to describe desirable attributes of benefit 
information (Medicines and Healthcare Products Regulatory Agency, 2005a, Medicines 
and Healthcare Products Regulatory Agency, 2005b, European Medicines Agency, 
2009).  
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Propositions to include benefit information in package leaflets have also been given a 
higher profile recently in current EU pharmacovigilance proposals (European 
Commission, 2010). Other international organisations, such as the US Food and Drug 
Administration (FDA), have also recognised the importance of moving towards better 
risk/ benefit communication by striking a balance and conveying information on benefits 
as well as harms (Fischhoff et al., 2011).   
Leaflets in circulation in Europe conform to the format described by the Quality Review 
of Documents template, which provides guidance on how to present package leaflets 
prior to application for marketing authorisations (Co-ordination Group for Mutual 
Recognition and Decentralized Procedures - Human, 2011). The European Medicines 
Agency's Working Group on Quality Review of Documents (QRD) develops, reviews 
and updates these templates. Recent changes to the QRD template for PILs have 
included the recommendation that information about the benefits of the treatment 
should be included in section 1: What (the medicine) is and what it is used for? (Co-
ordination Group for Mutual Recognition and Decentralized Procedures - Human, 2011) 
Currently there is limited research which explores the extent to which PILs include 
information about the benefits of treatments.  The inclusion of side-effect information in 
PILs has been more extensively studied and a survey conducted in 2006 (Carrigan et 
al., 2008) assessed the leaflets provided with the 50 most frequently prescribed drugs 
in England to determine the extent to which the likelihood of adverse events was 
described. This study suggested that patient needs were not being met and that few 
patient information leaflets contained side-effect information presented using the 
recommended frequency European Commission terms.  A similar study examining the 
extent to which benefits of medicines are described has not been undertaken.  
It has been shown that patients value side-effect information but frequently find that its 
inclusion in PILs conveys an overall negative message which can resonate quite 
strongly and impact upon perceptions of medicines in an adverse way (Raynor et al., 
2007, Fried et al., 2011). Recently regulatory bodies such as the MHRA have paid more 
attention to exploring how the provision of information about the benefits of medicines 
might impact upon perceptions of balance of harm and benefit in a leaflet, and how this 
might in turn impact upon patient perceptions of medicines (Medicines and Healthcare 
Products Regulatory Agency, 2005b). 
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Patients want balanced information, which includes information about the benefits of 
medicines, so they can weigh up the risk of harm and the likelihood of benefit before 
making an informed decision about taking a medicine (Grime et al., 2007). Currently 
benefit information is not required to be included in a PIL, however under EU 
regulations it can be included as long as it is not promotional (European Commission, 
2004). This has been identified as an area that warrants further research by European 
and other global medicines regulators. The MHRA has made several recommendations 
for the inclusion of benefit information (Medicines and Healthcare products Regulatory 
Agency, 2005b). 
Currently, it is not known whether these recommendations are being put into place and 
there is no information about whether benefit information is commonly included in PILs 
currently licensed for use, or how this benefit information is presented. The aim of the 
study reported in this chapter is to determine the extent to which information about the 
benefits of treatments is included in 100 PILs about medicines currently available in the 
UK and to categorise the different types of benefit information provided.  
 Research aims and objectives 5.2
 Aim 
The aim of this survey is to determine the prevalence and type of benefit information 
that is included in a regulated PIL in the UK. 
Objectives 
 Identify terminology used to communicate ‘benefit information’ in a PIL. 
 Survey PILs available in the UK to assess the extent to which benefit 
information is included in a PIL. 
 Categorise the range of information about benefits currently included in 
regulated PILs available in the UK. 
 Methods 5.3
This is a survey and content analysis of the ’benefit information’ content of patient 
information leaflets. Content analysis can be described as “the systematic, objective, 
quantitative analysis of message characteristics”  (Neuendorf, 2002). Content analysis 
can be a quick and efficient way of exploring written information in order to determine 
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the presence of specific words, concept or themes, (Berelson, 1952) in this case the 
prevalence and type of ‘benefit information’ in patient information leaflets. 
This survey and content analysis will use a process where ‘concepts’ of ‘benefit 
information’ in a PIL will be defined according to common characteristics identified from 
sources of guidance on writing benefit information (Medicines and Healthcare Products 
Regulatory Agency, 2005b, European Medicines Agency, 2009). These concepts will 
then be identified in the PIL, grouped according to their common characteristics and the 
frequency of their use assessed.  
The study uses an a priori design, where the concepts and sample are pre-determined 
in order to identify and collect relevant information in a systematic way. The pre-defined 
sample will then be searched for the presence of the concepts of benefit information 
and where appropriate, these will be both summarised into common themes and their 
frequency recorded. 
 Sample 5.3.1
Sampling was based on a form of random quota sampling of 100 regulated PILs for 
medicines.  The sample size was agreed by consensus in the research team (RD, PK, 
DKR, JM). 100 PILs was considered a large enough sample to map the breadth and 
depth of the various types of benefit information that leaflets might include and to 
identify and measure the frequency of common concepts of ‘benefit information’.  
The aim of using a quota sample was to gather data from two representative groups of 
leaflet types. The 100 medicines were divided into 2 groups of 50: 
[1] The top 50 dispensed medicines  
[2] 50 newly licensed medicines (from the so-called 'Black Triangle' list) 
The rationale for this sampling method was to obtain a range of medicines in common 
use in the UK.  Another justification was that it facilitated the exploration of differences 
between the inclusion of benefit information in a PIL for medicines that have been 
available for a long time and are used frequently, compared to more recently licensed 
medicines. It was hypothesised that PILs for newer medicines were more likely to 
include benefit information than older medicines, as patient information for newer 
medicines has been developed at a time when there is increasing interest from 
European and UK regulators to include benefit information in regulated PILs. 
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The sampling strategy aimed to obtain leaflets from a wide range of branded and 
generic products from different manufacturers in order to achieve maximum variation of 
leaflet type. This was to ensure that the benefit information was not obtained from a 
narrow, uniform source. The sampling strategy used is as follows: 
[1] The top 50 dispensed medicines were identified from prescription cost analysis 
data collated by the Information Centre for Health and Social Care for 2011 (Information 
Centre for Health and Social Care, 2011) (appendix 1). This information details of the 
number of items of prescriptions dispensed in the community in England i.e. by 
community pharmacists, appliance contractors, dispensing doctors, and items 
personally administered by doctors. The drugs dispensed were listed by British National 
Formulary (BNF) therapeutic class. 
The top 50 medicines from this list were chosen, as these were reflective of the most 
common medicines that patients receive in England, and therefore the most common 
leaflets that people receive.  
Where the list of top 50 dispensed leaflets referred to a non-specific medicine for which 
a leaflet might not be available, for example "Other Emollient Preps", the next item on 
the list was chosen. The list of the medicines was then randomised using a random list 
generator (www.random.org). The top half of the list (n=25) was allocated a leaflet from 
a branded medicine and the bottom half (n=25) a leaflet from a generic medicine. The 
rationale was to explore whether there were any differences in the type and frequency 
of ‘benefit information’ provided in generic and branded leaflets. The random sample 
approach ensured an indiscriminate spread of different manufacturers of leaflets. 
[2] Newly licensed medicines were identified from the MHRA “Drugs under intensive 
surveillance” list (also known as the Black Triangle list and referred to as ‘Black 
Triangle’ for the purpose of this study) (Medicines and Healthcare Products Regulatory 
Agency, 2012b). These drugs are subject to intensive monitoring because relatively 
limited information about their safety is available, although the Black Triangle symbol 
does not mean that the medicine is unsafe. 
The reason for choosing this group of medicines is that they are easily identifiable as 
products new to the market and therefore provide a comparison to the older, commonly 
prescribed medicines. This allows for comparison of the frequency and type of benefit 
information over time.  The rationale for including this group was to see whether the 
manufacturers of PILs were responding to regulatory moves towards for the inclusion of 
benefit information.  
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The Black Triangle list includes a number of different types of product. In order to 
prevent replication from the top 50 dispensed list only products identified as a new 
substance/ product were included. The following were excluded from the sample as 
they were identified as products for which the patient might not regularly receive a PIL, 
e.g. vaccines, or for which existing patient information is in circulation: 
 new vaccine 
 new combination of drugs 
 addition of paediatric use 
 different formulation for existing route 
 another route of drug administration 
 biosimilar product 
 change or addition of a therapeutic indication (excluding paediatric).  
As the Black Triangle list contained new products, all the leaflets were branded as no 
generic alternatives were available. The total sample therefore contained 75% branded 
leaflets (50% from the Black Triangle list and 25% from the top 50 dispensed group) 
and 25% generic leaflets (from the top 50 dispensed list). The full sample can be seen 
in appendix 23. 
 Obtaining the leaflets 5.3.2
A copy of each of the 100 PILs was obtained from the Electronic Medicines 
Compendium (eMC), a website which contains patient information leaflets licensed for 
use in the UK. The eMC contains more than 9,000 leaflets which have been approved 
by either the UK or European government agencies which license medicines 
(http://www.medicines.org.uk/emc). Leaflets were accessed between the period 7.01.13 
and 20.02.2013.   
The following steps were followed: 
[1] The eMC was searched for the medicines on both the branded and generic list. 
[2] For generic medicines, the British National Formulary (BNF) was used to identify a 
single listed manufacturer (Joint Formulary Committee, 2012). Where no single 
manufacturer was listed a random choice was made from a list provided by the eMC 
using a random number generator.  
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[3] Non-generic leaflets were chosen at random as a manufacturer is not explicitly listed 
in the BNF. A random list generator was applied to the list of manufacturers and the 
number 1 leaflet chosen. 
[4] When a particular manufacturer had a PIL included, that manufacturer was not used 
again (unless it was the only manufacturer of a leaflet).  
[5] If no generic leaflet was available for a medicine randomised to the generic group 
then the medicine was swapped for an alternative medicine on the branded list.  
 Benefit evaluation criteria 5.3.3
The information in each leaflet was evaluated for its provision of different types of 
‘benefit’ information.  Currently there is no existing categorisation of benefit information 
for medicines, therefore the benefit information criteria used for this analysis were 
derived from two sources; a report published by the European Medicines Agency (EMA) 
which explored patient, consumer and healthcare professional expectations of 
information on the risk and benefits of medicines (European Medicines Agency, 2009) 
and guidance developed by the Medicines and Healthcare products Regulatory Agency 
(MHRA) on patient information about medicines (Medicines and Healthcare products 
Regulatory Agency, 2005a). 
These two organisations enforce the regulation of medicines and medicines information 
in Europe and the UK and are responsible for maintaining and evaluating standards for 
medicines information. The reports were chosen because they both provide several 
potential criteria for what form benefit information might take, but also because they use 
a patient-centred approach to a definition of benefit information.  The aims of this thesis 
are to investigate patient preference for benefit information and to explore how it 
impacts upon knowledge, satisfaction and behaviour using a patient-centred approach. 
The EMA report, in particular, addresses patient’s expectations about what benefit 
information is and what they would be interested in seeing in medicines information.  
When combined with the MHRA suggestions as to what benefit information might 
include, there is a comprehensive source of various qualitative and quantitative criteria 
which describe what benefit information might be and what type of benefit information 
patients desire. A patient-centred approach to patient information is important to ensure 
that patient information meets the needs of those it aims to help (Raynor et al., 2007). 
In order to create a workable set of criteria to use as a framework for the analysis of the 
patient information leaflets, a basic content analysis and synthesis of the benefit 
203 
 
information collated by the two reports was undertaken. The documents were searched 
for definitions of benefit information and these were synthesised and categorised into 
10 categories, which included both qualitative and quantitative categories (Figure 16).
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 Figure 16: Diagram showing how EMA and MHRA benefit criteria was combined to develop the 10 criteria used for the analysis of the 
benefit information. 
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 Data extraction and quality assurance 5.3.4
The selected leaflets were searched for potential benefit information which would meet 
the criteria. This information was extracted and entered into a database which recorded 
the frequency and type of benefit information contained in the 100 PILs.   
Leaflets in the UK are set out according to the QRD human product information 
template (European Medicines Agency, 2012). This document defines the layout of a 
leaflet. Information about the benefits of the leaflet would typically be included in section 
1 of the leaflet: “What is X and what is it used for?” Hence the contents of section 1 
were copied and pasted into an Microsoft Excel spread sheet for further analysis. 
Additional scrutiny was also paid to Section 3 of the leaflet, which was searched for 
information regarding the duration of treatment. However, to ensure that no information 
was missed each leaflet in its entirety was read by RD. The leaflets were also searched 
for any additional sections which might contain benefit information. 
RD undertook the data extraction of relevant information and one of the supervisors, 
TR, undertook a randomly selected 10% check to assess for accuracy (Split into 2 x 5% 
checks). The first 5% check revealed a small number of missing data (in particular 
relating to identifying terms associated with conveying uncertainty). As a result, RD re-
checked the remaining data for any missing data. The final 5% check was consistent 
with both reviewers identifying the same data for each criterion.  
 Statistical analysis 5.3.5
Data were categorical and the following tests were applied 
 Chi-square test 
 Fishers exact test - used when the assumptions of the chi-squared test were 
violated (when cells had an expected count of less than 5) 
The Statistical Package for the Social Sciences (SPSS) version 19 was used to perform 
the analysis (IBM Corp, Released 2010). 
 Results 5.4
One hundred leaflets were obtained, of these leaflets, 50 were obtained from the  
prescription cost analysis data collated by the Information Centre for Health and Social 
Care (Information Centre for Health and Social Care, 2011),  25 of which were branded 
and 25 generic medicines. The other 50 were obtained from the MHRA black triangle 
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surveillance list. All 50 of these were branded medicines (appendix 20). Leaflets were 
included from 59 different manufacturers in all. 
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Table 11: Benefit criteria met (including statistical difference between leaflets for top 50 dispensed medicines and Black Triangle 
medicines). 
 
Criteria 
 
Total 
criteria 
met 
n=100 
Top50 dispensed n (%) 50 Black Triangle n (%) Chi-square statistic, 
probability (p) value. 
(df=1 for all 
comparisons) 
Generic n=25 Branded n=25 
1: Does it describe what the medicine is used for? 100  25 (100%) 25 (100%) 50 (100%) - 
2: Does it describe how the medicine works? 85  21 (84%) 21 (84%) 43 (86%) 0.078 (p=0.779) 
3: Does the leaflet describe the rationale for taking 
the medicine? 
45  5 (20%) 8 (32%) 32 (64%) 14.586 (p<0.001) 
4: Does the leaflet describe what will happen if you 
don’t take the medicine? 
22  7 (28%) 5 (20%) 10 (20%) 0.233 (p=0.629) 
5: Does the leaflet describe whether the medicine 
will cure or alleviate symptoms or is preventative? 
19  5 (20%) 4 (16%) 10 (20%) 0.065 (p=0.799) 
6: Is the duration of the treatment described as either 
short term or long term? 
53  8 (32%) 12 (48%) 33 (66%) 3.305 (p=0.069) 
7: Does the leaflet convey any uncertainty 
associated with the treatment? 
37  10 (40%) 10 (40%) 17 (34%) 0.386 (p=0.534) 
8: Does the leaflet illustrate the likely proportion of 
patients who will benefit and the extent of the benefit 
on the symptoms of the condition? 
0 0 0 0 
 
- 
9: Does the leaflet present any mean benefits of the 
medicine on a particular measure? 
0 0 0 0 - 
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 Categories one and two: Does the leaflet describe what the 5.4.1
medicine is used for and does it describe how the medicine works? 
All of the leaflets (n=100) described what the medicine was used for and 85% described 
how the medicine worked. For example: 
“Warfarin is used to prevent and treat clots forming in the legs, lungs, brain and 
heart.” (Warfarin, Branded- Marevan, Top 50 dispensed). 
“Eliquis contains the active substance apixaban and belongs to a group of 
medicines called anticoagulants. This medicine helps to prevent blood clots from 
forming by blocking Factor Xa, which is an important component of blood clotting”  
(Apixaban, Black Triangle, Branded – Eliquis). 
 
For these criteria there were no statistical differences between the proportion of black 
triangle leaflets or top 50 dispensed medicines leaflets which described how the 
medicine worked (n=42 compared to n=43,  p= 0.779). Neither was there any difference 
in the proportions of generic and branded leaflets that met these criteria (n=21 
compared to n=21).  
 Category three: Does the leaflet describe the rationale for 5.4.2
why you are taking the medicine? 
45 leaflets provided additional information about the rationale for treatment. Of these 45 
leaflets, 13 were from the top 50 dispensed leaflets and 32 were from the Black 
Triangle medicines. Significantly more newly licensed medicines provided additional 
information about the rationale for treatment when compared to medicines which are 
commonly dispensed (n=32 compared to n=13, p<0.001). Slightly more branded 
leaflets contained additional information than generic leaflets (n=8 compared to n=5), 
although these numbers were small and statistical significance was not measured.  
 
The leaflets contained varied amounts of information; some included only a small 
amount of detail, for example, a short sentence.  Whereas others contained additional 
paragraphs of information about the disease the medicine was used to treat and/or 
about how the medicine might impact on quality of life.  A post hoc analysis identified 4 
different categories of additional information, which were developed iteratively.  The 
frequency of type of additional information was counted.  A total of n=63 additional 
items of information were counted in the 45 leaflets (Total word count = 2357, mean 
number of words = 52, Range = 7 - 292, SD = 48). 
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This most common category was the provision of additional information about the 
disease or condition, for which 26 items of information were counted. An example of 
this type of information is provided below: 
 
 “In multiple sclerosis, inflammation destroys the protective sheath around the 
nerves leading to muscle weakness, muscle stiffness and difficulty walking.” 
(Fampridine, Black Triangle. Branded - Fampyra) 
 
The second most common type of additional rationale information was about the 
effects of the medicine on the disease or condition, for which 17 items of this type 
of information were provided: 
 
“It is used after you have had surgery to remove the tumour and together with 
chemotherapy to kill remaining cancer cells to reduce the risk of cancer coming 
back”. Mifamurtide, Black Triangle. Branded (Mepact) 
 
10 items were about the impact on the quality of life, an example of which is provided 
below:  
 
“RoActemra helps to reduce symptoms such as pain and swelling in your joints 
and can also improve your performance of daily tasks…RoActemra has been 
shown to slow the damage to the cartilage and bone of the joints caused by the 
disease and to improve your ability to do normal daily activities”. (Tocilizumab, 
Black Triangle. Branded - RoActemra) 
 
Finally, 10 additional items of information about other interventions, such as 
diet/exercise or treatments to maximise effectiveness were identified: 
 
 “Bydureon is used in combination with the following diabetes medicines: 
metformin, sulphonylureas and thiazolidinediones. Your doctor is now 
prescribing Bydureon as an additional medicine to help control your blood 
sugar. Continue to follow your food and exercise plan.” (Exenatide, Black 
Triangle. Branded - Bydureon) 
 
 Category 4: Does the leaflet describe what will happen if 5.4.3
you don’t take the medicine?  
22 leaflets described what could happen to the patient if they did not take the medicine. 
There were no significant differences between the top 50 dispensed medicines and the 
black triangle medicines (n=12 compared to n=10, p= 0.629). With regards to the top 50 
dispensed medicines, 7 of the branded products contained this information compared to 
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5 of the generic products. 18% of leaflets (n=18) explicitly described the impact of not 
taking the medicine, for example:  
 
“Do not stop taking this medicine as your heart problem may get worse. Talk to 
your doctor if you want to stop” (Digoxin, top 50 dispensed, branded – Lanoxin). 
 
One leaflet did not explicitly state what would happen if the medicine was not taken and 
instead implied what the consequences might be if the condition was left untreated. 
This information was provided as additional information about the disease: 
 
“Early on, osteoporosis usually has no symptoms. If left untreated, however, it 
can result in broken bones.” (Alendronic Acid, top 50 dispensed, generic). 
 
Three leaflets included some information about what might happen if the patient didn’t 
take the medicine, but were vague and did not refer to any specific impact on conditions 
or specified symptoms. For example: 
 
“If you stop taking lactulose the desired effects of the medicine may not be 
achieved” (Lactulose, top 50 dispensed, generic). 
 
Of these 22 leaflets  17 provided information about the impact of not taking the 
medicine on the condition, 3 reported the impact on symptoms, 1 provided information 
on withdrawal and 1 described the impact on drug resistance.  
 Category 5: Does the leaflet describe whether the medicine 5.4.4
will cure or alleviate the symptoms or is preventative? 
19 leaflets met the criteria for describing the purpose of the medicine (i.e. curative or 
alleviating symptoms or preventative). Of these leaflets 9 were top 50 dispensed 
medicines and 10 were Black Triangle medicines. The majority of these leaflets were 
for treatments which alleviated symptoms (n=13) and the remainder were for 
preventative treatments (n=6).  
 
A small majority of the statements (n=11) were explicit about whether the treatment was 
a preventative medicine or one to be used to alleviate symptoms. For example: 
 
“Pulvinal Salbutamol inhalation powder is used to help relieve the symptoms of 
mild, moderate and severe asthma, other chest illnesses and to avoid asthma 
symptoms brought on by exercise or other ‘triggers’.  Pulvinal must be used for 
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the relief of your asthma symptoms only. You may have other medicines which 
you take regularly to prevent the symptoms of your asthma.” (Salbutamol, top 50 
dispensed, branded - Pulvinal) 
 
8 leaflets were more implicit about the nature of the treatment, for example: 
 
“By blocking the activity of IL-1 beta, canakinumab leads to an improvement in 
these symptoms.”  (Canakinumab, black triangle, branded - Ilaris) 
 
There was no significant difference between the numbers in the top 50 dispensed group 
and the black triangle group, or between the generic and branded groups. 
 Category 6: Is the duration of treatment described as short 5.4.5
term or long term?  
53% of the leaflets described the duration of treatment. This was more common in the 
black triangle group (n=33) compared with the most dispensed group (n=20) (p= 0.069) 
23 of the 53 leaflets described a timescale for treatment. Sometimes this was described 
as long-term or short-term treatment: 
 
“Treatment with Cardicor is usually long-term. Cardicor is used to treat stable 
chronic heart failure.” (Perindopril, top 50 dispensed, branded - Cardicor) 
 
Other leaflets described a period of time using days, weeks or months, for example: 
 
“It will be given to you twice a week (at least three days apart) for the first 12 
weeks, then once a week for 24 more weeks”. (Mifamurtide, black triangle, 
branded - Mepact) 
 
13 leaflets did not describe any particular timescale, but made reference to the duration 
of treatment as something that should continue as long as the doctor recommends, or 
as something that should be decided by the doctor. However, although these leaflets 
did not describe a specific time-scale for treatment, some provided a good explanation 
for this uncertainty, for example: 
 
“There is no time limit laid down as a general rule for treatment with Levact. 
Duration of treatment depends upon disease and response to treatment.” 
(Bendamustine, black triangle, branded - Levact) 
 
“You will be treated with Avastin once every 2 or 3 weeks. The number of 
infusions that you receive will depend on how you are responding to treatment; 
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you should continue to receive this medicine until avastin fails to stop your 
tumour growing. Your doctor will discuss this with you.” (Bevacizumab, black 
triangle, branded - Avastin). 
 
13 leaflets described some information about the length of treatment, but the exact 
nature of the duration of treatment was unclear. So, sometimes the timing of the initial 
treatment programme was described but there was no further information on whether 
this was a long, medium or short-term programme.  
 
“Zopiclone is not meant to be used every day for long periods of time.” 
(Zopiclone, top 50 dispensed – generic). 
 
Four leaflets were unclear in their description of the duration of the treatment and 
described the frequency of dosing but not the duration. 
 
“As COPD is a chronic disease you should take SPIRIVA 18 microgram every 
day” (Tiotropium, top 50 dispensed, branded - Spiriva) 
 
47 leaflets did not describe the duration of the treatment, nor recommend that patients 
seek advice from their GP or healthcare professional about the duration of treatment. 
This was more common in the top 50 dispensed category, where 30 leaflets provided 
no information on the duration of treatment compared to 17 in the black triangle group. 
Slightly more branded leaflets (n=12), compared to generic leaflets (n=8) described the 
duration of the treatment. 
 Category 7: Does the leaflet convey any uncertainty 5.4.6
associated with the treatment? 
The content survey identified leaflets which conveyed uncertainty and developed 
categories for the different types of words used on a post hoc basis. It was noted that a 
total of 37 leaflets (37%) presented information that conveyed uncertainty in some way. 
There were no significant differences between the top 50 dispensed medicines and the 
black triangle medicines (n=20 compared to n=17).  These were categorised into 
different groups as follows:  
  
[1] No uncertainty is conveyed. 
The majority of the leaflets did not convey uncertainty (n=63). These leaflets tended to 
include information about the leaflet which was absolute, describing what the treatment 
treats. There were no terms used to express any uncertainty. For example: 
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“Elaprase is used as enzyme replacement therapy to treat children and adults 
with Hunter syndrome (Mucopolysaccharidosis II) when the level of the enzyme 
iduronate-2-sulfatase in the body is lower than normal. If you suffer from Hunter 
syndrome, a carbohydrate called glycosaminoglycan which is normally broken 
down by your body is not broken down and slowly accumulates in various organs 
in your body. This causes cells to function abnormally, thereby causing problems 
for various organs in your body which can lead to tissue destruction and organ 
failure. Elaprase contains an active substance called idursulfase which works by 
acting as a replacement for the enzyme that is at a low level, thereby breaking 
down this carbohydrate in affected cells.” (Idursulfase, black triangle, branded – 
Elaprase).  
 
The remaining leaflets (n=37) used a mixture of terms which conveyed uncertainty and 
were categorised into the following groups: 
 
[2] Uncertainty about the impact of the treatment on the condition (associated 
with the effectiveness of the treatment) 
 
There appeared to be 2 different methods of conveying uncertainty (these were more 
implied as opposed to explicit statements about the uncertainty associated with the 
treatments). Several leaflets conveyed uncertainty through the use of words to qualify 
the treatment's effectiveness (such as ‘helps’) ; others used modal auxiliary verbs, 
which are verbs which help to indicate modality or likelihood (such as ‘may’) (Palmer, 
1986).  
 
2a: Implies uncertainty using the term ‘helps’. For example states ‘the treatment 
helps to treat’. ‘Help/s’ was the most commonly used ‘qualifier’. Other ‘qualifying’ terms 
included ‘contributes’.  
 Frequency of use in leaflets n=24 
o Helps prevent n=8  
o Help correct n=1  
o Help lower n=4  
o Helps to open n=3  
o Helps protect n=1 
o Helps reduce n=2  
o Helps rebuild n=1  
o Helps relieve n=1  
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o Helps slow down n=1  
o Helps you breathe n=1 
o Contributes to lowering n=1 
2b: Implies uncertainty using an auxiliary verb. For example states the treatment 
may help to treat.  The use of the term ‘may’ appears to add even further uncertainty to 
the possibility that the treatment might work. Similar terms used include ‘can’ and 
‘should’.  
 Frequency of use n=14  
o May prevent n=1 
o May help control n=1 
o May treat n=2  
o May relieve n=1 
o May reduce n=2 
o Should have an improvement n=1 
o Should help n=1 
o Can reduce n=2  
o Can help n=1 
o Can help relieve n=1 
o Can raise n=1) 
[3] Uncertainty associated with the likelihood of condition 
Several leaflets referred to the risk or chance of a condition occurring, these leaflets 
referred to treatments ‘reducing the risk or chance’ of that condition. There appeared to 
be 2 levels of uncertainty: 
 
3a: Implies uncertainty using the terms ‘risk’ or ‘chance’. The treatment reduces 
risk/ chance of condition (n=10; reduce risk n=8, reduce chance n=2) 
 
3b: Implies uncertainty using the terms ‘risk’ or ‘chance’ and uses an auxiliary 
verb.  The treatment may reduce the risk/chance of a condition. (n=5; Can reduce 
risk n=3, may reduce risk n=1, will increase your chances n=1) 
 Category 8 and 9: Numerical presentations of benefit 5.4.7
None of the leaflets surveyed included any numerical format of benefit information, 
defined as information which illustrates the proportion of patients who will benefit and/or 
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the extent of the benefit on the symptoms of the condition, or information that presents 
any mean benefits of the medicine on a particular measure. 
  Discussion 5.5
There is evidence that the public desire good quality information about the benefits of 
their medicines. However this survey and content analysis of 100 currently available 
PILs shows that benefit information is inconsistently communicated.  Current leaflets 
were found to communicate what the medicine is used for, but other types of benefit 
information were ambiguous or absent from many leaflets for medicines currently 
available in the UK. While leaflets are not currently obligated to provide benefit 
information, there are moves towards encouraging the manufacturers of medicines 
information to consider adding information about the benefits of treatments in leaflets 
(Medicines and Healthcare products Regulatory Agency, 2005a, Co-ordination Group 
for Mutual Recognition and Decentralized Procedures - Human, 2011).   
 
This study showed that currently less than half of leaflets (45%) contained additional 
information about the rationale for treatment. The most common form of this additional 
information about the rationale for treatment communicated information about the 
disease or condition. The inclusion of rationale information was more common in newly 
licenced medicines (n=32 compared to n=13 top 50 dispensed). It has been shown that 
the addition of extra information about the effectiveness and benefits of the medicine 
may have a positive impact of people’s judgements and intent to take a medicine 
(Bersellini and Berry, 2007a, Bersellini and Berry, 2007b, Vander Stichele et al., 2002). 
Interviews undertaken with the users of simvastatin showed that, when discussing the 
type of benefit information that would be valued in PILs, additional information about the 
rationale for treatment was desirable (chapter 6).  It has also been shown that patients 
want information which is set in the context of their illness, but currently few leaflets 
contain such information (Raynor et al., 2007).   
 
Recent changes to the QRD template, which describes the official content and wording 
of regulated PILs, now means that it specifies that information about the benefits of the 
treatment could be included in section 1: ‘What X is and what it is used for’ (European 
Medicines Agency, 2012). Guidance on the QRD states that information on the benefits 
of the treatment could be included in this section, as long as it is compatible with the 
“Summary of Product Characteristics”, useful for the patient, and not promotional.  The 
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guidance says that such information should be presented in a clear and concise way 
and could include any of the following: 
 additional information on the signs and symptoms of the target disease, in 
particular for non-prescription medicines, but also for medicines to be taken “on-
demand” (e.g. treatment of migraine) 
 Summary of benefits in descriptive terms (e.g. “this medicine reduces pain 
associated with arthritis”, “this medicine has been shown to reduce blood sugar, 
which helps to prevent complications from your diabetes”). The benefit may be 
described in terms of prevention of disease complications (e.g. anti-diabetic), if 
established.  
 Information on the amount of time the medicine usually takes to work may be 
presented if relevant for the patient (e.g. pain-killer, antidepressant, etc). (Co-
ordination Group for Mutual Recognition and Decentralized Procedures - 
Human, 2011) 
For patient-centred communication of medicines information, which is congruous with a 
patient empowerment approach to producing patient information, it is important that 
benefit information should communicate patient centred-outcomes, such as how the 
medicine impacts upon the patient’s quality of life.  An EMA report which focused on the 
provision of information on benefit-risk of medicines suggested that “a quality of life 
benefit can translate into an enormous added value from the patient’s perspective” 
(European Medicines Agency, 2009). 
The writers of medicines information could consider this an opportunity to include more 
detail about the rationale for treatment and consider presenting succinct and non-
promotional additional information about the disease, how the medicine works and 
other interventions which will optimise treatment outcomes.  In particular, attention 
could be paid to communication of secondary endpoints which report quality of life 
benefits for patients. 
Just over a fifth of leaflets communicated what might happen if the patient did not take 
the medicine. Most of these leaflets were explicit about the consequences of not taking 
the medicine, but a small minority either implied the consequences or were vague. If 
information about what might happen to the patient if they do not take the medicine is to 
be included in PILs, then this information needs to be communicated explicitly so as to 
avoid confusion and better inform the reader about potential consequences.   
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Many leaflets did not explicitly communicate whether the medicine was intended to cure 
the condition, alleviate symptoms or be preventative. This is important information 
which patients may need to be aware of in order to take their medicines to optimum 
effect, in order to take their medicines safely and effectively.  Leaflets would benefit 
from more explicit information on this in order to better inform the patient about what to 
expect from their treatment and how it might impact on their condition. Only a small 
proportion of leaflets provided detailed information about the duration of treatment of 
the medicine (communicating specified periods of days, weeks, months or for life to the 
length of treatment).  Many leaflets communicated duration of treatment using implicit 
terms which were unclear or non-specific, and in slightly less than half of the leaflets 
there was no information about how long the treatment should be used. For some 
treatments the duration of treatment will be based on the individual patient's 
circumstances, such as their condition or response to treatment, however, this can be 
better communicated.  An example of this was for bendamustine, which provided a 
good example of the terminology that could be used to convey that duration of 
treatment is uncertain or dependent upon individual response.  
“There is no time limit laid down as a general rule for treatment with Levact. 
Duration of treatment depends upon disease and response to treatment.” 
(Bendamustine, branded – Levact, black triangle.) 
More leaflets could benefit from using clearer terminology, specifically providing a 
timescale which describes the duration of treatment or describing whether treatment 
duration is uncertain. 
It was apparent that the majority of leaflets either did not convey the uncertainty 
associated with treatments, or conveyed uncertainty in a way that was largely 
inadequate or unclear. For example, the use of the term ‘helps’, which appears to be 
used to convey uncertainty about the treatment, can be confusing  and seems to imply 
that the treatment works,  but only in a contributing sense. It could be misconstrued as 
conveying that the treatment is effective, but only in conjunction with other treatments 
when this is not necessarily the case. The term is ambiguous and not clear enough to 
convey uncertainty in any meaningful way. The use of axillary verbs such as ‘can’ or 
‘may’ were also used in some leaflets. This technique conveys more uncertainty than 
using ‘helps’ alone, however it is still ambiguous because it is unclear as to how much 
the treatment may help or may reduce the risk of a condition. There is also some 
redundancy with the use of axillary verbs when combined with terms such as ‘risk’ or 
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‘chance’ which already suggest uncertainty. This might lead to misunderstanding about 
the potential effectiveness of the medicine. 
Communicating uncertainty is a challenge, certainly in healthcare where many 
conditions and treatments may have ambiguous or individual consequences (Politi et 
al., 2007).  Research has shown that uncertainty about healthcare treatments is not 
always adequately communicated during medical consultations (Braddock et al., 1999, 
Elwyn et al., 2004, Towle et al., 2006). Chapter 3 described how patients frequently 
struggle to comprehend the concept of uncertainty about their treatments. Patients are 
often unaware of any uncertainty associated with their medicines or that the quantitative 
benefits of medicines are over-estimated (often by a large proportion) (Hamrosi et al., 
2012). The inclusion of well-written harm and benefit information in written medicines 
information could be a move towards supporting patients in understanding more about 
the benefits and limitations of their treatments. This may in turn help patients to make 
autonomous decisions about taking treatments and be part of a number of processes, 
including shared-decision making, within the GP consultation. 
One of the challenges of communicating uncertainty is that many treatments have 
uncertain or unknown outcomes. The British Medical Journal undertook an evaluation of 
3000 treatments that had been reported in randomised controlled trials and were used 
in healthcare settings. They identified that at least 50% were of unknown effectiveness 
and that, in the author’s view, a further 7% involved a trade-off between benefits and 
harms (British Medical Journal, 2013).   
Communicating uncertainty is an important challenge to meet if patients are to be 
aware of and understand the impact of their treatments and also to ensure they engage 
in informed or shared decision-making. Politi et al (2007) describe 5 main types of 
uncertainty associated with medical interventions. These are:  
1) risk or uncertainty about future outcomes;  
2) ambiguity or uncertainty about the strength or validity of evidence about risks;  
3) uncertainty about the personal significance of particular risks (e.g. their severity, 
timing);  
4) uncertainty arising from the complexity of risk information (e.g. the multiplicity of 
risks and benefits or the instability of risks and benefits over time); and  
5) uncertainty resulting from ignorance (Politi et al., 2007).  
The writers of medicines information should pay attention to the different types of 
uncertainty when describing treatment outcomes and further research into the 
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linguistics of communicating uncertainty in PILs would be welcome to highlight 
terminology which adequately communicates uncertainty. 
None of the leaflets conveyed the benefits associated with taking a treatment using 
numerical terms. The findings from chapter 2 show that techniques such as summary 
statistics or graphs have been shown to be useful in providing information about the 
quantifiable benefits of taking a treatment. It is surprising that none of the leaflets 
conveyed benefit information in numerical terms, particularly in light of an increasing 
interest in the provision of information about the likelihood of benefit and risk of harm 
from global medicines regulators (Medicines and Healthcare Products Regulatory 
Agency, 2005b, European Medicines Agency, 2009, Food and Drug Administration, 
2009).  
Currently numerical information is provided with side effect information and there is 
evidence that providing numerical benefit information can counterbalance the impact of 
what is perceived to be negative risk information.  Also, for patients to make informed 
decisions about their treatments it could be argued that they should be provided with 
information which is comparable with the presentation of information about the risk of 
harm. The provision of well-written benefit information in this context would be a 
welcome accompaniment to the numerical frequency of side-effects already presented 
in PILs (Raynor et al., 2007, Medicines and Healthcare Products Regulatory Agency, 
2005a, Fischhoff et al., 2011). 
It has been shown, in previous work within this thesis (See chapters 2, 3 & 6), that there 
are many challenges to providing numerical/statistical benefit information to the users of 
PILs. This information can be difficult to understand, can be misconstrued as negative 
rather than ‘benefit’ information and can provoke an emotional response in the reader 
(see chapters 2 & 6). However, it is apparent that the provision of this information can 
also facilitate a more detailed consideration of the potential benefits of a treatment and 
provide information about the proportion of patients who benefit.  People value this 
information being made available (Hamrosi et al., 2012, Carling et al., 2009). It is also 
important to note that many lay-people struggle to understand numerical data. 
Gigerenzer refers to the problem of ‘innumeracy’ in the general population. This is the 
concept that many struggle to understand statistical information and this affects an 
individual’s ability to reason about uncertainty and risk (Gigerenzer, 2002). This might 
create a reluctance to include additional numerical information in leaflets about the 
benefits of the treatments. There can also be concerns from the manufacturers about 
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being seen to be too promotional, which may result in the lack of benefit information in a 
PIL.  
There was a slight tendency for 'black triangle' leaflets to include more benefit 
information than the top 50 dispensed leaflets on most, but not all, criteria. For two 
criteria the differences were statistically significant. These were duration of treatment 
(category 3) and whether the leaflet described the rationale of the treatment (category 
6). It is possible that this increased performance relates to the more complex nature of 
some of the newly licenced treatments. The black triangle list contained a range of 
different drug types to the list of top 50 dispensed and the differences in the inclusion of 
benefit information might reflect this difference. There were more monoclonal antibodies 
in the black triangle list (n=7) compared to the top 50 dispensed list (n=0) and a larger 
number of drugs for use in malignant disease and immunosuppression. 14 drugs in the 
black triangle list were new anticancer drugs which have been associated with an 
increased risk of toxic death and serious adverse events (Niraula et al., 2014, Niraula et 
al., 2012). It is possible that the differences in inclusion of benefit information reflect the 
changing nature of the type of drugs that are currently being licensed.  
This might also reflect a trend for newer leaflets to produce better quality information in 
line with some of the recent recommendations about improvements to the 
communication of medicines information (Co-ordination Group for Mutual Recognition 
and Decentralized Procedures - Human, 2011). This increased inclusion of benefit 
information might also reflect a better availability and quality of effectiveness data as a 
result of undertaking of bigger and better designed trials over recent years.  
It is important to note that there was variation amongst the type and frequency of 
information included in the different leaflets. It is apparent that some providers of 
medicines information include more information about the benefits of a treatment than 
others. The use of terminology between the leaflets also varies. This has a potential 
impact on the reader receiving information about their medicines that varies from 
product to product and is inconsistent. The impact of this upon a patient’s knowledge 
and understanding about their medicines is not known. 
Good quality written information that is patient-centred has been shown to have a 
positive impact upon knowledge, satisfaction and confidence with information (Raynor 
et al., 2007). In order to optimise understanding of medicines and optimise their use, 
patients need to be aware of how their medicines work and how likely they are to 
benefit. The provision of good quality benefit information in written medicines 
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information is one way in which this can be achieved.  This study has shown that 
currently many leaflets on the market in the UK do not contain clear or adequate 
information about the potential benefits of medicines. Leaflets do not consistently 
provide simple benefit information such as the rationale for treatment, the impact on 
patient-centred outcomes, the duration of treatment or whether the treatment is 
intended to be preventative, curative or symptomatic.  Uncertainty about treatment 
outcomes is largely inadequately communicated, with leaflets using terminology that 
does not describe the proportion of patients who are likely to benefit from the treatment.  
It is also important to note that across Europe leaflets are designed in English and 
translated into their respective languages (Nisbeth Jensen and Zethsen, 2012). The 
impact of translation on the meaning of current techniques used to convey uncertainty 
is not known.  
 Strength and limitations 5.5.1
The use of the sampling strategy facilitated the collection of 100 leaflets which provided 
a large sample from which to obtain the benefit information. The inclusion of leaflets 
that were commonly used and leaflets that were newer facilitated a historic comparison 
of the frequency and type of benefit information. 
The sampling strategy also allowed variation in the type of leaflets that were included in 
the analysis. A range of leaflets from different manufacturers were obtained and these 
included a variety of branded and generic products. The inclusion of the newly licenced 
medicines meant that the sample was weighted towards branded products. As a result, 
this limited the evaluation of any statistical significance between generic and branded 
products, due to the small numbers in the comparison. A larger sample comparing 
generic and branded leaflets would add weight to this analysis. The use of a 10% check 
ensured there was an acceptable degree of inter-rater reliability in the sample. 
The criteria were developed from two sources, the EMA report of benefits and the 
MHRA’s ‘Always Read the Leaflet’, which described what benefit information might 
include (European Medicines Agency, 2009, Medicines and Healthcare Products 
Regulatory Agency, 2005a). It is possible that the consideration of additional sources of 
benefit information might have led to the development of different criteria to define 
benefit information.  However, there would probably be no impact on the frequency of 
numerical benefit information observed in patient information leaflets.  
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The criteria used to evaluate the type and frequency of benefit information was not 
necessarily evidence-based. There has been some research examining the impact of 
providing additional rationale information and numerical information in written medicines 
information on the impact of patient satisfaction and understanding (Bersellini and 
Berry, 2007b, Carling et al., 2009, Tait et al., 2010b). However, there is limited evidence 
evaluating the impact on patient satisfaction and understanding of providing information 
on whether a treatment should be used in the long or short term, or whether the 
medicine is curative or preventative. Consequently while it has been identified that 
patient information leaflets lack certain elements of benefit information, the impact of 
providing this information on patient satisfaction and understanding is not known.   
 Conclusion 5.6
This survey of a 100 patient information leaflets for licensed medicines showed variety 
and inconsistency regarding the communication of information about the benefits of 
medicines. This inconsistency may be problematic for patients who currently are not 
provided with a standardised format which describes the effects of their medicines. This 
issue could be greater for patients prescribed more than one medicine as they may 
receive PILs which use different terms to convey the same meaning.  
There is a duty to attempt to inform patients regardless of whether the information being 
communicated is complex  (Fischhoff, 2012). It has been suggested that the package 
leaflet is an excellent place to communicate information about the benefits of medicines 
as it is something that is regulated and should be provided with all medicines (Goldacre, 
2012). The manufacturers and regulators of medicines information need to be aware 
that at present PILs for medicines that are currently available in the UK are lacking in 
their delivery of benefit information. 
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  Interview study (Study 5) Chapter 6
What is the impact of providing benefit information about a medicine in a PIL on 
the attitudes and beliefs that actual users of medicines hold about their 
treatments? 
 Introduction 6.1
This chapter describes a study based on qualitative semi-structured interviews 
undertaken with patients taking simvastatin. The study was designed to elaborate on 
the findings from the focus group study (chapter 3) and explore the impact of providing 
benefit information in a more naturalistic setting. A key finding from the previous study 
was that the provision of numerical benefit information in a PIL provoked varied and 
often complex responses.  
Occasionally the information was viewed as a valuable addition to a PIL, which helped 
inform the participants about the potential benefits of their treatments and encourage 
informed decision-making.  More commonly, the numerical benefit information was 
perceived as unsettling and confusing. A great deal of anxiety was reported; there was 
a considerable emotional response with a significant number of participants expressing 
a strong dislike for, and concern about, the inclusion of such information. It was also 
apparent that, despite this dislike, the provision of this type of information also 
motivated a minority of patients to consider the benefits of their treatments in more 
detail and as a result these participants stated they might change their medicine or 
information-seeking behaviour. Currently it is not known whether this response will be 
reported by those who receive benefit information about their own medicines. 
The focus groups in the previous study recruited people representative of typical 
medicine–users and explored opinions on benefit information based on real-life clinical 
data, but were hypothetical, to the participant’s current situation. This may impact upon 
the representativeness of the findings. It is unclear whether patients who are taking the 
medicine concerned would report similar influences on their medicine or information-
seeking behaviour, or report similar levels of affect.  More research into the impact of 
providing information about the real-life benefits of medicines to real-life users of 
medicines will be valuable to understand the impact on patients’ perspectives about 
their treatments. This next stage responds to that need for a more naturalistic setting, 
by recruiting a sample of patients who receive a prescription for simvastatin and 
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explores the impact that real-life numerical information has on attitudes, opinions and 
beliefs about medicines. 
 Aims and objectives 6.2
Aims 
The aim is to evaluate the impact of providing benefit information about medicines in 
written medicines information on the attitudes, opinions and beliefs that the real-life 
users of medicine hold about their treatments. 
Objectives 
 Identify the range opinions held by people taking simvastatin on the inclusion of 
benefit information about simvastatin in a PIL. 
 Identify preferences for different formats of benefit information about simvastatin 
in a PIL. 
 Map the range of factors that affect preference for benefit information in a PIL 
 Identify the impact that benefit information has on people’s knowledge and 
satisfaction with their medicines and medicines information. 
 Describe the potential impact on medicine-taking behaviour, decision-making 
and relationships with healthcare professionals.  
 Identify the concerns expressed by users of simvastatin about the inclusion of 
information about the benefits of simvastatin in a PIL. 
 Explore any differences in opinions about the inclusion of benefit information 
between people receiving the information for hypothetical medicines and those 
receiving the information for the medicines that they are using. 
 Methods 6.3
For this qualitative, semi-structured interview study a purposive sample of participants 
was recruited from a single GP practice, via a practice database search. They were 
invited by letter to participate in audio-recorded interviews (appendix 24). The sample 
included both males and females and a range of participants from different age bands, 
levels of education and indications for statin use.  
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 Methodology 6.3.1
A qualitative descriptive approach was used, as described in Chapter 3 (focus group 
studies).This approach is well-suited to the aims of this research, which are to identify 
and map the range of opinions about and the potential impact of the provision of benefit 
information on real-life users of medicines. Further description of the methods for the 
data analysis can be found in section 6.6 below. 
 Data collection methods 6.3.2
This study uses semi-structured individual interviews to collect data. This approach was 
chosen for a number of reasons. Firstly, unlike the focus group study, the aims of this 
study were more targeted, using personal, real-life scenarios to explore experiences of 
receiving benefit information for prescribed treatments. This creates the potential for the 
participants to share more sensitive information than might be imparted during a focus 
group which is exploring hypothetical scenarios. Therefore it is more appropriate to 
conduct in a private, one-to-one environment where the participant can share their 
views and thoughts on a more personal level with the researcher alone, rather than in a 
group setting. This should promote a deeper exploration of the emotional responses 
that the benefit information provokes, enabling the participant to share more freely the 
underlying emotions and thoughts on the provision of benefit information.  
In addition, this study provides multiple PILs containing different formats of benefit 
information to the participants. Individual interviews will enable the researcher to spend 
more time with each participant to discuss the benefit statements in detail and explore 
how the statements provoke a deeper understanding of a person’s medicines.  During 
the focus groups a large number participants struggled to understand the benefit 
information and the structure of the focus groups did not allow full explanations to take 
place.  
The semi-structured interviews used a topic guide designed to generate data about 
specific areas of interest which include the following: 
[1] ‘Typical’ medicine taking behaviour and beliefs about medicines of the participant: 
participants’ previous experience of being prescribed a statin, the information they 
required and desire, and their typical medicine-taking behaviour. This will provide 
historic context about the participant’s medicine beliefs and behaviour. 
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[2] Opinions on and experiences of ‘typical’ PILs – again this will provide some historical 
context in order to interpret any changes to opinions on patient information that might 
be elicited by the provision of the exemplar PILs. 
[3] Opinions on, and preferences for, the different formats of benefit information in the 
exemplar PILs: participants were asked their opinions on the 3 benefit statements 
including their understanding, preferences and thoughts on the different statements. 
[4] The potential impact that the provision of benefit information in a PIL might have on 
medicine-taking behaviour, beliefs about medicines and relationships with HCPs, future 
information needs, desires and decision-making.  
 Research ethics consideration 6.3.3
Research Ethics approval was obtained from NRES Committee Yorkshire & the 
Humber - Humber Bridge (13/YH/0180).  
 Recruitment 6.4
A purposive sampling strategy was employed and the target sample was patients 
prescribed simvastatin for prior myocardial infarction (MI) or established coronary heart 
disease (CHD) (such as angina, unstable angina, previous Coronary Artery Bypass 
Graft (CABG) or angioplasty) and recruited from one GP practice in a city in northern 
England.  This group of participants are representative of the sample of participants 
recruited to the Heart Protection Study, which was used to generate the data for the 
benefit statements.  (See section 6.5)  
The study used a purposive sample for two main reasons. Firstly this approach 
facilitates the recruitment of a sub-group of participants whose disease severity is the 
same as the sample of participants in the clinical trial which was used to derive the 
numerical data used in the benefit statements.  Simvastatin can provide different levels 
of benefit depending upon whether the patient has existing cardiovascular disease or 
not, and is used for primary or secondary prevention of cardiovascular outcomes such 
as MI or stroke. This interview study presented data on the benefits of simvastatin for 
patients with existing cardiovascular disease derived from the Heart Protection Study 
(HPS) (Heart Protection Study Collaborative Group, 2002). Consequently, it is important 
that the patients recruited to this study have the same disease severity as those from 
the HPS study, to ensure that the data provided is as accurate and relevant to the 
participant as possible. 
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Secondly, this approach was used in order to obtain a range of views from a sub-set of 
participants with a mix of different characteristics but who were also broadly 
representative of the population of interest.  The participant sample had a mix of age 
groups, genders, educational backgrounds and items of medicines prescribed. A 
purposive sample is useful in this approach as it can facilitate the deliberate recruitment 
of participants with a range of characteristics in order to capture variation from the 
sample. However, this strategy can be criticised as the selection of the participants can 
be biased by the subjectivity of the researcher and may lead to lack of representation of 
the sample when compared to the wider population (Spencer et al., 2003). The sample 
recruited to this study met a range of characteristics that were representative of the 
general GP population (table 12).  No fixed quota was set for each category and no 
participants were required to be excluded, or additional numbers recruited, as the 
respondents who replied naturally created a diverse spread across the categories.   
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Table 12: Demographics of patients taking simvastatin in the General Practice 
and participants in the study. 
 
Sex Age range Patient Count 
Total in the General 
Practice (%) n=176 
Interviewed in study 
n=21 
Female 40-59   7 (4%) 2 (10%) 
Female 60-79 30 (17%) 5 (24%) 
Female 80+ 29 (16%) 1 (5%) 
Male 40-59 15 (9%) 0 
Male 60-79 64 (36%) 8 (38%) 
Male 80+ 31 (18%) 5 (24%) 
 
The Quality and Outcomes Framework (QOF) registers were searched using a number 
of terms in order to identify participants meeting the inclusion criteria. A note of the 
number of patients on each register was taken in order to evaluate whether the 
purposive sample used in the research was representative of the general practice 
population.   
 
The searches were as follows: 
 CHD (Includes MI) n=485 
 Peripheral arterial disease n=131 
 Stroke n=231 
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Combined searches: 
 MI/CHD and Simvastatin n= 176 
 (cerebrovascular disease n=19) 
 (diabetes n=45) 
 (Peripheral vascular disease (PVD) n=46) 
 
The generated list was then checked by a GP for suitability and the following patients 
were excluded: 
 Care home residents 
 Patients receiving palliative care 
 Those with cognitive impairments limiting their ability to participate in the 
research 
 Non-English speaking patients. 
The remaining patients were sent a research pack inviting them to participate. The 
research pack contained the following: 
 A letter inviting the participant to take part in the research 
 A patient information sheet (appendix 24)  
 An ‘expression of interest’ form and a stamped addressed envelope. 
(Participants were also advised they could contact the researcher by e-mail or 
telephone) 
 Setting 6.4.1
Interviews were undertaken at the participant’s home, apart from one interview 
undertaken in a room at a local GP practice at the participant’s request. Interviews 
lasted approximately an hour. Participants were provided with written information prior 
to the interview and informed consent was obtained prior the interview. During the 
interviews the participants were provided with 3 exemplar PILs containing different 
benefit statements, plus additional related benefit statements (see section 6.5.6) and 
were asked to discuss their views.  
The interviews were audio-recorded and transcribed by an external company. 
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 Developing the benefit statements 6.5
In total 3 leaflets were developed and provided for discussion during the interviews, and 
2 additional statements were also provided alongside the leaflets. The leaflets were all 
for the medicine simvastatin and contained the following benefit statements: 
[1] Textual benefit statement 
[2] Numerical benefit statement provided as a NNT 
[3] Numerical benefit statements provided as natural frequency with additional 
statements: 
 Natural frequency (Positive frame) 
 Natural frequency (Treatment first) 
The leaflets were designed to look like PILs typically available in the UK.  Simvastatin 
was given the hypothetical name “Rebastatin” and each leaflet was marked with a 
highlighted section that stated ‘This leaflet is for research purposes only’ in order to 
ensure the leaflet was not mistaken for a real-life leaflet and used to provide medicine 
information out of the context of the research study.  During the interviews the 
participants were informed that Rebastatin was a hypothetical name for simvastatin and 
the benefit statements were for simvastatin. 
The section below describes the various stages to the development of the benefit 
statements used in the exemplar PILs. 
 Deciding upon the medicine 6.5.1
The benefit statements were developed by RD in consultation with the members of the 
supervisory team and 3 pharmacists, including a cardiology specialist (DP, DG, RK). 
There were several stages to the development of the statements.  
The medicine that was chosen for use was simvastatin. Simvastatin is a commonly 
prescribed medicine used to treat adults with clinical evidence of cardiovascular 
disease (CVD) and in adults considered to be at risk of CVD (National Institute for 
Health and Clinical Excellence, 2006). Simvastatin was chosen for the following 
reasons: 
1] It is commonly prescribed and this provides a large sampling frame from which to 
recruit. 
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2] It has what may be perceived as a small individual benefit on a condition which can 
have serious outcomes. Some medicines have better benefits, but others have smaller 
benefits. Our previous work showed that medicines perceived as having quite small 
benefits can create upset amongst participants (Hamrosi et al., 2012). Hence the use of 
a medicine with a perceived small benefit was avoided, although in a previous chapter 
in this thesis similar responses were reported with benefits presented for simvastatin. 
3] A leaflet for simvastatin had been presented in a previous part of this doctoral study, 
and continuity allows comparisons to be made more easily. 
4] Simvastatin is used to treat an asymptomatic condition. As a result there can be an 
in-depth exploration of the experiences and decisions to take a medicine for which 
patients may not immediately feel the benefit.  
 Responding to the findings of the previous focus group 6.5.2
study 
In the first stage of development of the benefit statements to be used, we excluded two 
options, as a result of the findings of the focus groups described in Chapter 3. Firstly, 
the percentage statement was discarded. During the focus groups this was the least 
popular of the statements and it was reported not to facilitate understanding in a similar 
way to the other formats. Secondly, as the participants stated they found the combined 
framing to be challenging to read it was decided that only one type of framing would be 
used. Initially, in discussions, the supervisory team agreed that the positive statement 
should be used, as that was identified as the preferred statement during the focus 
groups.  
 Identifying the source of data 6.5.3
Simvastatin can have different levels of benefit depending on whether it is used for 
primary or secondary prevention of cardiovascular disease (Minder et al., 2011, Naci et 
al., 2013, Taylor et al., 2013). Patients who have already experienced a cardiovascular 
event, such as a heart attack or stroke, might derive larger benefits than those who 
have a risk factor for cardiovascular disease, but not a previous cardiovascular event 
(Taylor et al., 2013). Therefore a decision was made to target the benefit statements to 
people taking simvastatin who had a particular level of cardiovascular risk. It was 
important to target the benefit statements so they were as relevant to the participant as 
possible. It was expected that, as the statements were specific to a patient’s condition 
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and level of cardiovascular risk, this may facilitate a more in-depth discussion about the 
meaning and relevance the participants might attribute to the benefit information. 
In order to do this it was important to identify data that were specific to cardiovascular 
risk groups. A number of resources were identified as potential sources of data, 
including NICE guidelines - national evidence-based guidelines in the UK, developed to 
facilitate clinical decision-making about treatments. The NICE guidelines on statins for 
the prevention of cardiovascular events are based on a meta-analysis of data related to 
studies of a variety of statins. Hence this could not be used, as the data needed to be 
specific to simvastatin. Of the 14 studies used for the NICE guidelines, 4 were relevant 
to simvastatin (Pedersen, 2004, Teo et al., 2000, Bestehorn et al., 1997, Maas 
Investigators, 1994). These papers were considered in detail and the Heart Protection 
Study (HPS) was chosen from which to derive the data for the benefit statements (Heart 
Protection Study Collaborative Group, 2002) 
 
The HPS is the world’s largest trial of simvastatin and was run by the Medical Research 
Council and the British Heart Foundation. It was chosen for a number of reasons; statin 
benefits can be variable depending upon condition and previous risk factors. The HPS 
study provides specific data for a secondary prevention population which describes the 
benefits in a specific population and is specific to the outcomes of taking simvastatin, 
rather than the outcomes of taking any statin. Therefore the HPS study can provide the 
most relevant data from which to derive the benefit statement.  
 Identifying the specific data to be presented 6.5.4
The next stage of designing the benefit statements was to define the focus of data to be 
presented. The HPS study measured multiple primary and secondary clinical endpoints 
including all-cause mortality, coronary events, strokes and revascularisation and it was 
important to consider which measures of the benefits of simvastatin should be 
presented in the benefit statements. 
 
Patients generally want to know about what the medicine does and what it is for 
(Dickinson and Raynor, 2003). When considering benefit information, it has been 
reported that patients want to know how the medicine treats the disease for which it is 
designed; the impact on patient-centred outcomes (particularly the impact on their 
ability to carry out day-to-day activities); the degree of efficacy of the drug and the 
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proportion of patients who meet primary endpoints (European Medicines Agency, 
2009).   
 
After discussion with the supervisory team and other pharmacists and health care 
professionals (1 GP (AZ), 1 nurse consultant (CG), 3 pharmacists (DP, DG, RK)) it was 
agreed that for simvastatin the primary endpoint likely to be most of interest from the 
HPS data would be likelihood of heart attack or stroke. Consideration was given to the 
inclusion of secondary endpoint data such as reduction in cholesterol level and a 
decision was made to explore in the interview whether this type of benefit information 
would be valued.  
 
During review of the HPS data the following was noted in the paper:  
“Allocation to 40mg simvastatin daily reduced the rates of MI, of stroke and of 
revascularisation by about one-quarter. After making allowance for non-compliance, 
actual use of this regimen would probably reduce these rates by about one-third.” 
(HPS 2002, P.7) 
Consideration was given to whether patients would want to know the optimum benefit if 
they adhered to their treatment. It was considered that data presenting the benefits in 
fully adherent patients might be preferable for patients, as it would give them the 
optimum benefit associated with taking the medicine.  However, the use of this method 
would be based on an estimation, rather than actual data, which would not be 
appropriate to real-life patients taking simvastatin. Instead this was something that was 
incorporated into the topic guide (appendix 25). 
 Defining the specific participant inclusion criteria 6.5.5
The following group of patients was identified as meeting the inclusion criteria for the 
HPS study data which were used to create the benefit statements. Therefore the same 
type of patients were recruited to the study, i.e. patients who have experienced prior MI 
or angina (including unstable angina, CABG, angioplasty) and one of the following 
coexisting morbidities. 
+ cerebrovascular disease 
+ peripheral vascular disease 
+ diabetes mellitus 
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 Development of the benefit statements 6.5.6
The benefit statements underwent several rounds of refinement until consensus on the 
wording was achieved.   
In the following boxed examples the nature of the content is labelling for the purpose of 
reading the thesis. In practice the statements were coloured and labelled with reference 
to their colours. If there was more than one version of a coloured statement, this was 
indicated as ‘1: orange’ etc.  
 
The starting point was the following statements: 
PURPLE:  
Rebastatin can lower levels of cholesterol and tri-glycerides in your blood and can 
reduce the chance of you having a heart attack or stroke. 
 
 
GREEN:  
If 17 people take Rebastatin over the next 5 years, 1 of them will be prevented from 
having a heart attack or stroke. 
 
 
ORANGE:  
In 100 people, 72 who take no treatment will not have a heart attack or stroke.  If they 
take Rebastatin for 5 years, then 78 out the 100 people will not have a heart attack or 
stroke. 
 
 
Negative or positive statements 
It was agreed that the negative statement was easier to read than the positive 
statement. A decision was made to use the negative statement in order to avoid the 
double negative associated with the positive. This was ultimately a pragmatic decision 
but was guided by the findings from the focus groups (which were more ambiguous for 
the Rebastatin than the Janatriptan group), and the wider literature. The positive frame 
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was also included as a separate statement for the participants to consider in the topic 
guide, when their attitudes towards framing were explored.  
 
‘People like you’ 
During one round of amendments the phrase ‘people like you’ was removed from the 
statements. This phrase was viewed negatively during the focus groups. However, its 
removal was problematic, as it meant that the resulting statement ‘In 100 people who 
do not take this medicine…’, was inaccurate. The statements do not refer to 100 
people, but to 100 people in a high risk group. Consequently the phrase ‘people like 
you’ was re-instated. The topic guide was amended to further explore preferences for 
this.  
  
Text order 
A change to the order of the text in the ‘orange’ statement was considered. The initial 
order followed aetiology, identified here by the term ‘treatment second’: 
 
 
Orange Negative (treatment second):  
In 100 people like you who do not take this medicine, 28 will have a heart attack or 
stroke. But if they all take Rebastatin over the next 5 years, 22 will have a heart attack 
or stroke. 
 
However, a revised order was considered, in order to present the primary outcome from 
the trials first, followed by the surrogate outcomes (‘treatment first’) 
 
Orange Negative (treatment first): 
If 100 people like you take Rebastatin over the next 5 years, 22 of them will have a 
heart attack or stroke. But if the 100 people do not take Rebastatin over the next 5 
years, 28 will have a heart attack or stroke.  
 
This was because it was surmised that the outcomes of heart attack and stroke 
prevention are likely the most important to patients, and what they would prefer to read 
first. Relevant to this were the findings from the focus groups which revealed that 
patients experienced an emotional response when reading similar benefit statements. 
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Patients wanted positive information about the benefits of their medicines. The 
‘treatment first’ statement presents data in a way could be interpreted to represent an 
increase in incidence of heart attacks or strokes associated with not taking the 
medicine. The original statement (treatment second) presented a reduction in incidence 
of heart attack or stroke associated with taking the medicine.  
 
The potential for increased emotional response from the participants was considered 
and a decision was made to present the ‘treatment second’ statement in the context of 
the leaflet, but to also present the treatment first statement separately as part of the 
topic guide, to explore preferences for these two ways of ordering the text.  
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Purple: 
Rebastatin can reduce the chance of you having a heart attack or stroke. It does this by 
lowering levels of cholesterol and tri-glycerides in your blood.   
 
 
Green: 
If 17 people take Rebastatin over the next 5 years, 1 of them will be prevented from 
having a heart attack or stroke. 
 
 
Orange Negative: 
In 100 people like you who do not take this medicine, 28 will have a heart attack or 
stroke. But if they all take Rebastatin over the next 5 years, 22 will have a heart attack 
or stroke.  
 
Orange Positive:  
In 100 people like you who do not take this medicine, 72 will not have a heart attack or 
stroke. But if they all take Rebastatin, 78 will not have a heart attack or stroke. 
 
Orange Negative (treatment first): 
If 100 people like you take Rebastatin over the next 5 years, 22 of them will have a 
heart attack or stroke. But if the 100 people do not take Rebastatin over the next 5 
years, 28 will have a heart attack or stroke.  
 
Figure 17: The 5 versions of benefit information that were shown to the 
participants. The top 3 statements were included in the body of the leaflet. The 
bottom two statements were provided separately and shown as alternatives to 
the orange negative statement. These were labelled numerically for the 
participants.  
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 Data analysis 6.6
Data were organised and analysed using framework analysis. This approach is 
consistent with the use of qualitative description as the underpinning theoretical 
framework. The aims of qualitative description are not to provide a ‘thick’ description, to 
develop theory or create an interpretative meaning of an event or phenomena, but 
instead to produce a rich, straight description of the phenomena of interest. In this study 
that is the impact of providing benefit information about simvastatin to patients receiving 
a prescription for this medicine (Neergaard et al., 2009). 
The qualitative description approach tends to favour the use of forms of content 
analysis with modifiable coding systems as method of data analysis. Framework 
analysis is a form of content analysis which describes the development of an indexing 
system that can be clearly applied to large amounts of qualitative data and which uses 
a well-described and robust method for organising and analysing data.  
This method is consistent with previous work undertaken in this area of research (see 
chapter 3). 
The following stages of Framework analysis were undertaken: 
[1] Familiarisation 
After the interviews field notes were made and initial categories for coding considered 
(appendix 24). The audio-tapes were listened to and the transcripts re-read and 
checked for accuracy. Emerging themes were considered and discussed with the 
supervisory team. 
[2] Identifying a thematic framework 
The initial framework was developed iteratively. Two transcripts were read in detail and 
reflected upon. Notes were taken and field notes studied. The audio recordings were 
listened to again. 
One transcript was then used to chart emerging codes. Each quote was considered and 
an initial ‘in vivo’ code highlighted. Preliminary thoughts about what this initial code 
might relate to were noted and these were developed into initial themes.  These initial 
themes were then organised into sub-themes and categories through a process of 
charting (see appendix 25). 
A member of the supervisory team (JM) also undertook this process; however a 
miscommunication resulted in the application of a previous framework (from study 2) to 
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the data, as opposed to the generation of a new framework. The ‘alternative’ framework 
contained several categories which were similar, an example being ‘Relationships with 
healthcare professionals’ and ‘Talking about natural frequencies’. The author identified 
the categories which were similar and checked these against each other to identify 
whether there was consensus with regards to organising the themes. There was a good 
match between the themes, and consensus achieved when similar themes were 
applied to the interview data. RD and JM then discussed the process and the key 
themes and categories they felt were important to include. RD developed the final 
framework which was then checked by JM. 
As JM had familiarised herself with the data through the application of the ‘alternative’ 
framework she could review the framework that RD had developed and make 
recommendations for any additions or changes to themes or categories in order to 
improve the data. 
In order to further validate the framework an additional member of the team (PK) was 
provided with 2 transcripts, one of which was charted, and the stage 4 framework. 
Comments on the categories framework were obtained from PK. 
After comments were received, the author made some minor changes to the 
framework, including the following:  
 Under 'impact of benefit info' knowledge and understanding were combined 
under one code. PK noted they were different concepts but it was acceptable to 
combine them into a single code as long as this was explored in the analysis. (PK) 
 Under 'initial response to benefit info' PK suggested consideration of the 
participant's reaction (i.e. emotional or considered / thoughtful) and the differences 
between gist and impressionistic / thoughtful responses. (PK) 
 Under 'talking about uncertainty' PK suggested clarity was needed about coding 
words or concepts when considering the terms 'chance' and 'risk'. RD created 2 sub-
themes which were coded separately in order to explore this in more detail. (PK) 
 JM suggested a code that incorporated "trustworthiness of the information". This 
was included in the code ‘concerns about benefit information’. (JM) 
The framework was again scrutinised by the members of the research team. The 
framework was circulated 3 times in total until there was consensus that the framework 
identified as many potential themes and categories that could be seen in the data 
provided. 
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[3] Indexing 
The thematic framework was then applied to each interview. The interview was read 
and relevant data coded according to the framework. Initially NVivo, a computer 
programme designed to organise and assist with the analysis of qualitative data, was 
used to code the data. An example of a coded interview was provided to JM to check 
for agreement  
 [4] Charting 
The indexed data was then sorted into charts. Each chart presented a main theme; 
every patient was represented by a row and each column designated a sub-theme. This 
allowed for all pertinent quotes from patients on a particular sub-theme to be charted in 
a visually accessible way in order that the researcher could view a summary of the 
data, yet view the different themes emerging by case and/or category. This facilitated 
cross-case and cross-category comparisons and enabled the researcher to view 
sequences and patterns and make deeper level interpretations of the data, rather than 
just provide a descriptive narrative. JM had opportunity to view the charts and the 
original interviews; no changes to the charts were made as a result. 
 [5] Mapping and interpretation 
The final stage saw a process of mapping and interpretation which was undertaken by 
both RD and JM during 2 full-day meetings. RD and JM undertook a ‘post-it note’ 
exercise where each category and sub-category in the charts were summarised and 
arranged in emerging themes. Each researcher took a category and organised the 
emerging themes into sub-themes.  These would then be presented to the other 
researcher who had the opportunity to discuss each theme and re-arrange the post-it-
notes, until a coherent set of sub-themes had been developed for each category. 
For some categories, this was a more descriptive process (appendix 26). Occasionally 
the process of mapping and interpretation meant that themes from different categories 
were collated and combined to create a coherent, overarching narrative.   
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Figure 18: An example of the post-it-note exercise which shows the colour 
coding used to explore any groupings of opinion by age group. 
 
In order to facilitate this, different coloured post-it-notes were used to represent different 
age categories, this created a visual representation of whether particular age groups 
were grouped within particular emerging themes. (Although the findings suggested that 
different views were spread relatively equally and did not appear to be influenced by 
age). 
When the post-it-note exercise was complete, RD and JM made field notes and mind 
maps to present the emergent themes and identified the most-important themes from 
the framework (appendix 27). 
 Results 6.7
Letters were sent to 120 participants. 21 participants responded positively (17.5% 
positive response rate) and 4 more replied but declined to be involved. 20 participants 
were interviewed in their own homes and 1 participant was interviewed at their GP 
practice. Participant characteristics are reported in table 2. The participant’s 
characteristics were reflective of the typical population receiving a prescription for 
simvastatin.   
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8 participants were female. The age range was 55-92 (median age=75). 13 were 
educated to school level, 3 were educated to age 18 and 5 completed higher education. 
Participants received a prescription for a range of medicines (range 4-10, median=7). 
A range of views and responses were obtained on the inclusion of the different formats 
of benefit information in a PIL. 
 Typical perceptions of leaflets and medicines and 6.7.1
associated behaviour 
This section describes the range of typical behaviours that the participants described 
regarding leaflet-use and information-seeking and also their reported health beliefs. 
This context is important in order to be able to interpret and recognise any reported 
changes in these perceptions and behaviours which might be stimulated by the 
provision of the benefit information.  
 Information-seeking behaviour 
It was apparent that a majority of participants were passive receivers of information, 
rather than active seekers. The majority relied on information provided by their GP 
and/or from the leaflet supplied. A small number spoke of accessing other sources to 
obtain additional information when they were first diagnosed. One participant used the 
internet to read about health and medicine information. Two participants, both younger 
women, obtained information from charities such as the British Heart Foundation, as 
they did not find the information provided by their doctor, or in the leaflet, to be 
sufficient.   
Therefore, on the whole, interviewees did not appear to access additional sources of 
information. A small group of participants received their diagnosis and received an initial 
prescription for simvastatin whilst in hospital. These participants tended to state that 
they had not received a lot of information about their medicine or its benefits and, 
although this was not viewed as ideal, it was also not viewed as a significant cause for 
concern.  
Many of the participants had received a prescription for simvastatin for a long time, 
occasionally decades, and could not recall the quality or type of information they initially 
received with their prescription.   
“I was trying to think when I first started taking Simvastatin ……. we are talking 
16 years ago. I can’t honestly remember how much information I was given about 
simvastatin at the time …….. I probably took the verbal advice from the doctor at 
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the time and didn’t, I have never looked very closely at the content of the leaflets 
that come with medicines.” (P09, M, 72)  
 The leaflet as supportive information 
The leaflet was viewed as supportive information, secondary to receiving information 
from their GP. Not all the participants read their PILs. A number stated they did not read 
them all: 
”Well, they always have these little leaflets in them, but quite frankly, I tend to just 
ignore them.” (P02, M, 92) 
Several reasons were offered; PILs were viewed as being too inconsistent; too scary; 
too complex; containing too much information; too long; too small a font; they ‘put 
people off’ and were viewed as provided for legal reasons and not to benefit the patient:  
“Interviewer: What do you think about the leaflets? 
P16: Not a lot really. I don’t have a right lot to do with them. You just take things 
at face value don’t you…I know that they’ve got to cover their selves for certain 
things. So I think a lot of this information is unnecessary... its insurance isn’t it?” 
(P16, M, 68) 
When a participant did read their PILs they said they tended to skim read and pick out 
the important bits. However, most participants said that PILs in general were helpful 
and a few used them as a reference point for raising issues with their GP. 
 Positive medicine beliefs 
The participants tended to have very positive beliefs about their medicines. Simvastatin 
was frequently attributed with positive outcomes. A few participants spoke of how they 
had seen a marked reduction in their cholesterol levels after taking simvastatin, which 
was proof to them that the medicine was effective: 
“You’ve only got to go for your blood tests afterwards and it’s dropped 
[cholesterol level] and it makes you feel better in yourself.” (P03, F, 66) 
Many participants were apathetic about their medicines. They assumed that the 
medicines were working because the doctor had prescribed them and they trusted the 
doctor’s actions.  
“I’m happy taking them, you know, me tablets ‘cos I know they’re doing me good 
and I know I can’t do without them.” (P10, F, 69) 
A smaller number expressed negative beliefs about medicines which were linked to 
previous experience of adverse effects of a particular medicine.  
On the whole the participants expressed positive beliefs about their medicines and were 
passive receivers of information who did not always, or regularly, read their leaflets.  
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There appeared to be a desire to receive information which reinforced positive beliefs 
about medicines.  
 What formats of benefit information are preferable? 6.7.2
Part of the purpose of the research was to map the range of opinions on different 
options of formats that can be used to communicate the benefits of medicines in order 
to understand in more detail what patients prefer.  
Each format provoked a different range of responses from the participants, and there 
were also subtle differences in opinion regarding the presentation and framing of the 
benefit statements. Understanding these responses is important to develop a deeper 
understanding about which formats best inform patients about the potential benefits of 
their treatments. In this section the range of responses on each format is reported 
according to format, presentation and framing. 
 Textual 
The textual format was preferred by most participants and all the participants would be 
happy to receive a PIL which included such information.  The textual statement was 
viewed as positive, easy to read and helpful. It was perceived as reassuring and met 
the participants’ needs for information that reinforced their decision to take the 
medicine.  
“The most positive one to read is obviously [textual statement] because it’s just 
telling you that it’s gonna reduce your chance and you think “that’s good. I stand 
a good chance of not having a heart attack or stroke”. The other two are a bit 
more problematic in the sense that they are showing you that there’s quite a big 
percentage still, even though they’re taking it, are going to suffer from some sort 
of problem.” (P01, M, 75) 
Reading a statement which explained that the medicine reduced the chance of having a 
heart attack or stroke was perceived as simple information that the patient needed to 
know.  
“It’s simple and to the point and there’s no frightening statements in it like heart 
attacks or stroke, well, I mean more than the one [mention]. But when it does 
mention it it’s a positive. It can reduce your chances, which is what we all want.” 
(P04, M, 69)  
However, occasionally the textual benefit statement was perceived as lacking and 
sometimes considered to be too cautious. The lack of numerical data appeared to mean 
that a small number of participants’ felt they could not develop a deeper understanding 
about the proportion of participants who would benefit from the treatment, especially 
when they compared the textual statement to one of the numerical statements:  
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“I like to see that upfront [textual statement] but I’d perhaps be looking for 
perhaps something more…quantified benefits to back that up. I have… having, 
you know, talked about it, I think one of the quantified statements would be 
helpful.” (P09, M, 72)  
 
 Number Needed to Treat 
The number needed to treat (NNT) format appeared to cause a great deal of confusion. 
It was frequently misunderstood by the majority of participants, with the 
misinterpretation that 1 extra person would be saved but the other 16 would have a 
heart attack. The statement led many to think that they would also have a heart attack: 
“It’s a bit like saying a lottery, we’ve got seventeen people, one might be lucky 
and sixteen won’t be lucky, that’s what comes out of this…it’s almost like saying 
you’ve got a one in seventeen chance, haven’t you? The ball will roll and it could 
be that you could be the lucky one or not…your chances are one in seventeen, it 
almost says it’s luck doesn’t it…it sounds like sixteen people are not gonna 
survive but one will.” (P19, M, 76) 
This was very common and a large number of participants could not understand the 
statement even after further explanation from the researcher.  
The NNT was also viewed as ‘poor odds’, a low figure that was not worth bothering 
about: 
“You’ve got a 17 to one chance better than, you know, so people might say “Oh, 
why bother about that.” (P02, M, 92) 
The provision of the NNT seemed to create an emotional response in many 
participants. It undermined their confidence in their medicines, created anxiety and 
removed hope: 
“The one in seventeen, I don’t think would give me a lot of confidence.” (P11, M, 
77) 
 “I did like it at first, but now, when I’ve looked at the others and thought about 
them, the one extra person is a bit frightening…it’ll only help one person.” (P14, 
F, 66) 
There were, however, a few positive responses about the NNT. The statement was 
perceived as easy to read by these participants, and they did appear to struggle less 
when reading the NNT:  
“It’s just clearer…you don’t have to think about it.” (P20, F, 55) 
This was in comparison to the natural frequency, which often took some time to sink in 
(although it facilitated a deeper understanding of the benefit data – see under ‘Natural 
frequency’ below). 
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Participants also valued the smaller proportions presented in the NNT. The 
denominator of 17 was viewed as easier to comprehend than the denominator of 100 
used by the natural frequency: 
“I’d rather the purple one [textual], but I’d rather that one [NNT] than the orange 
one. As I say, it’s going out more towards, you know... People sort of, as I say, 
can understand it more with just sort of 17 people, whereas when you start 
talking about hundreds or tens of thousands it sort of blows it all out the 
window.”(P12, F, 64) 
 Natural frequency 
The natural frequency was liked, although there were significant concerns that 
participants expressed about this format. It was helpful for those who could invest the 
time into understanding the statement and it did seem to take several participants effort 
to read and re-read the statement and let the figures sink in. Several participants 
struggled to understand the natural frequency, and many did not understand it at all: 
“This one just takes a little bit of working out but I can understand it now, but if 
you take the odds are, as opposed to 72 it’s 78 isn’t it? It’s a bit hard…maths 
wasn’t my right good subject.” (P05, M, 75) 
The natural frequency format tended to be viewed as positive in comparison to the 
NNT, as the numbers were viewed as better. However, when considered on its own it 
did not convey large benefits to the patient and this was frequently viewed as 
disappointing: 
“It’s not terribly impressive is it? A reduction from 28 to 22? But I suppose as a 
percentage it’s about, mm, it’s not a bad percentage, about 25 percent about 
25…yeah, 28 down to 22…well, will that worry people being told those figures? I 
think a lot of people might be worried. They might think “oh, I’m the unlucky 1 in 
5”, we’ll call 22 one in 5.” (P17, M, 81) 
The level of benefit perceived from the natural frequency was frequently viewed as not 
as beneficial as they would have expected or liked, which created a negative perception 
of the statement.  However, it is the benefits of the medicine which are disappointing, 
rather than the format. It was difficult for participants to separate their disappointment 
with the data from their disappointment with the format of the statement. 
“Not a very big decrease is it in people? 28 from 22. It’s like saying 28% of you 
will have a heart attack if you take this tablet 22 of you will, so only 6% won’t…I 
honestly don’t think it’s a large enough percentage of people, six. I think it should 
tell you a lot more will [benefit]…I think it’s a bit on the low side, you know, it 
should be more people would benefit from it.” (P11, M, 77) 
The natural frequency statement was occasionally viewed as sounding threatening; this 
undermined confidence in medicines: 
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“I think that’s a bit frightening because you’ll be looking out and thinking I might 
going to be one of those 28 or 22 all the time I think.” (P14, F, 66) 
There were also concerns that the repetitive emphasis on the disease in the statement 
was unsettling: 
“Interviewer: Which is your favourite? 
P04: Definitely not that one [Natural frequency]. I think it’s too much emphasis on 
the heart attack and stroke. I think it is glaring out at somebody who might be a 
little bit anxious about the tablets anyway. I think you could be told about the 
benefits without all the ‘heart attacks’ and ‘strokes’.” (P04, M, 69) 
The natural frequency appeared to require more investment in reading time and was 
more difficult to understand than the other formats; however it did appear to help a 
small number of participants develop a deeper understanding about the proportion of 
people who would benefit from taking the medicine, even if this understanding was 
ultimately disappointing. 
 Framing of the natural frequency format 
The majority of participants preferred the positive framing. This was viewed as the more 
positive option as there was focus on not having a heart attack or stroke, as opposed 
to having a heart attack or stroke. This provided more hope and encouragement and 
was perceived as less frightening. Participants described how it gave a good reason for 
taking the drug: 
“It’s [positive] not as threatening, you know, 100 people like you do not take 28 
will have a heart attack or a stroke, whereas this one 100 people will not…it’s the 
same odds but one says not and one says will.” (P05, M, 75) 
A small number of participants didn’t understand the difference in framing of the 
statements and were ambivalent to either frame. Only one participant preferred the 
negative framing. This participant struggled with ease of reading of the double negative 
that was used on the positive frame and found the negative framing easier to read: 
“I think if you tell people a negative “it will not”, that doesn’t necessarily register. I 
think if you tell them “You will have”, I think that registers linguistically… You see 
people trying to figure out double negatives in their head and it doesn’t work. I 
prefer the [negative framing].” (P08, F, 56) 
However, the overwhelming majority preferred the positive framing because it was seen 
as more encouraging because of its positive emphasis: 
“It’s a play on numbers in that you are saying 28 will have a heart attack and this 
you are saying 72 will not have a heart attack, and in a way that will possibly 
encourage to take it, whereas the other might not…I think it would ease my mind 
to know that a lot of people have not had a stroke rather than to know that 28 
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have. Think looking at its more positive if you think that people have been helped 
by it.” (P15, F, 72) 
 “People like you” in the natural frequency format 
A small number of people were ambivalent to the use of the phrase “people like you” 
and expressed no preference about its wording.  However it was also found to evoke an 
unexpected and strong response from a larger number of participants. The statement 
was viewed as too personal or overfamiliar. Many felt very uncomfortable with the 
phrase which was perceived as negative and occasionally accusatory: 
“It’s a little bit impersonal but it’s to the point. It’s a bit blunt…People like you, 
people who suffer with your symptoms…That sounds something that I would 
prefer…out of 100 people who suffer with your symptoms, 78 are likely to have a 
heart attack if you do not take simvastatin... It’s people like you that cause all this 
trouble in the world! [laughs.]” (P11, M, 77) 
 
Alternative suggestions to this phrase included reference to the disease or symptoms. 
 
 ‘Treatment first’ in the natural frequency format 
When presented with options of having the benefits of treatment data presented first, or 
second, in the natural frequency statement (treatment first compared to treatment 
second; see section 1.5.6), the participants responded in a number of ways. Some 
ambivalence was expressed, especially as the difference between the two formats was 
not understood or seen as too subtle to be concerned about for many participants. 
One person preferred the statement which presented the treatment second; she 
reported that the “treatment first” statements made her think she would have a heart 
attack: 
“I think I prefer [treatment second] to be honest…it’s like saying if you take this 
medicine you’re still going to have a heart attack. It gets a bit complicated and 
like I say a lot of people never have a heart attack…I mean, they have only put 
me on [simvastatin] as a precaution…that’s a necessity if you see what I mean is 
like saying you are going to have a heart attack [treatment first] but the other one 
is more subtle [treatment second].” (P14, F, 66) 
It was more common to prefer the ‘treatment first’ option because the participants 
wanted to know first and foremost what happens to those who take the medicine first: 
“The way this one is written [treatment first] I feel is more simple…it starts off by 
’22 will have a heart attack but if they do not take it then 28 will’, so they are 
telling you the good bit first and then the bad bit. If it’s me and I’m going to take it 
I‘d like to know what’s gonna happen to me first, then hear the other bit and if that 
changes my mind that will be fine.” (P15, F, 72) 
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 Barriers to the inclusion of benefit information in PILs 6.7.3
This category describes the barriers identified by participants regarding the provision of 
benefit information in PILs. These include a number of barriers which limit initial patient 
access to the benefit information, as well as a number of concerns which might 
influence the impact of the benefit information in a PIL in a real-life situation. 
It is important to be aware of these limitations and challenges in order to understand 
what the potential impact of the benefit information might be and to determine how the 
issues raised by the participants regarding the inclusion of benefit information in a PIL 
might be overcome. 
The biggest barrier was that a large number of participants do not read the leaflets. 
During the course of the interviews the participants, who would not typically read their 
leaflets, engaged with and valued the benefit information but still stated that they would 
be unlikely to read the leaflet in a natural situation.  
 “I don’t really think [I would read the leaflet] to be honest because at the moment 
I’m taking it because I’ve been told I need it, so that’s about it.”(P16, M, 68) 
For those who stated they didn’t or wouldn’t read the leaflet (and therefore the benefit 
information), the reason why was due to a lack of perceived relevance to their individual 
situation. The numerical information, in particular, was viewed as irrelevant because 
participants wanted to know the odds of what would happen to them and not to the 
wider population, and the numerical benefit statements could not inform the reader of 
such very personalised statistics.  
It was also potentially irrelevant, as many participants pointed out, that by the time you 
get the leaflet you have already made a decision to get the medicine; therefore the 
information is superfluous because the decision to take the medicine has already been 
made. Therefore the timing of the benefit information is an issue: 
“I mean, you wouldn’t see this leaflet though, unless you were taking the 
medicine would you?” (P05, M, 75) 
Interestingly, denial about the natural consequences of their disease was expressed 
amongst the participants who appeared to adopt an ‘ignorance is bliss’ approach to 
receiving information about their treatments. Many participants do not appear to want to 
hear the statistical truth about their medicine, as this was viewed as unpalatable.  
 “I don’t want to know that, I want them to tell me Simvastatin is doing you good 
and it will help prevent heart attacks, I don’t want to know that X number are still 
gonna have a heart attack.” (P01, M, 75) 
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A major barrier to accessing the benefit information was that many participants did not 
understand the benefit information.  Low levels of numeracy were perceived amongst 
the sample (although not measured). A moderate number of participants struggled to 
understand the information at all, whilst others made no attempt to try and understand 
it. Others found the information very difficult to process and understand and this was 
off-putting as it became a cognitive burden.  
“As I say, for the everyday person, I don’t think they would sort of…you 
know…just keep it plain and simple and everyday people like myself would 
understand it more than going into all the technology of, you know, 100 this and 
“we’ve done a survey of this, that the other.”” (P12, F, 64)  
However, not all the participants struggled to understand the benefit information. A 
significant proportion did have the level of numeracy skills required to understand the 
numerical benefit information. 
 Concerns about benefit information 
A small number of participants voiced no concerns about the inclusion of (numerical) 
benefit information in PILs and thought it a valuable addition to the leaflet and would 
have either a positive impact or a negligible impact on patients. However, the majority 
of participants expressed a range of concerns about the inclusion of benefit information 
in a PIL. These concerns were specifically concerning the inclusion of numerical, rather 
than textual benefit information.  
The users of simvastatin reported that numerical benefit data had the potential to 
provoke anxiety, worry and doubt and it was apparent that several of the participants 
found the information upsetting. The cause of this upset was the poor odds associated 
with the treatment: 
“It doesn’t seem as if it helps a lot of people that, not in that length of time. There 
are only six people it doesn’t help. Does that sound like sense?” (P21, F, 84) 
The statistical information provided was perceived as very poor and negative. 
Sometimes this undermined the confidence participants had in their medicines and 
there were concerns that this might put people off taking their medicines because of 
fear rather than a reasoned decision to not take the medicines: 
The information was not viewed as encouraging and this was in direct conflict with the 
desires of these participants who expressed positive beliefs about their medicines and 
want information which reinforces and encourages their decision to take the medicine. 
The numerical benefit information provided in the leaflets did not support patients with 
this and instead created anxiety and unease: 
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 “It doesn’t give me much…it doesn’t really give me a great deal of confidence 
that I’m going to be the one who’s going to be prevented from having the heart 
attack or stroke.” (P09, M, 72) 
Other concerns included worries that the benefit information contributed to ‘too much’ 
information that was provided with the leaflets. Suspicion of the statistics and their 
trustworthiness were also articulated: 
“You don’t want bombarding with these [facts and figures].” (P05, M, 75) 
“I’m suspicious of these numbers because you are talking about quite a wide 
population.” (P07, M, 85) 
While the most common concern was that the benefit information was very negative, 
conversely it was expressed that the benefit information could be perceived as too 
promotional or something which could coerce a patient into taking the medicine.    It 
would influence their view that without the medicine the patient might feel like they will 
die. The numerical benefit data was occasionally viewed as overly persuasive:  
“It’s more or less…not forcing people, but obviously if you think you are going to 
have a heart attack if you don’t take this medicine, then you’ll take it.” (P21, F, 84) 
 “It’s just a little bit threatening. It just says if you don’t take our statins then you 
are going to have a heart attack or stroke.” (P05, M, 75) 
 The benefits of benefits 6.7.4
This category describes the potential positive influences of the provision of numerical 
benefit information in PILs that were reported by participants. It was recognised that the 
participants tended to focus more on the perceived negative impact of the benefit 
information which, in both the previous focus groups and the current interview studies, 
stimulated strong emotional responses. The acknowledgements of the benefits of the 
benefit information tended to be more subtle. These are nevertheless of significant 
importance to those participants who desire encouraging, yet truthful, information about 
their medicines. 
The benefit information was seen to have positive attributes. It was viewed as helpful 
information that was useful to know. They felt that that numerical information provided 
better rationale about treatments, more information about how the medicine was going 
to benefit them and how it would do this: 
“I think you do need some facts and figures, it’s interesting to know that if I take 
them, people who take statins are less likely and the percentage is worth 
knowing.” (P05, M, 75) 
A small number of participants thought it might help them to compare the effects of 
different medicines. A few thought it might provide them with a stimulus to talk to their 
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GP about their medicines. A small number of participants felt the information gave them 
confidence about their medicines and was encouraging and optimistic: 
“It gives you a wee bit more confidence in the stuff that you are taking. If you 
know it gives you a better chance by X amount of people being…cholesterol 
being improved by it.” (P11, M, 77) 
For one participant in particular it put the concerns she had about her disease and 
treatment into context, which surprised her, but was very positive: 
“Of the five siblings my father died at 44 and his brother died at 40, the first heart 
attack so I’ve always thought the percentage was a lot higher from my own 
personal experience, I thought when I was diagnosed that was it, I wasn’t going 
to make it and nobody ever said what the percentages were. I know that you 
can’t get it exact because you don’t know about genes and lifestyle and things. 
But that’s more reassuring to me because, alright, 22 will have a heart attack or 
stroke but 78 won’t if you are good and take the medicine.” (P08, F, 56) 
The main benefit stated of providing benefit information was that it met the participant’s 
expectations of healthcare professionals’ duty to inform about the benefits of 
treatments. Participants felt that if this information is known by the producers of 
medicines information then it should be available for the patients to read. They 
expressed a sense of ‘needing to know’: 
“Not everybody will want quantified information or quantified benefits, but I think 
equally there’ll be a proportion who will look at the leaflet and will be looking for 
quantified information so they can actually say in quantified terms what the 
benefits are likely to be, so I would say yes.” (P09, M, 72) 
 The impact of providing benefit information on users of 6.7.5
simvastatin 
The provision of benefit information in PILs has been shown in this and the previous 
focus group study to stimulate an emotional response from the users of medicines and 
medicines information. However, what is not known from the focus group findings is the 
potential impact on patient knowledge and understanding about their medicines, nor the 
impact this might have upon decision-making and medicine–taking.   
 A negative positive: The impact on knowledge and understanding 
The impact of the benefit information on knowledge and understanding about medicines 
was varied and there was a range of responses. For many, the provision of benefit 
information in a PIL had no apparent impact on their knowledge or understanding about 
their medicines. There were several reasons for this. The information, particularly the 
numerical information, was viewed as too complicated and the participant frequently 
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didn’t understand it. Often this was because the participant appeared not to have the 
numeracy skills required to make sense of the information.  
There were examples where the participant developed a deeper insight into the benefits 
of their medicine when reading the benefit statements for the purpose of the research 
study: 
Int: “Do you think it’s helped you understand in more detail... 
 
P16:Yeah, I do, yeah, honestly it has yeah. It’s brought it home to me a bit, 
yeah… I’ll take them with more joy [laughs].” (P16, M, 68)  
 
However, it was apparent from what the participant had stated about their typical 
medicine taking and leaflet use that, without the stimulus of the research study, they 
would most likely not read the leaflet, even though they valued the benefit information 
and reported that it provided a deeper understanding of the benefits of the medicine. 
When the information did have an impact this was sometimes a mix of a positive and 
negative effect. For a few participants it did appear to help them develop a deeper 
understanding about the benefits of their treatments and encouraged them to weigh up 
the advantages and disadvantages of treatments in more detail, but it also created 
more emotional responses and was often perceived as negative by the reader.  
Despite the negative emotional responses that the numerical data frequently provoked, 
many participants were also satisfied that the numerical benefit information was 
included too. Participants wanted knowledge about the medicines to be made available. 
“I know it does make some people anxious, but, as I say, I wouldn’t be, but it still 
think it’s a good idea to put ‘em in.” (P06, M, 88) 
 Decision-making and medicine-taking: Doing what the doctor tells you 
While many participants voiced a concern that information on the benefits of treatments, 
in particular the numerical information, might put people off taking their medicines, it did 
not appear that benefit information would be a significant influence on decision-making 
and medicine-taking for the participants personally. 
The biggest reported influence for the majority of the participants regarding their 
medicine-taking was the recommendations of their GP. The participants stated that if 
their GP had advised they take a treatment, then they would take the treatment: 
“If the doctor told me to stick me head in a gas oven, I would do. I tend to believe 
in ‘em. I’ve had good results and I mostly go along with ‘em…” (P06, M, 88) 
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For a number of participants the decision whether to take simvastatin or not had been 
made previously, sometimes decades before. The benefit information presented here 
was not viewed as something that could impact on decision-making, but instead was 
something that the participants desired in order to reinforce their decision to take the 
medicine. In particular, the textual information met this desire and participants 
frequently described it as encouraging:  
“I’m not as impressed with that [numerical format], that’s not as reassuring and 
it’s not…it doesn’t mean a lot to me personally…… it’s just numbers and it’s not 
as personal. Reading something like this [textual statement] it’s speaking to me 
personally and it’s giving me a bit of reassurance.” (P20, F, 55) 
A few participants stated that they found the benefit information encouraging as they 
could see there were clear benefits to taking the medicine. Others found this 
information very discouraging and expressed concerns that the benefit information 
might make them think that the medicine was not worth bothering about. 
However, ultimately all of the participants did not appear to be deterred from taking the 
treatment. Participants reported that the hope they might have regarding their treatment 
and the confidence in the medicine might be slightly undermined by the numerical 
benefit information, but did not report that this would change how they took their 
medicines:  
“Interviewer: Do you think you would have done anything differently with your 
medicine? 
P02: I don’t think so, quite honestly I don’t think so because I’m one of these who 
has to trust the person who is doing the prescribing and what he says it will do for 
me. So, I think it all comes down to a matter of trust.” (P02, M, 92) 
One patient had some serious initial concerns about the numerical benefit information 
(which were more marked than for any other participant).  After reading and processing 
the benefit information he engaged in a process of re-assessment of his situation, 
where he used his experience of his medicine and his perception of the impact of 
changes to his lifestyle over recent years to appraise how he thought he would benefit 
from the treatment - in addition to the benefits presented. So, in order to cope with the 
negative perception of the benefit information he used his experience with the treatment 
and his good health to put a positive ‘spin’ on the information and to create a 
representation of his illness which led him to consider that the treatment would benefit 
him more than the proportion we had presented to him:  
“As I say, I’ve had no twinges, I’m touching wood, I’ve had no twinges 
whatsoever, so in my mind unless I get older and something else goes wrong I’m 
not gonna have a heart attack, that’s the way I feel at the moment. So fair 
  
256 
 
enough, that’s the best I can do for you….yeah, I don’t want to know if I’m gonna 
have a heart attack ‘cos I’m taking it, so if it’s doing me benefit I don’t need to 
know the rest, if it’s telling me I may still have a heart attack, I don’t want to know 
that.” (P01, M, 75) 
Despite negative feelings about the benefit information it was apparent that many 
participants appeared to try to employ coping strategies to apply the benefits of the 
treatment to their own situation.  Where participants could not grasp the meaning they 
engaged in a reassessment of their situation.  
Participants used their previous medicine-taking to measure their experiences against. 
As this was mostly positive, many of the participants were happy to take a ‘suck it and 
see’ approach to taking their medicines. They would try the medicines and see what 
would happen, or in the case of simvastatin, carry on taking the medicine and hope that 
they would be the one to benefit from the treatment. The benefit information did not 
appear to have a negative impact upon this approach to their medicine-taking. 
Concerns were frequently expressed that the benefit information might impact on the 
behaviour of others, particularly the elderly or less numerate. The main concerns were 
that the numerical benefit data might be worrying or put people off taking their 
medicines. However, there was little evidence that this would impact upon the 
participant’s own decision-making or medicine-taking behaviour.  
 Coping with uncertainty: How full is the glass? 6.7.6
This section explores the patient’s responses to the uncertainty associated with whether 
they will be the patient who benefits from taking the treatment. It also reports on 
whether the patients reported how the benefit information conveyed such uncertainty. 
Uncertainty is a state of having limited knowledge where it is impossible to predict the 
future outcomes. With regards to uncertainty about medicines, the benefit information 
should convey that the treatment has a benefit to more people who take than those who 
do not take the treatment, but should also convey that not all patients who take the 
medicine will necessarily benefit from the treatment. In the previous focus group study it 
was apparent that not all people were aware of the apparent uncertainty associated 
with medicines, or that the uncertainty was underestimated. This section aims to 
explore how the participants responded to the uncertainty associated with their 
treatments in more detail. 
It was apparent that there was a strong desire for certainty about the effectiveness of 
simvastatin. The participants wanted more certainty or better odds from their 
treatments:  
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P11: “Well I think that the word “can” it’s another word, “will” I honestly believe 
that “will” is a better word.  
Interviewer: Well I think what that is trying to say is that there’s a bit of uncertainty 
about the medicine, so it “might not” benefit you. 
P11: I thought that’s what the Simvastatin was for actually now that you’ve said, it 
was to lower the cholesterol… So it should, it should, will lower the cholesterol or 
else they’re rubbish.” (P11, M, 77) 
 
Lack of certainty was frequently perceived as threatening or off-putting and it was 
apparent that pre-existing issues such as anxiety might impact upon whether an 
individual had a negative or positive response to the uncertainty associated with the 
treatment. 
Participants wanted absolutes, to know whether the treatment would work for them . 
The numerical information presented was not always meaningful for the participants, 
who did not always want to know what would happen to other patients, but only what 
would happen to them: 
 “I’d rather the purple one [textual], but I’d rather that one [NNT] than the orange 
one. As I say, its going out towards, you know…people can understand it more 
with just 17 people, whereas if you are talking about hundreds or tens of 
thousands it sort of blows it all out the window…You’re sort of thinking, “well, as 
long as I am the one that benefits that is all that matters!”” (P12, F, 64) 
The benefit information provided did not meet the patients’ desire for absolutes and 
certainty regarding their treatment. The concept of uncertainty was complex; many 
participants felt that the lack of benefit information could increase uncertainty but others 
expressed concerns that the provision of benefit information might provide a sense of 
false certainty:  
“The [NNT] says ‘one extra person will be prevented from having a heart attack’, 
it doesn’t give a guarantee that they won’t have one. This one [natural 
frequency] tends to, well it does say ‘will not have a heart attack or stroke and 
that to me is a bit [too certain]. I can imagine if somebody took it and they had a 
heart attack or stroke they’d say “that blessed leaflet said, you know, we 
wouldn’t” sort of thing. They’d blame the tablet then. No, joking apart, don’t think 
you should promise something that you really have no control over.” (P15, F, 
72) 
At times it was noticed that participants could not comprehend the concept of 
uncertainty about the effects of their medicine at all, or it was something they did not 
appear to think about it detail.  In order to cope with uncertainty the participants’ 
reported a couple of coping mechanisms. One was to ignore the uncertainty.  
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 “You are, regardless of figures, better taking it and that’s the end result. That’s all 
I want to know. I don’t want to look at figures personally. That would be good 
enough for me, basically what they [the leaflets] tell you to so.” (P01, M, 75) 
Another was to adopt a sense of fatalism, to accept ‘what will be, will be’. However, 
‘what will be’ appeared to depend on the outlook of the individual participant. Onȇ group 
of participants adopted a more optimistic approach and tended to consider that even 
though there was uncertainty associated with taking simvastatin, any chance was good 
enough for them to continue taking the treatment: 
“I’m quite happy to take it to be honest. I’d rather have that chance of not having 
my heart clogged up. It still helps.” (P14, F, 66) 
These participants also tended to believe that if they adhered to the treatment then their 
chances would increase. 
Conversely, others adopted a pessimistic approach and identified more with the poor 
odds with the treatment, and rather than taking the chance of benefit associated more 
with the chance that they would be the unlucky one:  
“Everybody thinks at times, if they are down or not well are they the unlucky one? 
He would do it to himself, you think, well it will be our luck because we have had 
such a lot of things go wrong and we’ve just said “It will be our luck.”” (P04 Wife, 
F, age unknown) 
  “I want the benefits to scream out at me”: Desirable 6.7.7
attributes of benefit information 
The benefit information stimulated a range of responses, many of which were negative 
and there was a range of preferences for the specific types of formats that we 
presented. As has been said, it was apparent that the inclusion of benefit information in 
PILs can stimulate some negative responses and has the potential to be off-putting and 
create additional concerns for participants. The participants were questioned about 
whether the leaflet appeared more ‘balanced’ with the inclusion of the benefit 
information. However, a ‘balanced’ leaflet was not necessarily a desirable feature of the 
leaflet for participants who appeared to prioritise information that reassures and 
encourages them to take their medicines and who ultimately desire medicines which 
are more likely to help and which have fewer side effects.  
However, as presented above, the benefit information did not quite redress the balance 
of the leaflet, and for a proportion of people it only served to make the leaflet appear 
more negative. One issue was that as the side-effect information was perceived as so 
negative, the provision of benefit information could never balance that. The benefit 
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information that was provided about simvastatin did not have a sufficient positive impact 
to appear attractive: 
“I think the problem with these sorts of things is that there is too much emphasis 
on the bad side-effects. I know we’ve got to know, I know there is a duty of care 
and all the rest of it to tell us, you know, all the bad things that might happen but I 
want to be drawn into what is good, what’s good about  it… I want the benefits to 
scream out at me.” (P20, F, 55) 
The numerical benefits of the medicine were disappointing, but the participants still 
wanted an emphasis on the benefits. It was suggested that placing the benefit 
information in a prominent position at the top of the leaflet would help to ensure this 
information was seen: 
“I suppose it would [provide balance], yes, provided the top, or near the top of the 
leaflet. I think I would have given up before I reach the end in most cases.” (P19, 
M, 76) 
Participants acknowledged the challenges of using numerical information and were 
undecided about the optimum method of presentation for benefit information, however 
they occasionally suggested the use of textual descriptors such as “by a significant 
amount” regarding the benefits: 
“If you compare a hundred people taking the medicine with a hundred people not 
taking the medicine then the people in the former group, if that’s not too difficult a 
phrase for some folk, will have a reduced chance of a heart attack or a stroke by, 
you know, whatever it is……. So I think something like that would give you, give 
them the essence of this and then whether you then actually give them the figure 
or you say “by a significant amount”. You’ve got a choice of either giving them a 
number then with my formation, formulation, or just saying “by a significant 
amount”. Then of course they’ll say “oh you don’t know what it is”, you know, mm. 
[Interviewer laughs] Grumble, grumble, grumble. [Laughs]” (P17, M, 81) 
The appeal of use of qualifying words such as ‘drop’ to emphasise reduction in risk or 
‘increase’ to emphasise improvements provided by the treatment was noted. 
Participants wanted the information to be positive and to stress the benefits of the 
medicine. 
“The way I’m thinking at the moment is rather than being told, I’d like it you know, 
to be a positive statement, if you take Rebastatin your chances of having a heart 
attack will reduce and that could be quantified from twenty-eight in a hundred to 
twenty-two in a hundred, does that make sense? This is, it gives you the basic 
statement [reads from leaflet], “in a hundred people like you who take this 
medicine, twenty-two will have a heart attack or stroke, but if they don’t take 
Simvastatin, Rebastatin, twenty-eight will have a heart attack or stroke”, I don’t 
like the way the information’s presented, I would like it to be more positive, take 
Rebastatin and you will benefit in the following terms, whether you know, you will, 
your likelihood of having a heart attack will drop from twenty-eight in a hundred to 
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twenty-two in a hundred, I’d rather it was, any information was presented in a 
positive way.” (P09, M, TN) 
For a small amount of participants this could be achieved by using a combined textual 
and numerical statement. The textual statement was perceived as positive and was 
generally well-liked. Having this textual statement as a precursor to a numerical 
statement appeared to reduce the disappointment and reinforce the benefits of the 
medicines that participants desire to hear more about: 
“I still like [textual statement], I think I could just add the bit from 28 out of 100 
down to 22 out of 100…Whatever combination of purple and orange adds up to. I 
like the fact it says how it does it, yeah, but if you’re going to say it reduces the 
chances then tell people exactly how many it will reduce it by.” (P08, F, 56)  
Participants also desired information which reassured them and encouraged them to 
take their medicines. The numerical data on simvastatin failed to achieve this and was 
perceived as disappointing. However, it was apparent that the participants interviewed 
still desire benefit information from their medicines information, factual information 
which reassures them and responds to their desire to continue to take their medicines 
as prescribed. 
 Discussion 6.8
The aim of this study was to evaluate the impact of providing benefit information about 
medicines in written medicines information on the attitudes and opinions that the real-
life users of medicine hold about their treatments.  
This study was novel as it examined the impact of providing this benefit information 
about the medicines that patients are taking in a non-hypothetical scenario. Chapter 3 
described the findings from a focus group study where a sample of medicine-takers was 
asked their general opinions on benefit information. This discussion includes a 
comparison of the 2 studies and examines any differences between the opinions and 
preferences reported from the focus group participants and the real-life users of 
medicines. First, responses that were similar to those expressed in the focus groups will 
be explored. There will follow a discussion about the differences that the real-life users 
of medicine reported about the inclusion of benefit information in PILs. 
  Key finding: Textual information was preferred, but 6.8.1
numerical (natural frequency) information can help with judgements 
Most participants preferred the textual statement and were happy to have it included in 
their patient information. There appeared to be a desire for additional information about 
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the rationale for treatment that described the condition and treatment in more detail. 
However, despite the preference for the textual format, it was apparent the numerical 
statements had the potential to help a select sub-group of participants gain a deeper 
insight into the benefits of their medicines.  
Natural frequencies in particular appeared to foster a greater understanding of the 
meaning of the benefit information. This finding is supported by the findings of the wider 
literature, including the findings of the scoping review in chapter 2. Natural frequencies 
have been shown to facilitate the calculation of probabilities and may help assist with 
reasoning (Gigerenzer, 2002, Galesic et al., 2009b, Girotto and Gonzalez, 2002). 
However, it is important to note the natural frequency was still a difficult format for many 
of the participants to engage with. It only appeared helpful for those with a higher level 
of numeracy who invested time in reading the statement. 
These are findings that are reflective of the preferences of the participants in the focus 
groups.  The preference for textual format over numerical format for most people 
appears therefore to be a common theme. It must be noted that preference is not 
indicative of performance and it is possible that, despite some reported hostility to the 
numerical format, its use may likely facilitate a deeper understanding of the benefits of 
medicines when compared to the textual statement.  
  Key finding: NNTs are difficult to understand 6.8.2
It was apparent that, during the focus groups, some participants struggled to interpret 
the NNT. When it was viewed positively this was because it was regarded as short and 
easy to read. In comparison to the focus groups, the interviews allowed for more time to 
explore the participants’ understanding of the NNT and it was apparent that many did 
struggle to understand this format. The NNT was confusing and conveyed a sense of 
chance that was not accurately interpreted by the most of the patients. There was a 
tendency for many patients for the NNT statement to mean that 1 patient would survive 
as a result of taking the medicine and be a ‘lucky one’, but 16 would not. This 
misinterpretation generated a considerable emotional response and concern for those 
participants.  
The NNT has been described as ‘easy to understand’ and as providing ‘intuitive 
meaning’ about the measurements of therapeutic effect particularly for healthcare 
professionals, but it has been anticipated that lay-people might benefit from information 
presented in this format (Christensen and Kristiansen, 2006). Much of the research into 
NNTs has examined the persuasiveness of the technique rather than people’s 
  
262 
 
understanding (Malenka et al., 1993, Hux and Naylor, 1995). However, when evaluated 
in empirical studies it has been noted that lay-people do report difficulties in 
understanding NNTs.  
Halvorsen et al (2007) described NNTs to be like a lottery, where few people win the big 
prize. They considered that the NNT format did not adequately communicate the 
proportion of patients who benefit from taking a treatment or who would avoid an 
adverse event. People frequently perceived the NNT as communicating that the 1 in X 
was the ‘lucky one’. It was apparent that this phenomenon of being a ‘lucky one’ was 
conveyed by the NNT in a way which was disconcerting and misleading for the 
participants (Halvorsen et al., 2007). While the challenges of interpreting NNTs were 
apparent in the focus groups, this struggle was more obvious in the interviews, which 
may be due to more time being spent to discussing the different formats in detail.  
The findings from the interview study suggest that NNTs are not easily understood by 
lay people who frequently misinterpret the benefits of their treatments as meaning that 1 
in 17 will be ‘lucky’. NNTs were reported to be easier to read and patients appeared to 
have a greater verbatim understanding of this format compared to other formats. 
However, they frequently appeared unable to understand the gist meaning of the NNT 
which adversely affected their ability to accurately interpret the benefits of their 
treatments.   
  Key finding: A positive frame is valued 6.8.3
After being shown both a positive and a negatively framed statement, all but one of the 
participants preferred the positive frame. These findings are consistent with the findings 
reported in the focus groups (chapter 4). The positive frame was valued as it appeared 
more optimistic and encouraging to the participants who wanted to hear how likely they 
were to not have a heart attack, rather than how likely they were to have one. Even 
though the positive frame contained a double negative, which was not necessarily easy 
to read, only one person preferred the ‘simpler’ negative frame. 
  Key finding: Patients were surprised at the perceived low 6.8.4
benefits, but engaged in a process of “self-regulation” in order to 
adjust their expectations of benefit  
Another finding consistent with those of the focus groups was that most of the 
participants over-estimated the benefits of their statin therapy. Patients receiving a 
statin therapy did not appear to have a ‘realistic’ perception of how likely the treatment 
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was to benefit them. When presented with the numerical statements this provoked 
surprise and most participants expressed disappointment about the potential effects of 
simvastatin when presented in a numerical format.  
It is unclear why patients over-estimate the effects of their statin therapy. It was 
frequently reported that the information about the benefits of treatment had not been 
communicated verbally from HCPs, nor had the participants seen this information 
provided in written formats.  
The participants appeared to have generally positive medicines beliefs and were 
optimistic about the potential effects of their treatment, so it was unsurprising that they 
expressed some disappointment when they were given this information.  
A striking finding of the interviews was the less extreme emotional responses from the 
participants to the numerical information, in comparison to those in the focus groups. 
The focus group participants reported anger and mistrust when presented with the 
numerical benefit information. Whereas these responses were less apparent in the 
interview groups (although not non-existent). The real-life users of medicines expressed 
a good deal of anxiety and worry and disappointment, but less of an emotional 
response, and appeared to give more reasoned and considered responses to the 
information.   
The focus groups appeared heavily influenced in their decision-making by the affect 
heuristic i.e. an emotional response. The ‘real-life’ users appeared to consider the data 
more carefully. It was apparent that during the interviews the participants engaged in a 
process of emotional regulation. This could be attributed to the method of data 
collection. Interviews on a one-to-one basis were able to facilitate more in-depth 
consideration of the numerical data, as there was more time. Focus groups do not 
necessarily enable discussion of individual limitations with the understanding and 
meaning of the numerical statements - as those who do not understand the information 
may have felt embarrassed or intimidated to share their lack of understanding. And also 
during the focus groups, the participants can influence each other’s views, so if one 
participant has a particularly strong view, this might impact on the views of others 
(Kitzinger, 1995, Price et al., 2009)  
Another explanation for the responses from the real-life users of simvastatin can be 
provided using the common sense model of self-regulation (CSM). This model explores 
the processes that people engage in when they are faced with a threat to their health. 
The model assumes that people are active problem-solvers, and that in order to return 
  
264 
 
themselves to a normal state after experiencing a threat to their health, people 
undertake a process called self-regulation where they process the information they 
have, reappraise their situation and develop strategies to cope with any negative 
perceptions or emotions (Cameron and Leventhal, 2003). 
This model has been more recently developed to elaborate upon aspects of emotional 
regulation that patients undertake (Cameron and Jago, 2008). When considering the 
findings of both this study and those of the focus groups in chapter 4, it is apparent that 
the participants in the two groups undertook different processes of emotional regulation 
after receiving the benefit information.  
The benefit information was perceived as a threat by members of both groups but 
different reactions were apparent in each group. The focus group participants were 
frequently more hostile to the information, whereas those who actually used the 
medicine for which the benefit statements were created tended to be less hostile and 
respond more cautiously, expressing less extreme emotions. This suggests the 
possibility that when presented with information about the benefits of a medicine in a 
non-hypothetical situation, when that information is perceived as a threat the users of 
the medicine are more likely to engage in a process of emotional regulation in order to 
manage their specific health-related distress. Those who do not take the medicine do 
not need to engage in this process as the threat is entirely hypothetical.   
The model identifies different coping strategies used to mediate the relationship 
between the negative emotions and how the individual perceives their health. Three of 
these coping strategies include emotional suppression, reappraisal and wishful thinking.  
(Cameron and Jago, 2008, Cameron and Leventhal, 2003). It was apparent that several 
of the participants engaged different strategies in order to cope and moderate the 
emotional impact of receiving the benefit information. Some ignored the information and 
suppressed their responses to the information provided. Others re-appraised their 
health status in light of the benefit information. It was also apparent that some engaged 
in a process of wishful thinking, where they over-estimated the impact to their own 
situation or considered how their adherence to the treatment would improve their 
outcomes. 
This is important as it marks a difference between the hypothetical and real-life users. 
When faced with uncertain information, the real-life users appear to employ coping-
strategies and frequently use their prior experiences of the treatment to help them make 
sense of the benefits. In a hypothetical scenario it is not essential to do this therefore 
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the responses of those in the focus groups may appear more emotional or nihilistic due 
to the absence of the need for self-regulation.    
More research is needed specifically measure the impact of the emotional regulation 
that participants undertake when provided with benefit information about medicines on 
both their psychological and physical well-being.  
  Key finding: The reported impact on behaviour appears to 6.8.5
be minimal 
A concern about the provision of the benefit information that was identified during the 
focus groups was that participants reported that the information was ‘off-putting’ and 
might impact negatively on whether someone might take a medicine. It was apparent 
that the focus group participants displayed a lot of negative emotion and there was a 
concern that this might lead to patients making decisions about their treatment based 
on the affect heuristic rather than a reasoned consideration of the information (Slovic et 
al., 2004, Finucane et al., 2000). This subsequent interview study suggested that real-
life users did not appear to want to stop taking their medicines, or make changes to 
their medicines despite reports of the benefit information being ‘off-putting’.  
The main reported reason for this was due to the faith and trust placed in people’s GP. 
The overwhelming majority of the participants stated they would do what their doctor 
tells them. The benefit information did not appear to undermine the confidence that 
people had in their doctor’s advice in a way that led to a change in medicine-taking 
behaviour. 
It is possible that patients are influenced by a state of inertia, where they lacked 
motivation to change their decision to take a medicine. Most participants reported long-
term prescriptions for simvastatin and had therefore already made a decision to take 
this treatment. It is possible that the benefit information did not influence any change in 
decision-making or reported behaviour due to a status quo bias. The status quo bias is 
the “tendency to maintain a previous decision either by actively taking the default or by 
doing nothing” (Suri et al., 2013, Samuelson and Zeckhauser, 1988).  
It is important to note that this study only explored the opinions of the patients at one 
point in time, when they had initially viewed the information. It is feasible that decisions 
to change medicine taking behaviour might happen after the patient has had the 
opportunity to ruminate over the information and process its meaning. It is also feasible 
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that benefit information might impact differently on those who are considering whether 
to take a new treatment or not i.e. for patients who have not yet made a decision.  
Finally, it is important to note that some participants reported that this information would 
not impact upon their behaviours as they don’t read the leaflets in the first place. This is 
a significant barrier in engaging people about the benefits of their treatments using 
written patient information leaflets.  
  Key finding: Individual and relevant personalised 6.8.6
information is desirable 
Difficulties in interpreting personal meaning from the benefit statements were a 
significant barrier to how helpful the participants found the benefit information. The 
information was not always perceived to be relevant to the individual and while many 
participants appeared to understand the verbatim meaning of the information, it was 
difficult for them to interpret the gist of the numerical statements.  
Fuzzy Trace theory explains how people tend to rely on their gist understanding when 
decision-making (Brainerd and Reyna, 1990). A concern is that if the benefit information 
does not have relevant meaning for an individual, this may represent a lack of gist 
understanding about the benefits of the medicine which may lead to inaccurate 
assessments of the level of potential harms and benefit. This study did not measure 
whether the benefit statements effected both the verbatim and gist the understanding of 
the participants. 
Another issue to consider is how this lack of meaning was represented as a lack of 
relevance of the benefit information for the individual. The benefit statements were 
based on population data and it was reported that this is difficult for the participants to 
comprehend. There was a desire for more meaningful individualised information that 
communicates personalised likelihood of benefit to people. This desire for personalised 
information has been noted in previous research about tailoring patient information 
(Dickinson et al., 2013). In order to meet the needs of patients who desire a more 
personalised approach to their medicine’s information, the providers of patient 
information need to address the challenge of how to tailor patient information. This will 
be particularly pertinent, and indeed challenging for benefit information, especially as 
the individual benefits of medicines are not always known.  
  
267 
 
  Key finding: The benefit information does not appear to 6.8.7
make the leaflet more balanced for patients 
In Always Read the Leaflet, the MHRA consider the possibility that the inclusion of 
‘positive’ information in a PIL could provide balance in a leaflet which in turn could 
minimise concerns patients express after reading about the potential side effects of the 
medicine. 
The textual information was generally perceived as a positive inclusion to the leaflet. 
However, the textual benefit information did not necessarily provide the reader with an 
accurate portrayal of the benefits of the treatment, which were largely over-estimated 
until they were presented in a numerical format.  
The numerical benefit information was not described as something which helped make 
the leaflet more balanced and less frightening, conversely it made the leaflet appear 
more negatively weighted and more frightening. The participants did not report that they 
desire balance in their leaflets. This contrasts with the findings from the systematic 
review of Raynor et al (2007). Instead they appear to desire medicines which are more 
likely to help and which have fewer side effects.  This appears to be a deficiency of the 
medicine itself, rather than the accompanying information.  
This is an important finding, because it prepares us for the possibility that patients might 
find the inclusion of benefit information in PILs to be a negative addition, as opposed to 
a positive one. It is also important to note that although the participants in this study did 
not report they would do anything differently, the inclusion of benefit information might 
lead some to reject medicines on the basis that the balance of harms and benefits is 
negatively weighted. This in itself is not a negative concern as such, as long as patients 
are making informed decisions that are in line with their values. However, further 
research is required to measure the impact of providing this information and ensure that 
decisions being made are done so in a reasoned manner, as opposed to a knee-jerk 
reaction to a perceived imbalance that the provision of benefit information might 
stimulate.  
  Key finding: A minority of patients value benefit 6.8.8
information being made available 
While many participants did not like the inclusion of the numerical benefit data, it is 
important to note that participants still value and desire the inclusion of benefit 
information in their PILs. While the benefits of statins were not viewed as heartening, 
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some participants felt that if this information is known then it should be provided. 
Although not all participants stated they would value this information being made 
available, a small group thought this information was very important to include in 
communications about medicines.  
The makers of medicines information and healthcare professionals were viewed as 
having a duty to inform the patient about the benefits of their treatment, regardless of 
whether this information was something that was viewed as positive.  
 Strengths and limitations of the methods 6.9
A strength of this study was that the participants were patients receiving a prescription 
for simvastatin, in order to explore their opinions on the inclusion of benefit information 
about their own treatments. This facilitated a deeper exploration of the issues that users 
of medicines can face when informed about the benefits of their medicines. The 
research into the provision of, particularly statistical, benefit information to people has 
tended to use hypothetical samples or hypothetical medicines and situations (see 
section 2.7.7.) This study adds to the small number of research studies that have 
examined the provision of benefit information for patients taking the medicine 
concerned.  
The participants recruited to this study were broadly representative of the general 
practice population who take simvastatin. A range of opinions were obtained from a 
sample who all received that medicine, but were varied in age, gender, education and 
number of medicines taken. These different characteristics were recruited in proportions 
similar to the population of the general practice (although there was an under 
representation of younger males). However, this group who volunteered to take part in 
research might hold different views to those who declined to participate.  
Also it is important to note that the views on the benefit information were provided in the 
context of the participant receiving information about a treatment that had previously 
been prescribed, in some cases for many years. This only provides a snapshot of the 
possible opinions on the provision of benefit information. It is also possible that the 
views offered during this study were influenced by the participants’ prior experiences 
with taking simvastatin. People receiving a prescription for a different medicine with 
different benefits might express opinions or preferences on the provision of benefit 
information different from the ones expressed during this study. 
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A limitation of this study is that it did not measure directly the impact of providing benefit 
information, it only explored self-reported behaviours. It is possible that while the 
participants might have reported that they would ‘do what the doctor tells them’ and 
remain adherent to their medicines, it is possible that the provision of benefit 
information might change medicine-taking behaviour in some way.  
More research evaluating the following will be required to further measure the impact of 
providing benefit information to patients on medicines on the following: 
 adherence (both short-term and long-term intentions) 
 participant understanding (with a focus on the differences between patient 
preference and performance of format) 
 decisional-conflict and satisfaction with medicines information 
 health beliefs  
 status quo bias 
 verbatim and gist understanding of benefit information 
 Conclusion 6.9.1
This study builds upon the findings from the focus group study in chapter 3 by 
examining the impact that benefit information has when provided to patients who are 
currently using a medicine, in this case simvastatin. There were many similarities in the 
findings between the two groups of participants. It was apparent that both groups (the 
hypothetical and real-life users of medicines) over-estimated the benefits of medicines. 
This resulted in the provision of, in particular, numerical benefit information creating 
concern and anxiety as it did not appear to match the expectations the participants had 
about the effectiveness of their treatments.   
The participants in both studies overwhelmingly preferred the textual benefit 
information, although it was sometimes apparent that this information did not 
necessarily provide them with enough information to make informed decisions. More 
research could be undertaken to explore ways in which benefit information can be 
provided using words rather than numbers in a way that gives a more accurate 
representation of the proportion of people who might benefit from a treatment. 
The numerical information was difficult for many participants to understand. NNT 
formats in particular are very difficult for participants to understand and can be 
confusing. Although their shorter sentence structure appealed to many participants, it 
was apparent that they were frequently misunderstood. Natural frequencies appeared 
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to be better understood and appear to have potential for communicating the proportions 
that benefit for treatments more accurately. However, this was only when the reader 
could invest the time to read and attempt to comprehend the more complex sentence 
structure the natural frequency used. It is important to note that this numerical 
information is not valued or understood by everybody. 
A concern noted during the focus group studies was the extreme emotion provoked by 
the numerical benefit information. It was concerning that the routine provision of such 
information might promote decision-making based on the affect heuristic, rather than a 
rational consideration of the information. This extreme emotional response was less 
striking during the interviews with the real-life users of medicines. It was apparent that 
the participants were often shocked or disappointed with the benefit information, but 
they appeared to employ a number of coping strategies to help them deal with both the 
threat posed by the benefit information and the uncertainty associated with the 
effectiveness of the treatment. This is an important difference as it suggests that the 
users of medicines will be less likely to reject their treatments due to fear, and engage 
in a more reasoned considerations of the likelihood of benefit and risk of harm of the 
treatments before altering their behaviour. This was not measured by this body of work, 
and an exploration of the impact of benefit information on medicine-taking in the long-
term would be valuable in providing further knowledge about how informing people 
about the effectiveness of their treatment impacts on longer-term health outcomes.  
This is not to say that the information should not be given; the concepts of patient 
empowerment and engagement are based on transparent provision of all relevant 
information. If the outcome of a reasoned assessment of the information is that a 
medicine is not right for an individual, then that decision must be respected. 
The PIL is a mandatory and regulated piece of information that should be provided to 
every patient who is prescribed (or who buys) a licensed medicine. While several 
participants were hostile or ambivalent to the inclusion of this benefit information in their 
leaflets, a number felt that there was a duty to inform patients about the effectiveness of 
treatments. The PIL seems a logical place for the inclusion of information about the 
benefits of medicines – after all that is where the numerical information about side 
effects and their likelihood is to be found. The findings of this study suggest that people 
value the addition of extra textual information about the rationale of treatments. The 
provision of numerical information is more problematic as many people do not 
understand or value this information. However a small group of participants believed 
that if the providers of medicines information know the numerical benefits of medicines, 
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then this should be provided in the leaflet. There was an expectation that extra textual 
information about the rationale of treatment would be enhanced by the provision of 
numerical information about the effectiveness of the medicine. 
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 Discussion and conclusion Chapter 7
The inclusion of a headline section and information about the benefits of 
medicines in patient information leaflets 
 Introduction 7.1
The final chapter will present a discussion of the overall findings of the thesis, including 
an assessment of the strengths and limitations of the research. This includes an 
exploration of the implications of the findings related to the inclusion of both a headline 
section and information about the potential benefits of medicines in current patient 
information leaflets. The barriers and facilitators to making such changes are also 
considered.  
The context of the work in the wider literature will be discussed. There will also be 
recommendations for further research and policy. The chapter concludes with final 
remarks on the potential impact of including a headline section and information about 
the benefits of medicines, considering both patient and professional perspectives. 
 Summary of findings 7.2
The research work addressed the following question and had five aims:  
 Research question 7.2.1
What is the impact of the inclusion of a headline section and information about the 
benefits of medicines in patient information leaflets on patients’ satisfaction and 
potential understanding and medicine-taking behaviour? 
  Research aims 7.2.2
 To investigate methods for the presentation of a headline section in a regulated 
PIL. 
 To investigate methods for the inclusion of information about benefits in a 
regulated PIL. 
 To explore patient preference for a headline section and information about the 
benefits of medicines. 
 To explore how the inclusion of both headline and benefit information in a 
regulated PIL can impact upon patient knowledge and understanding of 
medicines. 
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 To explore the impact of the inclusion of both a headline section and benefit 
information on potential medicine-taking. 
Chapter one set out the background to the research. A history of the legislation of the 
patient information leaflet was provided, alongside a discussion of the role of the leaflet.  
This chapter also described the concepts of:  
o a headline section 
o information about the benefits of medicines 
Chapter two presented the findings from two scoping literature reviews. One focused 
on the headline section which suggested that there was a limited amount of research in 
this field. In contrast, the scoping review on benefit information presented a varied and 
diverse body of empirical research. The findings from this review were equivocal, but 
several potential formats were identified from which to develop statements about the 
benefits of medicines. 
Chapter three reported the findings from a series of focus groups, showing that most 
participants were open to the inclusion of a headline section in a PIL. The inclusion of 
information about benefits was a more divisive issue and participants reported a 
number of concerns about the inclusion of numerical benefit information. These 
concerns were serious and resulted in some emotional responses to the benefit 
information. Preferences for textual information were noted, although some participants 
developed a greater understanding of their medicines after reading and absorbing the 
accompanying numerical benefit information. Despite the expressed concerns about the 
numerical information a general desire for benefit information in medicines information 
remained. 
The thesis then continued with chapter four, a user-testing study which evaluated the 
performance of a headline section. This study found that the headline section was used 
by lay participants approximately one third of the time to locate key information about a 
medicine. It was noted that the headline tended to be the first place in a leaflet the 
reader would look. Participants reported positive opinions on the inclusion of a headline 
section in a PIL. 
A survey undertaken in chapter five showed substantial variability in the inclusion and 
presentation of benefit information in 100 PILs currently in use in the UK. A comparison 
showed that more recently licenced medicines were more likely to contain benefit 
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information than PILs for more established medicines. None of the leaflets included in 
the survey presented any numerical benefit data.  
Chapter six reported the final empirical study in the thesis, which recruited users of a 
medicine (simvastatin) to semi-structured interviews, where the participants were 
shown leaflets which contained both numerical and textual benefit information about 
simvastatin. This study reported that actual users of simvastatin found the information 
to be disappointing, difficult to understand and occasionally upsetting, but that patients 
did not report that they would change their behaviour after reading the information. 
While benefit information is complex and can provoke emotional responses from people 
taking medicines, it was felt that this type of information should be made available. 
 What this work adds 7.3
 Benefit section 7.3.1
This work adds to the understanding of the impact of providing benefit information in 
written medicines information in a number of ways. Firstly it provides the first evaluation 
of the extent to which benefit information is currently included in PILs and the first 
categorisation of the forms of benefit information that are currently in use. There was 
also been an evaluation of the preferences and opinions on the inclusion of benefit 
information as a whole, including an exploration of different formats for presenting 
benefit information. The impact of providing benefit information on patients’ 
understanding about medicines and potential health behaviours has also been 
evaluated. Several key findings are noted:  
 What is benefit information and how prevalent is it in current PILs? 
The survey provides evidence that currently benefit information is variably 
communicated to patients.  There is no clear existing guidance on how benefit 
information might ideally be presented and the findings from the survey contribute to 
our understanding of what type of information might be described as benefit 
information, and how it might be communicated in a PIL.  
The survey raises questions about the most effective methods of communicating 
uncertainty to patients and identifies inadequacies in current methods. The survey also 
highlighted the absence of numerical benefit information in PILs. None of the PILs in the 
sample contained numerical benefit information about the potential benefits of the 
treatment. While this information is challenging to communicate, and in some instances, 
for older medicines, may not be available, it is disappointing that newer medicines on 
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the market are not providing patients with this type of information. Patients will be less 
able to make informed decisions about their treatments if they are unaware of the 
magnitude of benefit of their treatments. 
 The development of benefit information is challenging 
The development of benefit information that can be included in written medicines 
information and be understood by the lay person is not an easy task. There are many 
barriers and complexities to including this information in a PIL including the following: 
o There is no consensus for the best format for numerical or textual benefit 
information in a PIL. 
The thesis explored patient preference for format (discussed below). It is important to 
note that preference is not indicative of performance and a highly preferred method 
might also mislead the patient into misinterpreting the benefits of medicines. The 
scoping literature review identified several potential methods for the presentation of 
benefits. These were used to explore patient preference and opinion, but their 
performance was not measured. It is currently not known which method of benefit 
information performs best at aiding understanding and encouraging patients to make 
informed, empowered decisions about their medicines. Until more is known then this 
will be a challenge to the inclusion of benefit information in a PIL.   
o Identifying a reliable source of data on which to base numerical benefit 
information  
Developing an accurate benefit statement relies upon the availability of accurate data 
on the effectiveness of a treatment. Not all medicines, for example older medicines, will 
necessarily have this type of data available. In recent years, clinical trials have 
improved in both quality and increased in size; therefore it is possible that the quality of 
data from which to derive benefit statements differs for older drugs than newer drugs 
(Sorenson et al., 2011). It might not be possible to calculate accurate benefit 
information for all medicines.  
The clinical database, Clinical Evidence, provides evidence-based summaries about the 
prevention and treatment of clinical conditions, based on thorough searches and 
appraisal of the research literature. It has evaluated 3,000 treatments and concluded 
that 50% were of unknown effectiveness. These treatments are not all medicines, and 
are not necessarily commonly in use. However, it is important to note that there are 
potentially a significant number of medicines which are of unknown effectiveness and 
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this creates significant challenges in communicating this lack of evidence and 
uncertainty of effectiveness to patients (British Medical Journal, 2013).  
Medicines which have been tested extensively in clinical trials will have multiple sources 
of benefit data, presenting a challenge in choosing the most accurate and appropriate 
source of information for the benefit statements.  
It is broadly accepted that systematic reviews of randomised controlled trials are the 
gold standard to evaluate effectiveness of medicines (Greenhalgh, 1997).   The 
hierarchy of evidence is one potential approach that could be applied to identify the best 
available research from which to generate the benefit statements. 
However, using this approach in this study was not a simple process. A decision was 
made to use the hierarchy of evidence from which to identify research on simvastatin 
and the systematic review was considered ‘gold-standard’. However, systematic 
reviews which include simvastatin combined data from multiple RCTs evaluating the 
effectiveness of various statins (Ward et al., 2007). The use of a systematic review or 
meta-analysis as the source of benefit data may not therefore be feasible. This is 
particularly pertinent if the review:  
 combines data from multiple sources  
 includes research that is not specific to benefit of interest  
 or includes benefit data which is diluted by the inclusion of data that is not 
specific to the particular population of interest i.e. the indications for which the 
medicine is licensed.  
Similarly, clinical guidelines on statins also combined data from all statins and were not 
appropriate to use in the context of providing data for one statin (National Institute for 
Health and Clinical Excellence, 2006).  
There is the possibility that benefit statements might be developed from benefit 
information provided in the European Public Assessment Report (EPAR)(European 
Medicines Agency, 2014). An EPAR summary is an information resource produced by 
the European Medicines Agency designed to inform the public about the process by 
which a medicine was granted a licence. This resource contains information about the 
benefits of treatments and could be an important source for benefit data which would be 
seen as impartial. More research into the feasibility of this would be important.  
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It is important to consider how the quality and rigor of the research can influence the 
trustworthiness and accuracy of the data being presented to patients and whether the 
PIL needs to communicate the quality of benefit data too.  
o Where patients have different levels of risk this can be difficult to communicate 
Some meta-analyses and guidelines regarding simvastatin combined data generated 
from the treatment of patients with varying levels of risk. This means that data for high 
risk and low risk patients were combined into one single outcome/benefit figure. This 
leads to a measure of the benefit of the treatment that is less specific to an individual 
patient’s level of risk. It would be inappropriate to provide patients with data that is 
potentially an under- or over-estimate of their actual benefit. It was apparent that there 
was potential for this when presenting data for simvastatin. The benefits of other 
medicines may also vary depending upon the patient’s severity of disease. It can be 
difficult to obtain accurate, reliable data on how a medicine might individually benefit a 
patient depending upon their level of risk, but this is essential in order to present 
information that is as accurate as possible. Potentially this might require the 
development of multiple leaflets tailored to a patient’s individual level of risk. However, it 
has been noted that the use of tailored leaflets, while desirable is also associated with 
concerns about getting the right leaflet to the right patient (Dickinson et al., 2013). 
o It may be challenging to choose the measure of benefit to present  
Most medicines have effects on multiple outcomes. For example Derry et al presented 
multiple outcomes from taking sumatriptan including: 
- Pain free at 2 hours 
- Headache relief at 1 hour 
- Headache relief at 2 hours 
- Use of rescue medication 
- Relief of associated symptoms 
- Relief of functional ability 
It is not feasible to present all outcome measures in a PIL, as this would be complicated 
for patients, who tend to want succinct information and would pose a problem regarding 
the amount of space available. The manufacturers of patient information must carefully 
consider the type of benefit information likely to be most helpful for patients. This can 
only come from patients themselves i.e. what outcomes matter most to them.  
o Medicines with multiple indications 
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Some medicines, for example prednisolone, have multiple indications. It might not be 
feasible to present benefit information for all indications in one patient information 
leaflet. A significant barrier to including benefit information in a PIL is that it can be 
challenging to identify ways in which a patient can be provided with benefit information 
specific to their condition. 
To conclude, it is important to note that it can be difficult to identify accurate and 
relevant information from which benefit statements can be generated. Benefit 
information might not always be specific to all patients, and data should be accurate as 
possible according to each person’s level of risk. For some medicines it is possible that 
benefit data exists that is of sufficient quality or accuracy. Other medicines have 
multiple indications and this will be a barrier to providing benefit information that is 
usable and specific to the patient’s particular condition.  
 Benefit information about medicines can provoke emotional responses 
from the reader 
The focus group study adds to our understanding of how people react when provided 
with benefit information. It is known that certain types of benefit information can have 
more influence. The literature review (chapter 2) identified formats which should be 
avoided, e.g. relative risk, which can negatively influence decision-making by leading to 
over-estimation of benefit.   
A study co-authored by the current writer (Hamrosi et al 2012) presented representative 
samples of medicine-users with information about an anti-platelet medicine.  This was 
presented as an NNT and stated the following: 
If 100 people took this medicine for 2 years: 
o 3 of them would be saved from having a heart attack 
o 1 of them would be saved from having a stroke 
The benefits of this treatment were perceived as low and the benefit information 
stimulated an emotional, and often angry, response from the participants (Hamrosi et 
al., 2012).  
The findings from the focus groups in the current body of work add to our understanding 
of the varying responses that different forms of benefit information (in particular 
numerical benefit information) can provoke. The use of two types of medicine (a statin 
and a triptan) with different levels of benefit has facilitated a comparison of responses 
according to magnitude of benefit and enabled a deeper exploration of how people 
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react to benefit information. A limitation of the Hamrosi study was  that, as it presented 
the benefits of only one medicine, it was difficult to know whether people were hostile to 
the inclusion of benefit information as a whole, or just the benefit information associated 
with that particular medicine (Hamrosi et al., 2012). It is apparent however that hostility 
to numerical benefit information remains even when bigger magnitudes of benefit are 
presented such as here for sumatriptan. Benefit information is frequently perceived as 
surprising and concerning, regardless of its perceived magnitude. 
Subtle differences in the initial responses from those taking and those not taking the 
medicine were observed. Although both groups expressed surprise about the perceived 
poor benefits, there appeared to be less hostility and nihilism expressed during the 
interviews with the actual users of medicines. Although this group were frequently 
disappointed by the level of potential benefits from the medicine, they appeared to 
engage in various coping strategies to help them come to terms with the information. 
For example there was a type of negotiation, where the participant would consider the 
benefits in light of their previous experience with the medicine or their past health, 
which is reflective of the type of behaviour described by the Common Sense model of 
self-regulation of health and illness (Cameron and Leventhal, 2003, Leventhal et al., 
1998).  
Benefit information can provoke a strong response from people. There is evidence that 
people tend to over-estimate the benefits of their treatments by thinking that they will 
work more effectively than they actually do and when shown numerical data about their 
medicines this can provoke an emotional response (known as the affect heuristic) 
(Finucane et al., 2000). This response is noted with medicines with varying degrees of 
benefit; even treatments with relatively greater benefits can stimulate a negative 
response.  There do appear to be differences in how people initially respond to the 
benefit information. Real-life users of medicines appear to engage in a process of self-
appraisal which involves consideration of what the benefits mean in light of their 
personal experience with taking the medicine and an appraisal of their current health 
states. It is possible that this process of self-appraisal reduces the impact of the affect 
heuristic meaning that, despite disappointment, benefit information might not lead to 
poor judgements based on an emotional, rather than reasoned response. To some 
extent this mirrors findings in the wider literature where it has been shown that 
moderately raised anxiety can lead to a more thorough examination of information, but 
high levels can lead to the application of heuristics which are not conducive to informed 
decision-making (Bekker et al., 1999, Loewenstein and Lerner, 2003). While the 
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participants in the interview study were influenced by an emotional response to the 
benefit information, it did not appear to hinder their decisions significantly.  
To conclude, there was evidence that numerical benefit information can provoke an 
emotional response from the reader. This response exists regardless of the magnitude 
of benefit being presented but does not appear to hinder decision-making. Prior 
experience of taking a medicine and having a health condition appears to moderate the 
extent of this emotional response.  
 Patients desire additional information about the rationale of their 
medicines 
The survey indicated that current leaflets contain limited amounts of information on the 
rationale for the medicine. The findings from the qualitative studies indicate that patients 
desire more information about the rationale for their treatment. Additional information 
about what the medicines is for and how likely it is to help them would be welcome in a 
leaflet. A recent survey showed that the provision of information about the risks of 
medicines, specifically adverse drug reactions, which are currently included in PILs 
helped patients feel more knowledgeable about the risks of their medicines (Krska and 
Morecroft, 2013). It is possible that the inclusion of additional information about the 
rationale for taking a medicine will help patients feel more knowledgeable about the 
benefits of their medicines. More research is needed into the best methods of 
presenting such verbal descriptions of benefit information and how this impacts upon 
patients’ knowledge about their medicines.  
 Numerical formats are challenging and not easily understood 
There is a significant body of research showing that large proportions of the population 
have low numeracy skills and find it difficult to interpret statistical information, such as 
the benefit information presented here (The Department for Education and Skills, 2003, 
Gigerenzer et al., 2007). There also is a body of research which shows that healthcare 
professionals can also struggle to understand and can be misled by statistical 
information (Gigerenzer, 2002, Gigerenzer et al., 2007). The issue is not something that 
can be easily resolved. Many people simply cannot understand numerical benefit 
information, although it has been argued that “problems in understanding numerical 
information often do not reside in people's minds, but in the representation of the 
problem”  (Garcia-Retamero et al., 2010, P.1019). 
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There is evidence that different formats can lead to better understanding, and that this 
can include a deeper understanding of what the information means to the individual (Akl 
et al., 2011a, Carling et al., 2009, Tait et al., 2010a, Tait et al., 2010b).  
The findings from this study reflect the consensus that large proportions of people find it 
difficult to understand numerical formats of benefit information. However, the study 
showed that, where people can invest the time and cognitive effort into understanding 
the benefit information, they report developing more knowledge about the benefits of 
their medicines (even if this knowledge is unwelcome) and frequently a deeper 
understanding about their medicines. 
 Which formats of benefit information are most preferred? 
A range of perspectives and preferences on the formats was reported. The textual 
format was frequently the most preferred. However, a small number of participants 
noted that this format did not help them gain perspective about the benefits of their 
medicines when compared to the numerical formats. The numerical formats were often 
perceived as upsetting and difficult to understand. However, the natural frequency 
was more often observed to be helpful and was preferred above the NNT and 
percentage formats.  Participants tended to find the percentage format ‘off-putting’ and 
difficult to understand. It was apparent that there was significant scope for the patients 
not just to fail to get the meaning of NNTs, but to actually misunderstand them.  
 Does the inclusion of benefit information impact upon understanding 
about medicines? 
While the impact of benefit information on patient understanding was not explicitly 
measured it was apparent that its provision did have at least one significant impact on 
patient’s estimations about the benefits of their medicines, although this was frequently 
negative. Most participants appeared to over-estimate the benefits of their medicines 
and after reading the benefit information appeared more aware of the limitations of their 
treatments.  
For patients to make informed choices about their medicines it is essential that they 
understand their limitations.  As well as their considerable potential benefits, medicines 
also have the capacity to harm. Currently patients do not appear to be in possession of 
accurate harm/benefit information. This is concerning. While harm information is 
currently provided in a leaflet (e.g. ‘common – affects less than 1in 100 people), this is 
not the case for benefit information. If a patient experiences any significant side-effect 
then it is important they are aware of the likelihood of benefit before making a decision 
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about the trade-offs of continuing to take the medicine. Without an awareness of the 
benefits, patients might expose themselves to additional harm, for example by tolerating 
side-effects because they are over-estimating the potential benefits of their treatments  
(McCartney, 2012b).  
It was observed that after reading the benefit data, most participants became more 
aware of the limitations of their treatment, but it was difficult to evaluate whether this 
helped increase their knowledge and understanding about their treatments. While a 
small number of participants were able to invest time and effort into understanding the 
information, others found this difficult. This is concerning as it might mean that patients 
only understand the limitations of the treatment and not then go on to make risk-benefit 
analyses and understand the trade-offs they might have to make. More research is 
needed to examine how well patients can interpret and apply the meaning of the benefit 
information to their own situation.  
The natural frequency format was more frequently reported as facilitating understanding 
when compared to the other numerical formats, although there are still significant 
problems in using this format. The natural frequency format was viewed as complicated 
and many people complained that it took time to read and comprehend. However, when 
it was understood it did appear to provide a better insight into the benefits than other 
formats. 
Another challenge with the natural frequency format was that many patients did not 
appreciate the need for the baseline information about those who did not take the 
treatment. It was frequently felt that this information was irrelevant to an individual’s 
situation and that the information was therefore not personal enough. People desire 
individualised information that is relevant to their personal health outcomes (Dickinson 
et al., 2013). This type of information is challenging to communicate and, almost 
always, the individual likelihood of benefit is not known. More effort is required to 
communicate this to patients in order to facilitate a deeper understanding about 
medicines, support informed decision-making and ensure transparency.  
One suggestion made by participants was the possibility of a combined textual and 
numerical statement, although it is possible that a combined numerical statement, for 
example percentages and natural frequencies, might help facilitate understanding.  This 
approach has been recommended by both the MHRA and NICE (Medicines and 
Healthcare Products Regulatory Agency, 2005b, National Institute for Health and Care 
Excellence, 2009), however, requires more research into effectiveness. Research has 
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shown that when participants are provided with combined textual and numerical 
statements about the harms of their medicines this tends to be preferred over single 
presentations of risk. A study into a combined textual and numerical format suggested 
that this combined format did not show any improvement understanding (Knapp et al., 
2013). 
 The impact of benefit information upon behaviour  
A concern about the inclusion of benefit information in a PIL is that it might impact 
negatively upon medicine-taking behaviour by creating an emotional response to the 
information which causes patients to reject their medicines. It is a concern that patients 
may make a decision not to take a medicine based upon information they might not be 
able to critically understand (Hamrosi et al., 2012) and this undermines the aim of 
providing benefit information.  
The findings from the focus groups suggested that patients might change their 
behaviours after reading the benefit information. The potential for this to happen was 
explored in more detail in study 5 (Chapter 6) during individual interviews with people 
who were users of simvastatin. Most patients in this study reported that they would not 
change their medicine-taking behaviour after reading the benefit information and would 
rely upon the advice of their GP. While the focus group participants appeared more 
likely to reject their medicines it is feasible that in reality they would undertake a 
different assessment of their medicine-taking behaviour. However, this was not 
measured, nor was any long-term impact evaluated.  
It is important to note that the majority of patients using simvastatin had taken the 
medicine for many years, often decades. The provision of benefit  information may not 
influence their medicine-taking behaviour because of status quo bias; a preference for 
the current state of affairs (Suri et al., 2013, Samuelson and Zeckhauser, 1988).  
 What is the role of patient information: Education or empowerment? 
This study takes the perspective that the aim of providing benefit information is not to 
educate the patient to be adherent to their medicines but to provide accurate 
information about the relative harms and benefits of a medicine, to facilitate informed 
decision-making.  This is something that sits within the patient empowerment discourse 
on medicines information. It is important to note that a patient empowerment view 
acknowledges that patients might make decisions to not take a medicine. From this 
perspective, the ultimate goal of providing benefit information is not to increase 
adherence but to help people make their own decisions (The Lancet, 2012). 
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The findings of this work suggest that the patient information leaflet is not frequently 
used as a decision-making tool.  The majority of patients preferred to rely on their 
doctor’s advice to assist their decision about taking a medicine.  However, currently 
benefit information is not present in the PIL, so a patient cannot use their leaflet to 
assist in informed decision-making, even if they want to do so.   
It is apparent that not every participant will wish, or have the ability to engage in 
informed decision-making (Flynn et al., 2006, Chewning et al., 2012). The findings from 
this study showed that some participants did not value the PIL and, despite their 
willingness to participate in research about them, did not read their leaflet. This is a 
significant barrier to engaging with patients about the benefits of their medicines. The 
findings from the headline section studies suggest that current leaflets do not meet 
patient expectations for good design and it is possible that responding to this may 
increase readership. In order to educate or empower the reader it is important to at 
least engage with them first. 
An important finding of this research is that patients appear to over-estimate the 
benefits of their treatments. This situation needs to be resolved. Patients need good 
quality information which provides realistic expectations about the benefits of their 
treatments. It has been noted that a regulated and standardised PIL is a good place for 
this information to be included (Goldacre, 2012). 
Currently in the United Kingdom there is a public debate focussing on the wider 
prescribing of statins. The National Institute for Health and Care Excellence has 
recently published draft guidance which recommends a wider use of statins (National 
Clinical Guideline Centre, 2014), reducing the prognostic threshold for initiating 
treatment. Opponents to this change suggest that the benefits for low-risk patients often 
do not outweigh the possible side-effects of the drug (McCartney, 2012a). 
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Figure 19: An example of news headlines regarding the current debate about 
the prescribing of statins in the UK. 
 
The debate has focused upon how an increased use of statins at a population level may 
decrease the deaths from cardiovascular disease, which currently results in about 
140,000 deaths each year in the UK (Department of Health, 2013). This debate is 
currently not focused upon the individual benefits, but instead on the population 
benefits, which include both health outcomes and costs, when compared to the 
potential individual harms that a patient might experience as result of having a side 
effect.  
Opponents of the extended prescribing recommendations for statins express the view 
that the side-effects of statins are not adequately communicated and there is current 
debate about the accuracy of the side-effect data currently available (Godlee, 2014, 
Finegold et al., 2014). There is evidence that current methods used to express the 
likelihood of side-effect happening have several limitations which can lead patients to 
over and under-estimate risk (Berry et al., 2003a, Berry et al., 2003b, Knapp et al., 
2009a, Knapp et al., 2013). However at least this information is made available in a PIL 
and should be provided to every patient with their medicines. Currently this cannot be 
said for benefit information. For a patient to make an informed decision about their 
medicines they need accurate and impartial information about both the risk of harms 
and the likelihood of benefit. 
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This debate about statins is timely and very relevant to the findings of this thesis. While 
there are significant barriers to the inclusion of this information, and it has been shown 
that the inclusion of benefit information might increase concerns about medicines and 
decisional conflict about taking treatments, it’s availability to patients is essential if they 
are to engage in decision-making about their medicines.  More research is needed to 
explore ways in which this information can be delivered with minimal emotional impact.  
A patient should be able to access unbiased information about the likelihood of benefit 
and the risk of harm associated with their treatments. The findings of this thesis suggest 
that patients both desire benefit information and feel there is a duty to be informed 
about the potential harms and benefits of their treatments by their healthcare 
professionals. As the only regulated information for patients about medicines, a PIL is 
the obvious place for such information in order to optimise patient understanding and 
decision-making, although this is limited by the timing of the provision of a PIL, which 
generally is provided after a patient has been prescribed a medicine. 
To conclude, patients do not appear to be making fully informed decisions about their 
medicines because they are not aware of the limitations of their medicines’ benefits.  
The inclusion of numerical benefit information in a PIL might be a good way to 
communicate this information to patients, and while not every patient will use the leaflet 
to make decisions about their medicines, if a patient is to be empowered then this 
information should be made available. 
 The wider impact of the provision of information about the benefits of 
medicines 
The wider impact of informing the public about the likelihood of benefit from medicines 
on medicine-taking is not known. There is the possibility that patients might choose not 
to take a medicine which, in the absence of benefit information, they would have 
otherwise adhered to.  In an RCT of ‘decision analysis’ and an information video for 
newly diagnosed hypertensive patients these interventions were measured as having a 
moderate, negative effect on participant’s intentions regarding starting treatment 
(Montgomery et al., 2003).  
If presenting patients with additional information about their treatments stimulates 
changes in medicine-taking behaviours, this might have an impact upon public health.  
With regards to statins this could potentially result in the rejection of treatments, which 
in turn might impact negatively upon cardiovascular death rates (Taylor et al., 2013).  
  
289 
 
There is potentially a significant public health impact to informing patients about the 
benefits of their medicines. However, there is also an ethical obligation to make sure 
this information is available to patients. If the likelihood of benefit of various treatments 
is known by the medical establishment then there is a duty to inform. Engaging honestly 
about the likelihood of benefit of medicines should be a central part of clinical 
consultation, with written information providing a supportive role.  
As a result, the inclusion of benefit information, particularly numerical benefit 
information, might also influence the way in which health professionals consult and 
counsel their patients about medicines. The face of modern healthcare has changed 
over the last few decades and there has been a move away from a more paternalistic 
approach to consultation with the adoption of models of shared-decision making (Towle 
et al., 2006). However, the findings from this thesis suggest perhaps the goal of shared 
decision-making has not been fully achieved as patients are unaware of the limitations 
of their treatments and are making decisions about taking medicines based on false 
assumptions that the medicines are more effective than they are.  
If information about both the likelihood of benefit and risk of harm is included in written 
information accompanying medicines then healthcare practitioners will be required to 
ensure that they can also communicate it during spoken consultations.  There is 
evidence that patients desire both spoken and written information (Raynor et al., 2007). 
Healthcare practitioners will need to develop techniques for communicating uncertainty, 
which is something that is challenging to do so effectively. There is the possibility that 
the communication of the uncertainty of treatments and health outcomes might be 
something that could alter and potentially undermine the relationship between 
healthcare practitioners and patient.  
There is evidence that despite the complexities associated with harm-benefit 
communication, there can be positive outcomes that result from communicating harm-
benefits to patients. High levels of patient satisfaction have been reported, however it is 
important to note that additional training costs have been identified as important to 
facilitate this approach and the time that can be devoted to increased engagement in 
communicating harm-benefit is limited in a real life setting where consultation length is 
limited. (Davis et al., 2003). 
The language used during consultation might require consideration and standardisation. 
While there are agreed terms used to communicate risk, for example the verbal 
descriptors ‘common’ and ‘rare’, there is currently no agreed similar banding for terms 
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used to communicate benefit. The complexities of communicating this and how patients 
might respond to the language of benefit is not known (Knapp et al., 2013). While 
attempts to standardise the language of harm-benefit communication have been 
investigated, it is difficult to place this within consultation.  
“Such attempts to standardise have some immediate appeal, but most 
commentators believe they fail to recognise the dynamic linguistic reality of 
variable use of terminology and rapid evolution of meanings. Hence we do not 
believe this is an appropriate solution to the undoubted problem of the language 
of risk.” (Thomson et al., 2005, P.466) 
 
 Headline section 7.3.2
In contrast to the topic of benefit information, the subject of a headline section proved 
less controversial. The range of views expressed regarding the inclusion of a headline 
section was narrower than the range of views expressed regarding benefit information.  
There was a greater level of unanimity of opinion regarding the inclusion of this 
adaptation, and the opinions expressed were overwhelmingly positive. The topic was 
not accompanied with the same level of emotional response and none of the 
participants expressed anger or significant concern about the inclusion of a headline in 
a PIL. Overall, the research suggested that the inclusion of headline section was 
simpler and less divisive than the inclusion of benefit information.  
Existing research on the inclusion of a headline section in written medicines information 
is limited. Currently there is very little evidence on which to base decisions about the 
inclusion of this adaptation. This body of research adds to the small amount of literature 
in this field.  
The findings are generally supportive of the inclusion of a headline section in a PIL. The 
focus group study (reported in chapter 3) is the only qualitative research in this field 
which explores patient perspectives on the inclusion on a headline in a PIL. It also 
examines patients’ reporting on the likelihood of using one. This study found that a 
headline section is valued by patients and viewed as a welcome addition. The user-
testing study tested whether patients would use a headline section. The headline was 
observed to be the first place the reader would look in a document. Patients tended to 
use the headline to find short, self-contained pieces of information; it was used 
approximately a third of the time to locate relevant information during the test.  
The headline section was viewed very positively by the large majority of participants. It 
was viewed as an improvement to the leaflet, something which met the readers’ needs 
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for simple information that was easy to access. The headline section addressed 
concerns about the complexity of the technical document a PIL is viewed to be. While a 
few concerns were expressed that the headline might potentially put some people off 
reading the entire leaflet, it was also considered that the headline might encourage 
those who did not read the leaflet to read at least the important facts contained in the 
headline section.  
There is limited evidence that a headline section does not impact upon a patient’s ability 
to find and locate relevant information. Dolk et al (2011) allowed a participant to read 
and familiarise themselves with the leaflet prior to applying the test. The study in the 
current work used a modified user-test method to evaluate whether a headline section 
would be used when a patient was first presented with a PIL, as would happen in real 
life.  
There was no evidence that the use of graphical signposts within a PIL aided the reader 
in any way. The graphical signposts used in this study were rarely noticed by the reader 
and their use should therefore be carefully considered. Currently the findings from this 
thesis suggest that the use of textual signposts is preferable to the use of graphical 
signposts. 
Overall, the inclusion of a headline section in a PIL does not appear to hinder the 
reader and is viewed as a welcome addition. The findings from this body of work are 
supportive of the inclusion of a headline section in a PIL, similar to the type suggested 
by the MHRA. 
 Strengths and limitations of this thesis 7.4
The strengths and limitations of each method have been discussed in the respective 
chapters; this section discusses the strengths and limitations of the research as a 
whole.  
 Strengths and limitations of the methods 7.4.1
The pragmatic approach employed to investigate the research question was useful for 
this body of work which aimed to focus on the outcomes of the research as opposed to 
the underlying philosophies of the methods. Consequently the studies conducted 
prioritised methods that were best placed to answer the research question, rather than 
focussing on one particular method or a specific epistemology.   
This absence of commitment to any one system of philosophy of research means that 
the researcher is not limited to one particular methodological perspective, such as 
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quantitative or qualitative, and that a mix of appropriate methods can be used to 
address the research problem (Creswell, 2013). A strong point of this approach is that it 
can facilitate a broader and more in-depth exploration of the research question. 
The pragmatic approach has received criticism for a lack of focus on epistemological 
underpinnings and critics express concern this might impact on the reliability and 
generalisabilty of research findings, especially when compared to approaches which 
have a stronger theoretical underpinning, for example grounded theory. However, this 
perceived lack of theoretical grounding can be addressed with a focus on rigour and 
credibility (Creswell, 1994, Onwuegbuzie and Leech, 2005). The use of a pragmatic 
approach was well-suited to address the research questions and the use of a mix of 
methods facilitated the use of different approaches to examining the concepts of a 
headline and benefit information.  
A significant limitation of this thesis is that the use of a qualitative approach to explore 
the inclusion of benefit information in a PIL meant there was no measure of the 
performance of the benefit information. (The performance of the headline section was 
evaluated using user-testing, discussed in the section below). Opinions on the inclusion 
of benefit information were explored but there was no objective measurement of 
whether the participants had understood the information. (Originally user-testing of the 
benefit statements was planned but unable to be undertaken due to the lack of 
consensus from the focus groups on the preference for wordings).  It was apparent that 
many participants did not understand the numerical information and it was difficult to 
assess the varying levels of understanding among them. It was possible to observe 
whether a participant could read and recite the benefit statements verbatim but it was 
not possible to examine whether the provision of this information made an impact on 
what the information actually means in the context of the patient’s individual health, or 
their decision-making.  
Because the performance of the different formats was not measured, this study cannot 
conclude whether one particular method of presenting benefit information is more or 
less effective. The participants expressed a preference for one particular method over 
another but preference is not necessarily indicative of performance (Garcia-Retamero 
et al., 2010). Formats such as the NNT were observed to be difficult for the participants 
to understand, but understanding was not measured formally. Previous research in this 
field has shown that relative risk formats of benefit information are valued by 
participants and viewed as intuitive and easy to understand. However, when 
understanding of this format is measured, relative risk has been shown be misleading 
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(Akl et al., 2011a), particularly when provided in the absence of absolute risk 
information. There is the possibility that the views and opinions expressed in this study 
are not indicative of the performance of the difference formats in facilitating 
understanding about the benefits of medicines.  
Another limitation of the qualitative approach taken was that while the aims of the study 
were to explore the potential impact that the provision of benefit information had on 
health behaviours, this was not measured objectively. During the focus groups many 
participants reported that they may be influenced by the numerical benefit information, 
for example some patients reported they might choose not to take a medicine. It is not 
known whether patients would choose to reject a medicine in real-life and so the longer-
term impact on issues such as adherence, satisfaction with treatment, and health 
outcomes in terms of months and years, of providing benefit information is not known.    
Subtle differences were noted between the findings from the focus groups, where the 
participants were less involved in a hypothetical scenario, and the interview study, 
where the participants were given information about the medicines they currently use. 
Those less involved were more likely to express hostility to the numerical benefit 
information and more likely to state they would be ‘put off’ from taking the medicine. 
Patients already using simvastatin appeared less likely to state they would not take the 
treatment. These findings were based on self-report and this study did not measure the 
impact of providing benefit information on initial decision-making about whether to take 
a treatment. As the patients were not followed up it is not known whether the provision 
of this information has influenced long-term decision-making. There is no evidence on 
whether the benefit information has any impact on adherence to medicines, or whether 
it helps a patient make more empowered decisions about whether to take a treatment. 
This is an area that warrants further research. 
To conclude, this research used a pragmatic approach which focuses on the outcomes 
of the research rather than on the underlying epistemology. Alternative paradigms were 
considered but their lack of flexibility towards the use of a mixture of methods was not 
considered conducive to the aim of the research. A mixed methods approach was 
chosen as multiple methods were better suited to answer the research questions 
identified, although the methods used in this body of work are more a ‘mixture’ of 
methods rather than a mix of methods as the findings from each study were not 
triangulated (Burke Johnson et al., 2007, Williamson, 2004). The research methods 
used have several limitations which have been described. However there were also 
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several strengths which include the employment of well-defined, robust processes of 
analysis in order to maintain the credibility of the research.  
This thesis presents a number of studies with slightly different sampling strategies. The 
aim of the qualitative research was to obtain a range of opinions from a sample that 
was representative of the wider population, but diverse enough to generate a mix of 
views and opinions on the interventions of interest.  
The focus group study used a convenience sample, although this sample did include a 
mix of different age, genders and education levels. A criticism of a convenience sample 
is that it can be difficult to extrapolate convincingly from the findings and apply them to 
the wider population.  
The user-testing study used a quota sampling technique to obtain a sample of 
participants with certain age, gender and education characteristics. This was necessary 
to ensure that a mix of participants was recruited. Without such a fixed quota, which 
stipulates a proportion of certain characteristics such as educational ability, the sample 
might not be representative of the population as a whole and this could impact upon the 
generalisability of the findings. Restricting the number of graduates and ensuring that 
the sample is reflective of the educational abilities of the wider population facilitates a 
fairer test of the leaflet and reduces potential over-performance of the leaflet (Raynor, 
2013, Raynor, 2008).  
The interview study also recruited a quota of participants who were representative of a 
‘typical’ group of patients receiving a prescription for a simvastatin registered with a GP 
practice in the UK. The study recruited slightly fewer younger men receiving a statin 
than the general practice population, so the views of this group are under-represented 
in this research. 
All of the participants in this research study were aged over 50. The views of people 
younger than 50 receiving medicines have not been examined and it is possible they 
might hold  different views to the views obtained here, especially with regards to views 
on relationships with doctors, as the under-50 population are more likely to have taken 
part in shared decision-making as opposed to a more paternalistic approach to their 
healthcare (Godolphin, 2009, Charles et al., 1997). It is possible that younger people’s 
views on the level of involvement in decision-making, and the assistance that providing 
benefit information has on this, may differ from the opinions of the older population. 
Equally, the lack of representation of younger participants in the sample might impact 
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upon the generalisability of the findings from the headline section. It is possible that 
younger people might use or respond to the headline section in a different way.  
 Transferability of the findings  7.4.2
There are limitations to the applicability of the findings from this body of work to the 
wider population of medicine users.  We do not know the impact of providing benefit 
information for other types of medicines to patients. It is possible that patients may react 
differently to benefit information depending upon a number of different criteria including: 
 Magnitude of benefit (Dahl et al., 2007) 
 Severity of health condition the treatment is for (Horne et al., 1999) 
 Whether the medicine is preventative, curative or symptomatic (Pound et al., 
2005) 
 The relative availability of alternative medicines or other interventions 
However, this study designed benefit statements for two medicines (simvastatin and 
sumatriptan) for different conditions, in order to obtain a range of responses to explore 
this. 
It is possible that the findings of the focus group study were limited by the recruitment of 
patients who were asked to make decisions about a hypothetical medicine. It has been 
shown that participants who are less ‘involved’ in a scenario may make different 
decisions to those who are; therefore hypothetical decisions may have different 
outcomes to real-life decisions (Kühberger et al., 2002, Bryant et al., 2013). In order to 
make the scenario as realistic as possible the participants were asked to imagine they 
had been prescribed this medicine and had to make a decision about whether to take it. 
The benefit information was not hypothetical and was derived from clinical trial data for 
commonly used medicines. However, it is important to note that the findings of the 
focus group study might not be reflective of decisions made in real-life.  
This is one of the first studies in this field to recruit actual users of medicines and 
provide specific benefit information that had been tailored to the patient’s level of risk. 
This is a strength, as there has previously been little research into the impact of 
providing benefit information to real-life users of medicines; most research in this area 
uses hypothetical scenarios or non-representative samples (chapter 2: Literature 
review). 
One consequent limitation is that the participants had frequently been taking 
simvastatin for a long period; hence their decisions may be more fixed and immovable 
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than those of someone prescribed a new medicine. This phenomenon is called status 
quo bias and describes how frequently people make decisions that disproportionately 
maintain the status quo (Samuelson and Zeckhauser, 1988). The findings of the 
interview study might not be applicable to patients who are prescribed a new medicine 
and having to make a decision about whether to take a treatment or not.  
 Recommendations for further research 7.5
 Headline section 7.5.1
 An evaluation of the most effective format for a headline section. This study 
used a shaded box. However the use of this format was not compared with any 
other format. An alternative format, for example boxes or outlines, may perform 
better. 
 The longer-term impact of the inclusion of a headline section in a PIL on 
patients’ satisfaction with the information and their information-seeking 
behaviours are not known. If such an intervention is to be included in a PIL (as 
is recommended here) then the longer-term impact needs monitoring to 
understand whether it increases the number of people accessing key 
information about their medicines. 
 An evaluation of the impact of the headline section on a patient’s beliefs about 
medicines would also be valuable. If the headline promotes the accessibility of 
key information for patients, does this impact upon decisions about medicines, 
understanding and long-term health behaviours? A quantitative evaluation of 
these measures would enhance our understanding of the impact of including a 
headline section in a PIL.   
 Exploring the use of graphical signposts could help identify whether this 
technique can be improved in order to aid the patient to navigate the leaflet. The 
ones used in this study were not noticed and it was decided that no further 
investigation into their use was to be undertaken, as this was not a primary 
outcome of the study. However, there is the potential to undertake more 
research to explore whether a different format of graphical signpost performs 
better.  
 Benefit information 7.5.2
Implications for further research 
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The issue of including benefit information in a PIL is complex and many unanswered 
questions remain. Overall, it is argued that benefit information should be included in a 
PIL, largely because there is a duty to inform patients about the benefits of their 
medicines. This is an ethical issue. However to ensure the provision of good quality 
information to patients more research into benefit information is required: 
 A quantitative evaluation of the format which best promotes understanding is 
required. Currently this is unclear; there are multiple formats which have 
potential. Patients report preferences for some formats above others, but 
preference is not indicative of performance and it is not known which format best 
promotes understanding about medicines when presented in a PIL. The best 
formats for presenting benefit information would then require user-testing. 
 The impact of providing benefit information on behaviour is also not known. 
More research will be required to examine how the provision of benefit 
information influences decisions to take medicines and adherence to long-term 
treatments. 
 The participants in the studies reported significant emotional impact from the 
benefit information. An evaluation of whether this type of information and 
resulting emotional impact affects decisional-conflict, which is defined as a state 
of uncertainty about which course of action to take, would add to our 
understanding of the impact of benefit information in a PIL.  
 Further research into the development of textual methods of presenting benefit 
information will be valuable. Patients’ desire detailed information about the 
rationale for their medicines. The best method to undertake this, and the impact 
of providing more detailed rationale, will be valuable.  For example: what is the 
impact of providing additional information on whether a treatment is long-term or 
short-term on patient knowledge and understanding, satisfaction with 
information and medicines and medicine taking behaviour? 
 Also, the consideration of using verbal descriptors will be helpful. Currently 
verbal descriptors are used to present harm information, with side effects being 
described as ‘rare’ or ‘common’ alongside numerical information. A similar 
method might be considered for the use of benefit information. More research 
into the feasibility and effects of this would add to our understanding of the topic. 
 There is research into the use of a combined format for side-effect information, 
which showed that while a combined format was preferred it did not appear to 
impact upon estimations of side-effects incidence. A similar exploration of the 
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use of a combined format for benefit information, or for both benefit and harm 
information, would be beneficial to contribute of our understanding of the impact 
of combined textual and numerical formats (Knapp et al., 2013).  
 A linguistic evaluation of the optimum method for communicating uncertainty 
about treatments to patients would help develop understanding about the most 
effective ways to communicate uncertainty. 
 An evaluation of the best approaches to communicate the quality of benefit data 
is essential. Currently little is known about what patients want and what they 
understand about the quality and rigor of the data used to communicate 
information about medicines.  
 This study did not examine patient opinion on visual formats such as graphs and 
charts. This was due to the limitations of including such formats in a PIL. 
However, as we are moving towards web-based provision of medicines 
information the potential impact of including visual benefit information in web-
based medicines information will be valuable. This is especially with regards to 
the consideration of the use of interactive formats of benefit information. 
 Finally, there is a need for an exploration of what healthcare professionals think 
about the inclusion of benefit information in PILs. Currently their views are not 
known. The PIL could be a valuable source that healthcare professionals might 
use to provide education and involve the patient in shared decision-making.  A 
deeper understanding about what healthcare professionals think about the 
inclusion of benefit information in written medicines information and how they 
might use it to facilitate shared decision–making is needed. 
Implications for policy 
 Policy makers should work towards standardising the definition of benefit 
information and provide regulated evidence-based guidance on the type of 
benefit information that should be provided in a PIL. It is important that all mean 
the same thing. 
 Serious consideration should be given to the inclusion of a headline section in a 
PIL. The headline section should be the first thing the reader sees and should 
be placed before any statutory information required.  A well-designed headline 
section will set out the key messages for safe and effective use and help the 
reader assimilate the more detailed information with the body of the document. 
 While it is apparent that the provision of numerical benefit information is a 
complex process, the producers of medicines information need to consider how 
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this type of information can be best incorporated into a PIL. The information 
provided must not be promotional but should aim to support the patient with their 
decision-making about medicines. 
 The producers of medicines information need to be aware that subtle 
differences in the wording of a benefit statement can influence how a patient 
might respond to the information provided. It is important to note that a 
preference for a positive, as opposed to negative framing and the provision of 
information which presents the treatment first, as opposed to last, can influence 
patient satisfaction with information. In order to ensure satisfaction with 
medicines information, the producers of such information should pay attention to 
how this information is developed and build aspects of user-involvement into the 
process. The end product should be subject to appropriate user-testing. 
 The regulators of medicines should provide guidance on the best methods for 
presenting the benefits of treatments ensuring that the needs of patients are at 
the forefront of any recommendations. 
Implications for practice 
 Currently many patients over-estimate the benefits of their treatments. The 
prescribers of medicines need to ensure that the benefits and potential 
limitations of treatments are clearly explained to patients to ensure they have a 
more accurate understanding of the benefits of their treatments. 
 While this thesis focused upon the inclusion of information in a written format, 
healthcare professionals should be aware of the different ways in which benefit 
information can be communicated. Methods of benefit presentation, such as the 
formats presented here, could be helpful to explore the benefits of treatment in 
consultation with the patient and facilitate informed decision-making. 
 Healthcare professionals also need to be aware of the potential for benefit 
information provoking negative responses in some patients. There was no 
evidence that the provision of benefit information would influence patients to 
reject medicines. However it is possible that this information may stimulate 
patients to seek additional information about their treatments, specifically in 
relation to alternative treatments. In this respect, healthcare professionals 
need to be able to respond to patients’ needs and concerns, and cater for 
the varied responses the provision of benefit information may provoke. 
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  Headline section and benefit information combined 7.5.3
 An initial aim of the research was to explore a combination of the headline 
section and benefit information. Due to time limitations a full exploration of 
this is was not possible. Further research which evaluates providing benefit 
information in a headline section is necessary to understand the impact of 
this.  
 Plans for dissemination 7.6
The aims of this body of research were pragmatic and the plan for dissemination has 
reflected that. The development of a deeper understanding of the impact of a headline 
section and information about the benefits of medicines in a PIL were evaluated and 
recommendations are being made to the appropriate regulatory bodies. 
This research has already been disseminated to both the MHRA and EMA, who 
regulate the type of information that is included in a PIL.  A presentation was made in 
July 2013 to the MHRA’s expert advisory group. In March 2014 the findings from the 
PhD were reported at the EMA plenary meeting of the QRD working group. This is 
potentially the highest level of impact for European medicines information. 
The research has also been disseminated through poster and presentation sessions at 
the following: 
 
 Conferences and meetings 7.6.1
 European Medicines Agency. London, 2014  
Information about benefits in patient information leaflets: Patient perspectives. R. 
Dickinson. 
 Medicines and Healthcare Products Regulatory Agency. London, 2013  
Including a headline section and information about benefits in patient information 
leaflets: Patient perspectives. R. Dickinson. 
 
 Health Services Research and Pharmacy Practice Conference. Preston, 
2013 
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Headline, headline read all about it! The impact of a headline section in patient leaflets 
on satisfaction, knowledge and behaviour. R. Dickinson, DK. Raynor, P. Knapp and J. 
MacDonald. Abstract:  http://onlinelibrary.wiley.com/doi/10.1111/ijpp.12028_3/pdf  
 European Patient’s Academy on Therapeutic Intervention: A vision for 
2020. Rome, 2013 
What do patients think about ‘benefit’ information in patient leaflets? R. Dickinson. 
Presentation: http://www.patientsacademy.eu/index.php/en/news/168  
 
 Yorkshire Concordance Conference. Leeds, 2013 
Information about treatment benefits in written medicines information: Patient 
Perspectives. R. Dickinson 
 School of Healthcare Postgraduate Research Conference. Leeds, 2013  
Providing headline and 'benefit' information in patient information leaflets: Does the 
inclusion of a 'Headline’ section & information on benefits in written medicines 
information impact on patients’ satisfaction and understanding? R.Dickinson 
 Medicines and Healthcare Products Regulatory Agency. London, 2011  
Providing tailored and 'benefit' information in patient information leaflets: patient 
perceptions and opinions in the UK and Australia: A focus group study 
 Posters 7.6.2
 Royal Pharmaceutical Society. Birmingham, 2013  
Do patients use a headline section in a patient information leaflet to find key information 
about their medicines? Findings from a user-testing study. R. Dickinson, DK. Raynor, 
P. Knapp and J MacDonald. 
 Academic journals 7.6.3
Further dissemination will include articles to academic journals.  
 Conclusions 7.7
This thesis examined the impact of the inclusion of a headline section and information 
about the benefits of medicines in patient information leaflets on patients’ satisfaction 
and potentially also on their understanding and their medicine-taking behaviour. An 
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important finding was that the two adaptations provoked very different responses from 
medicine-users. 
The inclusion of a headline section was viewed positively by the large majority of 
participants in these studies. It was an adaptation that the participants noticed and 
engaged with. It was viewed as a potential solution to the prospect of reading an 
existing leaflet; which is frequently viewed as a daunting prospect and a boring, 
technical document of limited personal relevance. The addition of the headline section 
responded to a reported desire for good information design and it contained information 
that was regarded as important by current medicines users.  
When tested in a user-test scenario it was noted that information was found in the 
headline section approximately a third of the time and that its inclusion did not appear to 
hinder the reader. A potential concern about this adaptation is that it might deter people 
from reading the entire leaflet, encouraging the reader to only engage with the 
information in that section. However, it was reported that it had the potential to engage 
those who did not normally read their leaflets to at least read that one section. The use 
of a headline section was viewed as a valuable adaptation in a patient information 
leaflet. 
In contrast to this, the inclusion of benefit information in a PIL was far more divisive and 
provoked strong and complex responses from the users of medicines. The inclusion of 
benefit information has the potential to better inform patients about the benefits of their 
treatments. It also has the potential to be viewed negatively and not as information 
which communicates benefits of treatments, but instead is information which is negative 
and which only highlights the limitations of a treatment. There was evidence of an over-
estimation of the benefits of current preventative treatments and the provision of benefit 
information in a PIL. While frequently disappointing for medicines users this is 
something that may reduce this misunderstanding about medicines. 
There was very limited evidence that the provision of benefit information would impact 
negatively upon medicine-taking behaviour. Despite initial reports that the benefit 
information was upsetting and might put people off, when patients actually taking the 
medicine were asked about their intentions, it did not appear that the benefit information 
had a negative influence on medicine taking. Relationships with GPs and previous 
experience of taking the treatments appeared to exert stronger influences on decisions. 
Other influences on the response to the benefit information appear to be mediated by 
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patients’ perceived severity of their condition, an individual’s perception of themselves 
as an optimist or a lucky person, and their ability to cope with uncertainty. 
There are significant barriers to the inclusion of benefit information in a PIL. Firstly, not 
all patients read these leaflets and they are frequently viewed as documents designed 
to protect pharmaceutical companies rather than serve the needs of patients. There is a 
desire for better design of leaflets to make them more visually appealing, and a 
headline section might contribute to this.  
Designing benefit information is a challenge. It might not be possible to provide 
accurate, reliable information for all medicines and all indications. Although this should 
not mean that the producers of medicines information could not rise to the challenge. 
There is significant interest in the communication of risk and benefit information to 
patients and over recent years the field of risk communication has seen the 
development of many innovations which can facilitate understanding. The survey of 
PILs highlighted a need for clearer terminology when communicating the benefits of 
treatment, as well as less variability in the type of information that might be 
communicated. While numerical data might be challenging to report, a more consistent 
approach to presenting textual benefit data is essential. 
Even after consideration of the best formats for the presentation of benefit information it 
is apparent that people struggle to understand complex numerical presentations of 
benefits. Formats such as the NNT were frequently misunderstood. Significant effort 
was required by participants to understand the natural frequency format, although this 
format appeared to provide better insight into the benefits of the medicines when 
participants invested effort into reading it. While more research is required into 
measuring which formats can best promote understanding of the proportion of patients 
that will benefit, it is valuable to have a deeper insight into the emotional responses that 
can be provoked by the provision of this information. 
The emotional impact of the provision of benefit information in a PIL was notable. 
Benefit information has the potential to be upsetting and provoke anxiety, anger and 
fear. If it is to be included in a PIL, this needs to be framed in a way which minimises 
any negative emotional impact and reduces potential decisional conflict.  
Finally, despite the significant barriers and concerns regarding the inclusion of benefit 
information and the unwillingness of groups of patients to engage with it, it is important 
to note that the inclusion of benefit information fulfils a duty to inform patients about 
both the potential benefits of their treatments and the potential limitations. Without this 
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information a patient cannot make an informed decision about whether to take a 
treatment. The inclusion of benefit information also has the potential to facilitate a 
relationship with the providers of medicines information that is based on respect: 
“I think that seems like a good reason to come clean. To put it in the patient 
information leaflet, because you know, that's what it is: An information leaflet, it is 
not advertising. I think that the patient deserves to be treated with enough respect 
to have this information, and to be able to understand this information. I didn't 
know either how few people would benefit from this medicine.” (M, 60, FG4, 
JANA) 
The patient information leaflet is a regulated document; it is made available with most, if 
not all medicines. Despite concerns that the leaflet is not the right place, nor provided at 
the right time, as some patients prefer verbal information and/ or might not read the 
leaflet, it is a place where a standardised format can be provided.  
The provision of benefit information in a patient information leaflet has the potential to 
support patients to understand more about the benefits and the limitations of their 
medicines. 
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Appendix 1: Combination of search terms employed in the search strategy for the literature review 
Key Concept Keywords MESH Terms 
Risk Benefits Risk*, benefit*, harm*, risk-benefit*, framing (Fram*), risk communication, 
?decision making, numeracy,  risk perception, risk factor*, risk analys*, 
pharmaceutical decision making, risk benefit analys*, patient risk*, risk 
perception*, risk analys*, risk taking, framing effect* 
Risk, uncertainty, risk assessment, risk 
factors  
Headline Information Key information, text design, priority information, instructional design, 
instructional text, informational text design, outline*, summary box*, 
summary information,  information box*, drugs facts box*, format, category 
header*, patient safety, label design, ‘warning’ label*, safety design, safety 
sign*, hazard communication, warning label*, boxed aside*, graphical 
device*,  persuasive communication, printed communication media, visual 
perception, visual attention, visual display, eye scanning headline sections, 
key information, key points design and layout, macro theme1 
 
Medicines 
Information 
Patient information leaflet*, pamphlet*, written medicines information, 
consumer medicines information, package insert*, Information literacy, drug 
labelling, drug packaging, product labelling, print* material*, booklet, 
brochure, information resource*, teaching material*, consumer health 
information, patient education, medicines information, drug information, 
patient information sheet*, written communication, medication instructions, 
Patient education, consumer health 
information, pamphlets,  
1 Suggestions from librarian (Deirdre Andre, Research Support Officer, 
LUCID Health, Health Sciences). 
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Appendix 2: Example of search strategy for both headline section and benefit 
information as initially employed in Medline 
 
Searches Results Search Type Actions 
 
1 risk.mp. or exp Risk/ 1200924  
 
2 benefit*.mp. 336189  
 
3 harm.mp. 16629  
 
4 harmed.mp. 825  
 
5 fram*.mp. 185190  
 
6 
(risk* adj2 communicat*).mp. [mp=protocol 
supplementary concept, rare disease supplementary 
concept, title, original title, abstract, name of 
substance word, subject heading word, unique 
identifier] 
1448  
 
7 exp Decision Making/ 97922  
 
8 
(numeracy or numerate).mp. [mp=protocol 
supplementary concept, rare disease supplementary 
concept, title, original title, abstract, name of 
substance word, subject heading word, unique 
identifier] 
309  
 
 
 
 
 
9 
(risk* adj2 perception*).mp. [mp=protocol 
supplementary concept, rare disease supplementary 
concept, title, original title, abstract, name of 
substance word, subject heading word, unique 
identifier] 
2757  
 
10 
(risk* adj2 analys*).mp. [mp=protocol supplementary 
concept, rare disease supplementary concept, title, 
original title, abstract, name of substance word, 
subject heading word, unique identifier] 
8853  
 
11 pharmaceutical decision making.mp. 1  
 
12 
(patient* adj2 risk*).mp. [mp=protocol supplementary 
concept, rare disease supplementary concept, title, 
original title, abstract, name of substance word, 
subject heading word, unique identifier] 
52286  
 
13 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 1712526  
 
14 patient information leaflet.mp. 85  
 
15 exp Patient Education as Topic/ 61711  
 
16 exp drug labelling/ or exp drug packaging/ 8409  
 
17 exp product packaging/ or exp product labelling/ 13885  
 
18 information literacy.mp. or exp Information Literacy/ 151  
 
19 exp Health Education/ 120739  
 
20 exp Pamphlets/ or booklet*.mp. 4196  
 
21 brochure*.mp. 1172  
 
22 information resource.mp. 434  
 
23 exp Consumer Health Information/ 1293  
 
24 medicine* information.mp. 171  
 
25 drug information.mp. 4757  
 
26 
(patient information adj sheet*).mp. [mp=protocol 
supplementary concept, rare disease supplementary 
66  
  
324 
 
concept, title, original title, abstract, name of 
substance word, subject heading word, unique 
identifier] 
 
27 written communication*.mp. 255  
 
28 medication instruction*.mp. 92  
 
29 medicine* instructions.mp. 4  
 
30 
14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 
or 24 or 25 or 26 or 27 or 28 or 29 
141115  
 
31 key information.mp. 561  
 
32 
(design adj2 text).mp. [mp=protocol supplementary 
concept, rare disease supplementary concept, title, 
original title, abstract, name of substance word, 
subject heading word, unique identifier] 
28  
 
33 priority information.mp. 30  
 
34 instructional design.mp. 180  
 
35 instructional text.mp. 18  
 
36 summary box.mp. 1  
 
37 information box.mp. 3  
 
38 
(drug adj box*).mp. [mp=protocol supplementary 
concept, rare disease supplementary concept, title, 
original title, abstract, name of substance word, 
subject heading word, unique identifier] 
20  
 
39 category header*.mp. 1  
 
41 
(label adj2 design).mp. [mp=protocol supplementary 
concept, rare disease supplementary concept, title, 
original title, abstract, name of substance word, 
subject heading word, unique identifier] 
640  
 
42 warning label.mp. 69  
 
43 safety design.mp. 53  
 
44 safety sign*.mp. 270  
 
45 hazard communication.mp. 101  
 
46 graphical device*.mp. 12  
 
47 exp Persuasive Communication/ 2502  
 
48 printed communication media.mp. 0  
 
49 visual perception.mp. or exp Visual Perception/ 172444  
 
50 visual attention.mp. 2450  
 
51 key point*.mp. 2817  
 
52 
(design adj3 layout).mp. [mp=protocol supplementary 
concept, rare disease supplementary concept, title, 
original title, abstract, name of substance word, 
subject heading word, unique identifier] 
94  
 
53 macro theme.mp. 0  
 
54 
31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 
or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or 
50 or 51 or 52 or 53 
180472  
 
55 30 and 54 753  
 
56 13 and 30 30900  
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Appendix 3: Revised search strategy for the benefit information scoping 
search (PyscInfo/ Embase/ Web of Science) 
RISK (HARM) BENEFIT  
((risk* or harm* or benefi*) adj3 (communicat* or understand* or explain* or explan* or 
educat* or inform* or present* or percept* or analys*)).mp. [mp=protocol supplementary 
concept, rare disease supplementary concept, title, original title, abstract, name of substance 
word, subject heading word, unique identifier]  
 
PATIENT INFORMATION 
(patient* adj (educat* or informat* or communicat*)).mp. [mp=protocol supplementary 
concept, rare disease supplementary concept, title, original title, abstract, name of substance 
word, subject heading word, unique identifier] 
 
(health adj (informat* or communicat* or educat*)).mp. [mp=protocol supplementary concept, 
rare disease supplementary concept, title, original title, abstract, name of substance word, 
subject heading word, unique identifier]  
 
(drug or medicine* or medicat*) adj1 (literature or leaflet* or instruct* or label*) 
 
Decision AID search(patient* adj (educat* or informat* or communicat*)).mp. [mp=protocol 
supplementary concept, rare disease supplementary concept, title, original title, abstract, 
name of substance word, subject heading word, unique identifier] 
OR 
(health adj (informat* or communicat* or educat*)).mp. [mp=protocol supplementary concept, 
rare disease supplementary concept, title, original title, abstract, name of substance word, 
subject heading word, unique identifier]  
 
AND 
((risk* or harm* or benefi*) adj4 (communicat* or understand* or explain* or explan* or 
educat* or inform* or present* or percept* or analys*)).mp. [mp=protocol supplementary 
concept, rare disease supplementary concept, title, original title, abstract, name of substance 
word, subject heading word, unique identifier]  
AND 
Decision Aid (as keyword.) 
Other keywords 
Numeracy 
Framing  
Search Strategy: Web of Science 
Topic= ((risk* or harm* or benefit*) SAME (communicat* or understand* or explain* or 
educat* or inform* or present*)) AND Topic= ((patient*) SAME (Educat* or informat* or 
communicat*
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Appendix 4: Example of data extraction form used during the scoping literature reviews to record the characteristics of the 
included studies. An example is provided for both the headline section and the benefit reviews 
 
ARTICLE WHO WHAT WHERE HOW SUMMARY of 
AUTHOR 
CONCLUSION 
RELEVANCE 
Population Intervention Setting Design Outcomes Findings Conclusion 
 
BERSELLINI 
et al 
2006 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Study 1: n=454.  
Age: 22 (16-65). 
Females: n=293. 
High levels of 
education.  
Study 2: n=292. 
Age: 18-75. 
Female: n=150. 
Education: 
15.4% no formal 
qualifications, 
19.9% GCSEs, 
26% A-levels, 
38.7% degree. 
Study 3: n=248.  
Age: 18-80. 
Female: n=142. 
Education: 
21.8% GCSE, 
23.3% A-level, 
38% degree. 
Textual 
 
Study 1:  
Simple benefit 
(effectiveness) 
statement in 
explanation 
about a 
medicine.   
 
Study 2:  
simple 
statement about 
medicine's 
effectiveness 
and short 
rationale about 
how medicine 
worked. 
Participants 
received either 
UK.  
Study 1: 
Participants 
recruited from a 
University campus 
and questionnaire 
undertaken on the 
spot.  
 
Study 2: 
Participants 
recruited from 
general 
population in a 
town centre.  
Undertook 
questionnaire on 
the spot.  
 
Study 3: 
Participants 
Study 1:   
A two-factor 
(with/without 
benefit 
information X 
severe/mild 
disease) cross-
sectional 
between 
participants 
design.  
 
Study 2: A 
two-factor 
(with/without 
effectiveness 
statement X 
with/without 
rationale 
statement) 
cross-sectional 
[1] Satisfaction with 
information. 
  
[2] Perception of 
effectiveness of 
medicine 
 
[3] Perception of 
benefit to health.  
 
[4] Perception of risk 
to health.  
 
[5]Intention to take 
medicine.  
 
[6] Perception of 
overall effect on 
health of taking 
medicine.  
 
Study 1: information 
about benefits 
enhanced the 
judgements but did not 
influence the intention 
to comply.   
 
Study 2: both the 
forms of benefit 
information were 
effective in improving 
judgements but had no 
effect on intention to 
comply.  
 
Study 3: found both 
types of benefit 
information (plus side 
effect information) 
improved the intention 
to comply, as well as 
All three studies show 
positive effects of the 
inclusion of simple 
benefit information in an 
explanation about a 
prescribed medicine.  
 
Higher ratings of 
intention to take the 
medicine in the group 
where participants are 
presented with side 
effects information too.   
 
It is likely the provision 
of this information 
increased perceptions 
of the perceived barriers 
to taking the drug, 
which increased the 
need for information 
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effectiveness 
statement, 
rationale 
statement or a 
combination or 
neither 
intervention.  
 
Study 3:  
two types of 
benefit 
information 
when presented 
with side effect 
information. 
recruited from 
town centre. 
Undertook 
questionnaire on 
the spot. 
between 
participants 
design.  
 
Study 3: A 
two-factor 
(with/without 
rationale 
statement) 
cross-sectional 
between 
participants 
design 
 
Randomised 
groups 
[7] Beliefs about side 
effects. 
ratings on the other 
measures. 
about the drugs 
benefits. 
 
 Inclusion of benefit 
information positively 
influenced people's 
judgements, including 
their intention to take 
the medicine. 
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ARTICLE WHO WHAT WHY WHERE HOW SUMMARY of AUTHOR 
CONCLUSION 
RELEVANCE 
Population Intervention Setting Design Outcomes Findings Conclusion 
 
 
Dolk et al 
2011 
 
 
 
N=80 potential users of 
medicines.  
 
Those with background 
in medicines 
information excluded. 
 Age 18-34 (49 
mean) 
 37 females 
For each round match 
in terms of gender, 
education & age 
Headline 
section in PIL for 
carbamazepine.  
The headline 
section consisted 
of light grey 
shaded box 
containing key 
safety messages 
about the 
medicine 
UK & 
Netherlands. 
Participants 
recruited from 
the general 
population 
Interviews 
untaken in 
interview rooms 
with little 
external stimuli 
to avoid 
distractions. 
User test 
methods  
2x2 factor 
design 
(English & 
Dutch, with 
headline & 
without 
headline)  
 
Varying 
language was 
a moderating 
rather than 
independent 
variable. 
Findability of 
information,  
comprehensibilit
y of information  
perception of 
the design 
Findability: headline did not have a 
negative effect on findability and 
comprehensibility of information.  
 
Comprehension: information was 
found and comprehended in both 
sections - headline section did not have 
a positive effect on findability and 
comprehension of information.  
 
Perception of design: scores for PIL 
with headline did not differ statistically 
from those without. Headline section 
was perceived to be as difficult, well-
designed or useful as without. Semi-
structured interviews showed that 
participants were enthusiastic about 
headline section, but UT suggested they  
didn’t seem to use it. 
 
A user-test did not 
reveal differences 
in how well 
participants could 
find and 
understand the 
information in the 
leaflets.   
 
When asked for 
general 
impressions of 
headline section 
most participants 
evaluated it 
positively. 
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Appendix 5: Topic guide for the focus group studies (chapter 3/ study 2) 
General leaflet questions (5-10  mins) 
 
K, B1 – Have you ever seen an information leaflet like this inside your packet of medicine? What 
have you done with this information? 
(Prompts: Do you read it? When? Do you refer to it? How often? Do you keep the leaflets? How 
do you use the information?) 
A –In general, what do you think of this leaflet?  
Prompts:   
 Easy/ hard to read? How do you find reading the leaflet? 
 Easy/hard to find the information you need? 
 Length?  
 Design/ layout?) 
(Refer to colleague to check for any information that could be expanded upon) 
 
HEADLINE section Questions (30 mins) 
 
We would like to show you an amended leaflet. (10 minutes - tea if required) 
 
I refer you to the grey shaded box on leaflet 2. This is titled ‘important things to know about 
your medicine’. 
 
A, K – Did you notice this section on the leaflet? What do you think of it by comparison with 
this leaflet that doesn’t have a headline section? 
A, K – What do you think of this style of presentation? (Prompt: Ask about colour, text size, 
font, shading) 
A, B – If you could receive a leaflet which included a headline or summary section, what 
information would be most important to include? 
 (Prompt: specific age group, condition, safety message) 
B – If you received a leaflet containing this information, rather than an existing one, do you 
think you would do anything differently? 
(Prompt: Read more or less of the leaflet? Change or stop your medication? Take it differently? 
Seek advice from Doctor or other HCP?) 
A-On balance would you prefer a leaflet with or without this information? 
(Refer to colleague to check for any information that could be expanded upon) 
 
 BENEFIT Information Questions (40 mins) 
 
I now refer you to leaflet 3. This leaflet contains information about the possible benefits from 
taking the medicine. these are the multi-coloured flaps that are on the leaflet. There are 4 
different formats, they are coloured purple, blue orange and green 
K, A - What did you think of this information?  
K, A- Which of these different formats do you prefer? Why?  
B- Imagine you were first prescribed this medicine, what difference would this information 
make to what you did and thought about the medicine?  
                                              
1 K= Knowledge, A= Attitudes, B=Beliefs 
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(Prompt: do you think you would do anything differently? Change your medication? Take it 
differently? Stop your medication? Seek advice for Doctor or other HCP? Ask your family for 
advice? Look at the internet) 
A – What changes if any would you recommend to this section?  
 (Prompt: explore issues with any concerns and anxieties, feeling reassured and informed) 
 
K, A, B – if you have the choice of having one of these formats which one would you have and 
why? 
 
(Refer to power point.) 
 
There are two sentences in the orange and blue sections. One is a positive frame, telling you 
how likely it is the medicine will make you feel better/ prevent a heart attack. The other is 
negative frame, telling you how likely it is the medicine will not make you feel better/ not 
prevent a heart attack. 
 
K, A, B- Do you have any preference for either of these sentences? Or do you prefer the 
combined format that is on the leaflet? 
 
SIDE EFFECT information Questions (10-15 mins) 
 
(Refer to leaflet and highlight the side effect information.)  
 
Finally, I’d like to talk to you briefly about the side effects section. Currently the side effects of 
this medicine are described using both verbal descriptors and frequencies. These are the terms 
‘common, uncommon and very rare’ and the numbers may affect up to 1 in 10, 1 in 100 
 
A – What do you think about the way the side effect information is presented in this leaflet? 
A -Would you like to see side effect information presented in a different way? 
(Prompt: using percentages, graphical formats, consider the presentation of side effect 
information separately) 
 
A -What do you think about the balance of information (about the benefits and harms) in the 
leaflet? 
Closing Questions 
 Any other comments about the leaflets you get with medicines? 
 Any other suggestions about ways in which medicine leaflets can be improved? 
Thank you for all your help 
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Appendix 6: Participant information sheet for the focus groups (chapter 3/ 
study  2) 
Participant Information Sheet 
 
Title of Study: Improving the Content and Format of Medicines Leaflets (CoFoMeL) 
 
We would like to invite you to take part in the above named study but before you 
decide, please read the following information.   
You can choose not to take part without having to give a reason and without 
penalty. 
 
What is the purpose of this study? 
 
When a new medicine is prescribed all patients receive an information leaflet in the 
medicine box.  We would like to find out more about what people think about the 
information provided with medicines.  We would like to ask your opinions about different 
ways of presenting information that could be provided with the leaflet in boxes of 
medicine. 
 
Some of the issues we would like to find out about include: 
 Including positive information in medicine leaflets, this includes information on 
how the medicine works, what it does and what are its benefits? 
 Using a summary box at the top of the medicines leaflet which contains 
important information of the medicine. 
 
By doing so we hope to understand more about how we can improve the information 
provided with medication and help patients understand more about their medicines. 
 
Who is doing the study?  
 
The study is being done by researchers from the University of Leeds, Medicines 
Management Group. The study is being conducted as part of PhD, undertaken by Mrs. 
Rebecca Dickinson. The supervisor is Professor Theo Raynor. 
 
Who is being asked to participate?  
 
You have been invited to participate because you are over 50 years of age and are 
taking one or more long-term medicine (this can be a tablet, liquid or inhaler).  If you 
would like to take part you must be able to speak and read English. 
 
What will be involved if I take part in this study? 
 
 If you are interested you will be invited to take part in a discussion with some 
other people taking long-term medicines.  You will be given some medicine 
leaflets to look at and asked for your opinions.  
 A researcher will ask a few questions and you will be free to talk with other 
group members about the subject.   
 The discussion will take no more than 2 hours in total and refreshments will be 
provided. 
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What are the advantages and disadvantages of taking part? 
 
There are few disadvantages of taking part in this study, although you may find the task 
tiring. You will be free to leave at any time. The group discussion will take two hours of 
your time. You may not get any personal medical benefits from agreeing to take part. 
However, the study may highlight better ways of proving information with long-term 
medicines. This could help patients in the future.  If you do participate you will be given 
a £20 gift voucher at the end of the meeting to acknowledge the time you have given.   
 
Can I withdraw from the study at any time?  
 
You do not have to take part in the study, no-one will mind if you say no.  You can say 
yes and then change your mind. You are free to withdraw from the study at any time 
and do not have to give a reason why.  Once the focus groups have been undertaken 
then it will not be possible to exclude any information you have given from the research. 
However, any information will be made anonymous so you will not be identified in any 
way. 
 
Will the information I give be kept confidential? 
 
To keep an accurate record of what is discussed the meeting will be audio recorded. 
The recordings will be typed up and made anonymous. Then the recordings will then be 
destroyed. All information you offer during the research will be kept private and 
confidential. It will be stored for 4 years in a locked filing cabinet in a secure office. It will 
not be possible to identify you in any way from the publications, reports and guidelines 
that are produced. 
 
What will happen to the results of the study? 
 
The results from the study will form part of a PhD thesis. They will be written as a 
document and sent for publication in a medical journal. We will also present the results 
of the study to the Medicines and Healthcare products Regulatory Agency to help them 
improve the regulations about patient information leaflets. 
 
Who has reviewed this study? 
 
The University of Leeds School of Healthcare Research Ethics Committee has 
reviewed this study. 
If you agree to take part, would like more information or have any questions or 
concerns about the study please contact: 
 
Mrs Rebecca Dickinson, 
Research Nurse, School of Healthcare, University of Leeds, LS2 9LN 
Tel: 0113 3431190 
E-mail: r.dickinson@leeds.ac.uk 
Thank you for taking the time to read this information sheet. 
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Appendix 7: Examples of the patient information leaflets shown to 
participants during the focus groups (chapter 3/ study 2) 
 
 Example of typical leaflet 
 
 
 
 
 
  
334 
 
 Example of headline leaflet 
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 Example of benefit leaflet 
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Appendix 8: Chart illustrating the development of the framework. This shows the process by which the initial transcript was 
indexed from the raw data into the index which was applied to analyse the rest of the focus groups. 
Quote Initial code Preliminary thoughts Initial themes Categories 
GENERAL LEAFLET 
So you get a lot of blurb, which doesn’t tell you the 
basic thing and it’s the one thing the pharmacists 
are constantly asked. ‘How do I take them? When 
do I take them?’ So there’s just far too much 
information. LL  
Too much information Balance of information Role of leaflet Concerns about the 
leaflet 
Well, I re-read mine because of this and I thought 
‘why am I taking this?’ because it was so negative 
and it never once said what the benefits were. It 
was dreadful.JM 
Negative message with 
leaflets 
Desire for benefit 
information 
Role of leaflet Concerns about the 
leaflet 
My mum was private person and if that had 
happened to her she would’ve never gone back to 
the doctors again, but they said to me ‘persevere’, I 
did. I think that kind of thing needs to be put in a 
leaflet, that you may feel like this for a couple of 
weeks because your body needs to adjust to taking 
it, and then if that doesn’t happen then go back to 
your GP. But it didn’t.JM 
Type of person 
What needs to be in a 
leaflet 
Role of leaflet Patient Characteristics Patient as an 
individual 
When you get the leaflets, you open them up and 
your heart literally sinks and you think ‘Oh!’ All that 
verbiage and all that...small print. That’s one thing, 
very small print... I mean you’ve highlighted some 
things, and highlighting in colour shows some 
things. It’s much better the contrast. RG 
Your heart sinks 
Small print and 
highlighting 
Negative message with 
leaflets 
Design features of 
leaflets (format) 
Role of leaflet Concerns about the 
leaflet 
And so the first thing I am going to look for is allergy Priorities for Role of leaflet (safety Role of leaflet Providing 
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advice. And the second thing is side effects because 
often those two are very closely linked, having said 
that I would sincerely hope that when I go to be GP I 
do not get prescribed something that is contra-
indicated with my allergies.JP 
information net) 
Information needs 
information and 
protecting 
But the GP would then turn around and say that you 
haven’t told us that you’ve had any reaction to this. 
You can give them back to the chemist, but then the 
chemist may not tell the GP that, so the GP’s 
attitude is that you should’ve told me...LL 
Chemist may not tell GP 
GP attitude 
GP/HCP relationships Role of healthcare 
professionals 
Providing 
information and 
support 
When I got the tablets from the pharmacist, the 
instructions I got from the pharmacist was don't 
take any antacids of the two hours after taking this 
tablet and on the leaflet it said just an hour each 
side. So they sort of contradicted each other... I just 
assume that is easy, quick and this refers to leaflets. 
I just assume they are in there for the litigation 
purposes. VW 
Leaflet helped 
Leaflet for litigation 
purposes 
Role of leaflet 
(litigation) 
The role of the leaflet Providing 
information and 
protecting 
Concerns about 
leaflet 
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Appendix 9: Thematic framework 
The thematic framework was developed using the process above and was 
used to code the focus groups transcripts during the indexing stage 
of the analysis. 
1. The role of the leaflet in providing Information (GENERAL) 
1) Providing Information and protecting 
2) Supporting HCP advice 
3) Helping patient to make decisions 
4) Patient engagement with the leaflet 
5) Design of the leaflet (GENERAL) 
6) Concerns about the leaflet 
2. Using the HEADLINE section (HEADLINE) 
1) Noticing the HEADLINE 
2) Impact upon patient knowledge about medicines 
3) Impact upon patient satisfaction about information and medicines 
4) Impact upon behaviour 
5) Concerns about HEADLINE section 
3. Patient preference for the design of the leaflet (HEADLINE) 
1) Content of the HEADLINE 
2) Format of the HEADLINE 
4. Talking about the different formats of information (BENEFIT) 
1) Talking about TEXTUAL information 
2) Talking about PERCENTAGES 
3) Talking about NATURAL FREQUENCIES 
4) Talking about NNTs 
5) Talking about FRAMING 
6) Talking about alternative formats 
5. Impact of BENEFIT information (BENEFIT) 
1) on knowledge and understanding of medicines 
2) on satisfaction with information 
3) on information seeking behaviour 
4) on health behaviours 
5) on making decisions 
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6) on medicine-taking  
7) Anxieties and concerns about benefit information 
8) other 
6. Numeracy and numbers 
1) Attitudes to numerical information  
2) Context of numerical information 
3) Accuracy of information 
4) Trustworthiness of information 
7. Talking about side effect information 
1) Concerns about side effect information 
2) Talking about balance of information 
3) Impact of side effect information on knowledge and understanding 
4) Satisfaction with side effect information  
8. Patient characteristics 
1) The patient as an individual 
2) Experience of numbers 
3) Ability to use information  
4) Preferences for decision making 
5) Personal health and condition 
6) Family and friends (normative values)  
9. Relationships with HCPs 
1) Providing information and support  
2) Trust 
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Appendix 10: Example of headline chart. Data were charted with each participant represented as a row and the data 
from each index represented by a column. This facilitated cross-case comparison of any emerging themes. 
 
Participants Noticing the 
HEADLINE 
Impact upon 
patient 
knowledge 
about 
medicines 
Impact upon 
satisfaction 
about 
information 
and 
medicines 
Impact upon 
behaviour 
Concerns about 
headline section. 
Researcher 
comments 
MF, 68, F 
FG1 JANA 
4 items of 
meds 
Advanced  
White British 
 
Thinks maybe a 
different colour tint 
might make it more 
legible. (179) 
  Thinks you might 
be less likely to 
read the leaflet _ 
people would 
only read that 
part…. (393) 
Less concerned 
about repetition. 
Don’t repeat things 
that don’t need 
repeating! (517) 
Good quote on 
behaviour. 
PM, 56, M 
FG1 JANA 
5 items 
Advanced 
White British 
 
   Feels that to 
stimulate 
behaviour 
change and get 
people to notice 
the section it 
needs to be more 
frightening.(327) 
 
Thinks that the 
précis means it 
relates more to 
the reader and 
Thinks the whole 
leaflet could be 
more simple and the 
headline changed to 
be more in your face 
and simplistic. (257)  
 
Thinks it is too 
verbose. Wants in 
your face danger 
warnings. (319) 
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that is more 
tempting to read 
and it 
encourages you 
to read more 
(because you 
don’t have to go 
through the 
whole 
leaflet).(419) 
 
 
Participants Noticing the 
HEADLINE 
Impact upon 
patient 
knowledge 
about 
medicines 
Impact upon 
satisfaction 
about 
information 
and 
medicines 
Impact upon 
behaviour 
Concerns about 
headline section. 
Researcher 
comments 
BJ, 78, F 
FG1 JANA 
12 items 
intermediate 
White British 
 
It does catch your 
eye immediately and 
makes it readable. 
(305) 
 It’s a good 
idea 
It’s quite short 
in comparison 
to the rest of 
it. (367) 
Thinks that if the 
leaflet is too 
frightening it will 
put people off 
and cause them 
to just throw 
away their 
tablets. (325) 
Thinks it should be 
cross-referenced, 
but there is a lot of 
repetition. (191) 
 
Doesn’t want to be 
frightened (in 
response to PM). 
(321) (325) 
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I S,76, M 
FG1 JANA 
Three items 
advanced 
White British 
It is an 
improvement, it 
catches your eye. 
Thought it was 
noticeable and a 
good idea. (97) 
 It’s a good 
idea. (93) 
Thinks it might 
make people 
read just that bit. 
 
The only thing is 
that some, who 
would not 
ordinarily read 
the leaflet if they 
think that the rest 
doesn’t matter/ 
it’s possible. 
(343) 
Is concerned it might 
make people read 
just that bit. (343) 
 
Also expresses 
concerns about the 
leaflet being too big 
and repetitive. (456) 
 
Expresses concerns 
that others might not 
read the rest of the 
leaflet, just the 
Headline. 
Concerned about 
superfluous words 
and length making 
the font too small. 
(484) The 
HEADLINE is 
boring! (484) 
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Appendix 12: Example of benefit chart 
 
Participants 
On knowledge and 
understanding 
On satisfaction On information 
seeking 
behaviour 
On health 
behaviours 
On making 
decisions 
On medicine 
taking 
Anxieties and 
concerns 
MF, 68, F 
FG1 JANA 
4 items of 
meds 
Advanced  
White British 
 
It needs simplifying. 
You do need the 
info, but it needs to 
be simpler. (611) 
 
The leaflet is too 
difficult to convey its 
main message (that 
the medicine 
doesn’t work for 
everyone) The 
figures distract from 
this message. (629) 
 
MF also explains 
the baseline 
information to IS 
and stresses it’s 
importance. The 
medicine isn’t as 
good as expected. 
(865) 
 
People need to be 
given the 
 If the info is 
too difficult 
probably 
wouldn’t seek 
it out. (735) 
 
Having the 
benefit info 
isn’t relevant. 
Most people 
would skip 
over if they 
didn’t have 
any problems 
or they would 
go see their 
GP. (975) 
 There is general 
principle to being 
given information, 
we need all the 
information to 
make a decision, 
the more 
information you 
have helps you 
make an informed 
decision. (869) 
 
It’s too complicated 
and needs 
simplifying because 
it says a 1 in 4 
chance, which isn’t 
very high and might 
affect how people 
take their 
medicines. (611) 
 
The info is relevant 
to people hanging 
to make decisions 
It might make 
a difference 
to how she 
feels about 
her 
medicines. 
(667) 
 
It’s relevant 
info and 
might help 
people to 
make a 
choice. (857) 
 
If it’s 
prescribed by 
a dr. most 
people would 
skim the 
leaflet and 
take the 
tablet if their 
dr. told them 
to. (967) 
People do 
need to know 
that their 
medicine 
might not 
work…they 
need to know 
it happens to 
other people, 
but I don’t 
think that is 
what this is 
trying to do. 
(585) 
 
It needs 
simplifying; 
people need 
to know that 
the medicine 
isn’t going to 
work for 
everyone. It 
needs to be 
simpler. (611) 
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information so they 
can make an 
informed choice. 
The more 
information you 
have the better. 
(869) 
Understand the 
context information 
and is able to 
explain it to her 
fellow participants. 
(881) 
about taking lots of 
medicines – do 
they want to take 
more. The benefit 
info is useful in 
providing the 
chances of 
improvements. 
(853) 
 
Helps people make 
balanced 
decisions. (857) 
 
There is general 
principle at stake. 
People need this 
info to make 
informed decisions. 
(869) 
 
 
 
 
 
 
 
Some people 
(my husband) 
would say 
‘I’m not taking 
those’ 
because of 
what they 
have read. A 
lot will just 
take it. (975) 
 
It wouldn’t 
stop you 
taking it, but it 
might make 
you think ‘is it 
worth it’. 
(677) 
 
 
 
 
 
 
 
 
 
 
 
 
Voices 
concerns that 
this info would 
encourage her 
husband to 
not take his 
medicines or 
to go back to 
see his GP 
(971) 
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Participants On knowledge and 
understanding 
On satisfaction On 
information 
seeking 
behaviour 
On health 
behaviours 
On making 
decisions 
On medicine 
taking 
Anxieties 
and 
concerns 
PM, 56, M 
FG1 JANA 
5 items 
Advanced 
White British 
 
Struggles to 
understand the 
maths in all the 
examples. (589)  
Finds it very 
confusing. 
The double 
negative is 
confusing. (601) 
 
I would be so 
confused by them I 
wouldn’t bother 
(631) 
You are giving me 
very little hope and 
telling me things I 
don’t want to know. 
I’m supposed to be 
intelligent but I’m 
bamboozled. I can’t 
get me head 
around them and I 
have no real 
indication of 
anything. (687) 
Wants 
encouragement 
to be more 
satisfied with the 
information. 
Wants 
rewording of the 
statement to 
include the word 
‘rises’ or 
‘increases’ to 
emphasise the 
benefit. (707) 
Likes the 
second half of 
the purple. 
(651) 
 
You are giving 
me very little 
hope and I 
don’t want to 
know. And you 
are 
bamboozling 
me. (687) 
 He wouldn’t take 
this 
medicine.(although 
it’s difficult to know 
whether this is due 
to the info). (613) 
 Is the maths 
right? It 
doesn’t make 
sense. 
Struggle to 
understand 
how all the 
stats related. 
Wants it to 
say doubling 
of chances 
instead (as it 
is more 
positive). 
Hates the 
double 
negative. 
(593) 
 
The numbers 
are confusing 
and I’s think 
‘what’s the 
point’? (631) 
 
You are giving 
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Wants positive 
encouragement  as 
this simplifies 
things. (713) 
 
Understands the 
context of the 
baseline information 
and explains it to 
other participant. 
(819) 
 
Acknowledges this 
is important 
information.  
Suggests the 
numerical 
information could 
say it doubles your 
chance and this is 
explained  as 
inaccurate 
me very little 
hope and 
telling me 
what is going 
to happen to 
me and I don’t 
want to know.  
The ones with 
confusion in, I 
can’t get my 
head around 
(and I’m 
supposed to 
be scientific 
and logical) 
they are 
confusing.  
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Appendix 11: Mapping and interpretation: Headline – content 
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Appendix 12: Mapping and interpretation: Headline – format 
 
 
 
 
 
 
 
  
349 
 
Appendix 13: Indexing diagram for using the headline section. This diagram 
shows the development of the key categories from the initial index 
(chapter 3/ study 2) 
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Appendix 14: Example of Mapping and interpretation for the descriptive 
analysis of the 'preference for format' (chapter 3/ study 2) 
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Appendix 15: An example of the patient information leaflet for the user-
testing study (chapter 4/ study 3) 
Name of Centre: University of Leeds, Academic Unit of Medicines Management 
 
Participant Information Sheet 
 
Title of Study: Improving the Content and Format of Medicines Leaflets (CoFoMeL) 
 
We would like to invite you to take part in the above named study but before you 
decide, please read the following information.   
You can choose not to take part without having to give a reason and without 
penalty. 
 
What is the purpose of this study? 
 
When a new medicine is prescribed all patients receive information about the medicine 
in the form of a leaflet in the medicine box. A criticism of this information is that it is too 
complex and difficult to read. The aim of this research is to improve the quality of the 
leaflets provided with medicines.  
 
We want to ask people who are likely to receive a leaflet like this in the future to test this 
information and see how easy it is to read and understand. The test is not an 
assessment of your memory, as you will have the leaflet to refer to throughout the 
interview. It is a test of how well the manufacturer has written and presented the 
information on the leaflet.    
 
Who is doing the study?  
 
The study is being done by researchers from the University of Leeds, Medicines 
Management Academic Unit. The study is being conducted as part of a PhD, 
undertaken by Mrs. Rebecca Dickinson. The supervisor is Professor Theo Raynor.  
 
Who is being asked to participate?  
 
You have been invited to participate because you are over 50 years of age and are 
taking one or more long-term medicines (this can be a tablet, capsule, liquid or inhaler).  
If you would like to take part you must be able to speak and read English. 
 
What will be involved if I take part in this study? 
 
 If you are interested you will be invited to take part in a User Test   
 A User Test involves reading a Patient Information Leaflet and answering a few 
simple questions about the leaflet during an informal interview. 
 Interviews typically take around 1 hour. You will receive a small token of £20 as 
thanks for your participation.  
 The interview is not a test of your memory, as you will have the leaflet to refer to 
throughout the interview. It is a test of how well the leaflet is written and presented.  
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What are the advantages and disadvantages of taking part? 
 
There are few disadvantages of taking part in this study, although you may find the task 
tiring. You will be free to leave at any time. The user-testing will take approximately an 
hour of your time.  You may not get any personal medical benefits from agreeing to take 
part. However, the study may highlight better ways of proving information with long-term 
medicines. This could help patients in the future.  If you do participate you will be given 
£20 at the end of the meeting to acknowledge the time you have given.   
 
 
Can I withdraw from the study at any time?  
 
You do not have to take part in the study, no-one will mind if you say no.  You can say 
yes and then change your mind. You are free to withdraw from the study at any time. 
 
Will the information I give be kept confidential? 
 
To keep an accurate record of what is discussed the interview will be audio recorded. 
The recordings will be typed up and made anonymous.  Then the recordings will be 
destroyed. All information you offer during the research will be kept private and 
confidential, in accordance with the Data Protection Act. 
 
What will happen to the results of the study? 
 
The result of the study will be used as part of a PhD thesis. They will be written as a 
document and sent for publication in a medical journal. We will also present the results 
of the study to the Medicines and Healthcare products Regulatory Agency to help them 
improve the regulations about patient information leaflets. 
 
Who has reviewed this study? 
 
The University of Leeds School of Healthcare Research Ethics Committee has 
reviewed this study. 
 
If you agree to take part, would like more information or have any questions or 
concerns about the study please contact: 
 
Mrs Rebecca Dickinson, 
Research Nurse, School of Healthcare, University of Leeds, LS2 
9LN 
Tel: 0113 3431190, E-mail: r.dickinson@leeds.ac.uk. 
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Appendix 16: Photograph of the leaflet used for the user-testing study 
(chapter 4/ study 3) 
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Appendix 17: Results of the pilot user-test (chapter 4/ study 3) 
P Criteria Q1 Q2 Q3 Q4 Q5 Q6 Q7 Q8 Q9 Q10 Q11 Q12 Q13 Q14 Q15 
1 Found FD F F F F F FD F FD F F F FD F FD 
Unders U U U U U U U U NU U U U U U U 
Headline Yes Yes Yes NA No No No NA No No NA NA NA NA NA 
Signpost NA NA NA NA No No NA NA NA NA NA NA NA NA NA 
2 Found F F F F F NF F F F F F F F F F 
Unders U U U U U NU U U U U U U U U U 
Headline Yes Yes No NA NA No Yes NA No No NA NA NA NA NA 
Signpost NA NA NA NA NA No NA NA NA No NA NA NA NA NA 
*Highlighted columns are indicative of questions which test the headline section 
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Appendix 18: Example of charting for thematic analysis (chapter 4/ study 3) 
Participant Can you recommend 
any improvements 
Would you do anything 
differently if you leaflet 
came with HEADLINE 
Signposting. Other comments 
01PM  
F, 52, 1, no lit. 
Difficult interview/ found 
it difficult to read.  
 
No noted When people are on 
medicines they read the 
most important things 
and the side effects, not 
everything.  
 
I don’t look for everything,  
 
But what it is with me is 
that it takes me a while to 
register things and I think 
I would go for the most 
important things and I 
think it tells you on there, 
and what it’s used for 
You’ll understand it better and you’ll find 
all the rest of it when you are looking for 
it.  
 
It’s like a book and then you look for that 
number, like on here (refers to signpost?) 
 
What did I think of what... Oh like A, B 
and C, Oh yeah I didn’t notice them. I 
didn’t see them and I should’ve and I 
didn’t. I didn’t see them. I didn’t take any 
notice.  
 
 think a lot of people are like me though. 
Aha, like A goes with A. Yeah.  
 
No, I didn’t see them, I didn’t take any 
notice of them or I would have found 
them answers quicker…  
None noted 
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Yes and It would have helped me find 
them quicker. But I didn’t notice and 
that’s what took my time. Stupid that… I 
would have found them answers quicker. 
 
Participant Can you recommend 
any improvements 
Would you do anything 
differently if you leaflet 
came with HEADLINE 
Signposting. Other comments 
02 SW 
F, 56, 1, no lit, 
Took a while with the 
interview, but was slow 
and systematic. 
Struggled in parts but 
understood that layout of 
the leaflet in general. 
None noted I think I would be more 
liable to read that bit and 
not any of the other, just 
read the important things 
bit and not read any of 
the other 
No, I didn’t. I never used them once and 
I’d only noticed them now.  
That is very good really.  
That would have saved me having to go 
all the way through it. I think they should 
be underlined a bit more though. Cause 
when I was reading that it never dawned 
on me, until you said now. And I probably 
would have found it a lot quicker. That is 
definitely a good way 
None noted 
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Appendix 19: Example of the mapping and interpretation diagram for 
qualitative element of the user-testing study (chapter 4/ study 3) 
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Appendix 20: List of leaflets surveyed indicating generic or brand and manufacturers (chapter 5/ study 4) 
Medicine Top 50 or 
newly 
licensed 
Branded/generic Listed manufacturers Chosen 
manufacturers 
Date chosen 
Ramipril Top 50 Generic Accord, Zentiva, Rosemount, Pfizer, 
Aurobindo, Actavis, Winthrop 
Winthrop 
Pharmaceuticals 
07.01.13 
Simvastatin Top 50 Generic Dexcel, Actavis, Zentiva, Kent 
Pharmaceuticals, Aurobindo, 
Rosemont, Accord 
Zentiva 07.01.12 
Amitriptyline 
Hydrochloride 
Top 50 Generic Accord, Mercury, Avantis Accord 07.01.13 
Tramadol Top 50 Generic Mercury, Actavis, Kent, Accord Accord 09.01.13  
Metformin Top 50 Generic Pfizer, Zentiva, Wockhardt, Winthrop Winthrop 
Pharmaceuticals 
09.01.13 
Omeprazole Top 50 Generic Zentiva, Dexcel, Actavis Zentiva 07.01.13 
Hydrocortisone Top 50 Generic Actavis Actavis 07.01.13 
Alendronic acid Top 50 Generic Actavis, Rosemont, Accord, Zentive Rosemont 07.01.13 
Lactulose Top 50 Generic Intrapharm laboratories Intrapharm 07.01.13 
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Lamoratories 
Atenolol Top 50 Generic Wockhardt, Actavis, Accord Wockhardt 07.01.12 
Co-codamol Top 50 Generic Boots, Zentiva, Mercury Pharma 
Group, Actavis, Bayer 
Boots 07.01.12 
Levothyroxine Top 50 Generic Wockhardt, Mercury, Actavis Mercury Pharam 
Group 
07.01.12 
Beclamethosone Top 50 Generic Orion Pharma Orion Pharma 07.01.12 
Losartan Top 50 Generic Dexcel, Kent Pharmaceuticals Ltd., 
Zentiva, Actavis, Accord 
Kent Pharmaceuticals 
Ltd. 
09.01.13 
Lisinopril Top 50 Generic Zentive, Accord, Aurobind, Milpharm 
Ltd., Actavis 
Actavis 09.01.13 
Zopiclone Top 50 Generic Kent pharmaceuticals Ltd., Actavis Kent Pharmaceuticals 
Ltd. 
09.01.13 
Naproxen Top 50 Generic Actavis, Accord, Aurobind pharm - 
Milpharm Ltd. 
Actavis 09.01.12 
Flucloxacillin Top 50 Generic Actavis, Kent Pharmaceuticals, 
Aurobind pharm –Milpharm ltd. 
Kent pharmaceuticals 09.01.13 
Aspirin Top 50  Generic Actavis, Wockhardt, Interpharm, The 
Boots Company Plc.,  
The Boots Company 
Plc. 
09.01.13 
Folic Acid Top 50 Generic Wockhardt, Intrapharm, Actavis Wockhardt 09.01.13 
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Isosorbide 
Mononitrate 
Top 50 Generic Accord, Actavis Actavis 09.01.13 
 Furosemide 
(injection) 
Top 50 Generic Hameln pharmaceuticals Ltd., Accord, 
Actavis, Mercury Pharma Group, 
International Medication Systems 
(UK) Ltd., Wockhardt UK Ltd. 
Hameln 
Pharmaceuticals Ltd. 
09.01.13 
Amoxicillin Top 50 Generic Accord, Kent Pharmaceuticals Ltd., 
Aurobind Pharm - Milpharm 
Accord 09.01.12 
Bendroflumethiazi
de 
Top 50 Generic Actavis Actavis 09.01.13 
Diazepam Top 50 Generic Actavis, Desitin Pharma Ltd, Hameln 
Pharmaceuticals,  
Desitin Pharma Ltd. 09.01.13 
Ibuprofen Top 50 Branded - Brufen Brand identified in BNF Sept 2012 Abbot Healthcare 
products 
07.01.13 
Warfarin sodium Top 50 Branded - Marevan Brand identified in BNF Sept 2012 Mercury Pharma 
Group 
07.01.13 
Tamsulosin 
Hydrochloride 
Top 50 Branded - Flomaxtra Brand identified in BNF Sept 2012 Astellas 07.01.13 
Amlodipine Top 50 Branded - Isitin Brand identified in BNF Sept 2012 Pfizer 07.01.13 
Perindopril Top 50 Branded – Coversyl 
Arginine 
Brand identified in BNF Sept 2012 Servier 07.01.13 
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Bisoprolol Top 50 Branded - Cardicor Brand identified in BNF Sept 2012 Merck Serono 07.01.13 
Diclofenac Top 50 Branded - Volterol Brand identified in BNF Sept 2012 Novartis 07.01.13 
Fluoxetine Top 50 Branded - Prozac Brand identified in BNF Sept 2012 Lilly 07.01.13 
Alfa-calciferol * Top 50 Branded – One-
Alpha 
Brand identified in BNF Sept 2012 Leo Pharma 26.03.13 
Citalopram Top 50 Branded - Cipramil Brand identified in BNF Sept 2012 Lundbeck 07.01.13 
Doxazosin Top 50 Branded - Cardura Brand identified in BNF Sept 2012 Pfizer 07.01.13 
Paracetamol Top 50 Branded - Panadol Brand identified in BNF Sept 2012 GSK 07.01.13 
Lansoprazole Top 50 Branded - Zoton Brand identified in BNF Sept 2012 Wyeth 07.01.13 
Atorvastatin Top 50 Branded - Lipitor Brand identified in BNF Sept 2012 Pfizer 07.01.13 
Cetirizine Top 50 Branded - 
Pollenshield 
Brand chosen at random from eMC Actavis 07.01.13 
Digoxin Top 50 Branded - Lanoxin Brand identified in BNF Sept 2012 Aspen 07.01.13 
Prednisolone Top 50 Branded - 
Deltacortril 
Brand identified in BNF Sept 2012 Alliance 07.01.13 
Candesartan 
Cilexetil 
Top 50 Branded - Amais Brand identified in BNF Sept 2012 Takeda 07.01.13 
Senna Top 50 Branded - Senokot Brand identified in BNF Sept 2012 Reckitt Benckiser 07.01.13 
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Gliclazide Top 50 Branded - Diamicron Brand identified in BNF Sept 2012 Servier 07.01.13 
Clopidogrel Top 50 Branded - Plavix Brand identified in BNF Sept 2012 SANOFI 07.01.13 
Fluticasone Top 50 Branded - Flixotide Brand identified in BNF Sept 2012 Allen and Hanbury’s 09.01.13 
Tiotropium Top 50 Branded - Spiriva Brand identified in BNF Sept 2012 Boehringer Ingleheim 09.01.13 
Salbutamol Top 50 Branded - Pulvinal Brand identified in BNF Sept 2012 Chiesi Limited 09.01.13 
Felodipine Top 50 Branded - Plendil Brand identified in BNF Sept 2012 AstraZenica 09.01.13 
Deferasirox Black triangle Beanded - EXJADE NA Novartis 19.02.13 
Pasireotide Black triangle Branded - Signifor NA Novartis 19.01.13 
Fampridine Black triangle Branded - Fampyra NA Biogen Idec 19.02.13 
Perampanel Black triangle Branded - Fycompa NA Eisai Europe Limited 19.02.13 
Canakinumab Black triangle Beanded - Ilaris NA Novartis 19.02.13 
Mifamurtide Black triangle Branded - MEPACT NA Takeda 19.01.13 
Bromfenac Black triangle Branded - Yellox NA Bausch and Lomb 19.02.13 
Velaglucerase Black triangle Branded - VPRIV NA Shire Human 
Genetics 
19.02.13 
Palifermin Black triangle Branded - 
Keipvance 
NA Swedish Orphan 
Biovitrum 
19.02.13 
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Ticagrelor Black triangle Branded- Brilique NA AstraZenica 19.02.13 
Natalizumab Black triangle Branded - TYSABRI NA Biogen Idec 19.02.12 
Fingolimod Black triangle Branded - Gilenya NA Novartis 19.02.13 
Indacaterol Black triangle Branded – Onzbrez 
inhaler 
NA Novartis 19.02.13 
Belimumab Black triangle Branded - Benlysta NA GSK 19.02.13 
Idursulfase Black triangle Branded - Elaprase NA Shire Human 
Genetics 
19.02.13 
Exenatide Black triangle Branded - 
BYDUREON 
NA Bristol Myers Squibb 
Astra Zenica 
19.02.13 
Telaprevir Black triangle Branded - INCIVO NA Jannsen Cilag 19.02.13 
Temsirolimus Black triangle Branded - Torisel NA Pfizer 19.02.13 
Ruxolitinib Black triangle Branded - Jakavi NA Novartis 19.02.13 
Pazopanib Black triangle Branded - Votrient NA GlaxoSmithKlein 19.02.13 
Boceprevir Black triangle Branded - Victrelis NA Merck, Sharpe and 
Dohme 
19.02.13 
Rifaximin Black triangle Branded - Xifaxanta NA Norgine 19.02.13 
Prucalopride Black triangle Branded - Resolor NA Shire 
Pharmaceuticals 
19.02.13 
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Bivalirudin Black triangle Branded - Angiox NA The Medicines 
Company 
19.02.13 
Vinflunine Black triangle Branded - Javlor NA Pierre Fabin 19.02.13 
C1 Inhibitor 
(Human) 
Black triangle Branded - Cinryze NA ViroPharma 19.02.13 
Cannabidiol Black triangle Branded - Savitex NA GW Pharma (Bayer) 19.02.13 
Erdosteine Black triangle Branded - 
Erdosteine 
NA Galen Limited 19.02.13 
Ranolazine Black triangle Branded - Ranexa NA A. Menarini 
Farmaceutica 
Internazionale 
SRL 
19.01.13 
Bendamustine Black triangle Bradned - Levact NA Napp 
Pharmacueticals 
19.02.13 
Conestat Alfa Black triangle Branded - Ruconest NA Swedish Orphan 
Biovirtum 
19.02.13 
Axitinib Black triangle Branded - Inlyta NA Pfizer 19.02.13 
Fondaparinux Black triangle Branded - Arixitra NA GlaxoSmithKlein 19.02.13 
Tolcapone Black triangle Branded - Tasmar NA Meda 
Pharmaceuticals 
19.02.13 
Tocilizumab Black triangle Branded - NA Roche Products 19.02.12 
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RoActemra Limited 
Agomelatine Black triangle Branded - Valdoxan NA Les Laboratoires 
Servier 
 
Certolizumab Black triangle Branded - Cimzia NA UCN Pharma Limited 20.02.13 
Ferumoxytol Black triangle Branded - Rienso NA Takeda 20.02.13 
Aclidinium Black triangle Branded – Eklira 
Genuair 
NA Almirall 20.02.13 
Tapentadol Black triangle Branded - Palexia NA Grunenthal 20.02.13 
Rilpivirine Black triangle Branded - 
EDURANT 
NA Jannsen Cilag 20.02.13 
Ofatumumab Black triangle Branded - Arzerra NA GlaxoSmithKlein 20.02.13 
Fidaxomicin Black triangle Branded - Dificlir NA Astellas Pharma 20.02.13 
Asenapine Black triangle Branded - Sycrest NA Lundbeck 20.02.13 
Apixaban Black triangle Branded - Eliquis NA Bristol-Myers Squibb 
Pfizer 
20.02.13 
Cabazitaxel Black triangle Branded - JEVTANA NA Sanofi 20.02.13 
Bevacizumab Black triangle Branded - Avastin NA Roche Products 
Limited 
20.02.13 
Abiraterone Black triangle Branded – Zytiga NA Jannsen Cilag 20.02.13 
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Varenicline Black triangle Branded - Champix NA Pfizer 20.02.13 
Dronedarone Black triangle Branded - Multaq NA Sanofi 20.02.13 
*No Ergocalciferol PIL was available on the eMC, therefore we chose the nearest pharmacological equivalent which is alfacalciferol. 
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Appendix 21: Example of patient information sheet used for study 5 
Participant Information Sheet 
 
Title of Study: The impact of benefit information in medicines leaflets. 
 
We would like to invite you to take part in this study but before you decide, please read 
the following information.   
 
You can choose not to take part without having to give a reason and without 
penalty. 
 
What is the purpose of this study? 
 
When a medicine is prescribed all patients receive an information leaflet in the 
medicine box.  We would like to find out more about what people think about this 
information.  We would like to ask your views on different ways of presenting some of 
the information that could be provided. 
 
One important issue we would like to find out about looks at including benefit 
information in medicine leaflets. Benefit information includes information on how the 
medicine works, what it does and its possible benefits. We would like to find out what 
patients who take medicines think about the inclusion of this information in their 
medicines leaflets. 
 
By doing so we hope to understand more about how we can improve the information 
provided with medicines and help patients understand more about their medicines. 
Who is doing the study?  
 
Researchers from the University of Leeds are doing the study. Mrs. Rebecca Dickinson 
is doing the study as part of her PhD. The supervisor is Professor Theo Raynor. 
Who is being asked to participate?  
 
You have been invited to participate because you are currently receiving a prescription 
for simvastatin. If you would like to take part you must be able to speak and read 
English. Your GP will be aware of your invitation to participate in this study. 
 
What will be involved if I take part in this study? 
 
 If you are interested we will invite you to take part in an interview. You will be 
given some medicine leaflets which contain information about the benefits of 
your medicine to look at and we will ask for your views.  
 A researcher will ask questions and you will be free to talk about your views on 
the medicines leaflets and the benefit information.  
 The interview will take approximately 1 hour in total and can be done 
somewhere convenient for you, this could be at your own home, or if you prefer 
an alternative location such as Leeds University or the GP practice. 
 
What are the advantages and disadvantages of taking part? 
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There are few disadvantages of taking part in this study. You may find the task tiring 
but you will be free to stop the interview at any time without giving a reason. You may 
not get any personal medical benefits from agreeing to take part. However, the study 
may highlight better ways of providing information with medicines.  
 
Some of the benefit information provided about your medicines might be surprising or 
difficult to understand and reading about it might raise some new questions about your 
medicines. If you have any questions about your medicines as a result of taking part in 
this research, and which cannot be addressed by the researcher, you should speak 
with your GP or pharmacist.  If you do participate you will be given a £20 gift voucher at 
the end of the meeting to acknowledge the time you have given.   
Can I withdraw from the study at any time?  
 
You do not have to take part in the study, no-one will mind if you say no.  You can say 
yes and then change your mind. You are free to withdraw from the study at any time 
and do not have to give a reason why. If you do change your mind please let Rebecca 
Dickinson know within 1 month of participation. After this time it might be difficult to 
remove any data you provide from the research reports, although this data will be 
anonymous.  
Will the information I give be kept confidential? 
 
To keep an accurate record of what is discussed the meeting will be audio recorded. 
The recordings will be typed up and made anonymous. Then the recordings will be 
destroyed. All information you offer during the research will be kept private and 
confidential. It will be stored for 4 years in a locked filing cabinet in a secure office. It 
will not be possible to identify you in any way from the publications, reports and 
guidelines that are produced. There is a duty to disclose to a relevant person if a risk of 
harm to self or others is disclosed during the interview. 
What will happen to the results of the study? 
 
The results from the study will form part of a PhD thesis. They will be written as a 
document and sent for publication in a medical journal. We will also present the results 
of the study to the Medicines and Healthcare products Regulatory Agency to help them 
improve the regulations about patient information leaflets. 
Who has reviewed this study? 
 
The National Research Ethics Service has reviewed this application. Reference: 
13/YH/0180 
 
If you agree to take part, would like more information or have any questions or 
concerns about the study please contact: 
 
Mrs Rebecca Dickinson 
Research Nurse, School of Healthcare, University of Leeds, LS2 9LN. 
 
Tel: 0113 3431190.      E-mail: r.dickinson@leeds.ac.uk 
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Appendix 22: Illustrative topic guide used to guide the interviews for study 5 
(chapter 6). The topic guide was adapted for each interview. 
Research study: The impact of benefit information in medicine leaflets 
Historical questions 
 Can you tell me about the information you got when you were first prescribed 
simvastatin? 
(Prompts: Who was this from? Was it spoken or in writing?) 
 Have you ever seen an information leaflet like this inside your packet of 
medicine? What have you done with this information? 
(Prompts: Do you read it? When? Do you refer to it? How often? Do you keep 
the leaflets? How do you use the information?) 
 
 In the last month, have there been any times where you have not taken your 
medicines as prescribed? 
 
Benefit information 
I’m going to show you 3 versions of a leaflet about your medicine which talks about the 
benefits of the medicine in different ways: 
Refer to: 
1) General description in words 
2) In a 100 people like you who do not take this medicine, 22 will have a heart 
attack or stroke over the next five years. But if they all take Rebastatin over the 
next 5 years, 22 will have a heart attack or stroke.(NEGATIVE - no treatment 
first) 
3) If 17 people like you take simvastatin over the next 5 years, 1 of them will be 
stopped having a heart attack or stroke. 
 
 What did you think of this information? 
 Have you ever seen or been told information like this before? 
(Prompt: in another leaflet? Website? Has a doctor or pharmacist ever 
discussed this type of information with you?) 
 Which one of these did you prefer? Why? 
 What changes if any would you recommend to this section?  
 (Prompt: explore issues with any concerns and anxieties, feeling reassured 
and informed. Also other types of benefit, for example revascularisation and 
lowering of cholesterol as benefits to be included? More or less benefit 
information? ) 
 Can I ask some questions specifically about the orange statement? 
 Here is a statement similar to first orange statement, only it is put in a positive 
way, that is it tells you how likely you are to not have a heart attack. Which of 
these statements do you prefer and can you tell me why. (Present positive on a 
slip of paper) 
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 This statement could be organised in a different way, with the numbers of those 
taking the medicine put before those who don’t take the medicine, so it might 
say (read below). Can you tell me which of these you prefer and why? 
3. ORANGE  
 
In 100 people like you who take this medicine, 22 will have a heart attack or stroke. But if they 
do not take Rebastatin over the next 5 years, 28 will have a heart attack or stroke.  
 Finally, can I ask what do you think about the phrase ‘people like you’? (Prompt: 
can you think of any alternatives? 
These leaflets already contain numbers about the chance of side effects of the 
medicine. Having these numbers would also tell you about the chance of benefit.  
 Do you think that having this information about the chance of benefit and the 
chance of side effects helps you make a decision about whether the medicine is 
right for you? 
 Imagine you received this information when you were first prescribed this 
medicine, what difference do you think this would have made to what you did 
and thought about the medicine?  
(Prompt: do you think you would do anything differently? Change your 
medication? Take it differently? Stop your medication? Seek advice for Doctor 
or other HCP? Ask your family for advice? Look at the internet) 
 Do you think, if this type of information was commonplace in the leaflets, it 
would make people to do anything differently with their medicines? 
 Having has our discussion, if you have the choice of having one of these 
formats which one would you have and why? 
 
Additional questions (time permitting): 
• Would you be interested in reading benefit information in other medicines 
leaflets? (Prompt: what about OTC medicines? Or medicines for a different condition? 
Or if you had a choice about different medicines to take? Prompt: about whether 
numbers or texts would be preferred in other medicines leaflets 
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Appendix 23: Example of field note written after benefit interview (chapter 6/ 
study 5) 
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Appendix 24: Example of framework development for the interview stage (chapter 6/ study 5) 
Quote In-vivo code Preliminary thoughts Initial themes Categories 
Well, they just told us it was for lowering 
cholesterol. Erm… and you can read the leaflet, like 
you say, cos there’s that much long words and you 
think, “What does that mean? What does that 
mean?” some of em are confusing but, and when I 
looked at the LDL and the HDL thing and I’m 
thinking, “Well, L for lardy, fats and stuff, those are 
bad ones”, that’s the way I looked at it. And the H 
ones, those are the happy ones, so they’re good 
ones. And that’s the way I saw the LDL [laughs]. 
 The doctors 
told me it was 
for 
cholesterol. 
 The leaflet is 
too long… too 
long words. 
Confusing 
 Source of 
information: written 
‘v’ verbal 
 Reading the leaflet 
is difficult 
Typical information 
behaviour. 
 
Typical leaflet-use 
Typical  Patient 
actions 
 Typical 
leaflet use. 
 
Barriers to benefit 
info. 
Oh, yeah, she told me everything, yeah, yeah, she 
was really good, because I take the heart medicines 
as well, as I say, I had two heart attacks, one in the 
classroom…And one in hospital when I got there, 
yeah, so, and I’ve got COPD as well. So I’ve got 
medication for that and sprays, so really, I’m a wreck 
[laughs]. So the tablets actually keep me going, 
basically, yeah. 
 Doctor told 
me everything 
 Heart attack, 
COPD,  
 The tablets 
keep me going 
 Source of 
information: written 
‘v’ verbal 
 Multiple health 
conditions 
 Positive medicine 
associations 
Role of leaflet 
Health 
Experience with 
medicines 
Typical patient 
actions 
After I got the letter from you, I’d just got a new 
month’s supply, so I actually read them all, and I was 
bog-eyed by the by the end of it… you know! 
 I was bog-
eyed by the 
end of it 
Reading the leaflets is 
difficult 
Perceptions of 
typical leaflet 
Typical patient 
actions 
 Leaflet use 
and thoughts 
I:Do you normally read them or…? 
P:No. 
I:Do you read any of them? 
 Doesn’t 
normally read 
leaflets unless 
 Engagement with 
leaflet 
 Reading the leaflet 
Engagement with 
leaflet 
Typical patient 
actions 
 Leaflet use 
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P:Sometimes, well, if it’s a new one, yeah, but, like 
you say, sometimes you’re reading and you don’t 
know what you’ve read, you don’t really understand 
what you’ve read. 
 
new medicine 
 You don’t 
really 
understand 
what you 
have read 
is difficult and thoughts 
Yeah, exactly, yeah, yeah. I know what doesn’t mix 
with this and you can’t take this if you’re taking that 
and it’s… so you look through, “Do I take them? No, I 
don’t” so you’re alright, you can take em, but, yeah, 
sometimes they are a little bit confusing, especially 
as you’re getting older as well 
 I know what 
doesn’t mix 
with this and 
you can’t take 
this if you’re 
taking that 
 “Do I take 
them? No, I 
don’t” so 
you’re alright, 
you can take 
em 
 sometimes 
they are a 
little bit 
confusing, 
especially as 
you’re getting 
older as well 
 Leaflet tells her how 
to take/ what she 
can take them with 
 Reading the leaflet 
is difficult - AGE  
Typical leaflet use 
Barriers to reading 
leaflet 
Typical patient 
actions 
 Leaflet use 
and thoughts 
 
Barriers to benefit 
info 
Yes, a hundred people like you do not take, twenty 
eight will have a heart attack or a stroke but if they 
all take Rebastatin over the next five years, twenty 
Reads the leaflet 
 Right, it only 
 Surprise at the 
benefit 
Affect/ emotional 
responses 
Initial response to 
benefit info 
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two will have a heart attack. Right, it only lowers it 
by six, doesn’t it? 
lowers it by 
six, doesn’t 
it? 
Well, it’s clear enough but is it genuine, this, or not? 
Is it just like a make up type thing, say, if they hear 
what you’re doing? 
 It’s clear 
enough but 
is it genuine? 
 Is it just 
make-up 
type thing? 
 Surprise at the 
benefit 
 Scepticism/ 
mistrust… 
Initial response 
concerns 
Initial response to 
benefit info 
Right. Mmm, yeah, it’s clear enough, int it, like I say.  it’s clear 
enough, 
 understanding of 
information 
Knowledge and 
understanding 
Knowledge and 
understanding  
No, well, it, like I say, here where twenty eight will 
have an heart attack or stroke, but if they all take 
Rebastatin over the next five years, twenty two will 
have, well, yes, it does have a number but… 
Reads the leaflet Does not require coding  Does not require 
coding 
It’s, yeah, it’s helpful, I suppose, yeah, but, I mean, 
what’s the other one? Seventeen people over the 
next five years, one extra person will be prevented 
from having a heart attack or a stroke. There is, but 
there again, you don’t know what lifestyle they 
were, what type of folk they, all these other things 
what come into it. Erm… yeah, they’d have to higher 
level of it to take statins anyway, don’t they, they 
have to have a higher level of cholesterol. 
 It’s helpful I 
suppose [not 
convinced] 
 You don’t 
know what 
the lifestyle is 
 They’d have 
to have high 
levels of it to 
take statins  
 Some uncertainty 
about the benefit 
statement 
 How relevant is 
this information to 
me! 
 Who are these 
people? Are they 
similar to me?  
 Barriers to 
benefit 
info 
Impact of benefits 
 Barriers/ 
facilitators 
to benefit 
info 
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Appendix 25: Example of index applied to each interview (chapter 6/ study 5) 
 
Typical patient actions 
 Medicine-taking and beliefs about medicines 
 Relationship with GP 
 Decision-making 
 Leaflet use and thoughts on the role of the leaflet 
 Health and well-being 
 Personal characteristics 
 Experience with numbers 
 Information seeking 
 Initial information 
 
Impact of benefit info 
 Positives about benefit 
 Concerns about benefit info 
 Barriers to benefit info 
 Impact on decision-making and medicine taking 
 Impact on other behaviours 
 Knowledge and understanding 
 Initial response to benefit info 
 Balance of harm and benefits. 
 Timing of delivery of benefit info. 
 On others 
 
Talking about format 
 NNT 
 NF 
 TEXTUAL 
 Framing 
 Other formats 
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 Wording of benefit info 
 Desirable attributes of benefit  info 
 Numbers in general 
 
Talking about uncertainty 
 Chance 
 Risk 
 
Talking about HCP relationships 
Other influences on medicine taking 
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Appendix 26: Example of mapping and interpretation for the descriptive 
analysis of the 'preference for format': Textual (Chapter 6/ study 5) 
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Appendix 27: Example of the mapping and interpretation stage of the 
framework analysis for the interview stage of the research (chapter 6/ 
study 5) 
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